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Abstract 
 
‘Dioxin-like’ (DL) compounds occur ubiquitously in the environment. Toxic responses associated 
with specific dibenzo-p-dioxins (PCDDs), dibenzofurans (PCDFs), and polychlorinated biphenyls 
(PCBs) include dermal toxicity, immunotoxicity, liver toxicity, carcinogenicity, as well as adverse 
effects on reproduction, development, and endocrine functions. Most, if not all of these effects are 
believed to be due to interaction of these compounds with the aryl hydrocarbon receptor (AhR).  
With tetrachlorodibenzo-p-dioxin (TCDD) as representatively most potent congener, a toxic 
equivalency factor (TEF) concept was employed, in which respective congeners were assigned to a 
certain TEF-value reflecting the compound’s toxicity relative to TCDD’s.  
The EU-project ‘SYSTEQ’ aimed to develop, validate, and implement human systemic TEFs as 
indicators of toxicity for DL-congeners. Hence, the identification of novel quantifiable biomarkers 
of exposure was a major objective of the SYSTEQ project.  
In order to approach to this objective, a mouse whole genome microarray analysis was applied 
using a set of seven individual congeners, termed the ‘core congeners’. These core congeners 
(TCDD, 1-PeCDD, 4-PeCDF, PCB 126, PCB 118, PCB 156, and the non dioxin-like PCB 153), 
which contribute to approximately 90% of TEQs in the human food chain, were further tested in 
vivo as well as in vitro. The mouse whole genome microarray revealed a conserved list of 
differentially regulated genes and pathways associated with ‘dioxin-like’ effects.  
 
A definite data-set of in vitro studies was supposed to function as a fundament for a probable 
establishment of novel TEFs. Thus, CYP1A induction measured by EROD activity, which 
represents a sensitive and yet best known marker for dioxin-like effects, was used to estimate 
potency and efficacy of selected congeners. For this study, primary rat hepatocytes and the rat 
hepatoma cell line H4IIE were used as well as the core congeners and an additional group of 
compounds of comparable relevance for the environment: 1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-
HxCDF, 1,4,6-HpCDF, PCB 77, and PCB 105. 
 
Besides, a human whole genome microarray experiment was applied in order to gain knowledge 
with respect to TCDD’s impact towards cells of the immune system. Hence, human primary blood 
mononuclear cells (PBMCs) were isolated from individuals and exposed to TCDD or to TCDD in 
combination with a stimulus (lipopolysaccharide (LPS), or phytohemagglutinin (PHA)). A few 
members of the AhR-gene batterie were found to be regulated, and minor data with respect to 
potential TCDD-mediated immunomodulatory effects were given. Still, obtained data in this regard 
was limited due to great inter-individual differences.  
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Theoretical Background 
 
1.1. Aryl hydrocarbon Receptor (AhR) 
 
Induction of drug-metabolizing enzymes due to polycyclic aromatic hydrocarbon (PAH)-exposure 
has been reviewed earlily in literature (Nebert and Gelboin, 1968a; Nebert and Gelboin, 1968b; 
Nebert et al., 1977; Nebert et al., 1975). Verified by specific binding of [3H]TCDD to hepatic 
cytosol from C57BL/6J mice, Poland et al. (1976) ascertained that aromatic hydrocarbon 
responsiveness was determined by a single locus, providing evidence for the presence of a ligand-
dependent receptor, and proposing the requirement of a receptor-ligand-complex initiating the 
expression of respective genes (Poland et al., 1976). Within this study, the authors found an overall 
correspondence between potencies of 23 tested halogenated dibenzo-p-dioxins and dibenzofurans to 
induce aryl hydrocarbon hydroxylase (AHH) in vivo and their affinities for the proposed receptor 
which became known as aryl hydrocarbon receptor (AhR). 
 
1.1.1. AhR-ligands 
 
Halogenated aromatic hydrocarbons (HAHs) like polyhalogenated dibenzo-p-dioxins (PCDDs), 
dibenzofurans (PCDFs), and biphenyls (PCBs), as well as polycyclic aromatic hydrocarbons 
(PAHs) such as dibenz[a,h]anthracene, benzo[a]pyrene, 3-methylcholanthrene, or chrysene, 
accomplish high affinity for AhR (Bandiera et al., 1982; Bandiera et al., 1984; Bigelow and Nebert, 
1982; Okey and Vella, 1982; Sawyer et al., 1983). Further synthetic AhR-ligands are β-
naphthoflavone, or carbaryl, for instance (Denison et al., 1998; Sugihara et al., 2008). Exemplary 
chemicals exhibiting lower AhR-affinity are N,N’-Diphenyl-p-phenylendiamine, 2-Mercapto-5-
methoxybenzimidazole, or primaquine (Backlund and Ingelman-Sundberg, 2004; Sugihara et al., 
2008). To date, several naturally occurring and even endogenous AhR-ligands are known. Among 
these are indoles (indole-3-carbinol, tryptophan, e.g.), arachidonic acid metabolites (prostaglandin 
G2, e.g.), and tetrapyrroles (bilirubin, biliverdin) (Bjeldanes et al., 1991; Heath-Pagliuso et al., 
1998; Phelan et al., 1998; Seidel et al., 2001). Notably, yet found natural ligands bear comparable 
low affinities for the AhR, whereas some metabolites of weak agonists (indole-3-carbinol, 
tryptophan) were found to yield higher affinities, exemplifying indolo[3,2-b]carbazole (ICZ) with a 
relative binding affinity of 3.7*10-2 compared to TCDD’s relative binding affinity for the receptor, 
which was detemined in the course of Bjeldanes and co-workers’ study using AhR prepared from 
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mouse livers (Bjeldanes et al., 1991; Perdew and Babbs, 1991). Recently, the tryptophan 
metabolites kynurenine and kynurenic acid were as well identified to be endogenous AhR-ligands 
(DiNatale et al., 2010; Opitz et al., 2011). However, for several weak ligands, which were reported 
to induce AhR-dependent gene expression, varying results were determined regarding their ability 
to competitively bind the AhR. Omeprazole, e.g., for which Backlund and Ingelman-Sundberg 
(2004) failed to determine its potential AhR-binding affinity, did competitively bind the receptor in 
a study by Hu et al. (2007).  
 
Quantitative structure-activity relationship (QSAR) analyses propose steric and lipophilic 
properties, as well as chemical softness, electrophilicity index, hydrogen bonding capacity, and 
dispersion and electrostatic interaction are crucial properties attributing AhR-binding affinities of 
chemicals (Arulmozhiraja and Morita, 2004; Kafafi et al., 1992a/b; Poso et al., 1993; Safe et al., 
1986; Waller and McKinney, 1992; Zhao et al., 2008b). Chlorination patterns of HAHs affect their 
ability to interact with the receptor. Laterally chlorinated molecules possess highest polarizabilities 
along the lateral direction and exhibit maximum AhR-binding properties (Kafafi et al., 1993; Mhin 
et al., 2002). By comparative molecular field analysis (CoMFA), a threedimensional QSAR 
paradigm, Waller and McKinney determined the AhR binding site size (maximal van der Waal’s 
dimensions) to measure 14 Å x 12 Å x 5 Å (Waller and McKinney, 1995).  
 
1.1.2. Transcriptional activation by the AhR 
 
In the organism, the AhR is expressed in many types of cells and tissues with considerable 
expression levels found in liver, lung, and thymus (De Montellano et al., 2005). AhR function is 
proposed to be connected to toxicological as well as physiological functions. In this regard, the AhR 
is involved in hepatic growth and development, teratogenesis, immune function, cell proliferation 
and differentiation, nephrogenesis, apoptosis, adipogenesis, tumor promotion, and reproductive 
function (Alexander et al., 1996; Chopra et al., 2009; Chopra et al., 2010a; Falahatpisheh et al., 
2011; Fernandez-Salguero et al., 1995; Hernández-Ochoa et al., 2009; Ma and Whitlock, 1996; 
Mimura et al., 1997; Moennikes et al., 2004; Puga et al., 2009; Schmidt et al., 1996).  
 
The mechanism for transcriptional activation by the AhR is demonstrated schematically in figure 1.  
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Figure 1: Transcriptional activation by the AhR, schematically demonstrated (according to Denison et al., 2011; 
Kawajiri and Fujii-Kuriyama, 2007). 
 
The AhR is a ligand-activated basic-loop-helix (bHLH)/Periodic (PER)-aryl hydrocarbon receptor 
nuclear translocator (ARNT)-single minded (SIM) (PAS) transcription factor. In a latent state, the 
AhR is associated with a 90-kDa heat shock protein (HSP90) dimer, the AhR interacting protein 
(AIP; also: immunophilin-like hepatitis B virus X-associated protein 2 (XAP2), or Ah receptor-
associated protein (ARA9)), and the co-chaperone phosphoprotein p23 in cytoplasm (Carver and 
Bradfield, 1997; Carver et al., 1998; Kazlauskas et al., 1999; Ma and Whitlock, 1997; Meyer et al., 
1998; Nair et al., 1996; Perdew, 1988). The potentially inducing compound diffuses across the 
plasma membrane and ligates the AhR. Upon ligand-binding, the AhR is presumed to undergo a 
conformational change, which exposes its N-terminal nuclear localization sequence (NLS) and 
leads to translocation of the complex into the nucleus (Ikuta et al., 1998; Ikuta et al., 2000). In the 
nucleus, chaperone proteins are displaced by ARNT, and the resulting ligand-AhR/ARNT-complex 
is generated. Following recruitment of coactivators like steroid receptor coactivator 1 (SCR-1), 
nuclear coactivator 2, SRC-2 (NcoA2), p300/CBP cointagrator protein, SRC-3 (p/CIP), and 
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receptor-interacting protein 140 (RIP 140), engenders the transcriptional activator complex 
(reviewed in Hankinson, 2005). The AhR/ARNT-complex specifically recognizes nucleotide 
sequences referred to as xenobiotic-responsive elements (XREs; also: dioxin-responsive elements 
(DREs)), which contain the core sequence 5’-TNGCGTG-3’ (Bacsi et al., 1995; Denison et al., 
1988; Shen and Whitlock, 1992). The transcriptional activator complex binds to and activates 
transcription from XRE-containing promoters, for which the gene encoding cytochrome P450 1A1 
(CYP1A1) represents one of the best characterized. Expression of CYP1A1 is regulated through at 
least three kinds of regulatory DNA elements: the TATA box sequence, XREs, and the basic 
transcription element (BTE), a GC box sequence located in the gene’s proximal promoter 
(Kobayashi et al., 1996; Yanagida et al., 1990; AhR activation reviewed in Denison et al., 2002; 
Denison et al., 2011; Fujii-Kuriyama and Kawajiri, 2010; Hankinson, 1995). 
 
Upon AhR-activation, a further bHLH-PAS protein termed AhR repressor (AhRR) represses AhR’s 
transcription activity by competing with AhR for heterodimer formation with ARNT and preventing 
the AhR/ARNT-complex from binding XREs. Enhanced SUMOylation of both ARNT and AhRR, 
as well as recruitment of the corepressor Ankyrin repeat family A protein 2 (ANKRA2), and histone 
deacetylases (HDACs) HDAC4, and/or HDAC5 results in formation of the transcriptional repressor 
complex. Since AhRR’s expression is induced by AhR-activation through binding to the XRE 
upstream of the AhRR gene, AhR function is regulated by feedback inhibition. Secondly, AhR 
signaling can be down-regulated by proteasomal degradation in cytoplasm (Baba et al., 2001; Ma 
and Baldwin, 2000; Mimura et al., 1999; Oshima et al., 2007; Oshima et al., 2009). 
 
Of peculiar interest is AhR’s function in organisms in absence of exogen ligands, and quite a few 
endogen AhR-agonists were figured out, as quoted above. An approach within this scientific section 
using AhR-/--mice indicated various implications of the AhR. In these animals, a range of 
physiological defects was displayed, including slower growth rates associated with decreased body 
weight, reduced liver size, immune system impairment, the appearance of a patent ductus venosus – 
a portocaval vascular shunt, which postnatally closes during the first 48 h in wild-type mice, portal 
tract fibrosis, and reduced fertility (Baba et al., 2005; Fernandez-Salguero et al., 1995; Lahvis et al., 
2000; Lahvis et al., 2005; Schmidt et al., 1996).  
 
The understanding of endogenous AhR-ligands together with obvious and considerable 
physiological alterations in AhR-/--mice substantially support relevance of research on role and 
impact of AhR-regulation with respect to physiological function(s). 
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1.1.3. Cytochrome P450 Isoenzymes 
 
Among yet predicted AhR-target gene products, such as UDP-glucuronosyltransferase 1a6 
(UGT1A6), Glutathion S-transferase (GST) Ya subunit, or NAD(P)H (quinone) dehydrogenase 1 
(NQO1), CYP1A-isoenzymes were excessively studied (Favreau and Pickett, 1991; Jaiswal, 1991; 
Owens, 1977; Rushmore and Pickett, 1990).  
Cytochromes P450 (CYPs) constitute a superfamily of heme enzymes. CYP enzymes, which 
possess at least 40% homology in their amino acid sequence, are classified in different families and 
are designated by Arabic numerals (CYP1, e.g.). The further division into subfamilies is delineated 
by ≥ 55% sequence homology in mammalians and is denoted by capital letters (CYP1A, e.g). 
Within subfamilies, proteins exhibiting more than 3% divergence are assigned individual CYP 
members (CYP1A1, e.g), unless (i) functional differences have been ascertained, or (ii) 
nontranslated regions are clearly divergent, indicating distinct genes (Nelson et al., 1993; Rendic 
and Di Carlo, 1997).  
 
The CYP family of isoenzymes represents an important class of phase I xenobiotic-metabolizing 
enzymes (‘monooxygenases’), which catalyze the introduction of functional groups to lipophilic 
compounds. In CYPs, the prosthetic group is constituted of an iron(III) protoporphyrin-IX 
covalently coupled to the protein by the sulfur atom of a proximal cysteine ligand. Characteristic 
reactions catalyzed by CYPs are hydroxylations of saturated carbon-hydrogen bonds, epoxidations 
of CC-double bonds, oxidations of heteroatoms, and oxidations of aromatics. The appropriate CYP 
enzyme uses molecular oxygen, inserts one oxygen atom into the substrate, and reduces the second 
oxygen to water, applying two electrons, which are provided by nicotinamide adenine dinucleotide 
(phosphate) (NAD(P)H) via cytochrome P450 reductase (Meunier et al., 2004). 
Transcripts of relevant AhR-responsive genes are the three members of the CYP1 gene family: 
CYP1A1, CYP1A2, and CYP1B1 (Nebert et al., 2000; Tsuchiya et al., 2003; Zhang et al., 1998). 
CYP1A1 is expressed in many mammalian tissues including lung, liver, brain gastrointestinal tract 
(GIT), lymphocytes, and heart, whereas CYP1A2 is mainly a hepatic enzyme. CYP1B1 was found 
in skin, brain, heart, lung, placenta, liver, kidney, GIT, and spleen (reviewed in Anzenbacher and 
Anzenbacherova, 2001). 
 
For CYP1A2 as well as for CYP1B1, AhR-independent mechanisms for transcriptional regulation 
were established. It was discussed that CYP1A2 might as well be regulated by constitutive 
androstane receptor (CAR), whereas CYP1B1 was demonstrated to be regulated via estrogen 
receptor (Lee et al., 2007; Tsuchiya et al., 2004). 
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So far, it is not proven, if CYP1A1-expression is exclusively regulated by the AhR. Sérée et al. 
(2004) reported evidence for a regulation pathway involving peroxisome proliferator-activated 
receptor α (PPARα), and two peroxisome proliferators response elements (PPREs) in an in vitro-
model (Sérée et al., 2004). However, the AhR was neither antagonized nor was its response 
silenced in the course of this study. Therefore, and in particular due to findings from Wang et al. 
(2011), who postulated an AhR-mediated route for Ppara-expression, a general AhR-involvement 
regarding CYP1A1-induction cannot be excluded (Wang et al., 2011). 
CYP-isoenzyme members of the subfamilies CYP2B and CYP3A, which are inducible by non 
dioxin-like (NDL-)PCBs, are regulated by CAR, and/or pregnane X receptor (PXR), both of which 
are discussed to be involved in diverging contribution (Gährs et al., 2013; Timsit and Negeshi, 
2007; Wei et al., 2002; Xie et al., 2000). 
 
1.2. Polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls   
 
Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs) are 
lipophilic, highly persistent compounds, which are inadvertently formed by-products in thermal 
processes such as waste incineration, residential combustion, metallurgical processes, and upon the 
chlorine bleaching of paper pulp (Swanson et al., 1988; UNECE, 2010). Furthermore relevant is the 
formation of PCDDs and PCDFs (figure 2) during the production of chlorophenols and 
chlorophenoxy herbicides (Fuhrmann, 2006; Homberger et al., 1979; Suskind, 1985).  
 
Seven of 75 (PCDDs), and ten of 135 (PCDFs) congeners are classified as dioxin-like (DL) due to 
their chlorine substitution pattern and associated AhR-mediated activities, which demand chlorine 
atoms at (lateral) positions 2,3,7, and 8 in respective molecules (Bandiera et al., 1984; Harris et al., 
1990; van den Berg et al., 1994).  
 
 
 
 
 
Figure 2: Chemical structures of PCDDs (TCDD, left), and PCDFs (TCDF, right), chlorinated at positions    
2,3,7, and 8. 
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A further class of compounds is considered in terms of DL-mode of action. Of 209 possible 
polychlorinated biphenyl (PCB)-congeners (figure 3), twelve appeared to reveal binding affinities 
towards the AhR and thus were termed ‘dioxin-like’ (DL) PCBs. Of them, four are non-ortho-
chlorinated, and eight are mono-ortho-substituted PCBs, with 3,3’,4,4’,5-pentaCB (PCB 126), 
correspondent to a WHO-TEF of 0.1, being the most potent congener (Bandiera et al., 1982; van 
den Berg et al., 2006).  
 
 
 
 
 
 
 
Figure 3: Chemical structures of a non-ortho (PCB 126, left), and a mono-ortho substituted PCB (PCB 118, right) 
 
In non-ortho-substituted PCB-congeners, the two phenyl rings are able to rotate more easily about 
the shared bond, leading to a higher probability to reach a planar conformation, which further yields 
in higher binding affinities towards the AhR (reviewed in De Voogt et al., 1990). In accordance, the 
remaining congeners, which do not share DL-mechanisms through binding to the AhR, are termed 
‘non dioxin-like’ (NDL)-PCBs, and are known to exert their biochemical and toxicological effects 
via other cellular factors, namely constitutive androstane receptor (CAR), and/or pregnane X 
receptor (PXR) (Al-Salman and Plant, 2012). For industrial purposes, complex mixtures of PCBs 
formerly were produced to be used as dielectric insulating fluids for transformators or capacitors. 
Beyond, PCBs were applied in paints, plastics, and hydraulic fluids, and were produced in 
dimensions of thounds of tons, e.g. under the trade name Aroclor® (Monsanto Corporation, St. 
Louis, Missouri, USA) (Breivik et al., 2002; IARC, 2012; Safe, 1994). 
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1.2.1. Risk estimation and the toxic equivalency factor (TEF)-concept 
 
Although the international community has called for actions to reduce the emission of DL-
chemicals employing two legally binding instruments, namely ‘The Protocol on the regional 
UNECE Convention on Long-Range Transboundary Air Pollution (CLRTAP) on persitent organic 
pollutants (POPs) (The 1998 Aarhus protocol on POPs)’, and ‘The Stockholm convention on 
POPs’, their occurrence in the environment is still of concern since these chemicals represent a class 
of higly persistent chemicals and remain in the environment for a long time (Denier van der Gon et 
al., 2007; Karlaganis et al., 2001; UNECE, 2010; UNEP, 1013).  
In 1997, the International Agency for Research on Cancer (IARC) classified TCDD as a group 1 
human carcinogen (IARC, 1997). By this time, there was only limited evidence for its 
carcinogenicity towards humans, which was reinforced in the course of IARC’s reevalution in 2012. 
The most important studies for the evaluation of TCDD’s carcinogenicity in 1997 were four cohort 
studies, one each in the United States (Fingerhut et al., 1991), the Netherlands (Hooiveld et al., 
1996), and two in Germany (Becher et al., 1996; Ott and Zober, 1996), and further one cohort of 
residents living in the in 1976 contaminated area from Seveso, Italy (Bertazzi et al., 1993; Bertazzi 
et al., 1996). Contribution of novel epidemiological data regarding these cohort studies (Bertazzi et 
al., 2001; Boers et al., 2010; Pesatori et al., 2009; Steenland et al., 1999; Steenland et al., 2001), the 
IARC again proposed sufficient evidence for the carcinogenicity of TCDD towards humans (group 
1) in 2012 (IARC, 2012). Strongest evidence in this regard was for all cancers combined. A positive 
correlation was as well observed between TCDD-exposure and soft-tissue sarcoma, non-Hodgkin 
lymphoma, and lung cancer (IARC, 2012). According to the IARC Working Group, TCDD was 
supposed to be a human carcinogen with tumor-promoting properties which operates through 
modifications of cell replication and apoptosis, associating secondary mechanisms involving 
increased oxidative stress and accompanied DNA damage (IARC, 2012). 
 
Along with respective IARC reevaluation in 2012, 4-PeCDF, and PCB 126 were as well categorized 
as group 1 human carcinogens. This classification was based upon evidence of carcinogenicity in 
laboratory animals as well as upon exhibiting activity identical to TCDD for each step of TCDD’s 
proposed mechanism for carcinogenesis including binding to the AhR, changes of protein-activity, 
cellular replication, and oxidant/antioxidant imbalance (IARC, 2012).  
According to the IARC evaluation in 1997, PCDDs and PCDFs except for TCDD and 4-PeCDF 
were not classifiable as to their carcinogenicity to humans (Group 3; IARC, 1997). Referred to the 
currently valid evaluation from 1987 (IARC 1987), PCBs except for PCB 126 were classified as 
probably carcinogenic agents to humans (Group 2A). Suggested evidence for increased hepatobiliar 
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cancer risk associated with PCB-exposure was considered to be limited due to insufficient data 
including lack of dose-response relationship evaluations, and the enabled exclusion of other 
compounds’ potential roles (IARC, 1987; Robertson and Ruder, 2009). In IARC’s Monograph 
Volume 107, which currently is in preparation, PCBs are supposed to be upgraded to Group 1 based 
on strong supporting evidence from other relevant data (IARC-List of classifications 2014; Lauby-
Secretan et al., 2013).  
 
Based on lowest observed adverse effect levels (LOAELs) for the most sensitive responses in 
animal studies, namely hormonal, reproductive, and developmental effects, which were associated 
with budy burdens from which a range of estimated long-term human intakes of 14-37 pg TCDD/kg 
bw/day was calculated, a tolerable daily intake (TDI) range of 1-4 pg TEQs/kg bw was established. 
For TCDD, a half-life of 7.5 yrs was assumed (Van Leeuwen et al., 2000; WHO, 2000). In 2001, 
the Scientific Committee on Food (SCF) revised the previous established temporary tolerable 
weekly intake (t-TWI) from 2000 of 7 pg TEQ/kg bw/week (SCF, 2000), and decided on a TWI of 
14 pg TEQ/kg bw/week (SCF, 2001). A further provisional tolerable monthly intake (PTMI) of 70 
pg TEQ/kg bw/month was established by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA) in 2001 (JECFA, 2001).  
 
During a World Health Organization (WHO)-International Programme on Chemical Safety expert 
meeting in 2005, the toxic equivalency factors (TEFs) for DL-compounds, which were valid since 
1998, were reevaluated (Van den Berg et al., 2006). For inclusion of a certain compound in the TEF 
concept, a compound had to (a) show a structural relationship to the PCDDs and PCDFs, (b) bind to 
the AhR, (c) elicit AhR-mediated biochemical and toxic responses, and to (d) be persistent and 
accumulate in the food chain (Ahlborg et al., 1994; Van den Berg et al., 1998; Van den Berg et al., 
2006). In the TEF concept, relative effect potencies (REPs) determined for individual congeners 
regarding their biological or toxic effect(s) relative to a reference compound, usually TCDD, were 
used. Due to their combination of both toxicokinetic and toxicodynamic aspects, in vivo studies 
were attributed to the highest priority and are preferably used for setting TEFs. In accordance with a 
generally accepted additivity in mixtures, the total toxic equivalent (TEQ) was defined by the sum 
of the products of the concentration of each compound multiplied by its TEF value and represents 
an estimate of total ‘TCDD-like’ activity of a mixture. In table 1 (following page), WHO-TEFs 
from 1998 are compared to those from 2005 (Van den Berg et al., 1998; Van den Berg et al., 2006). 
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Table 1: Dioxin-like PCDDs, PCDFs and PCBs compiled with their corresponding WHO-TEFs (1998; 2005). 
 
WHO-TEF (1998) 
Van den Berg et al., 1998 
WHO-TEF (2005) 
Van den Berg et al., 2006 
Chlorinated Dibenzo-p-dioxins   
TCDD 1 1 
1-PeCDD 1 1 
1,4-HxCDD 0.1 0.1 
1,6-HxCDD 0.1 0.1 
1,9-HxCDD 0.1 0.1 
1,4,6-HpCDD 0.01 0.01 
OCDD 0.0001 0.0003 
Chlorinated Dibenzofurans   
TCDF 0.1 0.1 
1-PeCDF 0.05 0.03 
4-PeCDF 0.5 0.3 
1,4-HxCDF 0.1 0.1 
1,6-HxCDF 0.1 0.1 
1,9-HxCDF 0.1 0.1 
4,6-HxCDF 0.1 0.1 
1,4,6-HpCDF 0.01 0.01 
1,4,9-HpCDF 0.01 0.01 
OCDF 0.0001 0.0003 
   Non-ortho-substituted PCBs   
   PCB 77 (3,3’,4,4’-tetraCB) 0.0001 0.0001 
PCB 81 (3,4,4’,5-tetraCB) 0.0001 0.0003 
PCB 126 (3,3’,4,4’,5-pentaCB) 0.1 0.1 
PCB 169 (3,3’,4,4’,5,5’-hexaCB) 0.01 0.03 
   Mono-ortho-substituted PCBs   
   PCB 105 (2,3,3’,4,4’-pentaCB) 0.0001 0.00003 
PCB 114 (2,3,4,4’,5-pentaCB) 0.0005 0.00003 
PCB 118 (2,3’,4,4’,5-pentaCB) 0.0001 0.00003 
PCB 123 (2’,3,4,4’,5-pentaCB) 0.0001 0.00003 
PCB 156 (2,3,3’,4,4’,5-hexaCB) 0.0005 0.00003 
PCB 157 (2,3,3’,4,4’,5’-hexaCB) 0.0005 0.00003 
PCB 167 (2,3’,4,4’,5,5’-hexaCB) 0.00001 0.00003 
PCB 189 (2,3,3’,4,4’,5,5’-heptaCB) 0.0001 0.00003 
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1.2.2. Intake and absorption of dioxin-like compounds 
 
Due to their high lipophilicity and low biodegradation rate, PCDDs, PCDFs, and PCBs ubiquitously 
occur in soil, sediments, and air. Besides occupational or accidental exposures, food represents the 
major source for DL-compounds towards humans. Approximately 90% of daily intake is derived 
from the diet, with foods of animal origin and fish being the predominat sources. The remaining 
dose for instance originates from inhalation, or dermal contact rates (Liem et al., 2000).  
 
Dietary intake (lower bound estimates) ranges from 0.57 pg TEQ/kg bw/day (France; Sirot et al., 
2012), over 0.7 pg TEQ/kg bw/day (Sweden; Törnkvist et al., 2011), and 0.8 pg TEQ/kg bw/day 
(The Netherlands; De Mul et al., 2008) to 1.8 pg TEQ/kg bw/day (Belgium; Windal et al., 2010, 
and Germany; BFR, 2010), and 2.86 pg TEQ/kg bw/day (Spain; Marin et al., 2011) for adults. As 
for the last-mentioned, some parts of the population still exceed the TWI and/or PTMI; e.g. higher 
consumers (69.4-73.6 pg TEQ/ kg bw/month in China (Zhang et al., 2013); 22.04 pg TEQ/kg 
bw/week in Germany (BFR, 2010)), or concerning upper bound estimates (15.96 pg TEQ/kg 
bw/week in Italy (Fattore et al., 2006); 16.89 pg TEQ/kg bw/week in Germany (BFR, 2010)). 
Anyhow, TEQ-exposure by dietary intake decreased over the past years of inquiries, whereby, in 
accordance with the prohibition of PCB-production, a larger decrease regarding DL-PCBs was 
reported compared to PCDD/PCDF-reductions (Baars et al., 2004; De Mul et al., 2008; Sirot et al., 
2012; Tard et al., 2007). DL-PCB-contribution to TEQ-exposure by food intake amounts to about 
50-80% of TEQ-exposure (BFR 2010; De Mul et al., 2008; Sirot et al., 2012; Windal et al., 2010).  
 
Rates of absorption in organisms, as well as tissue distribution and elimination of DL-compounds 
are mostly controlled by their lipophilicity. Predominating limiting factors for the absorption from 
the GIT appear to be solubility and molecular size (Van den Berg et al., 1994). Accordingly, 
congeners containing 4, 5, or 6 chlorine-substituents are reportedly well absorbed, whereas hepta-or 
octa-chlorinated compounds tend to be absorbed to a lesser extent (Abraham et al., 1994; Abraham 
et al., 1996; Moser and McLachlan, 2001).  
 
Uptake, which is proposed to occur primarily through passive diffusion in the GIT, is dependent on 
both the administered matrix and the respective compound concentration(s) (Budinsky et al., 2008; 
Kitamura et al., 2005; Schlummer et al., 1998). Furthermore, absorption rates are assumed to be 
dependent on present blood level(s) and budy burden (Harrad et al., 2003; Moser and McLachlan, 
2001; Schlummer et al., 1998). Information regarding DL-compounds and associated absorption, 
distribution, metabolism, and excretion (ADME) in humans is limited. In the course of a self-
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experiment, Poiger and Schlatter (1986) reported on an absorption of more than 87% after ingestion 
of a single dose (1.14 ng/kg bw) of [3H]TCDD administered in corn oil. Moser and McLachlan 
(2001) reported on a net absorption of around 80% of 2,3,7,8-tetra-, penta-, and hexachlorinated 
PCDDs and PCDFs, as well as PCBs including PCB 77, 105, 118, and 126, and the NDL-PCB 153, 
e.g., in five male volunteers who ingested toxic equivalents of less than 2% of their body burden by 
consumption of naturally contaminated eggs. Net absorption rates decreased in line with increasing 
number of chlorine-substituents accounting for ~70% regarding heptachlorinated PCDDs/PCDFs, 
and for ~50% relating octachlorinated congeners, respectively (Moser and McLachlan, 2001). 
Further data declared particularly high excretion levels – most notably regarding higher chlorinated 
compounds – partially exceeding uptake levels, which were correlated with elevated blood 
concentrations, and therefore indicated the possibility of facilitated TEQ-elimination due to 
diminished TEQ-intake (Rohde et al., 1999; Schlummer et al., 1998; Schrey et al., 1998). The 
authors concluded strong evidence that contaminant concentrations in blood lipids are the major 
factor of influence determining absorption (Schlummer et al., 1998).  
 
1.2.3. Tissue-distribution of dioxin-like compounds 
 
Liver and adipose tissue constitute the major compartments for the disposition of PCDDs, PCDFs, 
and PCBs (Carrier et al., 1995a+b; Gasiewicz et al., 1983; Piper et al., 1973; Van Ede et al., 
2013a). Thereby, hepatic sequestration of DL-congeners was reported to be distinct in rodent 
experimental animals (DeVito et al., 1998; Hakk et al., 2009; Van Ede et al., 2013b). Tissue 
distribution was observed to appear in a dose-dependent manner in both mouse (Dilberto et al., 
2001) and rat (Abraham et al., 1988), whereas at lower doses distribution to adipose tissue was 
greater than to liver, shifting to a greater distribution of congeners to liver compared to adipose 
tissue for higher doses.  
Within the framework of SYSTEQ-project, three days studies with female Sprague Dawley and 
female C57BL/6 mice were performed (Van Ede et al., 2013b). Dose-dependent hepatic 
sequestration of TCDD, 1-PeCDD, 4-PeCDF, or PCB 126 was observed subsequent to oral 
administration of single doses for both species. The investigations with rats revealed highest 
liver/adipose concentration ratios between 4.7 and 58 for 4-PeCDF within the range of applied 
doses of 5 to 1000 µg/kg bw. No significant hepatic sequestration was observed for mono-ortho 
PCBs 118 or 156, or NDL-PCB 153 at doses ranging from 5 to 500 mg/kg bw (Van Ede et al., 
2013b). Chen et al. (2001) observed comparable findings. The authors additionally did not 
determine hepatic sequestration for non-ortho substituted PCB 77, and TCDF, which were orally 
administered as components of a mixture containing seven further DL-compounds, in female Long-
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Evans rats in single doses of 0.67-13.3 µg/kg bw (PCB 77), and 6.10-128 ng/kg bw (TCDF), as 
parts of total doses of 0.05-1.0 µg TEQ/kg bw (Chen et al., 2001).  
Following subchronic treatment (five days/week for 13 weeks), dose-dependent increases in the 
liver/fat concentration ratios were found for several DL-compounds including TCDD, 4-PeCDF, 
TCDF, OCDF, and PCB 126 in female B6C3F1 mice (DeVito et al., 1998). Excepting PCB 126, no 
hepatic sequestration was obtained for further DL-PCBs (mono-ortho substituted PCBs 105, 118, 
and 156) investigated in the course of this study. While non-ortho PCB 169 as well retained in 
adipose tissue to a greater extent than in animals’ livers, the liver/fat concentration ratios in contrast 
appeared to increase with doses of up to 3.9 mg/kg bw/day (DeVito et al., 1998). 
 
Regarding humans, the issue of potential hepatic sequestration of DL-compounds is yet not fully 
understood due to limited data. The topic was recently reviewed by van Ede and co-workers (Van 
Ede et al., 2013b). On grounds of evaluated liver/adipose concentration ratios of DL-compounds 
based on autopsy samples from the general population (Iida et al., 1999; Schecter et al., 1991; 
Thoma et al., 1990; Watanabe et al., 2013; Weistrand and Norén, 1998), the authors concluded little 
or no hepatic sequestration in humans at environmental exposure levels (Van Ede et al., 2013b). 
 
As indicated by means of animal experiments including studies on CYP1A2 k/o-mice, hepatic 
sequestration is believed to mainly be attributable to CYP1A2 and binding affinities of respective 
compound to this inducible hepatic protein (DeVito et al., 1998; Dilberto et al., 1997; Hakk et al., 
2009; Santostefano et al., 1996). In consistence, higher CYP1A2-induction owing to impact by high 
affinity congeners results in greater extent of hepatic sequestration of respective chemical (Chen et 
al., 2001; Dilberto et al., 1999). Both dose-dependency and interspecies differences referred to 
hepatic sequestration might as well - at least in parts - be attributable to higher senstitivity and 
inducibility of CYP1A2 in rodent hepatocytes compared to human cells (Budinsky et al., 2010; 
Schrenk et al., 1995; Silkworth et al., 2005; Xu et al., 2000; Zeiger et al., 2001). In consequence, 
further need for clarification exists regarding degree of availability of chemicals linked to hepatic 
CYP1A2 for AhR-interaction and resulting extent of biological and toxic responses (Dilberto et al., 
1999; Van Ede et al., 2013b). Subsequent to hepatic retention of respective congeners, 
redistribution into adipose tissue with time was proposed to impact the accessibility for metabolic 
degradation and elimination, which was discussed in the context of observations regarding CYP1A2 
and its role as inducible binding protein (Dilberto et al., 1995; Wang et al., 1997). 
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1.2.4. Metabolism, elimination and half-lives of dioxin-like compounds 
 
Fecal excretion represents major elimination pathway for DL-compounds in mammals (Gasiewicz 
et al., 1983; Lutz et al., 1984; Piper et al., 1973; Poiger and Schlatter, 1986; Rohde et al., 1999). 
Interestingly, cutaneous elimination is as well reported (Geusau et al., 2001). Data on two severely 
intoxicated women (initial TCDD-concentrations of 144,000 pg/g blood fat, and 26,000 pg/g blood 
fat, respectively) from unknown source excreted 1-2% of the overall daily TCDD elimination rate 
via skin (Geusau et al., 2001). 
Apparent half-lives vary from few weeks for rodents up to several years in humans (Gasiewicz et 
al., 1983; Piper et al., 1973; Poiger and Schlatter, 1986). As mentioned above, for estimation of a 
TDI range of 1-4 pg TEQs/kg bw, a half-life of 7.5 yrs for TCDD was assumed (Van Leeuwen et 
al., 2000; WHO, 2000). As a matter of fact, experimental data actually indicated a dose-dependency 
for TCDD’s half-life in organisms (Aylward et al., 2005; Emond et al., 2006). By means of a 
concentration-dependent toxicokinetic model, Aylward et al. (2005) proposed half-lives for TCDD 
ranging from less than three years at serum lipid levels above 10,000 ppt to more than ten years at 
serum lipid levels below 50 ppt (Aylward et al., 2005). Calculations on elimination kinetics for 
PCBs in humans were accomplished by Ogura in 2004 and outlined by Milbrath et al. (2009). 
Estimated half-lives ranged from 0.1 year for PCB 77, over 2.7 yrs for PCB 126, to 5.35 yrs for 
PCB 156, and 10.4 yrs for PCB 169 (Milbrath et al., 2009; Ogura, 2004). 
 
Although there is general consensus that metabolism appears to be limited as well as slow, several 
worthwile findings have been reported regarding metabolic modifications of DL-compounds.  
As part of the self-experiment reported by Poiger and Schlatter, half-life for [3H]TCDD accounted 
for 5.8 yrs after administration of a dose of 1.14 ng/kg bw (Poiger and Schlatter, 1986). Exhibiting 
levels of 108,000 pg TCDD/g lipid weight in blood serum about four months subsequent to 
poisoning in Victor Yushchenko, a half-life of 15.4 months was calculated following three years of 
monitoring of the patient’s TCDD levels in blood serum and subcutaneous fat (Sorg et al., 2009). In 
the course of this study, the authors analyzed samples from blood serum, adipose tissue, faeces, 
skin, urine, and sweat using gas chromatography and high-resolution mass spectrometry, and 
detected two metabolites - 2,3,7-trichloro-8-hydroxydibenzo-p-dioxin (OH-TrCDD), and 1,3,7,8-
tetrachloro-2-hydroxydibenzo-p-dioxin (OH-TCDD) - in faeces, blood serum, and urine, with 
faeces being the main route of elimination. These metabolites accounted for 38% of total TCDD 
eliminated. Furthermore, the authors confirmed previous findings with regards to correlative serum 
lipid-, and adipose tissue-concentrations of TCDD. An equibrilium between these two 
compartments was already declared in 1988 along with a study by Patterson et al. with 50 
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participants from Missouri (Patterson et al., 1988). Upon aforementioned self-experiment reported 
by Poiger and Schlatter (1986), a minimum, although not farther specified, metabolism of 50% of 
radiolabeled TCDD was observed (Wendling et al., 1990). 
 
As investigated by means of animal studies, metabolic transformation of PCDDs and PCDFs 
includes oxidation and hydrolytic or reductive dechlorination (Poiger et al., 1982; Poiger et al., 
1989). In the bile of a dog, who converts the chemical at a higher rate compared to rats, six 
metabolites were found after administration of a lethal dose of [3H]TCDD with 1,3,7,8-tetrachloro-
2-hydroxydibenzo-p-dioxin (OH-TCDD) representing the major metabolite (Poiger et al., 1982). 
Rearrangement of a chlorine substituent from a lateral to a peri-position, which is established for 
aromatic compounds as an NIH-shift, indicates metabolic transformation via an arene oxide. 
Additionally, two dihydroxy-TrCDDs, one of them as well being a major compound, were found. 
Further relevant metabolic pathway represents oxygen bridge cleavage, yielding a tetrachloro-
dihydroxy-diphenylether. Continuation of this pathway could explain the appearance of 1,2-
dichloro-4,5-dihydroxybenzene identified in the course of this study. Furthermore, 2,7,8-trichloro-
3-hydroxydibenzo-p-dioxin was detected as a metabolite in dog’s bile (Poiger et al., 1982). 
Hydroxylated PCDDs and ring-cleaved metabolites were as well identified from biles of rats, which 
were, in comparison to the dog, present as phase II-conjugates (Poiger and Buser, 1984). In contrast 
to absent sulfates, glucuronide-conjugates were found in biles of [14C]TCDD-treated rats, which 
was as well determined in in vitro studies using primary rat hepatocytes (Ramsey et al., 1982; 
Wroblewski and Olson, 1985).  
 
Although for most cases the precise attribution to the responsible enzyme triggering degradation of 
DL-compounds remains unresolved issue, CYP1A1 was established to mediate metabolism of 
TCDF in rat and human hepatocytes (Tai et al., 1990). Burka et al. (1991) identified 4-hydroxy-
2,3,7,8-TCDF and 3-hydroxy-2,3,8-TrCDF as biliary metabolites in the rat. Observation of trace 
amounts of 2,2’-dihydroxy-4,4’,5,5’-tetrachlorobiphenyl supported evidence that oxygen bridge 
cleavage is only of minor relevance for PCDFs (Burka et al., 1991). This hypothesis was confirmed 
by Kuroki et al. (1990) subsequent to administration of a mixture of 1,2,7,8-TCDF, 2,3,7,8-TCDF, 
and 1,2,3,7,8-PeCDF to rat (Kuroki et al., 1990). In contrast, for 4-PeCDF, ether-bond cleavage was 
obtained to be an important mechanism for degradation in rat livers. Major metabolites were 
hydroxy-, and dihydroxy-pentachlorobiphenyl in this regard (Poiger et al., 1989). Furthermore, 
hexa- and hepta-CDFs examined in the same study were poorly metabolized, if at all. Apart from 
one hydroxy-PeCDF formed from 1,6-HxCDF, no metabolites were detected for 1,4,6-HpCDF 
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(Poiger et al., 1989). In concordance with enhanced steric shielding by bulky substituents, no 
metabolites were found for OCDD or OCDF in in vivo experiments with rats (Tulp and Hutzinger, 
1978; Veerkamp et al., 1981).  
Hakk and Dilberto found hydroxylated metabolites in feces of [14C]TCDD-, and 1-[14C]PeCDD-
treated mice. They further investigated glucuronide ether-, and sulfate ester-conjugates in the urine 
of single-dose treated animals (Hakk and Dilberto, 2002; Hakk and Dilberto, 2003). Regarding 
PCBs, hydroxylated and methyl sulfone derivates emerged to represent the most important 
metabolites to be retained in biota (Letcher et al., 2000).  
 
1.3. Toxicological relevance of TCDD 
 
Among DL-compounds, TCDD still represents the most extensively studied congener regarding its 
toxicological relevance. Biological and toxic responses attributed to TCDD and presumably other 
DL-compounds, of which most, if not all, are believed to be mediated through the AhR, include 
dermal, hepatotoxic, endocrine, immunological, reproductive, developmental, and carcinogenic 
effects (ATSDR 2012; Van den Berg et al., 1994).  
 
After the industrial accident in the Seveso, Italy, area in 1976, upon which a large residential 
population was exposed to substantial amounts of TCDD, chloracne was the earliest effect 
established with definite exposure dependence (Bertazzi et al., 1998; Caramaschi et al., 1981). 
Characterized by hyperkeratinization of the stratum corneum and disappearance of sebaceous gland 
follicles in the formation of keratin cysts, chloracne is the most commonly reported effect 
attributable to TCDD-exposure in humans (Suskind, 1985). In the heaviest contaminated zone of 
the Seveso area, lipid-adjusted serum concentrations in samples of children from 1976 suffering 
chloracne ranged from 1,688 to 56,000 ppt TCDD, and from 54 to 8,750 ppt TCDD for those 
without chloracne. Notably, TCDD concentration ranges of these two groups overlap, which 
elucidates that the absence of chloracne subsequent to exposure does not necessarily imply low 
serum TCDD levels (Needham et al., 1997/98).  
 
Subsequent to poisoning of Victor Yushchenko, 108,000 ppt TCDD was measured in the 
politician’s blood lipids (Sorg et al., 2009). In his face, severe edemas appeared two weeks after 
poisoning, followed by development of cystic lesions termed harmatomas, which became 
widespread over the entire body with a peak clinical manifestation at month eleven. Thereafter, 
symptoms declined gradually but generation of novel hamartomatous lesions progressed until 
month 28 after the poisoning (Saurat et al., 2012).  
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Though comprehensive adjustment for confounding factors is sensitive topic, several 
epidemiological studies are available with respect to proposed adverse health effects in cohorts 
occupationally or accidentially exposed to TCDD including hepatic, cardiovascular, neurological, 
reproductive, and developmental effects (Baccarelli et al., 2008; Heilier et al., 2005; Neuberger et 
al., 1999; Pelclová et al., 2007; Steenland et al., 1999; Thömke et al., 1999). The role of TCDD as 
endocrine disruptor is as well of relevant concern, with potential alterations in glucose metabolism 
and thyroid function as important issues (Baccarelli et al., 2008; Kang et al., 2006; Pesatori et al., 
2009; Trnovec et al., 2013). 
 
Findings regarding thyroid function were discussed with respect to a population living in an 
organochlorine-polluted area in eastern Slovakia (Trnovec et al., 2013). Trnovec and co-workers’ 
purpose was to determine relative effect potencies (REPs) for systemic DL-concentrations in 
humans using thyroid volume and serum free thyroxine (FT4), observing regression coefficient-
derived REPs correlating with the WHO-TEF-values for both endpoints (Trnovec et al., 2013). 
These observations were investigated in the course of the EU-project ‘PCBRISK’ (EU Grant No. 
QLK4-CT-2000-00488), in which the main objective was the evaluation of human health risks of 
low-dose and long-term exposure to a group of POPs, including PCDDs, PCDFs, as well as PCBs 
and their metabolites (Trnovec et al., 2004). As part of the PCBRISK-project, further evidence was 
observed regarding antiestrogenic effects correlated with high exposure to DL-chemicals (Machala 
et al., 2004; Plíšková et al., 2005). Besides a significant suppression of human placental aromatase 
(CYP19) activity found in placental samples, a decrease of 17β-estradiol (E2)-blood levels in male 
serum was observed, which, however, appeared to be not statistically significant (Machala et al., 
2004; Plíšková et al., 2005). Induction of appropriate enzymes metabolically inactivating E2, 
namely CYP1A1, CYP1A2, CYP1B1, and CYP3A4, was discussed as presumable mechanism 
responsible for antiestrogenic effects (Plíšková et al., 2005). 
 
Furthermore, exposure to DL-compounds was discussed relating to increased risk of endometriosis 
(Eskenazi et al., 2002; Heilier et al., 2005). According to the authors, their results regarding 
increased risks correlating with an increment of 10 pg total TEQ-levels/g lipids accounting for 
endometriotic nodules (odds ratio (OR) = 3.3; 95% confidence interval (CI): 1.4-7.6), and for 
peritoneal endometriosis (OR = 1.9; 95% CI: 0.9-3.8), provided the first statistically significant 
evidence of an association between increased total TEQ-body burden and endometriosis (Heilier et 
al., 2005).  
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A respectable volume of data concerned with TCDD’s impact on the organism comprises a broad 
spectrum of biochemical and toxic effects in experimentally treated animals. Implied consequences 
correlated with TCDD-exposure, which are of substantial concern, range from tissue weight 
changes – in particular, increased liver weight, and decreased thymus weight, decreased body 
weight (‘wasting syndrome’), through to teratogenic and carcinogenic effects (DeCaprio et al., 
1986; Kociba et al., 1976; Kociba et al., 1978; NTP, 1982; Seefeld et al., 1984; Smith et al., 1976; 
Sparschu et al., 1971).  
 
Predicted hypotheses regarding TCDD-mediated carcinogenicity and its tumor-promoting 
properties include AhR-dependent impact on gene expression of networks of genes, which are 
involved in cell growth, differentiation, or senescence, induction of CYP-catalyzed activation 
pathways and potentially implied DNA-damages, as well as expansion of preneoplastic lesions by 
inhibition of apoptosis, positive modulation of extra- or intracellular growth-stimuli, or disruption 
of immune control and function (Dragan and Schrenk, 2000; IARC,1997; Ray and Swanson, 2009; 
Safe, 2001). Biochemical effects mediated by TCDD and selected structurally related compounds 
are basically classifiable as either altered metabolism due to enzyme induction, altered homeostasis 
as a result from changes in hormones and their receptors, or altered growth and differentiation as a 
result from changes in growth factors and their receptors. Further, these effects appear to be 
species-, as well as tissue-specific, and mechanisms are often not (fully) understood (Birnbaum, 
1994). 
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1.4. Proposed AhR-dependent immunological effects 
 
1.4.1. Epidemiological investigations 
 
Inquiries into TCDD’s impact on the immune system on the basis of epidemiological data bear not 
only various, but also controversial and even opposing findings throughout available literature.  
 
About 20 years after the Seveso incident, Baccarelli et al. (2002) investigated potential TCDD-
induced immunologic effects in 62 randomly selected subjects from the highest exposed zones in 
comparison to 59 individuals from the surrounding non-contaminated area. Dependent on lipid-
adjusted TCDD-plasma-concentrations, median plasma immunoglobulin G (IgG)-concentration 
decreased from 1,526 mg/dL in the group with lowest (< 3.5 ppt) TCDD-levels to 1,163 mg/dL in 
the group with highest TCDD-levels (20.1-89.9 ppt). Results were statistically significant               
(p = 0.0004) even after adjustment of several confounding factors (Baccarelli et al., 2002).  
 
In a further examination by Landi et al. (2003), gene expression analysis in peripheral blood 
mononuclear cells (PBMCs) obtained from TCDD-exposed Seveso residents was accomplished. 
Mean AHR-expression was statistically significantly (p < 0.05) higher (14.5*100,000 copies/µg) in 
PBMCs from individuals with lower plasma TCDD-levels (1.0-7.9 ppt) compared to those with 
higher plasma TCDD-levels (8.0-89.9 ppt; mean AHR-expression: 9.1*100,000 copies/µg) in 
uncultered, as well as in mitogen-stimulated cells (mean AHR-expression lower TCDD-levels: 
39.0*100,000 copies/µg; mean AHR-expression higher TCDD-levels: 30.9*100,000 copies/µg;       
p < 0.05). In mitogen-stimulated PBMCs, mean CYP1A1-expression was slightly, but statistically 
significantly (p < 0.05) higher (6.9*100,000 copies/µg) in cells from subjects from the highest 
exposed zones compared to CYP1A1-expression in cells from persons from the non-contaminated 
area (5.0*100,000 copies/µg).  
 
In contrast, lack of an association with AhR-dependent gene expression was observed for plasma 
(TEQ)-levels in in vitro mitogen-stimulated PBMCs from subjects, which were treated with TCDD 
(10 nM; 72 h). Plasma TCDD-levels further were negatively correlated with EROD-activity in those 
cells. These conflicting results led to the suggestion that long-term exposure to TCDD might 
perturb AhR-pathway regulation (Landi et al., 2003). 
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The most notable result regarding mortality studies and the Seveso incident was an excess of 
lymphatic and hematopoietic neoplasms with increasing risk with time (Consonni et al., 2008). In 
the most recent evaluation reflecting 25 years of follow-up, a relative risk (RR) of 2.23 (95% CI: 
1.00-4.97) for people living in the most polluted zone was established. Highest risks were obtained 
for non-Hodgkin’s lymphomas (RR = 3.35; 95% CI: 1.07-10.46) (Consonni et al., 2008). Enhanced 
risks of developing non-Hodgkin’s lymphomas were also reported for other TCDD-exposed cohorts 
(Floret et al., 2003; Kogevinas et al., 1997). 
 
The thymus is an early established target organ for TCDD’s AhR-dependent impact in experimental 
animals (Fernandez-Salguero et al., 1996; Kociba et al., 1976). In several studies, the thymus was 
in fact described to represent the most sensitive target organ as indicated by its perceptably reduced 
weight in response to TCDD-treatment (Harris et al., 1973; Kociba et al., 1976).  
 
1.4.2. Proposed role(s) of the AhR in immune cells and AhR-ligands’ impact 
 
Whereas epidemiological investigations on cellular level of immune response either reveal 
inconsistent, marginal or insignificant findings regarding exposure to TCDD, the in vitro and 
especially the in vivo research using provides clearer evidence in this regard, which approaches to 
verify mechanism(s) potentially mediated by TCDD – or even by AhR in particular. 
 
In organisms, epithelial or endothelial barriers provide the first line of defense against external 
pathogens. Within respective organs such as skin, lung, or gut, AhR is expressed in appropriate 
localized cells, as reported for keratinocytes, melanocytes, fibroblasts, Langerhans cells, or 
specialized intraepithelial lymphocytes (IELs), e.g. (Di Meglio et al., 2014; Jux et al., 2009; Luecke 
et al., 2010; Li et al., 2011; Martey et al., 2005; Potapovich et al., 2011).  
There, the AhR is believed to be involved in cell differentiation processes and cell cycle regulation, 
hence potentially affecting the formation of respective barrier. Dependent on the ligand’s properties 
and presence of AhR, the receptor is proposed to either promote cell cycle progression (endogen 
ligand/ transient activation), or to lead to growth arrest (exogen ligand/ sustained activation, or AhR 
absence) (Kalmes et al., 2011; Mitchell and Elferink, 2008). 
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1.4.2.1. Innate immune cells 
 
Among cells composing the innate immune system, macrophages, dendritic cells (DCs), human 
NK-22 cells, and murine lymphoid tissue inducer (LTi)-like cells were reported to express the AhR 
(Cella et al., 2009; Colonna, 2009; Frericks et al., 2007; Kimura et al., 2009).  
DCs and macrophages are antigen presenting cells linking innate immune response with adaptive 
immunity (reviewed in Moser and Leo, 2010). Macrophages and DCs promote T cell responses and 
express receptors, such as members of the Toll-like receptor (TLR) family, through which they are 
able to recognize pathogen-associated molecular patterns (PAMPs) or endogenous adjuvants and 
signals released by dying cells. To link innate to adaptive immune response, activated DCs and 
macrophages present high levels of particular major histocompatibility complex (MHC), molecules 
loaded with pathogen-derived peptides, express costimulatory molecules and secrete cytokines 
(Akira et al., 2001; Joffre et al., 2009).  
 
In figure 4, a schematically demonstrated excerpt of proposed involvement of the AhR and its 
ligands in immune signaling is presented. 
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Figure 4: Proposed complex network of AhR-ligands’ effects on immune signaling; schematically demonstrated 
excerpt. For detailed description, see text below. According to De Krey and Kerkvliet, 1995 [1]; Fujimaki et al., 
2002 [2]; Inouye et al., 2005 [3]; Jeong et al., 2012 [4]; Lee et al., 2007 [5]; Mezrich et al., 2010 [6], Negishi et al., 
2005 [7]; Nguyen et al., 2010 [8]; Prell et al., 2000 [9]; Quintana et al., 2008 [10]; Quintana et al., 2010 [11]; Ruby 
et al., 2004 [12]; Tucker et al., 1986 [13]; Veldhoen et al., 2008 [14]; Vogel et al., 2008 [15]; Vorderstrasse and 
Kerkvliet, 2001 [16]. FICZ*: Incubation of cells with FICZ under Th17-inducing conditions [10, 14]. 
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Dendritic cells and macrophages 
 
In mice, DCs were reported to be activated due to TCDD-exposure indicated by dose-, and AhR-
dependent elevated expression levels of ICAM-1, CD-24, B7-2, CD40 (Vorderstrasse and 
Kerkvliet, 2001). This activation was further accompanied by a significant decrease in numbers of 
splenic DCs in TCDD-treated wild-type mice, whereas TCDD-treatment in AhR-/--mice did not 
alter the quantity of DCs recovered from the spleen. These findings were discussed in the context of 
an early loss of DCs correlated with immune suppression by enhanced maturation and apoptosis of 
DCs due to exaggerated activation of DCs by TCDD (Ruby et al., 2004; Vorderstrasse and 
Kerkvliet, 2001). 
 
Studying the effect of in vivo TCDD-exposure in mice on DC-function ex vivo, DCs obtained from 
TCDD-treated mice mediated enhanced ability to activate T cells, which was demonstrated by 
augmented T cell-proliferation (Vorderstrasse and Kerkvliet, 2001). Similarly, enhanced tumor 
necrosis factor-α (TNF-α)-induced maturation of DCs impacted by TCDD was obtained in vitro in 
primary bone marrow-derived DCs (BMDCs) from C57BL/6 mice. These findings were indicated 
by increased expression-levels of MHCII, CD86, CD40, and CD54 on surfaces of cells (Ruby et al., 
2004). 
 
In vitro AhR-expression in BMDCs, splenic DCs, as well as peritoneal macrophages was 
demonstrated to be stimulated by the TLR-ligand LPS in cells obtained from mice (Kimura et al., 
2009; Nguyen et al., 2010). In macrophages from AhR-/--mice, mRNA-expression levels of 
interleukin (IL)-6 (Il6), TNF-α (Tnf), and IL-12 (Il12b) were significantly elevated by LPS in 
comparison to those in wild-type mice, which was furthermore accompanied by significantly altered 
kinetics for IL-6-, and TNF-α production, reflecting an enhanced LPS-induced proinflammatory 
cytokine production in AhR-/--mice. Thus, the AhR was discussed to be involved in the negative 
regulation of LPS-responses (Kimura et al., 2009). The authors demonstrated that the AhR 
negatively regulates the LPS signaling pathway by cooperating with signal transducer and activator 
of transcription 1 (STAT1) and nuclear factor-ĸB (NF-ĸB). In LPS-stimulated macrophages from 
wild-type mice, the AhR is able to form a complex with STAT1, which binds to NF-ĸB and as a 
result implicates the inhibition of the promoter activity of IL-6 (Kimura et al., 2009).  
It remains unresolved, which role (a) potentially present chemical(s) in the applied test system 
might play as (an) AhR-ligand(s). On the other hand, the AhR was reported to synergistically lead 
to induction of IL-6 expression in in vitro tumor cell systems, as its activation was coupled with 
inflammatory signals (DiNatale et al., 2010; Hollingshead et al., 2008). These findings were 
Theoretical Background 
 
  25 
observed, when the AhR was activated by its ligands TCDD or kynurenic acid, which was 
postulated to be an AhR-ligand just within respective study, and co-treated with IL-1β. According 
to the authors, these effects were ‘largely’ (but presumably not exclusively) dependent on the AhR 
(DiNatale et al., 2010; Hollingshead et al., 2008).  
 
Enhanced IL-6 expression is discussed along with the stimulation of tumor progression as well as 
an involvement in the pathophysiology of autoimmune diseases and chronic inflammatory 
proliverative diseases (Ishihara and Hirano, 2002; Pollard, 2004). Further, IL-6 was revealed to 
synergistically induce indoleamine 2,3-dioxygenase (IDO) expression in concert with other 
cytokines (Fujigaki et al., 2006). Thus, the activated AhR and accompanied IL-6 induction were 
suggested to play a role allowing tumor cells to escape immune surveillance and might be involved 
in molecular mechanisms related to immune mediated diseases (DiNatale et al., 2010). 
 
Indoleamine 2,3-dioxygenase (IDO) 
 
In BMDCs and splenic DCs from AhR-/--mice, IL-10 production, as well as the expression of IDO, 
was inhibited by LPS compared to respective expression in cells from wild-type mice (Nguyen et 
al., 2010). IL-10 production was also inhibited in LPS-stimulated peritoneal macrophages from 
AhR-/--mice compared to wild-type mice (Kimura et al., 2009). Since regulatory DCs, specialized 
subsets of DCs, function their T cell-activating ability by mediation of regulatory factors like IL-10 
and IDO, the authors speculated the AhR to play an anti-inflammatory role in BMDCs and splenic 
DCs (Nguyen et al., 2010). Investigations by means of AhR-/--models further revealed an AhR-
dependency of IDO-induction, which was determined in vitro in murine primary Langerhans cells 
and BMDCs, as well as in vivo in spleen and lung of mice (Jux et al., 2009; Vogel et al., 2008). 
 
IDO, which is induced in the presence of TLR-ligands or proinflammatory cytokines by either an 
interferon-γ (IFN-γ)-dependent pathway via STAT1-α and interferon regulatory factor (IRF)-1, or 
through an IFN-γ-independent mechanism involving p38 mitogen-activated protein kinase (MAPK) 
and NF-ĸB (Fujigaki et al., 2006; Taylor and Feng, 1991). The enzyme catalyzes the essential 
amino acid tryptophan (Trp) into kynurenine (Kyn), which represents, like the aforementioned 
kynurenic acid, another IDO-catabolite, which was quite recently identified to be an AhR-agonist 
(Opitz, et al., 2011; Taylor and Feng, 1991). 
 
IDO is often referred to as immunosuppressive enzyme and is discussed regarding its role in the 
regulation of naïve T cell-differentation. IDO-induced Trp-metabolites suppress T cell-response, 
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and IDO-induction in macrophages has been shown to lead to inhibition of T cell-proliferation 
(Bauer et al., 2004; Munn et al., 1999). DCs are able to directly and IDO-dependently activate 
(resting) mature regulatory T cells (Tregs) (Sharma et al., 2007). The enzyme both activates Tregs 
and blocks their conversion into Th17-like T cells (Baban et al., 2009). In reverse, when IDO is 
blocked, DCs were found to be stimulated to express IL-6, which represents a ’pro T helper 17 
(Th17) cell-stimulus’ (Baban et al., 2009; Jetten, 2009). In the fashion of a feedback loop, dendritic 
IDO expression was revealed to be synergistically inducible in combination with IL-6, TNF-α, or 
IL-1β (Fujigaki et al., 2006).  
 
Tryptophan-2,3-dioxygenase (TDO) 
 
Protein biosynthesis of tryptophan-2,3-dioxygenase (TDO), which degrades Trp to Kyn like IDO 
does, was also reported to be impacted by the AhR. Although usually predominantly expressed in 
the liver, Opitz et al. (2011) detected TDO in several human tumor tissues with increasing TDO 
protein levels corresponding to malignancy and to the proliferation index of respective tumor 
specimens. TDO-derived Kyn was correlated to lowered infiltration of immune cells in tumor tissue 
sections with elevated TDO-expression, and thus to suppression of antitumor immune responses. 
This was further demonstrated by a decreased release of IFN-γ by tumorspecific T cells and tumor 
cell lysis by spleen cells of mice afflicted with TDO-expressing tumors compared to mice bearing 
TDO-deficient tumors. The latter, as well as promoted tumor cell survival and motility, appeared in 
dependence of the AhR in an autocrine/paracrine fashion. The authors suggested that TDO-
expression might be a general trait of cancer and that the activation of Trp catabolism may represent 
an endogenous feedback loop to AhR-mediated restriction of inflammation (Opitz et al., 2011).  
 
Recently, studies by Bessede and co-workers discovered that an initial exposure of mice to LPS 
activated the AhR and TDO, providing Kyn as an activating ligand of the AhR. On LPS-
rechallenge, the AhR engaged in long-term regulation of inflammation, pointing a role for the AhR 
contributing to disease tolerance and correspondent ability of a host to reduce effects caused by 
infections on host fitness. Responses to primary LPS-challenge were mitigated by AhR and TDO-
dependent Trp catabolism, whereas endotoxin tolerance required combined effects of AhR, IDO, 
and TGF-β (Bessede et al., 2014).  
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1.4.2.2. Adaptive immune cells 
 
Among adaptive immune cells, the AhR was reported to be expressed (and to be partially inducible) 
in B cells, CD4+ helper T (Th) cells, and in CD8+ cytotoxic T lymphocytes (CTLs) (Green et al., 
2011; Kerkvliet et al., 2002; Sherr and Monti, 2013, Veldhoen et al., 2008). Differentiation of CD4+ 
T cells proceeds along transcription-factor-specific pathways including the T-box transcription 
factor T-bet and STAT4 for Th1 cells, GATA-binding protein 3 (GATA3) and STAT6 for Th2, 
retinoid related orphan receptor (ROR) γt and STAT3 for Th17, and forkhead box protein P 3 
(FoxP3) and STAT5 for Tregs (reviewed in Chen et al., 2011; Jetten, 2009; Kanhere et al., 2012).  
 
Th1 and Th2 cells 
 
Th1 and Th2 cells direct different immune response pathways, and either pathway is able to down-
regulate the other. Th1 cells (’cellular immunity’) secrete IFN-γ and activate inflammatory 
pathways mainly via macrophage activation and fight viruses and other intracellular pathogens, 
stimulate delayed-type hypersensitivity skin reactions, and eliminate cancerous cells. By contrast, 
Th2 cells (IgE-mediated ’humoral immunity’) proceed against extracellular organisms, and attribute 
to tolerance of xenografts and of the fetus during pregnancy, secreting cytokines IL-4 and IL-5, 
which upregulate antibody formation via B lymphocytes, eosinophils, mast cells, and other 
pathways (reviewed in Kidd, 2003). 
 
In several reports, AhR agonists, namely TCDD, β-naphthoflavone, M50354 (an active metabolite 
of M50367, an antiallergic agent), or 6-formylindolo[3,2-b]carbazole (FICZ) shifted Th1/Th2 
balance towards Th1 dominance in mouse experimental models in vitro and in vivo (Fujimaki et al., 
2002; Inouye et al., 2005; Jeong et al., 2012; Negishi et al., 2005). These AhR agonists suppressed 
GATA3-expression and STAT6-activation, and reduced production of IL-4 and IL-5 in naïve Th 
cells, overall leading to suppression of Th2 differentiation (Fujimaki et al., 2002; Inouye et al., 
2005; Jeong et al., 2012; Negishi et al., 2005). By use of AhR-deficient mice, Negishi et al. (2005) 
determined the modulating effects on Th1/Th2 balance to be AhR-dependent, even though AhR’s 
exact role in this regard remains largely unresolved. 
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B cells 
 
Reduced secretion of IgE, IgG1, and IgM, and accordant impaired humoral immune response are 
effects attributed to impact of AhR ligands (Fujimaki et al., 2002; Yoshida et al., 2012). Repressed 
IgM secretion in activated B cells by TCDD for instance, just as suppression of B cell 
differentiation by TCDD were found to appear AhR-dependently (Sulentic et al., 1998; Tucker et 
al., 1986).  
The reduction of Th2-derived IL-5 production, which apparently was thought to represent a 
considerably sensitive endpoint for detection of TCDD’s immunotoxicity, was proposed to 
mechanistically be due to impaired T cell function, suggesting that TCDD-induced suppression of T 
cell-derived cytokine production is involved in the impairment of antigen-specific antibody 
production (Inouye et al., 2005; Ito et al., 2002).  
Immune response from B lymphocytes therefore at least secondarily seems to be affected by the 
AhR or by AhR-ligands, respectively. Interestingly, AhR expression in B cells is inducible by LPS, 
or by the Th2-type cytokine IL-4 in vitro in murine and human cell systems (Marcus et al., 1998; 
Tanaka et al., 2005).  
 
Cytotoxic T cells (CTLs) 
 
Despite the shift of Th1/Th2 balance towards Th1 dominance, Th1-dependent CD8+ cytotoxic T 
cell (CTL)-mediated responses were found to be suppressed, and priming of naïve CTL-precursors 
was inhibited by TCDD in vivo (De Krey and Kerkvliet, 1995; Prell et al., 2000). Interestingly, 
expression of the AhR is required in both CD4+ and CD8+ T cells in this regard, and both cell 
subsets contribute to the full suppressive effect of TCDD (Kerkvliet et al., 2002). 
 
Differential results, which at least partially might be explainable by diverging study designs and 
endpoints, regarding excretion of IFN-γ were reported. Correspondent to facilitated Th1 
differentiation by TCDD, production of IFN-γ significantly increased in several studies (Fujimaki et 
al., 2002; Jeong et al., 2012; Negishi et al., 2005; Vorderstrasse and Kerkvliet, 2001), whereas 
agreeing with the further occurring suppression of CTLs by TCDD, IFN-γ levels were found to be 
significantly decreased in other investigations (Prell et al., 2000; Quintana et al., 2008). 
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Th17 cells and Tregs 
 
A considerable quantum of information is available regarding AhR’s influence on differentiation, 
development, and function of Th17 vs. Treg cells. Differentiation and function of Tregs and Th17 
cells are reciprocally controlled, as Th17 cells secrete the proinflammatory cytokines IL-17 and IL-
22 mediating exacerbation of inflammation and autoimmunity, whereas opposing Tregs produce 
TGF-β and IL-10 playing an indispensable role regarding immune tolerance and suppression of 
excessive immune responses (Hanieh, 2014; Sakaguchi et al., 2008).  
 
In the course of an experimental autoimmune encephalomyelitis (EAE), activation of the AhR by 
TCDD in vivo leads to enhanced production of TGF-β and reduced secretion of IL-17 in lymph 
node cells and to an increased frequency of Tregs in spleens of mice (Quintana et al., 2008). In vivo 
treatment with 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), an 
endogenous AhR ligand isolated from porcine lung in 2002, resulted in a higher frequency of Tregs 
and led to a lowered percentage of Th17 cells in murine splenocytes in an EAE model (Quintana et 
al., 2010; Song et al., 2002). Ex vivo, immunized lymph node cells secreted reduced amounts of IL-
17, whereas secretion of IL-10 and TGF-β was enhanced (Quintana et al., 2010). 
Nguyen et al. (2010) demonstrated that AhR-absence in BMDCs skewed naïve T-cell-
differentiation into Treg-cells (Foxp3+), facilitating Th17-cell development. In turn, addition of 
synthetic L-Kyn to the applied coculture system using BMDCs and naïve T cells from AhR-/--mice 
reversed the T-cell-differentiation to Tregs rather than Th17-cells (Nguyen et al., 2010).  
 
The AhR ligand FICZ, on the other hand, promotes Th17 cell differentiaton in vitro and in vivo 
(Quintana et al., 2008; Veldhoen et al., 2008). In murine CD4+ T cells cultured unter Th17 
conditions, the presence of FICZ (0-500 nM, 96 h) led to concentration-dependent up-regulation of 
IL-17 (Il17a, Il17f) and IL-22 (Il22) mRNA expression (Veldhoen et al., 2008). Besides its 
inhibitory effects on Treg cell differentiation, FICZ synergized with TGF-β1, IL-6, and IL-23 to 
drive Th17 cell differentiation and augmented the secretion of IL-17, IL-21, and IL-22 in vitro. In 
vivo, treatment with FICZ (1 µg/mouse) was associated with decreased frequency of CD4+Foxp3+ 
Treg cells, increased frequencies of CD4+IL-17+ T cells and CD4+IFN-γ+ T cells, and enhanced 
secretion of IL-17 and IFN-γ subsequent to in vitro stimulation (Quintana et al., 2008). Further, the 
absolute number of CD4+IL-17A+ and of CD4+IL-22+ cells in the spinal cord of immunized mice 
significantly elevated after treatment with FICZ (600 ng/mouse) on day 18 of an EAE-response 
compared to the control group. This effect was inverted in AhR-/--mice (Veldhoen et al., 2008). 
Since Th17 cells represent a driving force of pathogenesis for some autoimmune diseases, AhR 
activation potentially exacerbates Th17-mediated autoimmunity (Esser et al., 2009).  
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1.4.2.3. AhR and immune cells – critical view 
 
Based on available studies, it occasionally remains uncleared issue whether effects, e.g. shifts of 
cell (sub-)populations, are due to a primary ‘true induction’ of a cell type. Cell type specific 
inhibition of apoptosis by a ligand might simulate this outcome, or other cell types may be reduced 
by mechanisms like cell subset-specific cytotoxity or apoptosis. Impacted functionality of cells or 
cell counts and hence imbalanced cell subsets might emerge as a ‘feigned induction’ of a definite 
cell type (Prell et al., 2000; Ruby et al., 2004).  
 
Conclusively, the presence of the AhR itself and the receptor in collaboration with its endogenous 
or exogenous ligands is proposed to be interlocked in several sections of the complex network of 
immune reactions. To date, precise attribution of pathways impacted by the AhR and its ligands 
remains complex and involves inconsistency in a number of cases. The manner and course of effect 
directed in particular appears to be dependent on the occurrence and on the type of a ligand, and 
might also be contingent on the type of exposure and applied dose as well as the physiological or 
pathological condition of regarded organism.  
Of further relevance are inter-species differences as well as respective binding affinities of exogen 
vs. endogen ligands to the AhR. Although rodent AhR generally exhibits higher affinities towards 
exogen ligands than human AhR does, a reversed situation was found for several endogen ligands 
like kynurenic acid or indirubin (DiNatale et al., 2010; Flaveny et al., 2009; Ramadoss and Perdew, 
2004). Further on, widely used AhR-/--models on one hand are of relevant informative content but 
are still difficult to interpret, since estimation of impact of the receptor’s absence itself represents 
complex issue.  
 
Overall, AhR seems to play considerable but intricate role in immune response implying feasible 
divergence across species, ligand properties, dose and type of exposure.  
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1.4.3. Expression and induction of CYP1-isoenzymes in PBMCs 
 
As indicated in the previous chapter, expression of the Ah receptor was described in several blood 
cells like macrophages, DCs, T cells, and B cells, it is not all that surprising that several authors 
report on inducibility of CYP1-isoenzymes in immune cells (Frericks et al., 2007; Kerkvliet et al., 
2002; Kimura et al., 2009; Sherr and Monti, 2013).   
 
CYP1-induction in vivo – mouse  
 
In vivo experiments with rodents provide prelusive information in this regard. In immature CD4-
CD8--thymocytes and thymic emigrants from mice treated with TCDD (10 mg/kg bw; single i.p. 
dose) for seven days, Cyp1b1 was up-regulated (cut-off: ≥2fold change) in the course of a 
microarray gene expression analysis (Frericks et al., 2006). Cyp1b1 was also up-regulated in fetal 
thymic emigrants, for which fetal thymic lobes were taken from mouse embryos and cultivated for 
six days in the presence of 10 nM TCDD. Interestingly, Cyp1a1 was only up-regulated in fetal 
emigrants but not in adult immune cells, although the AhR – at least on mRNA-level – was 
markedly expressed in these cells. This was also the case subsequent to a short in vivo TCDD-
exposure of 24 h. As part of the latter investigation, Cyp1a1 and Ahrr were obtained to be up-
regulated in DCs from TCDD-treated mice (Frericks et al., 2006). In a further gene expression 
microarray experiment with mice using lower TCDD-concentrations (20 µg/kg bw, oral) and 
shorter treatment durations, Cyp1a1 was up-regulated (cutoff: ≥2 fold change) in CD4+-T cells (3 h 
or 24 h) and B cells (3 h) from spleens of in vivo exposed and Ovalbumin (OVA)-immunized mice 
(Nagai et al., 2005). In addition, mRNAs encoding TIPARP or AhRR appeared to be up-regulated 
in B cells (3 h, or 24 h), and in CD4+-T cells (24 h), respectively (Nagai et al., 2005).  
 
CYP1-induction in vivo – rat 
 
In PBMCs received in the course of studies with rats in vivo exposed to AhR ligands (3-
methylcholanthrene, or β-naphthoflavone), induction of EROD-activity in response to these ligands 
was obtained (Dey et al., 2001; Saurabh et al., 2010). Regarding WB analyses (CYP1A1, CYP1A2) 
and investigations examining mRNA-levels (Cyp1a1, Cyp1a2, and Cyp1b1) included in these trials, 
effects generally appeared to be slight, and respective AhR ligands were consistently less effective 
in PBMCs compared to their responses in livers of treated animals (up to seven times higher fold-
induction of EROD-activity). However, in a recent in vivo study with rats using doses of a PAH-
mixture accounting for 6 or 600 µg (of each of phenanthrene, pyrene, benzo[a]pyrene) per day for 
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28 days, the authors revealed dose- and time-dependent EROD inductions in PBMCs with maximal 
absolute values of around 90 or 200 pmol resorufin/min*mg protein, which was at least 
approaching comparable dimensions measured in liver samples (~440 or 970 resorufin/min*mg 
protein) (Chahin et al., 2013). 
 
CYP1-induction in vitro 
 
In concentration-dependent manner, CYP1A1 and CYP1B1 are also inducible by AhR-ligands in 
vitro in rodent PBMCs, which was investigated on both mRNA and protein level, while CYP1A2 
was not reported to be targeted (Lawrence et al., 1996; Mezrich et al., 2010; Nohara et al., 2006). In 
human PMBCs, CYP1A1 and CYP1B1 are constitutively expressed, whereas CYP1A2 expression 
appears to be detectable only sporadically and not in PBMCs from every investigated individual 
(Finnström et al., 2002; Krovat et al. 2000, Siest et al., 2008). On the basis of current information, 
CYP1A2 is also not inducible by AhR ligands in vitro in human blood cells.  
 
CYP1A1 – human blood cells 
 
In 1974, Kouri et al. already reported on concentration-dependent TCDD-inducible EROD (or 
CYP1A) activity in primary human PBMCs. At exposure duration of 24 h and TCDD-
concentrations ranging from 0.3 to 300 nM, they received a half maximal effective concentration 
(EC50) of 8 nM TCDD (Kouri et al., 1974). To date, a couple of articles on this subject are 
accessible, in which most of the experiments show great inter- and intra-individual variety and 
overall comparably low absolute induction values both on gene transcription and on protein level. 
Such results diverge considerably, as results from investigations using TCDD ranged from ~3fold 
(100 nM, 6 h) over ~20fold (10 nM, 72 h), and ~60fold (10 nM, 48 h) to ~160fold (10 nM, 48 h) 
CYP1A1-induction on mRNA-level in primary human PBMCs (Nohara et al., 2006; Vanden Heuvel 
et al., 1993; Van Ede et al., 2014b). In several studies, CYP1A1 mRNA- and EROD-induction by 
AhR ligands occurred concentration-dependently, implicating diverging EC50-values of ~800 pM 
(72 h) as well as the aforementioned value of 8 nM (24 h) for EROD-induction, and ~400 pM (48 h) 
and 1.4 nM TCDD (6 h), with respect to CYP1A1 mRNA-induction (Kouri et al., 1974; Nohara et 
al., 2006; Van Duursen et al., 2005; Van Ede et al., 2014b). 
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CYP1B1 – human blood cells 
 
CYP1B1 was as well reported to be up-regulated in response to TCDD. Respective maximum 
mRNA-levels achieved after TCDD-treatment varied from ~2-3fold (5 nM, 6 h; 5 nM, 72 h; or     
10 nM, 48 h), to around 5-8fold (1 nM, 48 h) induction in PBMCs (De Waard et al., 2008; Van 
Duursen et al., 2005; Van Ede et al., 2014b). Recently, van Ede et al. published data on 
concentration-dependent elevation of CYP1B1 mRNA in human PBMCs, implicating diverging 
effective concentration 20% (EC20)-values ranging from 77 to 164 pM (48 h treatment), dependent 
on the donor (Van Ede et al., 2014b). CYP1B1-induction has also been shown to vary contingent 
upon exposure duration. In respective investigation by Spencer et al. (1999), elevation of mRNA-
levels concentration-dependently increased with time until it peaked at 72 h of treatment, 
whereupon it continuously decreased up to the limit of the test series at five days of culture. 
 
AhR ligands other than TCDD and CYP1-induction 
 
Further exogen and endogen AhR-ligands lead to induction of CYP1-isoenzymes in primary human 
PBMCs, as indolo[3,2-b]carbazole (ICZ, 100 nM, 48 h) or 6-formylindolo[3,2-b]carbazole (FICZ, 
10 nM, 3 h) elevated CYP1B1 gene expression (~2fold or ~5fold), benzo[a]pyrene (1 µM, 12 h) or 
3-methylcholanthrene (0.1-1 µM, 12 h) enhanced CYP1A1 mRNA levels in these cells (De Waard 
et al., 2008; Komura et al., 2001; Tuominen et al., 2003). Two other members of the AhR-gene 
batterie, namely AhRR and TIPARP, were reported to be up-regulated in response to AhR-agonists 
in human PBMCs, which was shown to appear concentration-dependently regarding AhRR on 
mRNA-level by van Ede et al. (De Waard et al., 2008; Van Ede et al., 2014b; Wens et al., 2011). In 
this regard, around 10-14fold maximum AhRR-induction by TCDD with EC20s ranging             
120-240 pM was achieved after 48 h of incubation, whereas treatment with 1-PeCDD resulted in 
EC20s ranging 110-620 pM, and 4-PeCDF gained ~80 pM for EC20 (Van Ede et al., 2014b).  
 
Overall, treatment of human PBMCs with AhR-ligands leads to rather low absolute values and 
induction levels and of CYP1-isoenzymes. Besides considerable inter-species diversity, responses 
vary greatly among different individuals and deviate respectably regarding both efficacy and 
potency in different cell systems. Applying human PBMCs and their properties regarding induction 
of CYP1-isoenzymes as biomarker of exposure remains contentious issue, as it shows to represent a 
parameter, which so far appears difficult to adjust and reproduce (De Waard et al., 2008; Nohara et 
al., 2006; Spencer et al., 1999; Van Duursen et al., 2005).  
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2 
Assignment of tasks 
 
Within the framework of SYSTEQ project, seven individual congeners termed the ‘core congeners’ 
were chosen: TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 156, and the NDL-PCB 153. 
Core congeners, contributing approximately 90% of TEQs in the human food chain (Liem et al., 
2000), were tested in vivo as well as in vitro. A further, regarding environmental relevance likewise 
important, set of seven congeners was included for in vitro experiments of the present study:       
1,6-HxCDD, 1,4,6-HpCDD, TCDF, 1,4-HxCDF, 1,4,6-HpCDF, PCB 77, and PCB 105.  
 
Three major investigations were applied. In in vitro liver cell systems using both primary rat 
hepatocytes and the rat hepatoma cell line H4IIE, impact of the core congeners as well as the group 
of seven further compounds was investigated by means of EROD-induction. CYP1A-induction 
measured by EROD-activity represents a sensitive marker for dioxin-like effects, and was used to 
estimate potency and efficacy of selected chemicals. A definite data-set of in vitro studies was 
supposed to serve as a fundament for a probable establishment of novel TEFs with respect to the 
SYSTEQ project. 
 
One further important objective within the SYSTEQ project was to find potential novel biomarkers 
of exposure. Hence, a mouse whole genome microarray experiment using the seven core congeners 
was implemented. Of these compounds, five were investigated within present study: 1-PeCDD,     
4-PeCDF, PCB 118, PCB 126, and PCB 156. Though the microarray experiment was realized as 
one project, TCDD and PCB 153 were examined in a previous study by C. Lohr (Lohr, 2013). 
 
In order to gain knowledge with respect to TCDD-mediated effects towards immune cells, a further 
whole genome microarray experiment by use of human PBMCs was applied. To approach to this 
objective, freshly isolated PBMCs were characterized by flow cytometry and exposed to TCDD 
‘alone’ or combined with a stimulus (LPS, or PHA). 
 
Along with several experiments within the SYSTEQ project, a concluded compilation of eight 
‘potential’ AhR-target genes encoding CYP1A1, CYP1A2, CYP1B1, AHRR, TIPARP, ALDH3A1, 
CD36, and HSD17B2, was chosen and investigated in the course of all three models – mouse liver, 
rat liver cells, and human blood cells.  
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3 
Methods 
 
Test compounds were provided by The Dow Chemical Company (Midland, Michigan, USA). For in 
vitro experiments, congeners were dissolved in DMSO and added to respective incubation media 
constantly yielding final DMSO-concentrations of 0.1% (v/v). As part of in vivo studies, which 
were performed at the animal facility of the Utrecht University (Institute for Risk Assessment 
Sciences (IRAS), Utrecht, The Netherlands), congeners were diluted in corn oil. Accordingly, 
controls examined were either DMSO-, or corn oil-treated vehicles. 
 
Purity and quality of test compounds PCBs 118, 153, and 156, as well as the vehicles DMSO and 
corn oil, were checked at Umeå University (Department of Chemistry, Umeå, Sweden) using a 
carbon fractionation method in combination with a gas chromatography/high-resolution mass 
spectrometry (GC-HRMS)-analysis. PCB 118, formerly containing 85 ng/g TEQs, was cleaned to a 
final concentration of 6.6 ng/g TEQs, whereas PCB 156, initially containing 201 ng/g TEQs, was 
purified to 36 ng/g TEQs. PCB 153 was marginally contaminated with 0.41 ng/g TEQs 
(correspondence with P. Andersson, Umeå University, SE-901 87 Umeå, Sweden; Van Ede et al., 
2013a). 
 
Chemicals and reagents were obtained from Roth (Karlsruhe, Germany), or from Merck 
(Darmstadt, Germany). Fine-chemicals were from Sigma-Aldrich (Steinheim, Germany), unless 
otherwise stated. The same applies to all consumables, which were purchased from Greiner Bio-one 
(Frickenhausen, Germany). Buffers and solutions were aqueous, if not differently specified. 
 
3.1. H4IIE cells 
 
The rat hepatoma cell line H4IIE (Rat hepatoma Reuber H35, ATCC® CRL-1548; figure 5, 
following page) was established in 1964 (Pitot et al., 1964), and was purchased from The European 
Collection of Cell Cultures (ECACC; Public Health England, Salisbury, UK). The adherent, 
morphologically epithelial cell line originally was derived by the strain Rattus norvegicus, and is 
characterized by both low basal CYP1A-expression and high CYP1A-inducibility, and is useful for 
detection of picogram levels of AhR-ligands (Sawyer and Safe, 1982; Tillitt et al., 1991). 
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Figure 5: Light microscopic photograph of H4IIE-cells (magnification 100x). 
 
H4IIE cells were grown in Dulbecco's modified Eagle medium (DMEM) high glucose (4.5 g/L) 
with L-glutamine, without phenol-red (PAA Laboratories, Coelbe, Germany), supplemented with 
10% (v/v) fetal bovine serum (PAA Laboratories), 1% (v/v) penicillin/streptomycin (PAA 
Laboratories), and dexamethasone (100 nM) in 75 cm2-, or 175 cm2 cell culture flasks. Cells were 
cultured at 37°C, 95% relative humidity, and 5% CO2, and cell culture medium was renewed every 
2-3 days. Subculture was performed by use of trypsin/EDTA (PAA Laboratories) according to 
Lindl (2002). To be used within experiments, viable cells were counted using a Neubauer counting 
chamber via trypan blue (trypan blue solution, 0.4%) exclusion test (Evans and Schulemann, 1914; 
Rous and Jones, 1916), and seeded on either 24-well cell culture plates (1.2*105 cells/1 mL/well), 
60 mm cell culture dishes (1.3*106 cells/4 mL/dish), or 100 mm cell culture dishes (4*106 cells/7 
mL/dish). Cells were allowed to grow for 24 h. For incubation, medium was removed and 
incubation medium (DMEM high glucose (4.5 g/L) with L-glutamine, without phenol-red, 
supplemented with 10% (v/v) charcoal stripped fetal bovine serum (PAA Laboratories), 1% (v/v) 
penicillin/streptomycin, and dexamethasone (100 nM)) was applied. For details regarding tested 
compound concentrations in respective assays examined, see appropriate chapters. 
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3.2. Primary rat hepatocytes 
 
Primary rat hepatocytes (PRH, figure 6) were obtained from male Sprague Dawley® rats weighing 
150-250 g (Charles River, Sulzfeld, Germany) applying a collagenase-based, modified method 
originally established by Seglen in 1972 (Schrenk et al., 1992).  
 
 
Figure 6: Light microscopic photograph of primary rat hepatocytes (magnification 100x). 
 
Isolation of primary rat hepatocytes 
Prior to isolation of cells, required perfusion-solutions were preheated to 42°C. The particular 
animal was anesthetized by intraperitoneal (i.p.) injection of sodium pentobarbital (100 mg/kg bw), 
and full narcosis was verified via tail pinch response test. After the animal was fixed on the work 
bench, the abdomen was sprayed with 70% Ethanol, and the abdominal cavity was opened. Two 
loose ligatures were placed: One around vena porta ca. 1 cm beneath liver entry just above the 
branch to the spleen, and one around vena cava inferior just above the branch to the right kidney. 
100 µL of a heparin-solution (1000 U/mL in 0.9% NaCl) was injected into the vena cava inferior to 
prevent blood coagulation. About 1-2 cm below the ligation, vena porta was punctured with a 
cannula, through which Ethylenglykol-bis(β)-Aminoethylether-N,N,N',N'-Tetraacetat (EGTA)-
containing perfusion buffer 1 (PB1) was poured (3.6 mL/min). The ligature was fixed, and flow rate 
was sped up to 40 mL/min for 10 min, after the vena cava inferior was cut through ca. 2 cm below 
the ligation point. The liver exsanguinated, and due to EGTA-induced Ca2+-loss, desmosomal 
connections between hepatocytes loosened. During this perfusion step, the diaphragm was opened, 
whereby the lung collapsed and the animal died. By puncturing the right atrium, another cannula, 
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which was fixed with a further ligature, was inserted into the vena cava superior. Hence, perfusate 
flowed recirculating. Liver was flushed with PB2 containing freshly dissolved collagenase         
(100 CDU/mL) for 10 min (20 mL/min), leading to disintegration of the extracellular matrix 
structure. The liver was carefully cut out, put on a nylon-net (mesh size 250 µm) spanned over a 
250 mL-beaker, and the liver capsule was opened. Rinsing with washing buffer, hepatocytes were 
washed out and the procedure repeated with a nylon-net of mesh size 100 µm. The total volume of 
ca. 200 mL cell suspension was filled in four 50 mL-falcons, and centrifuged (20 g, 3-4 min, RT). 
Cells were washed twice with washing buffer, cautiously resuspended in ca. 25 mL washing buffer, 
and counted with the help of a Fuchs-Rosenthal counting chamber (Lindl, 2002) via trypan blue 
(trypan blue solution, 0.4%) exclusion test (Evans and Schulemann, 1914; Rous and Jones, 1916). 
Cell viability always exceeded 85% (modified method according to Seglen, 1972; Schrenk et al., 
1992). The components of perfusion buffers and required solutions, and respective storage 
conditions are summarized in table 2. 
 
Table 2: Solutions required for isolation of primary rat hepatocytes. 
Perfusion buffer 1 (PB1) Hank’s balanced salt solution (HBSS)1 
            without Ca & Mg 
            without phenol-red 
HEPES (10 mM) 
EGTA (0.1 mM) 
4°C 
Perfusion buffer 2 (PB2) DMEM low glucose (1 g/L) with L-glutamine1 
HEPES (10 mM) 
4°C 
prior to use: collagenase (100 CDU/mL), freshly dissolved 
Washing buffer  DMEM high glucose (4.5 g/L) with L-glutamine1  
            without phenol-red 
1% (v/v) penicillin/streptomycin1 
0.2% (v/v) bovine serum albumin (BSA; 30% solution1) 
HEPES (10 mM) 
4°C 
HEPES HEPES (1 M) 
pH 7.4 
4°C 
EGTA 
 
EGTA (100 mM) 
pH 8.0 
4°C 
Heparin-solution 1000 U/mL in 0.9% NaCl 
4°C 
Sodium pentobarbital-solution 33 mg/mL 
freshly prepared 
1PAA Laboratories, Coelbe, Germany 
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PRH were seeded on rat-tail collagen-coated cell culture vessels. Cells were seeded in hepatocyte 
seeding medium (HSM) on either 24-well plates (2*105 cells/1 mL/well), 60 mm dishes          
(2*106 cells/4 mL/dish), or 100 mm dishes (6*106 cells/7 mL/dish). Cells were allowed to attach for 
2 h before medium was changed to hepatocyte functional medium (HFM). After further 24 h, 
medium was replaced by fresh HFM, and PRH were incubated with test compounds. For details 
regarding tested compound concentrations in respective assays examined, see appropriate chapters. 
Composition of culture media and media additives are compiled in table 3 (following page). 
 
Preparation of collagen-solution and coating of cell culture vessels 
Ca. 20 rat tails were used to yield around 2 g collagen fibers. Rat tails were disinfected (70% 
ethanol), and skinned under the hood. Collagen fibers were drawn out from the tail tip, dried over 
night under UV light, hackled, and dried again under UV light. Collagen fibers were washed with 
purified water (1 h) and transferred into sterile filtered acetic acid (0.1%, 500 mL). After 24 h of 
stirring, undissolved fibers were separated (2300 g, 3 h, RT), and protein content of obtained 
collagen-solution was measured according to bicinchoninic acid (BCA) protein assay (Pierce® BCA 
Protein Assay Kit; Thermo Fisher Scientific, Karlsruhe, Germany), according to the manufacturer’s 
protocol. Collagen working solution was prepared (0.5 mg protein/mL; storage: 4°C), and used to 
coat cell culture vessels (modified method according to Elsdale and Bard, 1972). Freshly coated 
vessels were dried over night under UV light, and were hence ready to be used for cell seeding.  
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Table 3: Culture media and media additives used for cultivation of primary rat hepatocytes. 
Hepatocyte seeding medium (HSM) DMEM + Ham’s F12 (1+1): 
DMEM high glucose (4.5 g/L) with L-glutamine1 
            without phenol-red 
Ham’s F12 medium with L-glutamine2 
            without phenol-red 
            with 1.176 g/L NaHCO3 
5% (v/v) fetal bovine serum1 
HEPES (10 mM) 
gentamicin1 (50 µg/mL) 
insulin (100 nM) 
sodium selenite (100 nM) 
4°C 
Hepatocyte functional medium (HFM) DMEM + Ham’s F12 (1+1): 
DMEM high glucose (4.5 g/L) with L-glutamine1 
            without phenol-red 
Ham’s F12 medium with L-glutamine2 
            without phenol-red 
            with 1.176 g/L NaHCO3 
BSA/linoleic acid (5 µg/mL BSA, 0.5 mg/mL) 
HEPES (10 mM) 
dexamethasone (100 nM) 
gentamicin1 (50 µg/mL) 
insulin (100 nM) 
sodium selenite (100 nM) 
transferrin (5 µg/mL) 
4°C 
HEPES HEPES (1 M) 
pH 7.4 
4°C 
BSA/linoleic acid BSA (10% in DPBS) 
50 mg linoleic acid 
4°C 
Dexamethasone 
working solution 
Dexamethasone stock solution (25 mg/6.3 mL Ethanol, p.a.) 
diluted 1:100 with sterile filtered, purified water 
final concentration: 100 µM 
-20°C 
Insulin  
working solution 
Insulin stock solution (10 mg/mL in 25 mM HEPES) 
diluted with DMEM high glucose (4.5 g/L)  
            with L-glutamine (without phenol-red)1 
final concentration: 100 µM 
-20°C 
Transferrin  
working solution 
5 mg/mL in DMEM high glucose (4.5 g/L)  
            with L-glutamine (without phenol-red)1 
-20°C 
1PAA Laboratories, Coelbe, Germany 
2PAN-Biotech, Aidenbach, Germany 
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3.3. Alamar Blue® assay 
 
Alamar Blue® assay was used to determine viability of cells. The test is based on the reduction of 
non-fluorescent resazurin to fluorescent resorufin in the presence of NADH/H+ (O’Brien et al., 
2000). Although it has been proposed that mitochondrial, cytosolic, as well as microsomal enzymes 
are able to reduce resazurin (Gonzalez and Tarloff, 2001), it remains unclear, whether this occurs 
intracellularly or in the medium as a chemical reaction (O’Brien et al., 2000). 
 
H4IIE cells or PRH were seeded and incubated with test compounds in 24-well plates as described. 
Final concentrations of congeners are specified in table 4.  
Samples and controls (medium, DMSO 0.1%) were performed as doublets, and saponine (final 
concentration 0.1%) was used as positive-control for cytotoxic effects (reviewed in Podolak et al., 
2010). Subsequent to the incubation period of 24 h, incubation medium was removed, and cells 
were washed twice with phosphate buffered saline (PBS--, without Ca and Mg, 37°C). Resazurin 
working solution (37°C) was added and incubated for 1 h at 37°C, 95% relative humidity, and     
5% CO2. Afterwards, fluorescence was measured in a preheated (37°C) microplate fluorometer   
(ex, 544 nm; em, 590 nm; Fluoroskan Ascent FL, Thermo Fisher Scientific, Karlsruhe, Germany). 
Blank values were subtracted from measured values, and viabilities were displayed in per cent 
related to appendant solvent controls (DMSO 0.1%). For details regarding composition of Alamar 
Blue® assay reagents, PBS--, and respective storage conditions see tables 4 and 5.  
 
Table 4: Final congener-concentrations tested in Alamar Blue® assay (H4IIE, PRH). 
TCDD, 
1-PeCDD 
 
H4IIE, PRH 
 
10-10 M - 10-8 M 
1,6-HxCDD H4IIE, PRH 5*10-10 M - 3*10-8 M 
1,4,6-HpCDD H4IIE, PRH 5*10-9 M - 4.56*10-7 M 
TCDF H4IIE, PRH 10-8 M - 9.84*10-7 M 
4-PeCDF H4IIE, PRH 10-9 M - 10-7 M 
1,4-HxCDF H4IIE, PRH 5*10-9 M - 3*10-7 M 
1,4,6-HpCDF H4IIE, PRH 5*10-9 M - 1.58*10-7 M 
PCB 126 H4IIE 
PRH 
5*10-9 M - 10-7 M 
10-8 M - 10-6 M 
PCBs  
77, 105, 118, 153, 156 
 
H4IIE, PRH 
 
10-8 M - 10-6 M 
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Table 5: Alamar Blue® assay reagents, and PBS---components. 
Resazurin  
stock solution  
Resazurin (440 mM in DMF) diluted (1:1000)  
with NaPi-buffer (440 µM resazurin) 
4°C; four weeks 
Resazurin  
working solution 
Resazurin stock solution diluted (1:10)  
with respective culture medium (without supplements) 
prepared immediately prior to use (37°C) 
NaPi-buffer NaCl (154 mM) 
Na2HPO4*H2O (3.7 mM) 
KH2PO4 (1.1 mM) 
4°C 
Phosphate buffered saline 
(without Ca and Mg) 
PBS-- 
 
NaCl (137 mM) 
NaH2PO4 (6.5 mM) 
KCl (2.7 mM) 
KH2PO4 (1.5 mM) 
pH 7.4 
RT 
 
3.4. 7-Ethoxyresorufin O-deethylase (EROD)-assay 
 
As a parameter for AhR-activation, induction of CYP1A-mediated 7-ethoxyresorufin O-deethylase 
(EROD)-activity was determined in H4IIE cells and PRH (Burke and Mayer, 1974; Kennedy et al., 
1993). EROD-activity was measured according to van Duursen et al. (2005) with modifications. As 
described, cells were seeded and incubated with compounds in 24-well plates. Final concentrations 
of congeners applied are noted in table 6.  
Samples and controls (medium, DMSO 0.1%) were performed as doublets, whereas TCDD (1 nM) 
was used as positive-control for EROD induction. After 24 h of exposure, incubation medium was 
removed, and cells were washed twice with PBS-- (37°C). EROD medium (37°C; see table 7) was 
added, and plates were placed in a preheated (37°C) microplate fluorometer (Fluoroskan Ascent FL, 
Thermo Fisher Scientific, Karlsruhe, Germany), and fluorescence was measured at an excitation 
wavelength of 544 nm, and an emission wavelength of 590 nm, every 90 s for 30 min. Resorufin-
content was quantified with the help of a calibration curve (0-1000 nM resorufin). 
After measurement and removal of EROD medium, cells were washed twice with PBS-- and frozen 
to -80°C over night. Cells were cracked through a freeze-thaw-cycle (thawing: 3x, 15 min, RT; 
freezing in between: 3 h at least), and protein content was measured by BCA assay (Pierce® BCA 
Protein Assay Kit), according to the manufacturer’s protocol.  
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Kinetics of resorufin-formation due to impact of congeners was used as basis for calculation of 
EROD-activities. Values were indicated as pmol resorufin/min*mg protein (method modified 
according to van Duursen et al., 2005).  
 
Table 6: Ranges of final congener-concentrations tested in EROD-assay (H4IIE, PRH). 
TCDD 
 
H4IIE 
PRH 
5*10-13 M - 10-9 M 
10-14 M - 10-8 M 
1-PeCDD H4IIE 
PRH 
10-12 M - 5*10-10 M 
10-13 M - 10-8 M 
1,6-HxCDD H4IIE 
PRH 
5*10-12 M - 5*10-9 M 
10-12 M - 3*10-8 M 
1,4,6-HpCDD H4IIE 
PRH 
5*10-12 M - 5*10-9 M 
5*10-12 M - 10-7 M 
TCDF H4IIE 
PRH 
10-11 M - 10-7 M 
10-12 M - 10-8 M 
4-PeCDF H4IIE 
PRH 
10-13 M - 10-9 M 
10-12 M - 10-8 M 
1,4-HxCDF H4IIE 
PRH 
10-12 M - 10-9 M 
5*10-12 M - 5*10-8 M 
1,4,6-HpCDF H4IIE 
PRH 
5*10-11 M - 5*10-8 M 
10-11 M - 1.58*10-7 M 
PCB 126 H4IIE 
PRH 
5*10-12 M - 5*10-9 M 
5*10-12 M - 10-7 M 
PCBs 105, 118, 153 H4IIE, PRH 10-10 M - 10-6 M 
PCB 77 H4IIE  
PRH 
10-10 M - 10-6 M 
5*10-11 M - 10-6 M 
PCB 156 H4IIE 
PRH 
5*10-9 M - 10-6 M 
10-10 M - 10-6 M 
 
Table 7: EROD medium components. 
EROD medium  25 mL respective culture medium (without supplements) 
125 µL MgCl2 (1 M) 
25 µL Dicumarol (10 mM in 0.2 M NaOH) 
125 µL 7-ethoxyresorufin (1 mM in DMSO) 
prepared immediately prior to use (37°C) 
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3.5. SDS-PAGE and Western Blot 
 
For investigations on CYP1A1-protein via Western Blot (WB) analysis, H4IIE cells, or PRH, which 
were seeded on 100 mm cell culture dishes as described, were exposed to congener-concentrations 
depicted in table 8. 
 
Table 8: Final congener-concentrations tested via SDS-PAGE/Western Blot (H4IIE, PRH). 
TCDD 
 
H4IIE 
PRH 
5*10-12 M - 10-8 M 
10-13 M - 10-9 M 
1-PeCDD H4IIE 
PRH 
10-13 M - 5*10-10 M 
10-13 M - 10-8 M 
1,6-HxCDD H4IIE 
PRH 
5*10-12 M - 5*10-9 M 
10-12 M - 3*10-8 M 
1,4,6-HpCDD H4IIE 
PRH 
5*10-12 M - 5*10-9 M 
10-12 M - 10-7 M 
TCDF H4IIE 
PRH 
10-11 M - 10-7 M 
10-13 M - 10-8 M 
4-PeCDF H4IIE 
PRH 
10-13 M - 10-9 M 
10-12 M - 10-8 M 
1,4-HxCDF H4IIE 
PRH 
10-12 M - 10-9 M 
10-12 M - 5*10-8 M 
1,4,6-HpCDF H4IIE 
PRH 
5*10-11 M - 5*10-8 M 
10-12 M - 10-7 M 
PCB 126 H4IIE 
PRH 
10-12 M - 5*10-9 M 
10-12 M - 10-7 M 
PCBs 77, 105,  
118, 153, 156 
 
H4IIE, PRH 
 
10-9 M - 10-6 M 
 
After incubation of congeners for 24 h, cells were washed and scraped off from dishes using ice-
cold isotonic extraction buffer (IEB, 1 mL) containing protease inhibitor cocktail (0.1%). Cells were 
homogenized using an ultrasonic probe, and proteins were separated (12,000 g, 15 min, 4°C). From 
protein-containing supernatants, microsomes were isolated per ultracentrifugation (100,000 g, 1 h, 
4°C; Ultracentrifuge Optima TL, Beckman Coulter, Krefeld, Germany), and dissolved in NaPi-
buffer (100 µL, 50 mM). Protein content was measured by BCA assay (Pierce® BCA Protein Assay 
Kit) according to the manufacturer’s protocol.  
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To microsomes (20 µg protein/15 µL), Laemmli loading buffer (6x, 3 µL) was added, and proteins 
were denatured at 95°C for 5 min. Samples were stored at -20°C until used for SDS-PAGE. 
Microsomes were held at -80°C. Details regarding composition and storage conditions of required 
solutions are summarized in table 9. 
 
Table 9: Solutions required for protein sample preparation for SDS-PAGE/Western Blotting. 
Isotonic extraction buffer  
IEB 
Saccharose (250 mM) 
KCl (25 mM) 
HEPES (10 mM) 
EGTA (1 mM) 
pH 7.8 
4°C 
added prior to use: protease inhibitor cocktail (0.1%) 
                               P8340, Sigma-Aldrich 
NaPi-buffer 
50 mM 
Na2HPO4*H2O (43.5 mM) 
NaH2PO4 (6.5 mM) 
pH 7.6 
4°C 
Laemmli loading buffer  
(6x) 
50 mL Tris/HCl (0.5 M, pH 6.8) 
40 mL glycerin 
5 mL 2-mercaptoethanol 
1.24 g SDS 
160 mg bromphenol blue 
ad 100 mL 
-20°C 
 
Discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (disc SDS-PAGE) and 
Western Blot was performed according to Laemmli (1970), and Towbin (1979) as described 
previously (Chopra et al., 2010b) with modifications. Discontinuous gels composed of separating 
gels (10% acrylamide) and stacking gels (4% acrylamide) were poured (table 10), placed in vertical 
electrophoresis apparatuses (Bio-Rad Laboratories GmbH, Munich, Germany), and proteins of 
samples (20 µg protein/18 µL) were electrophoretically separated (140 V).  
Protein standards (#161-0375) were purchased from Bio-Rad Laboratories GmbH. Proteins were 
blotted onto polyvinylidene difluoride (PVDF)-membranes (pore size 0.2 µm, Bio-Rad Laboratories 
GmbH) by semi-dry blotting (figure 7; Semi-Dry Blotter TE77, Hoefer, Inc.; San Francisco, 
California, USA).  
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Figure 7: Semi-dry blotting procedure, schematic view. 
 
Subsequent to blotting for 75 min and 45 mA per membrane (7 x 9.5 cm), membranes were blocked 
(5% lowfat powdered milk in Tris-buffered saline with Tween-20 (TBS-T)) for 1 h at RT, or at 4°C 
over night. Appropriate membrane parts were incubated with rabbit anti-CYP1A1 (1:1000 in    
TBS-T; sc-20772, Santa Cruz Biotechnology, Inc., Heidelberg, Germany), or rabbit anti-voltage-
dependent anion channel (VDAC, 1:1000 in TBS-T; #4866, Cell Signaling Technology, Inc., 
Frankfurt on the Main, Germany), for 1 h at RT, or over night at 4°C. VDAC served as loading 
control. Membranes were washed (3 x 5 min) with TBS-T, and incubated with goat anti-rabbit IgG 
horseradish peroxidase (HRP) (1:5000 in TBS-T, sc-2004, Santa Cruz Biotechnology) for 1 h at 
RT.  
After washing of membranes (3 x 5 min with TBS-T, 1 x 5 min with TBS), CYP1A1 (56 kDa)-, and 
VDAC (32 kDa)-protein bands were visualized by means of chemoluminescence detetection. 
Therefor, 100 µL reagent B were added to containing reagent A, and membranes were incubated for 
1 min prior to detetection via Lumi Imager (Roche, Mannheim, Germany) and Lumi Analyst 
Software (Version 3.1, Roche). See table 10 for detailed information regarding required reagents 
(method modified according to Chopra et al., 2010b). 
 anode 
cathode; loaded with 5 kg of weight 
filter papers soaked with cathode-buffer 
filter papers soaked with anode-buffer II 
filter paper soaked with anode-buffer I 
PA-gel 
PVDF-membrane 
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Table 10: Gel components and buffers used for disc SDS-PAGE/Western Blot, and reagents for 
chemoluminescence detection. 
Separating gel 
(% acrylamide) 
Formulation per gel: 
purified water 
acrylamide (30%) 
1.5 M Tris/HCl (pH 8.8) 
sodium dodecyl sulfate (SDS, 10%)1 
ammonium persulfate (APS, 10%) 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
 
2 mL 
1.64 mL 
1.23 mL 
50 µL 
50 µL 
5 µL 
Stacking gel 
(% acrylamide) 
Formulation per gel: 
purified water 
acrylamide (30%) 
0.5 M Tris/HCl (pH 6.8) 
SDS (10%)1 
APS (10%) 
TEMED 
 
1.2 mL 
0.25 mL 
0.5 mL 
20 µL 
20 µL 
4 µL 
Electrophoresis-buffer Glycine (200 mM) 
Tris/HCl (25 mM) 
SDS (0.1%)1 
 
Tris-buffered saline 
TBS 
NaCl (130 mM) 
Tris/HCl (20 mM) 
pH 7.4 
 
TBS with Tween-20 
TBS-T 
TBS 
Tween-20 (0.1%)1 
 
Anode-buffer I Tris (300 mM) 
methanol (10%) 
pH 10.4 
 
Anode-buffer II Tris (25 mM) 
methanol (10%) 
pH 10.4 
 
Cathode-buffer Glycine (40 mM) 
Tris (25 mM) 
methanol (20%) 
SDS (0.005%)1 
pH 9.4 
 
Reagent A Luminol (50 mg in 100 mM Tris/HCl, pH 8.6) 
p-coumaric acid (11 mg/10 mL DMSO) 
10 mL 
1 mL 
Reagent B 100 mM Tris/HCl, pH 8.6 
H2O2 (30%) 
1 mL 
50 µL 
1Applichem GmbH, Darmstadt, Germany 
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3.6. Quantitative real-time PCR 
 
For determination of core congeners’ properties on gene transcription in vitro, definite mRNA-
levels in exposed H4IIE-cells, or PRH, were investigated via quantitative real-time polymerase 
chain reaction (qRT-PCR). To approach to this objective, transcription of eight potential AhR-target 
genes (Cyp1a1, Cyp1a2, Cyp1b1, Ahrr, Aldh3a1, Cd36, Hsd17b2, and Tiparp), were examined 
using TCDD-treated H4IIE-cells, or PRH (0.1 pM-1 nM TCDD, 24 h). Furthermore, effects on 
Cyp1a1, Cyp1a2, Cyp1b1, and Aldh3a1 after 24 h of treatment (H4IIE, PRH) were analyzed more 
extensively, studying effects of the complete set of core congeners (TCDD, 1-PeCDD, 4-PeCDF, 
PCBs 118, 126, 153, and 156), applying compound concentrations noted in table 11.  
 
Table 11: Final congener-concentrations used for investigations via qRT-PCR (H4IIE, PRH). 
TCDD 
 
H4IIE 
PRH 
10-13 M - 10-9 M 
10-14 M - 10-8 M 
1-PeCDD H4IIE 
PRH 
10-13 M - 10-9 M 
10-13 M - 10-8 M 
4-PeCDF H4IIE 
PRH 
10-13 M - 10-9 M 
10-12 M - 10-8 M 
PCB 126 H4IIE 
PRH 
10-12 M - 5*10-9 M 
10-12 M - 10-6 M 
PCB 118 H4IIE, PRH 10-9 M - 10-6 M 
PCB 153 H4IIE, PRH 5*10-9 M - 10-6 M 
PCB 156 H4IIE 
PRH 
5*10-9 M - 10-6 M 
10-9 M - 10-6 M 
 
From H4IIE cells, PRH, PBMCs, and mouse-, or rat liver tissues, mRNA was isolated using Qiagen 
RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer’s protocol. For 
details regarding PBMC-, mouse-, and rat liver samples, see respective chapters. Prior to use in 
microarray analysis, integrity of mRNA was checked applying Agilent RNA 6000 Pico Kit (Agilent 
Technologies GmbH, Waghaeusel-Wiesental, Germany), by means of 2100 Bioanalyzer (Agilent 
Technologies GmbH, Waldbronn, Germany), using 2100 Expert software (Agilent Technologies 
GmbH, Waldbronn, Germany).  
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For qRT-PCR, mRNA was transcribed to cDNA in a MyCycler™ Thermo Cycler (Bio-Rad, 
Munich, Germany). To accomplish reverse transcription, iScript™ cDNA Synthesis Kit (Bio-Rad) 
was applied according to the manufacturer’s protocol, using 1 µg mRNA per sample (NanoDrop 
ND-1000 Spectrophotometer, Wilmington, Delaware, USA). IQ™ SYBR® Green Supermix (Bio-
Rad) was used for dye-based quantitative PCR (Mastermix: 1 µL sample cDNA, 12.5 µL IQ™ 
SYBR® Green Supermix, 9.5 µL nuclease-free H2O, 1 µL forward primer, 1 µL reverse primer), 
whereas measurement of fluorescence was carried out in an iCycler iQ™ Thermal Cycler (Bio-Rad) 
according to the manufacturer’s protocol. For each experiment, gene transcripts of the housekeeping 
gene encoding β-actin were measured. Referring to Pfaffl (2001), ratios were calculated on the basis 
of the crossing point (CP), where the threshold fluorescence is crossed. The threshold fluorescence 
is defined as the point at which fluorescence appreciably rises above background fluorescence. 
Ratios were calculated with the aid of the ‘delta-delta-method’ (Pfaffl, 2001). Primer validations 
were implemented to investigate qRT-PCR-efficacies, unless primers were already established in 
the laboratory (Dörr, 2010; Lohr, 2013; Roos, 2011). Sequences of primers are listed in table 12 
(following page). 
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Table 12: Primer sequences used for qRT-PCR (for, forward; rev, reverse; Ta, annealing temperature). 
 
Gene name 
RefSeq  
accession number 
 
Primer sequences (5’ 3’)  
 
Ta  
 
Reference 
Human     
ACTB NM_001101 for: CGTGCGTGACATTAAGGAGAA; rev: CAATGCCAAGGAAGGAAGG 55.7°C Dörr, 2010 
AHRR NM_020731 for: CTTCATCTGCCGTGTGCGCT; rev: ATGAGTGGCTCGGGACAGCAGA 57°C Lohr, 2013 
ALDH3A1 NM_001135168 for: GCAAGCAAGTAAGGGAGCGGA; rev: ACCCGAGTCCTAAGCCGAACTG 60°C Lohr, 2013 
CD36 NM_001001547 for: AGATGCAGCCTCATTTCCAC; rev: CGTCGGATTCAAATACAGCA 60°C Chuang et al., 2009 
CYP1A1 NM_000499 for: CAGAAGATGGTCAAGGAGCA; rev: GACATTGGCGTTCTCATCC 60°C Andersson et al., 2011 
CYP1A2 NM_000761 for: CCCAGAATGCCCTCAACA; rev: CCACTGACACCACCACCTGAT 60°C Ooi et al., 2011 
CYP1B1 NM_000104 for: CGGCCACTATCACTGACATC; rev: CTCGAGTCTGCACATCAGGA 60°C Andersson et al., 2011 
HSD17B2 NM_002153 for: CTGAGGAATTGCGAAGAACC; rev: AAGAAGCTCCCCATCAGTTG 52°C Su et al., 2007 
TIPARP NM_001184717 for: GCGCACAAGTCTTCGTCTTCCTCC; rev: AAAAATCCTCCCGAGGAGCGTCCAA 60°C Lohr, 2013 
Rat     
Actb NM_031144 for: AGCCATGTACGTAGCCATCCA; rev: TCTCCGGAGTCCATCACAATG 58°C Roos, 2011 
Ahrr NM_001024285 for: GGGGACAGAGAAGAGGACGATCAGA; rev: ACTTCGCTGCTCTGTGCTCCA 65.4°C Validated primers 
Aldh3a1 NM_031972 for: TATCCCCCAAGCCCAGCCAAGA; rev: AGGACGGCAGGTGGGAATAAGC 60.1°C Validated primers 
Cd36 NM_031561 for: GGCTGTGTTTGGAGGCATTCT; rev: CCCGTTTTCACCCAGTTTTTG 59°C Dalgaard et al., 2011 
Cyp1a1 NM_012540 for : CCTCTTTGGAGCTGGGTTTG; rev: CCTGTGGGGGATGGTGAA 55°C Roos, 2011 
Cyp1a2 NM_012541 for: GCAAGGACTTTGTGGAGAATGT; rev: GTGATGTCCTGGATACTGTTCTTGT 64°C Mirek 
Cyp1b1 NM_012940 for: CTCATCCTCTTTACCAGATACCCG; rev: GACGTATGGTAAGTTGGGTTGGTC 58°C Mirek 
Cyp2b1 NM_001134844 for: ATGGAGAAGGAGAAGTCGAACC; rev: CTTGAGCATCAGCAGGAAACC 64°C Roos, 2011 
Cyp3a1 NM_013105 for: CCAGCAGCACACTTTCCTTTG; rev: GGTGGGAGGTGCCTTATTGG 52°C Roos, 2011 
Hsd17b2 NM_024391 for: TCGGTGTCCTGCTTCTTCCTTCTG; rev: CCCTCTTTATCCAGCACTCCAGCAA 64°C Validated primers 
Tiparp XM_003753596 for: TTGGAAATTCTTCTGTAGAGACCAC; rev: TTCAATTAGTCGAACAACAGACTCA 57°C Validated primers 
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3.7. Peripheral Blood Mononuclear Cells 
 
To approach novel findings regarding AhR’s role in immune cells, investigations on TCDD-treated 
human peripheral blood mononuclear cells (PBMCs) were performed. For this purpose, PBMCs 
(figure 8) were isolated from freshly drawn blood from four subjects, and characterized by 
fluorescence activated cell sorting (FACS) analysis. Cells were exposed to TCDD alone or co-
incubated with either lipopolysaccharide (LPS) or phytohemagglutinine (M Form; PHA), and 
mRNA was isolated after 24 h of treatment. Impact on transcription of eight potential AhR-target 
genes (CYP1A1, CYP1A2, CYP1B1, AHRR, ALDH3A1, CD36, HSD17B2, and TIPARP) was 
examined. Furthermore, human whole genome microarray analysis was performed. 
 
 
Figure 8: Light microscopic photograph of human PBMCs stimulated with LPS (1 µg/mL) for 24 h 
(magnification 100x). 
 
3.7.1. Isolation and treatment of human PBMCs 
 
Venous blood (40-45 mL) of four healthy, non-smoking individuals (two female, two male; 23-29 
years of age) was collected in EDTA-monovettes (Sarstedt, Nuernbrecht, Germany), carefully 
layered on Ficoll-Paque PLUS solution (GE Healthcare Europe GmbH, Freiburg, Germany; 
blood:Ficoll (v:v) = 3:4), and centrifuged at 400 g for 30 min at RT in 15 mL falcons (isolation 
method modified according to Bøyum, 1964). PBMC-layers were transferred to PBS--, washed (300 
g, 5 min, RT), and resuspended in PBMC culture medium (RPMI 1640 with L-glutamine, without 
phenol-red (PAA Laboratories, Coelbe, Germany), supplemented with 10% (v/v) charcoal stripped 
fetal bovine serum (PAA Laboratories), 25 mM HEPES, 1% (v/v) penicillin/streptomycin (PAA 
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Laboratories)), or PBMC culture medium containing PHA (1.5%). Cells were counted with the aid 
of a Neubauer counting chamber via trypan blue (trypan blue solution, 0.4%) exclusion test (Evans 
and Schulemann, 1914; Rous and Jones, 1916), yielding 1.2 (±0.5)*106 cells/mL blood. PBMCs 
were seeded on 6-well cell culture plates (6*106 cells/3 mL/well) in appropriate PBMC culture 
medium, and incubated (see table 13) for 24 h at 37°C, 95% relative humidity, and 5% CO2.  
 
Table 13: In vitro treatment of human PBMCs.  
Control I  DMSO 0.1% Incubation I TCDD 10 nM 
Control II DMSO 0.1% 
LPS1 1 µg/mL 
Incubation II TCDD 10 nM 
LPS1 1 µg/mL 
Control III DMSO 0.1% 
PHA2 1.5% 
Incubation III TCDD 10 nM  
PHA2 1.5% 
1LPS from E. coli 0111:B4 (L3012); Sigma-Aldrich, Steinheim, Germany 
2Gibco® Life Technologies GmbH, Darmstadt, Germany 
 
After incubation, PBMCs were separated from medium (300 g, 10 min, RT), and mRNA was 
isolated using Qiagen RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s protocol. Further preparations of samples accomplished prior to qRT-PCR-, or 
human whole genome microarray analysis are explained in respective chapters. 
 
3.7.2. Characterization of PBMCs by Flow Cytometry 
 
Isolated PBMCs were characterized by FACS analysis. Cells were washed (300 g, 5 min, 4°C), and 
resuspended in ice-cold Stain Buffer (BD Pharmingen, Heidelberg, Germany). To cells            
(106 cells/100 µL each), antibodies (20 µL) were added, and incubated on ice for 20 min (protected 
from light). Unstained cells, as well as cells stained with respective isotyp control antibodies (see 
table 14 for antibody details; following page), were used for control measurements. Subsequent to 
antibody-incubation, cells were washed twice (Stain Buffer; 300 g, 5 min, 4°C), and resuspended in 
100 µL ice-cold Stain Buffer per sample. Samples were measured using a BD FACS Canto II flow 
cytometer (BD Biosciences, Heidelberg, Germany).  
Cell populations were identified per forward scatter (FSC)/sideward scatter (SSC) dot blots, and 
distinguished via light detection from the 633 nm (red) laser enabled by a trigon detector array 
(bandpass filter: 660/20 nm). Required solutions for FACS analysis are listed in table 14 (following 
page). 
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Table 14: List of antibodies and solutions used in the course of FACS analysis for human PBMCs. 
APC Mouse Anti-human CD3 555335; BD Pharmingen (1) 
APC Mouse Anti-human CD14 561708; BD Pharmingen (1) 
APC Mouse Anti-human CD19 555415; BD Pharmingen (1) 
APC Mouse IgG1, κ isotyp control 555751; BD Pharmingen (1) 
APC Mouse IgG2a, κ isotyp control 555576; BD Pharmingen (1) 
BD FACS Clean Solution 340345; BD FACS™ (1) 
BD FACSFlow Sheath Fluid 342003; BD FACSFlow™ (1) 
BD FACS Shutdown Solution 334224; BD FACS™ (1) 
(1)Heidelberg, Germany 
 
The CD3 monoclonal antibody specifically binds to the human CD3ε-chain, a 20 kD subunit of the 
CD3/T cell receptor complex. CD19 is specifically expressed on B cells, and respective CD19 
monoclonal antibody binds to the 95 kDa type I transmembrane CD19 glycoprotein. The CD14 
monoclonal antibody specifically binds to CD14, a 53-55 kDa glycosylphosphatidylinositol-
anchored single chain glycoprotein expressed at high levels on the surface of monocytes and 
macrophages (information was taken from technical data sheets of antibodies; BD Pharmingen, 
Heidelberg, Germany). After FACS analysis, from relative fluorescence units (RFUs) of samples 
stained with CD3-, CD14-, or CD19-antibody, RFUs of respective isotyp control-stained cells were 
subtracted. For investigations of CD3+-, and CD19+-cells, IgG1, κ isotyp control was used, whereas 
for analysis of CD14+-cells, IgG2a, κ isotyp control was applied. 
 
Resulting ∆RFUs exceeding 4,000 referred to positively stained cells and were termed CDX+. 
Hence, CD3+-cells indicated the presence of T-lymphocytes, CD19+-cells designated B-
lymphocytes, and CD14+-cells indicated the presence of monocytes/macrophages. 
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3.8. Whole Genome Microarrays – human & mouse 
 
To reveal novel findings regarding potential AhR-dependent-, and AhR-independent impact of DL-
chemicals on gene transcription, mouse whole genome microarray analysis was performed. Within 
the framework of SYSTEQ project, female C57BL/6J mice were exposed to single doses of one of 
the seven core congeners (TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156) 
for three days. In the course of the entire experiment, impact of TCDD, and PCB 153 was closely 
studied by Dr. Christiane Lohr (Lohr, 2013). For the purposes of the work in hand, respective data 
obtained by courtesy of Christiane Lohr was partially required to attain reasonable considerations 
and findings, or to draw comparisons between congeners, which especially was inevitable regarding 
TCDD. 
 
To approach both potential effects of TCDD towards humans and to disclose its possible impact on 
immune system, in vitro studies on human PBMCs were implemented. From four subjects (one 
female, two male), mRNA of in vitro-treated PBMCs exposed to TCDD for 24 h was examined in 
terms of whole genome microarray analysis. 
 
From each treatment group within the mouse experiment, samples of all six treated animals as well 
as three controls were analyzed. Referring to PBMCs, incubations I, II, and III were included. 
Regarding both variants of starting material, procedure was performed as follows.  
 
From PBMCs and mouse liver samples, mRNA was isolated and checked on integrity as described 
and used for two-color microarray-based gene expression analysis, which was processed 
implementing dye-swop procedures. According to the manufacturer’s protocol (G4140-90050, 
version 6.5, 2010; Agilent Technologies, Waldbronn, Germany), 100 ng of mRNA per sample was 
applied. By means of low input quick amp labeling kit (Agilent Technologies GmbH, Waghaeusel-
Wiesental, Germany), fluorescent cRNA was generated. This method involved T7 RNA 
polymerase, which simultaneously amplified target material and incorporated cyanine (Cy)3-, or 
Cy5-labeled CTP.  
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All used reagents and buffers used for two-color microarray-based gene expression analysis are 
listed in table 15. 
 
Table 15: List of reagents und buffers used in the course of two-color microarray-based gene expression analysis. 
Low Input Quick Amp Labeling Kit, two-color 5190-2306; Agilent Technologies GmbH (1)  
RNA Spike In Kit, two-color 5188-5279; Agilent Technologies GmbH (1) 
Gene Expression Hybridization Kit 5188-5242; Agilent Technologies GmbH (1) 
Gene Expression Wash Buffer Kit 5188-5327; Agilent Technologies GmbH (1) 
Hybridization Gasket Slide Kit G2534-60011; Agilent Technologies GmbH (1) 
Human GE 4x44K v2 Microarray Kit G4845A; Agilent Technologies GmbH (1) 
Mouse GE 4x44K v2 Microarray Kit G4846A; Agilent Technologies GmbH (1) 
RNeasy Mini Kit Qiagen GmbH, Hilden, Germany 
Ethanol (absolute, reag. ISO, reag. Ph. Eur) Sigma Aldrich, Steinheim, Germany 
(1)Waghaeusel-Wiesental, Germany 
 
Hybridized microarray slides were scanned using Agilent Microarray Scanner System (Scanner 
Model G2505B, Agilent Technologies Scan Control Software Version A.7.0.1; Agilent 
Technologies GmbH, Waldbronn, Germany). Preliminary processing of data was made by means of 
Agilent Technologies Feature Extraction Software (9.5.1.1; Agilent Technologies GmbH). Data 
normalization and statistical analyses were performed using Bioconductor (Gentleman et al., 2004) 
R (version 2.15.1) package limma (version 3.12.3) (Smyth, 2004). Raw signals were background 
corrected subtracting local spot background. Two normalization steps were applied: firstly within 
arrays using the global loess method, and secondly between the arrays using the Aquantile method. 
Differential expression was assessed with the help of empirical Bayes moderated t-tests carried out 
in limma (Smyth, 2005) on the dataset. Cutoff criteria for further functional analysis were 
logarithmic (log2) fold change │lfc│ ≥ 1, and p-value < 0.05, corrected by false discovery rate 
(FDR) using the Benjamini-Hochberg method (Benjamini and Hochberg, 1995), and an A-mean 
value A ≥ 27. The clipped list was subjected to Gene Ontology (GO) analysis using the TopGO 
(version 2.8.0) package in R (Alexa et al., 2006). Classical enrichment analysis by testing over-
representation of GO terms within the group of differentially expressed genes was performed using 
Fisher’s exact test (correspondence with Karsten Andresen, Institute of Biotechnology and Drug 
Research (IBWF), Kaiserslautern).  
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3.9. Animal experiments 
 
All animal experiments were performed at the animal facility of the Utrecht University (Institute for 
Risk Assessment Sciences (IRAS), Utrecht, The Netherlands) with permission of the Animal 
Ethical Committee, and according to Dutch law on animal experiments 
(http://wetten.overheid.nl/BWBR0003081). Nine-week-old female C57BL/6 mice, and Sprague 
Dawley rats (Harlan laboratories, Venray, The Netherlands) were randomly assigned to treatment 
groups (six animals per group), and allowed to acclimate for 1.5 weeks. Animals were housed in 
groups in standard cages and conditions (temperature 23 (±2)°C, 50-60% relative humidity, 12 h 
dark and light cycle) with free access to food and water. Mice and rats received single doses (table 
16) of core congeners (TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156), 
which were administered in corn oil at a dosing volume of 10 mL/kg bw by oral gavage. Dependent 
on the congener and its current TEF, five different dosages (L, M, N, O, or P) were administered. 
Animals were sacrificed at day three after dosing by CO2/O2. One dose group (O-group) of each 
compound was added for an exposure time of 14 days (Van Ede et al., 2013a; Van Ede et al., 2011). 
For the work in hand, livers (snap frozen and stored at -80°C) were used as starting material for 
microarray or qRT-PCR experiments. The P-group was excluded from examinations and is 
therefore not displayed in table 16. 
 
Table 16: Overview of animal experiments (mouse, rat) performed at IRAS and administered doses; six animals 
per dose group; three days, and 14 days study. 
Single dose (µg/kg bw)  
Congener Kb L M N Ob 
 
WHO-TEF (2005)a 
       
TCDD 0 0.5 2.5 10 25 1 
1-PeCDD 0 0.5 2.5 10 25 1 
4-PeCDF 0 5 25 100 250 0.1 
PCB 126 0 5 25 100 250 0.1 
PCB 118 0 5000 15000 50000 150000 0.00003 
PCB 156 0 5000 15000 50000 150000 0.00003 
PCB 153 0 5000 15000 50000 150000 - 
aVan den Berg et al., 2006 
bDoses for both three days & 14 days study 
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3.10. Calculation of relative effect potencies and statistical analysis 
 
Half maximal effective concentration (EC50)-values of congeners as part of in vitro-studies were 
received by sigmoid fitting using Origin software (OriginLab 6.0, Microcal Software, Inc.; 
Northampton, Massachusetts, USA). Concerning EROD-measurements, EROD-activities in solvent 
controls were considered as background level, and subtracted from data. For effective concentration 
20% (EC20)-values, the upper limit of the respective TCDD-derived curve was set 100%, and test 
compound concentrations attaining its fifth part were defined as EC20. In accordance with the TEF-
concept, respective relative effect potencies (REPs) revealed the compounds’ potencies relative to 
the reference compound TCDD. 
Essentially, all models are wrong, but some are useful (George E. P. Box).  
Statistical significant differences of means (control vs. treatment group(s)) were determined using 
one-way analysis of variance (ANOVA) followed by either two-tailed unpaired t-test with Welch-
correction (applied for two groups), or Dunnett’s Post-Test (applied for ≥ three groups). Statistically 
significant values were marked with * (p-value < 0.05; significant), ** (p-value < 0.01; very 
significant), or *** (p-value < 0.001; extremely significant). Calculations were performed using 
GraphPad InStat version 3.00 (GraphPad Software, San Diego, California, USA). For detailed 
information regarding evaluation and statistical analysis of microarray experiments, see respective 
chapter. 
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4  
Results 
 
4.1. In vivo – animal experiments  
 
In the course of the SYSTEQ project, mouse and rat studies were performed in order to establish 
AhR-dependent effects. Mice and rats received single doses of TCDD, 1-PeCDD, 4-PeCDF, PCB 
118, PCB 126, or PCB 156 and were sacrificed after three days or 14 days of exposure. Treatment 
of animals with PCB 153 was used to specify AhR-independent effects. 
For the purposes of the work in hand, mRNA of liver samples of mouse three days study was 
isolated, checked on purity via Bioanalyzer, and applied to whole genome microarray analysis. 
TCDD-and PCB 153-derived effects on gene expression in mouse liver were closely studied by 
Christiane Lohr (Lohr, 2013), whereas impact of 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, or PCB 
156 were analyzed in the following. According to the TEF-concept, contrasting effects due to these 
DL-congeners to TCDD’s was essential and required for evaluation within the framework of the 
SYSTEQ project. By courtesy of Christiane Lohr, raw-data referring to TCDD’s impact on gene 
expression in mouse liver was used in this regard. Besides heat maps, principal component analyses 
(PCAs), and gene lists, pathway analyses by means of TopGO analysis were performed in order to 
gain further information regarding mechanism(s) of action among core congeners.  
Furthermore, liver samples of rat studies (three days, 14 days) were analyzed regarding AhR-, 
CAR-, and PXR-dependent effects of core congeners. To approach to these objectives, mRNA was 
examined via qRT-PCR with respect to Cyp1a1, Cyp2b1, and Cyp3a4. 
 
4.1.1. Mouse whole genome microarray analysis 
 
Subsequent to verification of purity of mRNA isolated from liver samples of treated animals, two-
color microarray-based gene expression analysis followed applying Mouse GE 4x44K v2 
Microarray Kits (Agilent Technologies GmbH, Waghaeusel-Wiesental, Germany). Of each 
treatment group, samples of all six treated animals and three controls were included, and processed 
individually implementing dye-swop procedures. Data normalization and statistical analyses were 
performed using Bioconductor R package Limma (Smyth, 2004), whereas data of the entire study 
was analyzed globally, including TCDD-, and PCB 153-derived data obtained by courtesy of 
Christiane Lohr (Lohr, 2013). Results were filtered by cutoff values for signal intensity A ≥ 27, 
logarithmic (log2) fold change │lfc│ ≥ 1, and p-value < 0.05.  
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4.1.1.1. Heat maps and Principal Components Analysis  
 
Initial inspection of microarray data implied clustering of information to reduce data 
dimensionality. To at first approximate variability of data, and to verify exhibited trends, principal 
component analyses (PCAs) were performed. 
Figure 9 shows PCA-results regarding whole genome microarray analysis and effects of core 
congeners on gene expression in mouse livers after three days of single dose exposure. 
 
 
Figure 9: PCA mouse whole genome microarray analysis (in vivo, three days). Examination of RNA of livers 
from mice treated with TCDD (cyan), 1-PeCDD (magenta), 4-PeCDF (blue), PCB 118 (yellow), PCB 126 (pink), 
PCB 153 (orange), or PCB 156 (brown), focusing on treatment groups (left), and contrasting dyes (right; red: 
control dyed Cy3, green: control dyed Cy5).  3D scatter plot view of data with respect to their correlation to the 
first three principal components (PCs 1-3).  
 
By means of PCA-results regarding mouse whole genome microarrays, reasonable clustering of 
data among animals of one treatment group was observed (figure 9, left). PCB 126 (pink), 4-PeCDF 
(blue), or PCB 118 (yellow) affected gene transcription in broader diversifying degree among 
treatment groups compared to TCDD’s, 1-PeCDD’s, or PCB 156’s effects. Clustering between 
treatment groups appeared less prominent referred to differently affected gene expression in mouse 
livers due to compound treatments but yet indicated consistency of mRNA integrity.  
Varying properties of samples referable to applied dye (figure 9, right) resulted in homogenous, but 
not highly deviated clustering of Cy3 (red, w.r.t. control)-, and Cy5 (green, w.r.t. control)-dyed 
samples. Adopted dye-swop was used in order to reduce diverging dye properties delineated in 
figure 9.  
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Microarray data visualized by means of a (bi)cluster visualization technique generated heat maps, 
which reflect congeners’ effects on gene expression in mouse livers. With the aid of heat maps, 
indication of congeners’ impact, including overlaps or distinctions among these, affecting gene 
expression may be outlined in this regard. 
Figure 10 presents a heat map regarding mouse microarray data and │lfc│ ≥ 1 (p-value < 0.05), 
comprising results of the entire study with all seven core congeners, including data by courtesy of 
Christiane Lohr (Lohr, 2013), observed by examination of TCDD-, and PCB 153-treated mice. 
 
 
 
Figure 10: Heat map (I) mouse whole genome microarray analysis (in vivo, three days). Examination of RNA of 
livers from mice treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156. For degree 
of up-regulation (red), and down-regulation (green) see Color Key and Histogram; │lfc│≥ 1, p-value < 0.05. 
Treatment groups (horizontal) vs. regulated genes (vertical).  
 
The heat map presented in figure 10 gives initial impressions concerning core congeners’ impact on 
gene expression in mouse livers considering │lfc│ ≥ 1. Correlating degree of red-, and green-
coloring, 4-PeCDF, PCB 126, or PCB 156 led to more pronounced effects regarding number and 
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extent of up-, and down-regulation of genes compared to TCDD, 1-PeCDD, PCB 118, or PCB 153. 
Interrelations between impact of TCDD and 1-PeCDD was indicated, as well as between PCB 156 
and 4-PeCDF, furthermore between these two congeners and PCB 126, continuing with a coherence 
of PCB 118 and the correlating group of PCB 126/PCB 156/4-PeCDF, and finally, to less 
prominent extent among DL-compounds, conforming TCDD/1-PeCDD to PCB 118/PCB 126/PCB 
156/4-PeCDF. Weakest compliance was obtained between DL-congeners and the NDL PCB 153. 
 
Specifying focus on highly regulated genes (│lfc│ ≥ 5; p-value < 0.05) led to a heat map, which is 
presented in figure 11. Results comprise data obtained by courtesy of Christiane Lohr (Lohr, 2013), 
regarding mRNA-analysis of TCDD-, and PCB 153-treated mice. 
 
 
 
Figure 11: Heat map (II) mouse whole genome microarray analysis (in vivo, three days). Examination of RNA of 
livers from mice treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156. For degree 
of up-regulation (red), and down-regulation down-regulation (green) see Color Key and Histogram; │lfc│≥ 1,   
p-value < 0.05. Treatment groups (horizontal) vs. regulated genes (vertical).  
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Since a low number of genes was affected to higher extent (│lfc│ ≥ 5) throughout the entire study, 
closer examination of regulated genes depicted in heat map in figure 11 was feasible. Most 
prominent degree of regulated genes was obtained due to 4-PeCDF-treatment, followed by PCB 
126, PCB 156, and PCB 118. Regarding coherence as well as distinctions between congeners’ 
effects, stronger correlations even by means of visual perception was given. Coherencies between 
congeners foreseen in figure 10 appeared in stronger dimensions.  
Coherent groups were TCDD/1-PeCDD; 4-PeCDF/PCB 156; PCB 126/PCB 156/4-PeCDF;       
PCB 118/PCB 126/PCB 156/4-PeCDF, and least of all, clustering of all DL-congeners lightly 
concurred with NDL-PCB 153’s effects. Interestingly, most obvious up-regulated genes due to 
treatment with all DL-congeners were Cyp1a1, and Cyp1b1, except for PCB 118, where the strict 
cutoff of │lfc│ ≥ 5 may have restrained Cyp1b1-inducing effects in the diagram. In contrast, NDL-
PCB 153 slightly repressed Cyp1a1, and Cyp1b1, but distinctly induced another Cyp (Cyp2c55).  
 
4.1.1.2. Regulated genes 
 
In terms of examination of genes, which were affected regarding their transcription rates due to 
congeners’ impact, data normalization and statistical analyses were performed using Bioconductor 
R package Limma (Smyth, 2004). In this regard, data of the entire study was analyzed globally, 
including TCDD-, and PCB 153-derived data by courtesy of Christiane Lohr (Lohr, 2013). Results 
were filtered by cutoff values for signal intensity A ≥ 27, │lfc│ ≥ 1 and p-value < 0.05.  
 
TCDD 
 
Relevant with regard to purposes of the work in hand were effects on gene transcription due to 
single dose-exposure (25 µg/kg bw, three days) of mice with TCDD. Taking account of defined 
cutoff values (A ≥ 27, │lfc│ ≥ 1, p-value < 0.05), the number of ≥ 2fold regulated genes by TCDD 
was 125 (up-regulated), and 95 (down-regulated), respectively. Top three up-regulated genes in 
descendant order were Cyp1a1 (NM_009992, A = 210.23, lfc = 9.478, fold induction = 713.12), 
Cyp1b1 (NM_009994, A = 27.16, lfc = 5.169, fold induction = 35.98), and Cyp1a2 (NM_009993,    
A = 213.33, lfc = 3.985, fold induction = 15.83). Top three down-regulated genes in descendant order 
were Klf10 (NM_013692, A = 28.11, lfc = -2.846, fold induction = 0.1391), Rgs16 (NM_011267,    
A = 28.35, lfc = -2.601, fold induction = 0.1648), and Serpina4-ps1 (BC031891, A = 29.43,               
lfc = -2.573, fold induction = 0.1681).  
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TCDD 1-PeCDD
45
374
55
319
95
125
# of down-regulated genes
# of up-regulated genes
4.1.1.2.1. 1-PeCDD – impact on gene transcription in mouse livers  
 
In figure 12, numbers of genes regulated in mouse livers subsequent to single-dose treatments with 
1-PeCDD (25 µg/kg bw) and three days of exposure are depicted. Comparison to data obtained by 
TCDD-treatment by courtesy of Christiane Lohr was included (Lohr, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Mouse whole genome microarray analysis. Numbers of regulated genes in mouse livers by 1-PeCDD 
(25 µg/kg bw, three days) compared to numbers of genes regulated by TCDD (25 µg/kg bw, three days), and 
numbers of genes regulated both by 1-PeCDD and TCDD (TCDD-raw data by courtesy of C. Lohr; Lohr, 2013). 
A ≥ 27, p-value < 0.05. 
 
Choosing cutoff values for signal intensity A ≥ 27, logarithmic (log2) fold change │lfc│ ≥ 1, and p-
value < 0.05, transcription of genes in mouse livers was up-regulated concerning 319, and down-
regulated for 374 genes (figure 12). Scaling up cutoff value to │lfc│ ≥ 1.585 (≥ 3fold induction), 
55 up-, and 45 down-regulated genes were impacted by 1-PeCDD. From 125 up-, and 95-down-
regulated genes due to TCDD-treatment, which were induced ≥ 2fold, 92 (up), and 61 (down) genes 
were accordantly affected by 1-PeCDD.  
In order to gain an insight into types of genes regulated in mouse livers subsequent to 1-PeCDD-
exposure, the Top 20 of 319 up-regulated genes (≥ 2fold) are compiled in table 17. 
 
 
TCDD 
≥ 2fold 
92↑ 
61↓ 
227↑ 
313↓ 33↑ 
34↓ 
1-PeCDD  
≥ 2fold 
≥ 2fold                     ≥ 2fold                     ≥ 3fold 
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Table 17: Mouse whole genome microarray analysis. Top 20 up-regulated genes in mouse livers by 1-PeCDD (25 
µg/kg bw, three days); descending order. Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
1-PeCDD 
 
lfc 
Gene  
systematic 
name 
 
 
Gene description 
 
 
Gene name 
 
 
  
9.092 NM_009992 cytochrome P450, family 1, subfamily a, polypeptide 1 Cyp1a1 
4.440 NM_009994 cytochrome P450, family 1, subfamily b, polypeptide 1 Cyp1b1 
3.975 NM_009993 cytochrome P450, family 1, subfamily a, polypeptide 2 Cyp1a2 
3.212 NM_027872 solute carrier family 46, member 3 Slc46a3 
2.871 NM_016865 HIV-1 tat interactive protein 2, homolog (human) Htatip2 
1.754-2.870 NM_201640 cytochrome P450, family 4, subfamily a, polypeptide 31 Cyp4a31 
2.798 NM_017379 tubulin, alpha 8 Tuba8 
2.747 NM_010210 fragile histidine triad gene Fhit 
2.641 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
2.526 NM_012006 acyl-CoA thioesterase 1  Acot1 
2.516 NM_201641 UDP glycosyltransferase 1 family, polypeptide A10 Ugt1a10 
2.476 NM_013786 hydroxysteroid (17-beta) dehydrogenase 6 Hsd17b6 
2.360 NM_026791 F-box and WD-40 domain protein 9  Fbxw9 
1.314-2.336 NM_206537 cytochrome P450, family 2, subfamily c, polypeptide 54 Cyp2c54 
2.231/1.466 NM_025341 abhydrolase domain containing 6 Abhd6 
2.174/1.104 NM_145079 UDP glucuronosyltransferase 1 family, polypeptide A6A Ugt1a6a 
2.172/1.081 NM_007618 serine (or cysteine) peptidase inhibitor, clade A, member 6  Serpina6 
2.135/1.134 NM_021282 cytochrome P450, family 2, subfamily e, polypeptide 1 Cyp2e1 
2.126 XM_885022 predicted pseudogene 6168   Gm6168 
1.721-2.123 NM_010011 cytochrome P450, family 4, subfamily a, polypeptide 10 Cyp4a10 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
The top three up-regulated and concurrently typical AhR-responsive genes in mouse livers 
responding to 1-PeCDD-treatment were Cyp1a1 (NM_009992; lfc = 9.092), Cyp1b1 (NM_009994; 
lfc = 4.440), and Cyp1a2 (NM_009993; lfc = 3.975) (table 17). Further up-regulated gene 
transcripts encoding CYP-enzymes within the Top 20-table were Cyp4a31 (lfc = 1.754-2.870), 
Cyp2c54 (lfc = 1.314-2.336), Cyp2e1 (lfc = 2.135/1.134), and Cyp4a10 (lfc = 1.721-2.123).  
Denoted CYP-enzymes share relevant roles regarding oxidation-reduction processes and are 
involved in lipid and fatty acid metabolism, as CYPs of the 4A subfamily catalyze                         
ω-hydroxylations of fatty acids, e.g. (Gibson et al., 1982; Hardwick et al., 1987; Tamburini et al.
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1984). CYP2C54 and CYP4A10 are proteins further correlated to arachidonic acid metabolism and 
are hence potentially able to play a role regarding prostaglandin-biosynthesis (Binns et al., 2009; 
Dimmer et al., 2012; Varvas et al., 2009). The encoded monooxygenases were discussed with 
respect to lipid peroxidation and oxidative stress and were further linked to hepatic steatosis and 
steatohepatitis (Chitturi and Farrell, 2001; Leclercq et al., 2000).  
By heterodimerization with the retinoic acid receptor α (RXRα), peroxisome proliferator-activated 
receptor α (PPARα) regulates Cyp4a-gene transcription (Keller et al., 1993; Kliewer et al., 1992; 
Muerhoff et al., 1992), and as well regulates gene transcription of Cyp4a10, and Cyp4a31 (Bumpus 
and Johnson, 2011). Being inducible by fatty acids, eicosanoids, or peroxisome proliferators like 
clofibrate (Krey et al., 1997; Lee et al., 1995; Sharma et al., 1988), PPARα-activation participates 
in the regulation of biological processes including lipid metabolism, cell cycle control, as well as 
inflammatory response (reviewed in Vanden Heuvel, 1999; Wahli et al., 1995). In particular, this 
transcription factor governs both microsomal (via CYP4A) and peroxisomal (β-oxidation) pathways 
of lipid oxidation and ultimate production of reactive oxygen species (ROS) (Chitturi and Farrell, 
2001). Though Ppara-responsive genes appeared up-regulated, Ppara-mRNA itself was not 
regulated by 1-PeCDD according to two of three oligos (NM_011144; lfc = 0.424), and was down-
regulated regarding the third of three available oligos on the microarray-slides (NM_011144;        
lfc = -1), however.  
Further genes indicating altered lipid metabolism and transport within and beyond the Top-20 gene-
list, which were up-regulated by 1-PeCDD in the course of the study in hand, were acyl-CoA 
thioesterase 1 (Acot1, NM_012006; lfc = 2.526), hydroxysteroid (17-β)  dehydrogenase 6 
(Hsd17b6, NM_013786; lfc = 2.476), abhydrolase domain containing 6 (Abhd6, NM_025341;      
lfc = 2.231 (max.)), CD36 antigen (Cd36, NM_007643, long chain fatty acid translocase family;   
lfc = 1.792), Cyp4a14 (‘lauric acid ω-hydroxylase 3’, NM_007822; lfc = 1.674), and Cyp8b1 
(‘sterol 12-α-hydroxylase’, NM_010012; lfc = 1.480) (Binns et al., 2009; Dimmer et al., 2012; 
Hunt et al., 2000; Muerhoff et al., 1992; Post et al., 2001).  
 
Up-regulation of these genes further might hint towards 1-PeCDD’s probable impact on eicosanoid 
biosynthetic processes (Abhd6, Cyp4a14) and involvement in bile acid synthesis (Cyp8b1) (Binns et 
al., 2009; Dimmer et al., 2012). Abhd6-induction was discussed in terms of macrophage activation 
in conjunction with the endocannabinoid system (Alhouayek et al., 2013). The endocannabinoid 
system is a lipid signaling system, which outside the brain crucially modulates physiological 
functions including the endocrine network, the immune system, and microcirculation (Rodríguez de 
Fonseca et al., 2005). The enzyme ABHD6 is able to hydrolyze the endocannabinoid                      
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2-arachidonoyl glycerol (2-AG), which potentially leads to a decrease of 2-AG in the cell and 
subsequent macrophage activation in case not only Abhd6 mRNA was induced by 1-PeCDD but 
also the ABHD6 protein itself (Alhouayek et al., 2013). Induction of Hsd17b6 might indicate        
1-PeCDD’s impact to alter steroid hormone metabolism, as respective HSD17B6 protein is capable 
of conversion of 5α-androstan-3α, 17β-diol to androsterone and of estradiol to estrone (Su et al., 
1999). Another gene-product within the Top 20-list related to endocrine function was serine (or 
cysteine) peptidase inhibitor, clade A, member 6 (Serpina6, NM_007618; max. lfc = 2.172), of 
which the translated protein is involved in pathways of chemical reactions with glucocorticoids 
including their metabolism and their regulatory function in carbohydrate and protein metabolism 
(Binns et al., 2009; Dimmer et al., 2012). F-box and WD-40 domain protein 9 (Fbxw9, 
NM_026791; lfc = 2.360), was also up-regulated by 1-PeCDD in mouse livers. The respective 
protein takes part in ubiquitin-dependent protein catabolic processes (Binns et al., 2009; Dimmer et 
al., 2012). 
 
Besides aforementioned transcripts encoding CYP-enzymes, further affected oligos within the Top 
20-list, which are involved or proposed to be involved in (xenobiotic) metabolism, were UDP-
glycuronosyltransferase 1 family, polypeptide A10 (Ugt1a10, NM_201641; lfc = 2.516), Ugt1a6a 
(NM_145079; lfc = max. 2.174), and the predicted pseudogene 6168 (Gm6168, XM_885022;       
lfc = 2.126). The latter pseudogene lies within a cluster of sulfotransferase family 2A genes on 
chromosome 7 A1 (Binns et al., 2009; Dimmer et al., 2012). Another indication regarding 
transcriptionally and metabolically active liver cells gave the up-regulation of solute carrier family 
46, member 3 (Slc46a3, NM_027872; lfc = 3.212). The encoded protein participates in 
transmembrane transport mechanisms including transport of nucleotides, peptides, steroids, 
carbohydrates, and hydrogen peroxide (Binns et al., 2009; Dimmer et al., 2012). 
 
HIV-1 tat interactive protein 2 (Htatip2, NM_016865; lfc = 2.871) constitutes a tumor suppressor 
protein acting as a repressive transcription factor in the nucleus. Among a number of other 
mechanisms, HTATIP2 was discussed in correlance with induction of apoptosis under oxidative 
stress through stabilization of p53 mRNA (Zhao et al., 2008a). Fragile histidine triad gene (Fhit, 
NM_010210; lfc = 2.747) represents another pro-apoptotic tumor suppressor gene induced by        
1-PeCDD-treatment. Tubulin, alpha 8 (Tuba8, NM_017379; lfc = 2.798), as the encoding tubulin 
represents a major constituent of microtubules, is at present annotated to biological processes 
including microtubule cytoskeleton organization, GTP catabolic processes, and protein 
polymerization (Binns et al., 2009; Dimmer et al., 2012). 
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The results obtained by means of classical enrichment analysis by testing over-representation of GO 
terms within the group of differentially expressed genes due to 1-PeCDD-treatment in mouse livers 
are presented in table 18 and in figure 13.  
 
Table 18: Mouse whole genome microarray analysis – TopGO analysis (1-PeCDD), Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; 
descending order. Mouse liver, 1-PeCDD (25 µg/kg bw, three days). Top five GO terms indicated in bold. 
1-PeCDD 
 
GO term 
 
 
GO ID 
 
sign./annot. 
probes 
 
 
raw p-value 
  
  
oxidation-reduction process GO:0055114 86/1237 1.6E-15 
long-chain fatty acid metabolic process GO:0001676 16/68 2.8E-11 
cellular ketone metabolic process GO:0042180 61/948 5.3E-10 
lipid metabolic process GO:0006629 72/1221 6.6E-10 
terpenoid metabolic process GO:0006721 12/42 7.5E-10 
carboxylic acid metabolic process GO:0019752 58/918 2.8E-09 
oxoacid metabolic process GO:0043436 58/918 2.8E-09 
xenobiotic metabolic process GO:0006805 11/38 3.3E-09 
cellular response to xenobiotic stimulus GO:0071466 11/38 3.3E-09 
organic acid metabolic process GO:0006082 58/937 5.8E-09 
response to xenobiotic stimulus GO:0009410 11/41 8.0E-09 
monoterpenoid metabolic process GO:0016098 5/5 1.4E-08 
cellular lipid metabolic process GO:0044255 54/876 2.3E-08 
monocarboxylic acid metabolic process GO:0032787 38/511 2.6E-08 
small molecule metabolic process GO:0044281 125/2829 3.4E-08 
isoprenoid metabolic process GO:0006720 13/75 1.0E-07 
very long-chain fatty acid metabolic process GO:0000038 10/43 1.7E-07 
drug metabolic process GO:0017144 8/25 2.0E-07 
coenzyme metabolic process GO:0006732 23/250 3.9E-07 
cofactor metabolic process GO:0051186 26/311 4.5E-07 
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Figure 13: Mouse whole genome microarray analysis – TopGO analysis (1-PeCDD, 25 µg/kg bw, three days; 
mouse liver): The GO subgraph plot induced by the top five GO terms identified by the classic algorithm for 
scoring GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant GO 
terms. Box color represents relative significance ranging from dark red (most significant) to light yellow (least 
significant).  
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The top five GO terms (indicated in bold in table 18) inducing the subgraph presented in figure 13, 
are linked to ‘oxidation-reduction processes’ (GO:0055114) and lipid metabolism (GO:0001676, 
GO:0042180, GO:0006629, GO:0006721). ‘Oxidation-reduction process’ is as well connected with 
metabolism and actually represents a parent term from lipid oxidation (GO:0034440), for instance, 
which in turn has child terms such as fatty acid beta-oxidation (GO:0006635). Another child term 
from ‘oxidation-reduction process’ is ‘oxidoreductase activity’ (GO:0016491) followed by inferred 
‘monooxygenase activity’ (GO:0004497). Among annotated genes up-regulated by 1-PeCDD 
within ‘oxidation-reduction processes’ (GO:0055114; 86/1237 significant probes), 29 probes       
(21 genes) encoded CYP-enzymes of families 1, 2, 3, 4, 8, and 26. Further significantly up-
regulated genes annotated to this GO term were Cd36 (NM_007643), hydroxysteroid (17-beta) 
dehydrogenase 2 (Hsd17b2, NM_008290), tryptophan 2,3-dioxygenase (Tdo2, NM_019911), and 
kynurenine 3-hydroxylase (Kmo, NM_133809). 
 
Obtained by testing over-representation of GO terms within the group of differentially expressed 
genes, further relevant biological processes significantly switched on by 1-PeCDD in mouse livers 
were related to drug and xenobiotic metabolism (GO:0017144, GO:0006805) as well as ancestral 
terms including coenzyme/cofactor metabolic processes (GO:0006732, GO:0051186) (Ashburner et 
al., 2000; Binns et al., 2009). 
 
Along the whole experiment, high correlation between 1-PeCDD-, and TCDD-derived effects was 
revealed. Of 43020 oligos (excluding intern controls), 13312 were assigned to signal intensities      
A ≥ 27 throughout the entire study concerning all seven core congeners. From these, lfc-expressing 
coefficients belonging to 1-PeCDD’s impact, which diverged at most ±1 from TCDD’s, were 
13170, 11322 lay in a range of ±0.5 TCDD’s lfcs, 3270 oligos were not exceeding ±0.1 TCDD’s 
lfcs, 1674 varied less or equal than ±0.05 from TCDD’s lfc’s, and 372 oligos conformed with 
TCDD’s lfcs to ±0.01. As mentioned above, of 319 up-regulated genes by 1-PeCDD, and 125 up-
regulated genes by TCDD, 92 genes were induced in response to both treatments in livers of mice. 
The respective Top 20-list (sorted referring to TCDD-derived effects) of up-regulated genes is 
presented in table 19. Raw data pertaining to TCDD-treatment was obtained by courtesy of 
Christiane Lohr (Lohr, 2013). 
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Table 19: Mouse whole genome microarray analysis. Top 20 genes (totaling 92) accordantly up-regulated in 
mouse livers by 1-PeCDD (25 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). Sorted based on 
TCDD-derived effects. TCDD-raw data by courtesy of Lohr (2013). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
1-PeCDD    
& TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
9.092 9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1  Cyp1a1 
4.440 5.169 NM_009994 cytochrome P450 family 1 subfamily b polypeptide 1  Cyp1b1 
3.975 3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2  Cyp1a2 
2.747 3.582 NM_010210 fragile histidine triad gene   Fhit 
2.798 3.379 NM_017379 tubulin alpha 8  Tuba8 
3.212 3.103 NM_027872 solute carrier family 46 member 3  Slc46a3 
1.349 2.903 NM_178892 TCDD-inducible poly(ADP-ribose) polymerase   Tiparp 
1.725 2.819 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
2.117 2.722 XM_001477458 predicted gene ENSMUSG00000054044   Gm9933 
2.871 2.678 NM_016865 HIV-1 tat interactive protein 2, homolog (human)  Htatip2 
2.641 2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
1.831 2.386 NM_013872 phosphomannomutase 1   Pmm1 
1.351 2.153 NM_023440 transmembrane protein 86B  Tmem86b 
2.360 2.123 NM_026791 F-box and WD-40 domain protein 9  Fbxw9 
1.427 1.978 NM_028747 RIKEN cDNA 0610012H03 gene  0610012H03Rik 
2.172/ 
1.081 
1.931/ 
1.039 NM_007618 serine (or cysteine) peptidase inhibitor clade A member 6  Serpina6 
1.606/ 
1.054 
1.857/ 
1.362 NM_013541 glutathione S-transferase pi 1  Gstp1 
1.251 1.853 NM_001122660 predicted gene 10639   Gm10639 
1.792 1.758 NM_007643 CD36 antigen  Cd36 
1.919 1.702 NM_007689 chondroadherin  Chad 
     
Values b/a from oligo b/oligo a. 
 
As suggestible due to the appropriate correlation regarding numbers of accordantly up-regulated 
genes by both 1-PeCDD and TCDD, the Top 20-list of up-regulated genes (table 19) in the main 
reflected 1-PeCDD’s Top 20-list of up-regulated genes. Gene transcripts of the top three CYPs were 
induced in the same ranking order (Cyp1a1 > Cyp1b1 > Cyp1a2) and to a highly correlative degree. 
In total, ten out of 20 genes appeared in both the 1-PeCDD-Top 20-list and the 1-PeCDD&TCDD-
Top 20-list.  
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TCDD-inducible poly(ADP-ribose) polymerase (Tiparp), of which TCDD-induced transcription 
was reported to be AhR-dependent, was up-regulated by both congeners (Ma, 2002; Ma et al., 
2001). Since Tiparp-inducing effects due to 1-PeCDD-treatment were less efficient compared to 
TCDD’s impact (lfc (1-PeCDD) = 1.349 vs. lfc (TCDD) = 2.903), and the Top 20 list in table 19 for 
1-PeCDD&TCDD was sorted referring to TCDD-derived effects, Tiparp did occur in table 19, but 
not in the Top 20-list of 1-PeCDD-up-regulated genes (table 17). The NAD+-ADP-
ribosyltransferase was proposed to be involved in several biological processes including estrogen 
metabolism or hemopoiesis (Binns et al., 2009; Dimmer et al., 2012).  
 
Another up-regulated gene related to immune response affected by 1-PeCDD as well as TCDD was 
Cd36 (NM_007643; lfc (1-PeCDD) = 1.792, lfc (TCDD) = 1.758), which is also linked to lipid 
metabolism. Further hints regarding both compounds’ effects on lipid metabolism were given due to 
effects on transmembrane protein 86B (Tmem86b, NM_023440; lfc (1-PeCDD) = 1.351,               
lfc (TCDD) = 2.153). The encoded enzyme lysoplasmalogenase catalyzes the degradation of 
lysoplasmalogens, which are formed by the hydrolysis of the abundant membrane 
glycerophospholipids plasmalogens (Binns et al., 2009; Dimmer et al., 2012). 
 
A dominating result within the Top 20-table (figure 19) of both examined dibenzo-p-dioxins was 
their impact on genes implicated in phase II metabolism: the glutathione S-transferases (GSTs) 
Gsta1 and Gstp1, as well as a transcript (NM_001122660) encoding a GST named protein 
Gm10639 (Binns et al., 2009; Dimmer et al., 2012). 
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Table 20 presents the Top 20-list of down-regulated genes in mouse livers in respond to single 
doses of 1-PeCDD (25 µg/kg bw). In total, transcription of 374 genes was inhibited by 1-PeCDD-
treatment according to chosen cutoff values (A ≥ 27, lfc ≤ -1, p-value < 0.05). 
 
Table 20: Mouse whole genome microarray analysis. Top 20 down-regulated genes in mouse livers by 1-PeCDD 
(25 µg/kg bw, three days); descending order. Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
1-PeCDD 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
-2.797-(-2.009) NM_007706 suppressor of cytokine signaling 2  Socs2 
-2.535/ 
-2.537 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-2.531 NM_001081141 gamma-aminobutyric acid B receptor 2  Gabbr2 
-2.381/-2.129 NM_134037 ATP citrate lyase  Acly 
-2.244-(-2.138) NM_207655 epidermal growth factor receptor  Egfr 
-2.123 NM_007988 fatty acid synthase  Fasn 
-2.087 NM_001111110 cytidine monophospho-N-acetylneuraminic acid hydroxylase   Cmah 
-2.070 NM_145148 FERM domain containing 4B  Frmd4b 
-2.040/-1.148 NM_029389 family with sequence similarity 35 member A  Fam35a 
-2.031 
ENSMUST00000
099037 Unknown    
ENSMUST0000
0099037 
-2.027 NM_007606 carbonic anhydrase 3  Car3 
-2.013 XM_001480325 similar to hepatocyte nuclear factor 6 beta   LOC100048479 
-2.010/-1.856 
ENSMUST00000
099683 Unknown    
ENSMUST0000
0099683 
-1.980/-1.922 
ENSMUST00000
099050 Unknown    
ENSMUST0000
0099050 
-1.964 NM_146153 thyroid hormone receptor associated protein 3  Thrap3 
-1.955/-1.586 NM_133904 acetyl-Coenzyme A carboxylase beta  Acacb 
-1.894 NM_009723 ATPase  Ca++ transporting plasma membrane 2  Atp2b2 
-1.889 XM_001003154 similar to Glucose phosphate isomerase 1 transcript variant 2  LOC676974 
-1.888 NM_020507 transducer of ERBB2, 2  Tob2 
-1.888 NM_013490 choline kinase alpha Chka 
  
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Suppressor of cytokine signaling 2 (Socs2, NM_007706; lfc (max) = -2.797) was the most 
efficiently down-regulated gene-transcript in livers from mice treated with 1-PeCDD (table 20). 
SOCS family proteins belong to a class of negative regulators of the Janus kinase/signal transducers 
and activators of transcription (JAK/STAT) pathway, which is a principal signaling mechanism for 
a wide array of cytokines and growth factors stimulating cell proliferation, cell migration and 
apoptosis. SOCS2 was proposed to play a role in mediating ubiquitination and subsequent 
proteasomal degradation of target proteins (Binns et al., 2009; Dimmer et al., 2012; Rawlings et al., 
2004).  
The two serine (or cysteine) peptidase inhibitor clade A member 4 pseuogene 1 (Serpina4-ps1, 
BC031891/NR_002861; lfc (max) = -2.537) gene transcripts representing the second highest down-
regulating effect on gene transcription by 1-PeCDD are non-protein coding. Other cysteine- or 
serine-type peptidase inhibitor proteins are involved in apoptotic processes or response(s) to 
cytokines (Binns et al., 2009; Dimmer et al., 2012). The down-regulated transcription of gamma-
aminobutyric acid (GABA) B receptor 2 (Gabbr2, NM_001081141; lfc = -2.531) might be 
correlated to reduced GABBR2-mediated coupling to G proteins and correlated G-protein coupled 
receptor signaling pathways, since GABBR2 together with GABBR1 builds the heterodimeric      
G-protein coupled receptor for GABA (Binns et al., 2009; Dimmer et al., 2012). 
 
An enzyme, which is involved in the citric acid cycle, is encoded by another down-regulated gene 
transcript, namely ATP citrate lyase (‘ATP citrate synthase’, Acly, NM_134037;                            
lfc (max) = -2.381). Shortened, the enzyme catalyzes the reaction of acetyl-CoA and oxalacetate to 
form citrate and Coenzyme A (CoA). A central role in de novo lipid synthesis is attributed to ACLY 
since the ability of citrate to leave the mitochondria allows transferring acetyl-CoA into cytoplasm, 
where it is required for fatty acid synthesis (Srere and Bhaduri, 1962). An inhibition of ACLY is 
therefore negatively correlated to lipid biosynthesis. Inhibition of lipid biosynthesis by 1-PeCDD 
was also indicated by down-regulation of fatty acid synthase (Fasn, NM_007988; lfc = -2.123), and 
acetyl-CoA carboxylase beta (Acacb, NM_133904; lfc (max) = -1.955). During fatty acid 
biosynhesis, Acacb catalyzes the carboxylation of acetyl-CoA to malonyl-CoA, whereas Fasn 
catalyzes the formation of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and NADPH 
(Binns et al., 2009; Dimmer et al., 2012). Beyond the top 20 list, further genes related to lipid 
metabolism were down-regulated by 1-PeCDD in mouse livers including acyl-Coenzyme A oxidase 
3 (Acox3, NM_030721; lfc = -1.063), apolipoprotein C-III (Apoc3, NM_023114; lfc = -1.155), 
apolipoprotein A-I (Apoa1, NM_009692; lfc (max) = -1.165) (Staels et al., 1992; Tugwood et al., 
1992). 
Results – mouse whole genome microarray analysis 
 
  77 
Among the Top 20-list, genes down-regulated by 1-PeCDD in mouse livers involved in altered 
carbohydrate- and glucose-metabolism were FERM domain containing 4B (Frmd4b, NM_145148; 
lfc = -2.070) and potentially ‘similar to hepatocyte nuclear factor 6 beta’ (LOC100048479, 
XM_001480325; lfc = -2.013). Frmd4b is a member of general receptor for 3-phosphoinositides 1 
(GRP1) signaling complexes, which are recruited to plasma membrane ruffles in response to insulin 
receptor signaling. GRP1 was further identified to play a key role in linking insulin signaling to 
glucose transporter type 4 GLUT4 recycling (Binns et al., 2009; Dimmer et al., 2012; Li et al., 
2012). Glut4 itself was regulated by neither investigated DL-congener in the course of the study in 
hand. The similarity of LOC100048479 to hepatocytes nuclear factor 6 (Hnf6) might hint a role of 
1-PeCDD in terms of glucose metabolism (Binns et al., 2009; Dimmer et al., 2012). Further, Hnf6 
and Fasn both are related to immune response. In particular, Fasn is involved in the cellular 
response to IL-4, whereas Hnf6 plays a role in B cell differentiation and spleen development, which 
together might hint towards 1-PeCDD-mediated suppression of B cell differentiation and B cell 
response (Binns et al., 2009; Dimmer et al., 2012).  
 
Regarding endocrine function, thyroid hormone receptor associated protein 3 (Thrap3, 
NM_146153; lfc = -1.964) was part of the Top 20-list of down-regulated gene transcripts. Thrap3 is 
involved in thyroid hormone receptor binding processes (Binns et al., 2009; Dimmer et al., 2012). 
Down-regulated genes within the Top 20-list related to oxidative stress were epidermal growth 
factor receptor (Egfr, NM_207655; lfc (max) = -2.244) and carbonic anhydrase 3 (Car3, 
NM_007607; lfc = -2.027). EGFR is able to activate signaling cascades including RAS-RAF-MEK-
ERK pathway or the STAT modules and may also activate the NF-ĸB signaling cascade (Binns et 
al., 2009; Dimmer et al., 2012).  
 
Setting chosen cutoff levels, the list for down-regulated genes by 1-PeCDD was examined 
performing classical enrichment analysis by testing over-representation of GO terms within the 
group of differentially expressed genes using Fisher’s exact test. The Top 20 GO terms obtained by 
means of this TopGO analysis is presented in table 21 (following page).  
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Table 21: Mouse whole genome microarray analysis – TopGO analysis (1-PeCDD), Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding down-regulated 
genes; descending order. Mouse liver, 1- PeCDD (25 µg/kg bw, three days). Top five GO terms indicated in bold. 
1-PeCDD 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
triglyceride metabolic process GO:0006641 15/109 1.1E-09 
triglyceride biosynthetic process GO:0019432 11/55 3.2E-09 
acylglycerol metabolic process GO:0006639 15/125 7.6E-09 
neutral lipid biosynthetic process GO:0046460 11/60 8.5E-09 
acylglycerol biosynthetic process GO:0046463 11/60 8.5E-09 
glycerol ether metabolic process GO:0006662 16/147 1.0E-08 
neutral lipid metabolic process GO:0006638 15/128 1.1E-08 
glycerol ether biosynthetic process GO:0046504 11/62 1.2E-08 
organic ether metabolic process GO:0018904 16/150 1.4E-08 
lipid biosynthetic process GO:0008610 29/572 6.5E-07 
glycerolipid metabolic process GO:0046486 20/308 8.9E-07 
fatty acid biosynthetic process GO:0006633 15/181 1.0E-06 
gland development GO:0048732 21/344 1.3E-06 
glycerolipid biosynthetic process GO:0045017 14/162 1.4E-06 
fatty acid metabolic process GO:0006631 22/391 2.8E-06 
regulation of lipid metabolic process GO:0019216 16/226 3.6E-06 
monocarboxylic acid metabolic process GO:0032787 25/511 7.1E-06 
regulation of biological quality GO:0065008 73/2614 7.5E-06 
small molecule biosynthetic process GO:0044283 23/448 7.5E-06 
cell development GO:0048468 52/1660 8.6E-06 
    
 
The most significant GO terms affected by 1-PeCDD regarding down-regulation of gene 
transcription were to highest degree related to lipid-biosynthesis and metabolism (table 21). 
Formally, these were divided into seven biosynthetic and nine metabolic processes among the Top 
20 GO terms. As the general structure of metabolic process terms correlates ‘cellular substance 
biosynthetic process’ and ‘cellular substance catabolic process’ as child terms of ‘cellular substance 
metabolic process’, several genes are often annotated to both biosynthetic and metabolic processes. 
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For instance, the term ‘triglyceride metabolic process’ (GO:0006641) represents a parent term to 
‘triglyceride biosynthetic process’ (GO:0019432).  
 
Accordingly, the down-regulated gene Fasn (lfc = -2.123) by 1-PeCDD is assigned to ‘fatty acid 
biosynthetic process(es)’ (GO:0006633) as well as to ‘fatty acid metabolic process(es)’ 
(GO:0006631). Consequently, the majority of most significantly clustering GO terms in response to 
in vivo treatment was related to inhibitory effects on gene expression correlated with lipid 
biosynthetic processes in mouse livers.  
 
With lowered significance (≥ 1.3E-06), further biological processes negatively regulated by           
1-PeCDD included ‘gland development’ (GO:0048732), ‘cell development’ (GO:0048468), and 
‘regulation of biological quality’ (GO:0065008). Among significantly affected probes belonging to 
‘gland development’ (21/344), the majority was not exclusively related to gland development 
including insulin receptor substrate 2 (Irs2, NM_001081212), Socs2 (NM_007706), apolipoprotein 
A-1 (Apoa1, NM_009692), Atp2b2 (NM_009723), and Egfr (NM_207655). A probe, which was 
down-regulated by 1-PeCDD-treatment and is more specifically involved in this process, was   
netrin 1 (Ntn1, NM_008744). Though belonging to a highly conserved family of axonal guidance 
signals, Ntn1 was proposed to serve as a survival factor to prevent the initiation of apoptosis 
(Ashburner et al., 2000; Binns et al., 2009; Püschel, 1999).  
GO-terms ‘cell development’ (GO:0048468), and ‘regulation of biological quality’ (GO:0065008) 
represent more comprehensive processes with many subordinated child terms. Significant probes 
(52/1660) within GO:0048468 partly coincided with those mentioned with respect to ‘gland 
development’ (Socs2, Apoa1, Atp2b2, Egfr, Ntn1), and further include Kruppel-like factor 10 
(Klf10, NM_013692), B-cell leukemia/lymphoma 6 (Bcl6, NM_009744), or mitogen-activated 
protein kinase 9 (Mapk9, NM_207692), for instance.  
A ‘biological quality’ represents a measurable attribute of an organism or part of an organism, such 
as size, mass, or shape (Ashburner et al., 2000; Binns et al., 2009). In terms of ‘biological quality’, 
73 of 2614 probes were inhibited by 1-PeCDD-treatment in mouse livers (Cd4 (NM_013488), 
complexin 2 (Cplx2, NM_009946), Socs2, Apoa1, Atp2b2, Bcl6, Ntn1, e.g.), whereas 57 probes 
were up-regulated, by contrast. Interestingly, these 57 probes contained Cyp1a1, Cyp1a2, Cyp1b1, 
Tiparp, Cd36, and Hsd17b2. 
 
The table presenting down-regulated genes affected accordingly by 1-PeCDD- or TCDD-treatment 
in mouse livers three days subsequent to single dose exposures is shown in the attachments. 
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TCDD
4-PeCDF
177261
404
631
1004
589722852
1082
1400
1905
2843
1731
3051
95
125
# of down-regulated genes
# of up-regulated genes
4.1.1.2.2. 4-PeCDF – impact on gene transcription in mouse livers 
 
Numbers of genes regulated in livers due to single-dose treatment of mice with 4-PeCDF           
(250 µg/kg bw) and three days of exposure are compiled in figure 14. Contrasting with data 
obtained by TCDD-treatment by courtesy of Christiane Lohr (Lohr, 2013) was included. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Mouse whole genome microarray analysis. Numbers of regulated genes in mouse livers by 4-PeCDF 
(250 µg/kg bw, three days) compared to numbers of genes regulated by TCDD (25 µg/kg bw, three days), and 
numbers of genes regulated both by 4-PeCDF and TCDD (TCDD-raw data by courtesy of C. Lohr; Lohr, 2013). 
A ≥ 27, p-value < 0.05. 
 
Subsequent to three days of exposure of single-dose treated mice with 4-PeCDF (250 µg/kg bw), 
vast numbers of genes were affected in livers (figure 14). Regarding selected cutoff values for 
signal intensity A ≥ 27, logarithmic (log2) fold change │lfc│ ≥ 1 (≥ 2fold induction/repression), and 
p-value < 0.05, 3051 genes were up-, and 2843 genes were down-regulated. Proceeding to raise 
cutoff value concerning lfc, levels below 1000 genes for up-, as well as down-regulation were 
gained beginning with ≥ 6fold induction/repression (│lfc│ ≥ 2.585; 404 genes up-, 852 genes 
down-regulated).  
TCDD 
≥ 2fold 
94↑ 
47↓ 
2957↑ 
2796↓ 
31↑ 
48↓ 
4-PeCDF  
≥ 2fold 
≥ 2fold    ≥ 2fold    ≥ 3fold    ≥ 4fold   ≥ 5fold   ≥ 6fold   ≥ 7fold   ≥ 8fold 
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Continuing examination up to │lfc│ ≥ 3 (≥ 8fold), at least regarding number of up-regulated genes 
(177 genes), orders of magnitude comparable to effects induced by TCDD (125 genes) was reached. 
Overlap between TCDD- and 4-PeCDF- derived effects accounted for 94 up- and 47 accordantly 
down-regulated genes.  
 
In table 22, attention was directed to types of genes affected in mouse livers after three days of 
exposure. Top 20 genes up-regulated by 4-PeCDF are overviewed. 
 
Table 22: Mouse whole genome microarray analysis. Top 20 up-regulated genes in mouse livers by 4-PeCDF 
(250 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
4-PeCDF 
 
lfc 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
5.994 NM_009992 cytochrome P450, family 1, subfamily a, polypeptide 1 Cyp1a1 
4.576/2.433 NM_011034 peroxiredoxin 1 Prdx1 
3.506-4.357 NM_031164 coagulation factor XIII beta subunit  F13b 
4.356 NM_008618 malate dehydrogenase 1 NAD (soluble)  Mdh1 
4.334 NM_145925 pituitary tumor-transforming 1 interacting protein  Pttg1ip 
4.303 NM_009028 RAS-like family 2 locus 9  Rasl2-9 
4.279/2.334 NM_008211 H3 histone family 3B  H3f3b 
4.227 NM_007643 CD36 antigen transcript variant 2 Cd36 
4.174 A_55_P2125868 Unknown    A_55_P2125868 
4.143 NM_026503 RIKEN cDNA 1110058L19 gene  1110058L19Rik 
4.137 NM_153798 polymerase (RNA) II (DNA directed) polypeptide B  Polr2b 
4.129 NM_001040396 RIKEN cDNA 2810407C02 gene  2810407C02Rik 
4.102 NAP029947-1 Unknown    NAP029947-1 
4.077 NM_175255 Sec24 related gene family member A (S. cerevisiae)  Sec24a 
4.041 NM_025535 SAR1 gene homolog B (S. cerevisiae)  Sar1b 
4.022 NM_013778 aldo-keto reductase family 1 member C13  Akr1c13 
3.996 NM_001113413 ring finger protein 13  Rnf13 
3.904 NM_023418 phosphoglycerate mutase 1  Pgam1 
3.902/2.030 NM_009725 
ATP synthase H+ transporting mitochondrial F0 complex 
subunit b Atp5f1 
3.882 NR_003625 RIKEN cDNA 1700073E17 gene  1700073E17Rik 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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The most effectively up-regulated gene in mouse livers due to 4-PeCDF-exposure was Cyp1a1 
(NM_009992; lfc = 5.994). AhR-dependent genes encoding CYP1A2, and CYP1B1 were absent 
within the Top 20 up-regulated genes list (table 22). Within chosen cutoff-values, Cyp1b1 
(NM_009994, lfc = 2.926) was lightly higher up-regulated than was Cyp1a2 (NM_009993,           
lfc = 2.414).  
 
Highest up-regulated target gene in mouse livers for 4-PeCDF-treatment Cyp1a1 was followed by 
peroxiredoxin 1 (Prdx1, NM_011034; lfc (max) = 4.576), and coagulation factor XIII, beta subunit 
(F13b, NM_031164; lfc (max) = 3.506). PRDX 1 is involved in regulation of intracellular H2O2-
concentrations, using reducing equivalents provided through the thioredoxin system to reduce 
peroxides (Chae et al., 1994a; Chae et al., 1994b; Iwahara et al., 1995). Furthermore, PRDX 1 was 
linked to inhibition of apoptosis (Berggren et al., 2001; Egler et al., 2005; Kim et al., 2000; Kim et 
al., 2008).  
Though not integrated in the Top 20 gene list shown in table 22, further members of the 
thioredoxin/thioredoxin reductase redox system were up-regulated within cutoff values. Besides 
thioredoxin 1 (Txn1, NM_153162), which was enhanced to 1.311 lfc, thioredoxin reductases 1 and 
3 were up-regulated reaching lfc values of 1.544 (Txnrd1, NM_001042523), and 2.642 (Txnrd3, 
NM_153162), respectively. Prdx1, Txn, and Txnrd were found to be overexpressed in a number of 
human cancers (Lincoln et al., 2003; Yanagawa et al., 1999), whereas Txn concurrently was 
correlated with enhanced cell proliferation and inhibition of apoptosis in vitro and in vivo (Baker et 
al., 1997; Gadaska et al., 1995; Grogan et al., 2000). In accordance, nuclear factor, erythroid 
derived 2, like 2 (Nfe2l2, NM_010902) was up-regulated (lfc = 2.473). NFE2l2 constitutes a 
transcription factor, which binds to antioxidant response elements and leads to hemin 
(ferriprotoporphyrin IX)-induced activation of the thioredoxin gene (Kim et al., 2001).  
 
Coagulation factor XIII (plasma transglutaminase, fibrin stabilizing factor) is a glycoprotein, which 
constitutes a tetramer consisting of two A and two B chains. In the course of blood coagulation, 
activated factor XIII covalently cross-links fibrin-monomers resulting in stable fibrin-clots. The B 
chain (F13B) is not catalytically active, but possesses influence on the rate of activation by 
thrombin (Chung et al., 1974; Ichinose and Davie, 1988). Two different probes for analysis of gene 
transcripts for coagulation factor XIII A1 subunit (F13a1, NM_028784) were spotted on the array, 
but neither was within set cutoff values for all congeners investigated.  
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Malate dehydrogenase 1 (Mdh1, NM_008618; lfc = 4.356) was up-regulated by 4-PeCDF. Besides 
its involvement in the tricarboxylic acid cycle, MDH1 was further considered to serve as biomarker 
for hepatocellular carcinomas and the severity of acute hepatitis (Amacher et al., 2005; Kawai and 
Hosaki, 1990), and was associated with hepatotoxicity and liver necrosis (Clifford and Rees, 1967; 
Zieve et al., 1985). Further, a 4-PeCDF-induced gene related to glycolytic processes was found 
within the Top 20-list: phosphoglycerate mutase 1 (Pgam1, NM_023418; lfc = 3.904) (Binns et al., 
2009; Dimmer et al., 2012).  
 
The protein encoded by pituitary tumor-transforming 1 interacting protein (Pttg1ip, NM_145925; 
lfc = 4.334), which was up-regulated in mouse livers after 4-PeCDF-treatment, specifically interacts 
with the oncogene pituitary tumor-transforming gene 1 (PTTG1) in vitro and in vivo, and facilitates 
PTTG1 nuclear translocation, subsequently enhancing its force as transcription factor (Chien and 
Pei, 2000; Li et al., 2013; Pei and Melmed, 1997). Pttg1 was also examined in the course of 
microarray analysis in hand. The presence of two different probes was intended to identify 
alterations of respective mRNA-levels, but no significant effect was observed throughout the 
complete mouse microarray experiment. 
Ras-like, family 2, locus 9 (Rasl2-9, NM_009028; lfc = 4.303), also referred to as encoding the 
GTP-binding nuclear protein RAN, was up-regulated within the mouse microarray-experiment by 
4-PeCDF. The Ras superfamily of small guanosine triphosphatases (GTPases) represent GTP-
binding proteins involved in nucleocytoplasmic transport of both proteins and RNA (Kadowaki et 
al., 1993; Melchior et al., 1993; Schlenstedt et al., 1995; Weis, 2003).  
 
Within the mouse microarray experiment, probes for H3 histone, family 3B (histone H3.3, H3f3b, 
NM_008211; lfc (max) = 4.279) revealed up-regulated levels of gene transcripts in mouse livers 
due to 4-PeCDF-treatment. As deposited at sites of nucleosomal displacement throughout 
transcribed genes, H3.3 was proposed to represent an epigenetic imprint of transcriptionally active 
chromatin (Dimmer et al., 2012; Wirbelauer et al., 2005). The number of oligos included within the 
present microarray analysis involved in histone-regulation amounted to 168. Among these, with due 
regard to cutoff values (A ≥ 27, │lfc│ ≥ 1, p-value < 0.05), 29 genes were affected in mouse livers 
by treatment with 4-PeCDF, of which 10 were up-, and 19 down-regulated. Besides discussed 
regulation of H3f3b, up-regulated genes comprised further histones and histone clusters. Down-
regulated oligos included genes encoding class II histone deacetylases (HDACs) (Hdac5, 
NM_001077696; Hdac6, NM_010413; Hdac7, NM_019572) (class II HDACs reviewed in Bertos 
et al., 2001; Yang and Grégoire, 2005).  
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In addition, and not least besides the high number of genes significantly induced, further evidence 
for 4-PeCDF’s role as a inducer of transcription and activator of cellular machinery were given by 
up-regulated genes within the Top 20-list (Binns et al., 2009; Dimmer et al., 2012): polymerase 
(RNA) II (DNA directed) polypeptide B (Polr2b, NM_153798; lfc = 4.137), Sec24 related gene 
family member A (Sec24a, NM_175255; lfc = 4.077; encoded protein involved in promotion of 
secretory, plasma membrane, and vacuolar proteins from the endoplasmic reticulum to the Golgi 
complex), and SAR1 gene homolog B (Sar1b, NM_025535; lfc = 4.041; encoded protein involved 
in intracellular protein transport), ATP synthase H+ transporting mitochondrial F0 complex   
subunit b (Atp5f1, NM_009725; lfc (max) = 3.902; encoded protein produces ATP from ADP, 
member of electron transport complex of the respiratory chain).  
 
Genes correlated with lipid metabolism obtained within the Top 20 of up-regulated genes by          
4-PeCDF were CD36 antigen transcript variant 2 (Cd36, NM_007643; lfc = 4.227), and aldo-keto 
reductase family 1 member C13 (Akr1c13, NM_013778; lfc = 4.022). The protein aldo-keto 
reductase 1C13 represents an oxidoreductase implicated in xenobiotic metabolic processes, and is 
able to catalyze the dehydrogenation of 17-beta-hydroxysteroids (Binns et al., 2009; Dimmer et al., 
2012).  
 
According to NCBI BLAST (BLASTN 2.2.28, Zhang et al., 2000), Probe A_55_P2125868         
(lfc = 4.174) might match with tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, theta polypeptide (Ywhaq, NM_011739; 54/60 identities, 90%). Regulation of Ywhaq was 
examined by means of five different probes on applied array slides, of which three revealed up-
regulations ranging from 1.375 to 2.507 lfc, and one declared down-regulation of 2.124 lfc.  
14-3-3 protein theta belongs a family of proteins, which mediate signal transduction by specific 
phosphoserine/phosphothreonine binding activities (Morrison, 2009; Yaffe et al., 1997), being 
connected with cell cycle regulation, apoptosis, or signaling molecules including members of the 
protein kinase C family (Meller et al., 1996; Peng et al., 1997; Zha et al., 1996).  
 
Data on up-regulation of genes by 4-PeCDF in mouse livers was studied performing classical 
enrichment analysis by testing over-representation of GO terms using Fisher’s exact test. By 
respective TopGO analysis, a Top 20 list, which is illustrated in table 23, of most significant GO 
terms was revealed. Respective subgraph induced by the top five GO terms is depicted in figure 15. 
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Table 23: Mouse whole genome microarray analysis – TopGO analysis (4-PeCDF): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; 
descending order. Mouse liver, 4-PeCDF (250 µg/kg bw, three days). Top five GO terms indicated in bold. 
4-PeCDF 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
metabolic process GO:0008152 2714/12490 3.8E-25 
cellular metabolic process GO:0044237 2353/10684 5.0E-24 
oxidation-reduction process GO:0055114 355/1237 6.8E-18 
small molecule metabolic process GO:0044281 703/2829 8.4E-17 
primary metabolic process GO:0044238 2277/10635 2.9E-16 
cellular catabolic process GO:0044248 487/1853 3.7E-16 
catabolic process GO:0009056 553/2156 5.0E-16 
translation GO:0006412 205/658 1.4E-14 
cofactor metabolic process GO:0051186 113/311 2.6E-13 
cellular ketone metabolic process GO:0042180 268/948 5.4E-13 
RNA processing GO:0006396 232/798 9.5E-13 
RNA splicing GO:0008380 146/451 3.7E-12 
cellular protein metabolic process GO:0044267 924/4045 6.3E-12 
intracellular transport GO:0046907 295/1088 7.7E-12 
coenzyme metabolic process GO:0006732 92/250 1.8E-11 
carboxylic acid metabolic process GO:0019752 254/918 2.5E-11 
oxoacid metabolic process GO:0043436 254/918 2.5E-11 
organic acid metabolic process GO:0006082 257/937 5.0E-11 
protein metabolic process GO:0019538 1058/4764 1.7E-10 
protein catabolic process GO:0030163 176/603 3.7E-10 
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Figure 15: Mouse whole genome microarray analysis – TopGO analysis (4-PeCDF, 250 µg/kg bw, three days; 
mouse liver): The GO subgraph plot induced by the top five GO terms identified by the classic algorithm for 
scoring GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant GO 
terms. Box color represents relative significance ranging from dark red (most significant) to orange (less 
significant). 
 
With a respectable statistical significance (3.8E-25) and more than 20% of 12490 significant 
annotated probes, the Top 20-list of biological processes for up-regulated genes by 4-PeCDF-
treatment (table 23) was headed and hallmarked by the GO term ‘metabolic process’ 
(GO:0008152). The Top 20-list comprised 16 GO terms involved in metabolic and catabolic 
processes plus four GO terms correlated with transcription/translation and processing of proteins 
(translation, GO:0006412; RNA processing, GO:0006396; RNA splicing, GO:0008380; 
intracellular transport, GO:0046907). The top five most significant GO terms were closely related 
to each other, hence leading to the very compact subgraph displayed in figure 15.  
Respective GO terms ‘cellular metabolic process’ (GO:0044237), ‘oxidation-reduction process’ 
(GO:0055114), ‘small molecule metabolic process’ (GO:0044281), and ‘primary metabolic 
process’ (GO:0044238) all represent direct child terms from the most significant GO term 
‘metabolic process’ (Ashburner et al., 2000; Binns et al., 2009). 
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In table 24, the Top 20 list of 2843 genes ≥ 2fold down-regulated in mouse livers by treatment with 
4-PeCDF (250 µg/kg bw, three days) is presented. 
 
Table 24: Mouse whole genome microarray analysis. Top 20 down-regulated genes in mouse livers by 4-PeCDF 
(250 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
4-PeCDF 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
-7.474 NR_004413 U1b6 small nuclear RNA   Rnu1b6 
-6.294 XM_001474429 similar to cyclic nucleotide gated channel beta 1  Gm2690 
-6.278-(-3.710) NM_009946 complexin 2  Cplx2 
-6.185/ 
-6.176 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-6.180 XM_001472970 similar to R10D12.10 (LOC100039488) Gm2264 
-6.149 XM_001472203 similar to Ubtf protein  Gm2033 
-6.118-(-4.014) NM_008103 glial cells missing homolog 1  Gcm1 
-5.987 NM_153522 sodium channel voltage-gated type III beta  Scn3b 
-5.943 AK036325 
16 days neonate cerebellum cDNA RIKEN full-length 
enriched library Syn3 
-5.926 XM_001478202 hypothetical protein LOC100047464  LOC100047464 
-5.914 NM_181319 T-box 22 (Tbx22) transcript variant 2  Tbx22 
-5.852 NM_001033960 RAB GTPase activating protein 1  Rabgap1 
-5.851 NM_016659 killer cell lectin-like receptor subfamily A member 1  Klra1 
-5.846 NM_001039959 AHNAK nucleoprotein (desmoyokin)  Ahnak 
-5.820 NM_011562 teratocarcinoma-derived growth factor 1  Tdgf1 
-5.815 NM_001169153 CD300 antigen like family member F  Cd300lf 
-5.801 NM_203492 MAS-related GPR member G   Mrgprg 
-5.768 NR_004439 ribonuclease P RNA-like 2 Rprl2 
-5.751 NM_011371 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1  St6galnac1 
-5.74 NM_172796 schlafen 9 Slfn9 
  
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
The Top 20 gene list representing most efficiently and apparently down-regulating effects of          
4-PeCDF on gene expression in mouse livers (table 24) comprises several gene segments of 
unknown or partly unresolved function, which complicates understanding and weighing the 
relevance of respective down-regulating effects.  
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Still, a considerable number of genes participating in immune function were down-regulated by     
4-PeCDF: complexin 2 (Cplx2, NM_009946; lfc (max) = -6.278; proposed involvement in mast cell 
degranulation), Serpina4-ps1 (BC031891/NR_002861; lfc (max) = -6.185), T-box 22 transcript 
variant 2 (Tbx22, NM_181319; lfc = -5.914; encodes a probable transcriptional regulator involved 
in developmental processes; major determinant crucial to palatogenesis), killer cell lectin-like 
receptor subfamily A member 1 (Klra1, NM_016659; lfc = -5.851; encodes T-cell surface 
glycoprotein YE1/48, a MHC class I receptor), teratocarcinoma-derived growth factor 1 (Tdgf1, 
NM_011562; lfc = -5.820), CD300 antigen like family member F (Cd300lf, NM_001169153;       
lfc = -5.815; encoded protein participates in osteoclast differentiation), and schlafen 9 (Slfn9, 
NM_172796; lfc = -5.74). Serpina4-ps1 and Tdgf1 are also implicated in apoptotic processes (Binns 
et al., 2009; Bustos et al., 2009; Dimmer et al., 2012). Further, Cplx2 was reported to be essential 
for normal neurological function in mice (Glynn et al., 2003). Down-regulated ST6 (alpha-N-
acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 
(St6galnac1, NM_011371; lfc = -5.751) encodes a glycosyltransferase, which plays a role with 
respect to protein glycosylation (Binns et al., 2009; Dimmer et al., 2012). 
RAB GTPase activating protein 1 (Rabgap1, NM_001033960; lfc = -5.852; encoded protein 
possesses Rab GTPase activator activity; might be involved in cell cycle regulation), and MAS-
related GPR member G (Mrgprg, NM_203492; lfc = -5.801; G-protein coupled receptor activity) 
are implicating G-proteins, of which gene transcription was inhibited by 4-PeCDF (Binns et al., 
2009; Dimmer et al., 2012). 
Implicated in cell-cell junctions, AHNAK nucleoprotein (Ahnak, NM_001039959; lfc = -5.846) 
was down-regulated by 4-PeCDF (Binns et al., 2009; Dimmer et al., 2012). 
 
In terms of classical enrichment analysis by testing over-representation of GO terms with Fisher’s 
exact test, down-regulated genes were analyzed in view of potential 4-PeCDF-derived effects on 
biological processes in mouse livers. In appendant table 25, the Top 20 GO terms obtained by this 
analysis are listed. 
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Table 25: Mouse whole genome microarray analysis – TopGO analysis (4-PeCDF), down-regulated genes: 
Fisher’s exact test. Top 20 GO terms identified by the classic algorithm for scoring GO terms for enrichment; 
descending order. Mouse livers, 4-PeCDF (250 µg/kg bw, three days). Top five GO terms indicated in bold. 
4-PeCDF 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
regulation of RNA metabolic process GO:0051252 587/3478 5.0E-10 
regulation of gene expression GO:0010468 657/3952 5.4E-10 
regulation of RNA biosynthetic process GO:2001141 574/3403 8.9E-10 
regulation of transcription, DNA-templated GO:0006355 573/3402 1.2E-09 
RNA biosynthetic process GO:0032774 588/3507 1.4E-09 
transcription, DNA-templated GO:0006351 587/3503 1.6E-09 
reg. of nucleobase-containing compound metab. pr. GO:0019219 656/4018 1.1E-08 
reg. of nitrogen compound metabolic process GO:0051171 659/4055 2.1E-08 
reg. of cellular macromolecule biosynthetic process GO:2000112 608/3707 2.2E-08 
negative regulation of transcription, DNA-templated GO:0045892 203/1052 4.1E-08 
regulation of macromolecule biosynthetic process GO:0010556 615/3789 8.2E-08 
neg. reg. of nucleobase-containing compound metab. pr. GO:0045934 224/1196 1.0E-07 
regulation of biosynthetic process GO:0009889 649/4036 1.4E-07 
negative regulation of nitrogen compound metab. pr. GO:0051172 225/1208 1.5E-07 
negative regulation of RNA metabolic process GO:0051253 204/1076 1.5E-07 
regulation of cellular biosynthetic process GO:0031326 642/3993 1.6E-07 
negative regulation of gene expression GO:0010629 216/1161 2.8E-07 
neg. reg. of transcription from RNA polymerase II promoter GO:0000122 133/650 3.5E-07 
reg. of transcription from RNA polymerase II promoter GO:0006357 260/1455 5.9E-07 
positive regulation of gene expression GO:0010628 249/1387 7.0E-07 
    
 
As both ‘regulation of gene expression’ (GO:0010468) and ‘regulation of RNA biosynthetic 
process’ (GO:2001141) represent direct parent terms from ‘regulation of transcription, DNA-
templated’ (GO:0006355), and GO:2001141 is a child term of both ‘RNA biosynthetic process’ 
(GO:0032771) and the most significantly occurring GO term ‘regulation of RNA metabolic 
process’ (GO:0051252), the top five GO terms appeared to be closely connected with each other 
(table 25). Besides these top five GO terms, all other GO terms within the Top 20 list for down-
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TCDD PCB 118
68
363
41
353
95
125
# of down-regulated genes
# of up-regulated genes
regulation by 4-PeCDF were members of the same path in which they issued into, namely 
‘regulation of transcription, DNA-templated’.  
 
Regulation of transcription and, due to view on down-regulated genes in this regard, regulation of 
RNA biosynthesis might implicate both initiation, resulting from 4-PeCDF exposure, and 
termination of RNA synthesis, which might be feasible three days after single dose exposures 
according to feedback mechanims.  
 
4.1.1.2.3. PCB 118 – impact on gene transcription in mouse livers 
 
Numbers of genes affected by PCB 118 in mouse livers after three days of treatment with a single 
dose of 150000 µg/kg bw are illustrated and compared to TCDD-derived effects in figure 16. Raw 
data for treatment with TCDD (25 µg/kg bw) was received by courtesy of Christiane Lohr (Lohr, 
2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Mouse whole genome microarray analysis. Numbers of regulated genes in mouse livers by PCB 118 
(150000 µg/kg bw, three days) compared to numbers of genes regulated by TCDD (25 µg/kg bw, three days), and 
numbers of genes regulated both by PCB 118 and TCDD (TCDD-raw data by courtesy of C. Lohr; Lohr, 2013).       
A ≥ 27, p-value < 0.05. 
TCDD 
≥ 2fold 
29↑ 
12↓ 
324↑ 
351↓ 96↑ 
83↓ 
PCB 118 
≥ 2fold 
≥ 2fold                     ≥ 2fold                     ≥ 3fold 
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Numbers of genes, which were regulated by PCB 118-treatment in mouse livers with respect to set 
cutoff-values, accounted for 353 up- and 363 down-regulated genes regarding ≥ 2fold induction and 
repression, respectively. Raise of cutoff to ≥ 3fold regulation (lfc ≥ 1.58) reduced the quantity to 41 
up- and 68 down-regulated genes. Although numbers of genes tended to appear in a comparable 
order of magnitude, the consensus with genes affected by TCDD emerged least substantial. A 
conserved group of 29 up- and 12 down-regulated genes remained. 
Table 26 gives an overview of PCB 118-affected genes and presents the Top 20-list for up-
regulation. 
 
Table 26: Mouse whole genome microarray analysis. Top 20 up-regulated genes in mouse livers by PCB 118 
(150000 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
PCB 118 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
7.799 NM_009992 cytochrome P450, family 1, subfamily a, polypeptide 1 Cyp1a1 
3.998 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
3.631/2.279 NM_001122660 predicted gene 10639  Gm10639 
3.311 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2 Cyp1a2 
2.697 NM_008182 glutathione S-transferase alpha 2 (Yc2)  Gsta2 
1.102-2.621 NM_145603 carboxylesterase 2 Ces2 
2.603 NM_198171 cDNA sequence BC015286  BC015286 
2.310/1.775 NM_013541 glutathione S-transferase pi 1  Gstp1 
2.282/1.990 NM_010358 glutathione S-transferase mu 1 Gstm1 
2.276/1.398 NM_206537 cytochrome P450  family 2 subfamily c polypeptide 54  Cyp2c54 
2.227 NM_023440 transmembrane protein 86B   Tmem86b 
2.162 NM_010002 cytochrome P450 family 2 subfamily c polypeptide 38  Cyp2c38 
2.101 NM_134144 cytochrome P450 family 2 subfamily c polypeptide 50  Cyp2c50 
2.095 NM_025797 cytochrome b-5 Cyb5 
2.027/1.751 NM_181796 glutathione S-transferase pi 2  Gstp2 
2.018 NM_027872 solute carrier family 46 member 3 Slc46a3 
1.997/1.450 NM_020559 aminolevulinic acid synthase 1  Alas1 
1.990/1.112 NM_175224 methionyl aminopeptidase 1   Metap1 
1.984 NM_025647 cytidine monophosphate (UMP-CMP) kinase 1 Cmpk1 
1.956 NM_023429 OCIA domain containing 1  Ociad1 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Highest up-regulated target gene for treatment of mice with PCB 118 (150000 µg/kg bw; three 
days) in livers was Cyp1a1 (NM_009992; lfc = 7.799). Within PCB 118’s list of up-regulated 
genes, Cyp1a2 (NM_009993; lfc = 3.311) ranked fourth (table 26). Effects on Cyp1b1-transcription 
were scarcely excluded from the Top 20-list by the lfc-cutoff of 1. Still, PCB 118 enhanced Cyp1b1 
(NM_009994) gene expression to an lfc of 0.935 corresponding to a 1.9-fold change.  
 
Prominent targets affected by PCB 118 obviously were genes encoding glutathione S-transferases 
(GSTs). Besides the second-highest up-regulated gene by PCB 118, Gsta1 (NM_008181;              
lfc = 3.998) was followed by another five Gsts within the Top 20-list including the predigted gene 
10639 (Gm10639, NM_001122660; lfc (max) = 3.631), which encodes a protein (protein 
Gm10639) exhibiting GST activity (Dimmer et al., 2012). In total, thirteen different Gsts were up-
regulated by PCB 118 within chosen cutoff-levels.  
 
Up-regulated genes involved in lipid metabolism and transport within the Top 20-list were 
Tmem86b (NM_023440; lfc = 2.227) and carboxylesterase 2 (Ces2, NM_145603;                          
lfc (max) = 2.621). Ces2 encodes an acylcarnitine hydrolase releasing fatty acids coupled to           
L-carnitine after entering the cell (Furihata et al., 2003). Genes related to arachidonic acid 
metabolism affected by PCB 118 in mouse livers were Cyp2c54 (NM_206537; lfc (max) = 2.276), 
Cyp2c38 (NM_010002; lfc = 2.162), and Cyp2c50 (NM_134144; lfc = 2.101) (Binns et al., 2009; 
Dimmer et al., 2012).  
Further up-regulated genes linked to enhanced transport, metabolism, and transcription in cells 
within the Top 20-list were represented by cytochrome b-5 (Cyb5, NM_025797; lfc = 2.095), 
Slc46a3 (NM_027872; lfc = 2.018), methionyl aminopeptidase 1 (Metap1, NM_175224;               
lfc (max) = 1.990), and cytidine monophosphate (UMP-CMP) kinase 1 (Cmpk1, NM_025647;      
lfc = 1.984) (Binns et al., 2009; Dimmer et al., 2012).  
 
For examination of pathways affected by PCB 118, classical enrichment analysis by testing over-
representation of GO terms using Fisher’s exact test was performed. The Top 20-list of most 
significant GO terms regarding biological processes obtained by means of TopGO analysis for PCB 
118 and it’s up-regulating effects on gene expression is shown in table 27, whereas respective 
subgraph induced by the top five GO terms is presented in figure 17.  
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Table 27: Mouse whole genome microarray analysis – TopGO analysis (PCB 118): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; 
descending order. Mouse liver, PCB 118 (150000 µg/kg bw, three days). Top five GO terms indicated in bold. 
PCB 118 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
glutathione metabolic process GO:0006749 16/48 6.6E-14 
xenobiotic metabolic process GO:0006805 14/38 5.0E-13 
cellular response to xenobiotic stimulus GO:0071466 14/38 5.0E-13 
xenobiotic catabolic process GO:0042178 9/12 1.4E-12 
response to xenobiotic stimulus GO:0009410 14/41 1.7E-12 
peptide metabolic process GO:0006518 16/84 7.6E-10 
sulfur compound metabolic process GO:0006790 21/189 4.7E-08 
oxidation-reduction process GO:0055114 67/1237 5.7E-08 
cellular modified amino acid metabolic process GO:0006575 18/164 5.1E-07 
drug metabolic process GO:0017144 7/25 3.1E-06 
cellular ketone metabolic process GO:0042180 49/948 1.2E-05 
secondary metabolic process GO:0019748 7/32 1.9E-05 
carboxylic acid metabolic process GO:0019752 47/918 2.4E-05 
oxoacid metabolic process GO:0043436 47/918 2.4E-05 
response to oxidative stress GO:0006979 19/244 3.8E-05 
organic acid metabolic process GO:0006082 47/937 3.9E-05 
exogenous drug catabolic process GO:0042738 4/10 9.6E-05 
cellular amino acid metabolic process GO:0006520 24/382 1.2E-04 
drug catabolic process GO:0042737 4/11 1.5E-04 
hydrogen peroxide metabolic process GO:0042743 7/44 1.6E-04 
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Figure 17: Mouse whole genome microarray analysis – TopGO analysis (PCB 118, 150000 µg/kg bw, three days; 
mouse liver): The GO subgraph plot induced by the top five GO terms identified by the classic algorithm for 
scoring GO terms for enrichment regarding up-regulated genes. Excerpt. Boxes indicate the five most significant 
GO terms. Box color represents relative significance ranging from dark red (most significant) to light yellow 
(least significant). 
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According to results from gene ontology analysis illustrated in figure 17 and table 27, impact of 
PCB 118 in view of up-regulated expression of genes was almost exclusively related to xenobiotic 
metabolism. Over several further significantly involved nodes within the gene tree (figure 17) like 
‘cellular modified amino acid metabolic process’ (GO:0006575), ‘cellular ketone metabolic 
process’ (GO:0042180), and ‘carboxylic acid metabolic process’ (GO:0019752), members of the 
top five biological processes switched on by PCB 118 issued into the most significant term 
‘glutathione metabolic process’ (GO:0006749), and into ‘xenobiotic catabolic process’ 
(GO:0042178). Induced targets behind these top five GO terms included seven different glutathione 
S-transferases (Gsta1, NM_008181; Gstm1, NM_010358; Gstm2, NM_008183; Gstm3, 
NM_010359; Gstp1, NM_013541; Gstp2, NM_181796; Gstt3, NM_133994), glutathione 
peroxidase 3 (Gpx3, NM_008161), and glutathione reductase (Gsr, NM_010344). The GO term 
‘cellular response to xenobiotic stimulus’ (GO:0071466) further included Cyp1a1, Ugt2b1, and 
aldo-keto reductase family 1 member 13 (Akr1c13, NM_013778).  
 
Affected probes according to ‘carboxylic acid metabolic process’ (GO:0019752) implicated several 
Gsts, as well as Cyp1a2, Htatip2 (NM_016865), abhydrolase domain containing 5 (Abhd5, 
NM_026179), fatty acid desaturase 2 (Fads2, ENSMUST00000025567), and Cyb5 (NM_025797), 
for instance. 
 
Connected to initiated metabolic processes and induced monooxygenases, two biological processes 
related to redox-homeostasis were among PCB 118’s Top 20-list for up-regulation of gene 
transcription. Formally, ‘hydrogen peroxide metabolic process’ (GO:0042743) not directly 
represents a child term of ‘response to oxidative stress’ (GO:0006979), but both pathways are 
consequences due to an imbalanced redox state apparently occurring in the cells. Consequently, 
annotated probes are similar for both GO terms. Up-regulated genes impacted by PCB 118 within 
these two processes were peroxiredoxin 1, (Prdx1, NM_011034), Prdx3 (NM_007452), glutathione 
peroxidase 3 (Gpx3, NM_008161), thioredoxin reductase 1 (Txnrd1, NM_001042523), Cyp1a1, and 
Cyp1a2, whereas the Cyps were annotated only for GO:0042743.  
 
In table 28 (following page), the Top 20 of 363 down-regulated genes in response to PCB 118-
treatment in mouse livers is depicted.   
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Table 28: Mouse whole genome microarray analysis. Top 20 down-regulated genes in mouse livers by PCB 118 
(150000 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 118 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
-3.057 NM_008341 insulin-like growth factor binding protein 1  Igfbp1 
-2.607- 
-1.415 NM_008103 glial cells missing homolog 1 (Drosophila)   Gcm1 
-2.558 XM_001472203 similar to Ubtf protein (LOC100039072)  Gm2033 
-2.449 XM_889044 Mus musculus predicted gene EG624491   Gm6508 
-2.270 BC052524 RIKEN cDNA 4833411C07 gene  4833411C07Rik 
-2.255 NM_001081212 insulin receptor substrate 2   Irs2 
-2.184 NR_001463 inactive X specific transcripts  Xist 
-2.149 AK017575 
8 days embryo whole body cDNA RIKEN full-length 
enriched library clone:5730419F03  5730419F03Rik 
-2.119 NM_009744 B-cell leukemia/lymphoma 6  Bcl6 
-2.114- 
-1.339 NM_009946 complexin 2  Cplx2 
-2.105 
ENSMUST0000
0115107 cDNA clone MNCb-1768cDNA sequence AB041803 ENSMUST00000115107 
-2.096 XM_001472970 similar to R10D12.10 (LOC100039488)  Gm2264 
-2.070 XM_001474429 similar to cyclic nucleotide gated channel beta 1  Gm2690 
-2.040 NM_011817 growth arrest and DNA-damage-inducible 45 gamma  Gadd45g 
-2.033 AK017236 
adult male pituitary gland cDNA RIKEN full-length 
enriched library clone:5330406M23 5330406M23Rik 
-1.955 A_55_P2050988 Unknown     A_55_P2050988 
-1.943 AK036325 
16 days neonate cerebellum cDNA  RIKEN full-length 
enriched library clone:9630056N24  Syn3 
-1.912 NM_203492 MAS-related GPR member G   Mrgprg 
-1.906 NM_153522 sodium channel voltage-gated type III beta  Scn3b 
-1.904 NM_016659 killer cell lectin-like receptor subfamily A member 1 Klra1 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
Of 363 genes in total, the most efficiently down-regulated gene by PCB 118 (table 28) named 
insulin-like growth factor binding protein 1 (Igfbp1, NM_008341; lfc = -3.057) represents an 
inhibited gene involved in insulin receptor signaling pathways, which was also proposed to be 
implicated in regulation of cell growth and tissue regeneration (Binns et al., 2009; Dimmer et al., 
2012). Further down-regulated genes related to insulin receptor signaling were insulin receptor 
substrate 2 (Irs2, NM_001081212; lfc = -2.255), and insulin-like growth factor 1 (Igf1, 
NM_184052; lfc = -1.502; not part of the Top 20-list).  
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Inhibited expression of the gene B-cell leukemia/lymphoma 6 (Bcl6, NM_009744; lfc = -2.119) 
hinted towards repressive properties with regard to type 2 immune response and B cell 
differentiation (Binns et al., 2009; Dimmer et al., 2012). Further genes implicated in immune 
response within PCB 118’s Top 20-list of down-regulated genes were growth arrest and DNA-
damage inducible 45 gamma (Gadd45g, NM_011817; lfc = -2.040), and killer cell lectin-like 
receptor subfamily A member 1 (Klra1, NM_016659; lfc = -1.904). Gadd45g, an intermediate 
upstream of p38 MAPK, has shown to be able to induce STAT4 serine phosphorylation and was 
thus discussed to be involved in correlated IFN-γ production and Th1-differentiation (Morinobu et 
al., 2002). Klra1 encodes a MHC class I receptor protein named T cell surface glycoprotein YE1/48 
(Binns et al., 2009; Dimmer et al., 2012). 
 
The Top 20-list of down-regulated genes in mouse livers affected by PCB 118 contained several 
gene products or solely predicted genes with insufficient experimental evidence at transcription 
level, for which information is rare and no GO terms are annotated to date. An appropriate 
interpretation was thus even more intricate. 
 
Classical enrichment analysis by testing over-representation of GO terms using Fisher’s exact test 
was applied. For down-regulated probes, the Top 20-list of GO terms presented in table 29 
(following page), was obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results – mouse whole genome microarray analysis 
 
  98 
Table 29: Mouse whole genome microarray analysis – TopGO analysis (PCB 118): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding down-regulated 
genes; descending order. Mouse liver, PCB 118 (150000 µg/kg bw, three days). Top five GO terms indicated in 
bold. 
PCB 118 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
positive regulation of synaptic plasticity GO:0031915 4/10 8.0E-05 
astrocyte fate commitment GO:0060018 3/6 3.2E-04 
carbohydrate mediated signaling GO:0009756 2/2 6.6E-04 
hexose mediated signaling GO:0009757 2/2 6.6E-04 
sugar mediated signaling pathway GO:0010182 2/2 6.6E-04 
glucose mediated signaling pathway GO:0010255 2/2 6.6E-04 
negative regulation of oxidative phosphorylation GO:0090324 2/2 6.6E-04 
glial cell differentiation GO:0010001 12/160 9.0E-04 
endothelial cell proliferation GO:0001935 8/88 1.9E-03 
regulation of oxidative phosphorylation GO:0002082 2/3 1.9E-03 
astrocyte differentiation GO:0048708 6/54 2.5E-03 
cell diff. involved in embryonic placenta development GO:0060706 4/23 2.6E-03 
neg. reg. of blood vessel endothelial cell migration GO:0043537 3/12 3.1E-03 
branching involved in labyrinthine layer morphogenesis GO:0060670 3/12 3.1E-03 
regulation of endothelial cell proliferation GO:0001936 7/77 3.6E-03 
negative regulation of hair follicle development GO:0051799 2/4 3.8E-03 
gliogenesis GO:0042063 12/192 4.2E-03 
blood vessel remodeling GO:0001974 5/43 4.7E-03 
cell fate commitment GO:0045165 15/272 4.7E-03 
endocrine hormone secretion GO:0060986 4/28 5.4E-03 
    
 
Overall, the over-representation of GO terms as well as correspondent statistical significances 
regarding appearance of clustered GO terms was limited for down-regulating effects of PCB 118 on 
gene expression (table 29). Three principal pathways induced by the top five GO terms included 
‘positive regulation of synaptic plasticity’ (GO:0031915), ‘astrocyte fate commitment’ 
(GO:0060018), and ‘hexose mediated signaling’ (GO: 0009757). The direct parent term from the 
latter, ‘sugar mediated signaling pathway’ (GO:0010182), and its parent term ‘carbohydrate 
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mediated signaling’ (GO:0009756), were both among the top five GO terms for down-regulating 
effects of PCB 118. Annotated and significantly occurring probes behind this hexose mediated 
pathway both encoded MLX-interacting protein-like (Mlxipl, NM_021455). Mlxipl is annotated to 
several further processes like ’glucose homeostasis’ (GO:0042593), ‘positive regulation of 
glycolytic process’ (GO:0045821), ‘fatty acid homeostasis’ (GO:0055089), ‘positive regulation of 
fatty acid biosynthetic process’ (GO:0045723). Encoded carbohydrate-responsive element-binding 
protein (ChREBP) is a transcriptional repressor, which was reported to reduce de novo lipogenesis 
as well as glycolysis in vivo. In a ChREBP-/- mouse model, ChREBP was shown to be required for 
basal and carbohydrate-induced expression of liver enzymes essential for these processes, such as 
liver-type pyruvate kinase, ATP citrate lyase, acetyl-CoA carboxylase 1, or fatty acid synthase 
(Binns et al., 2009; Dimmer et al., 2012; Iizuka et al., 2004). 
 
In addition to Mlxipl, regarding GO terms ’glucose homeostasis’ (GO:0042593), and ‘positive 
regulation of glycolytic process’ (GO:0045821), five genes among 99, and one among 17 annotated 
probes, respectively, were down-regulated by PCB 118. These included glucose-6-phosphatase 
(G6pc, NM_008061), transcription factor 7-like 2 (Tcf7l2, NM_001142920), adrenergic receptor, 
alpha 1b (Adra1b, NM_007416), and insulin-like growth factor 1 (Igf1, NM_184052). None of the 
further aforementioned genes related to carbohydrate metalism were affected by PCB 118. 
 
Significantly affected regarding ‘positive regulation of synaptic plasticity’ (GO:0031915) were four 
out of ten probes, which represented two genes: complexin 2 (Cplx2, NM_009946), and the 
predicted gene EG628080 (Gm6837, XM_900336; ‘This record was removed as a result of 
standard genome annotation processing’ (NCBI)). Besides its involvement in mast cell 
degranulation, Cplx2 was indicated to locally act at presynaptic sites by mediation of neurogenic 
differentiation 2 (NeuroD2) to suppress presynaptic differentiation (Yang et al., 2009).  
 
‘Astrocyte fate commitment’ (GO:0060018) was also observed in the Top 20-list containing 
potentially inhibited biological processes by PCB 118. Three out of six annotated probes were 
affected, whereas all of the three were specific for one gene: glial cells missing homolog 1 (Gcm1, 
NM_008103). The mammalian homolog of Drosophila gcm, mouse Gcm1, was reported to exhibit 
potential to induce gliogenesis, but might function in the generation of a minor subpopulation of 
glial cells (Iwasaki et al., 2003). In this regard, as also concerning related processes ‘glial cell 
differentiation’ (GO:0010001), astrocyte differentiation (GO:0048708), and ‘gliogenesis’ 
(GO:0042063), for interpretation of these results and accordant biological processes, tissue 
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specifities would need to be considered and discussed to assess relevance of them and their 
probable role for a PCB 118-exposed organism, as not least liver was investigated for the work in 
hand.  
 
Four GO terms involved in blood vessel-related processes and endothelial cells were members of 
the Top 20-list for PCB 118 and its inhibitory effects on gene expression. With respect to 
‘endothelial cell proliferation’ (GO:0001935) and its direct child term ‘regulation of endothelial cell 
proliferation’ (GO:0001936), around ten per cent of probes annotated were down-regulated by   
PCB 118, including Jun (NM_010591), fibroblast growth factor 2 (Fgf2, NM_008006), and 
vasohibin 1 (Vash1, NM_177354) for both GO terms. In related GO term ‘negative regulation of 
blood vessel endothelial cell migration’ (GO:0043537), down-regulated genes were also 
represented by Fgf2 and Vash1. The protein Vasohibin 1 represents an angiogenesis inhibitor, 
which selectively inhibits migration, proliferation, and network formation by endothelial cells. 
Besides its ability to inhibit macrophage infiltration, it was proposed to inhibit tumor growth and 
tumor angiogenesis acting in an autocrine manner (Ashburner et al., 2000; Binns et al., 2009; 
Dimmer et al., 2012).  
 
With a comparably low significance (5.4E-03), a GO term named ‘endocrine hormone secretion’ 
(GO:0060986) occurred within the Top 20 of biological processes probably suppressed by PCB 118 
in mouse livers. Four out of 28 probes were negatively affected by the compound in this regard: 
inhibin beta-A (Inhba, NM_008380), maternally expressed 3 (Meg3, NR_027652), urocortin 2 
(Ucn2, NM_145077), and leukemia inhibitory factor (Lif, NM_008501). These genes and their gene 
products, respectively, possess diverging functions from involment in erythroid differentiation or 
insulin secretion (Inhba), over suppression of food intake and delayed gastric emptying (Ucn2), to 
stimulation of acute-phase protein synthesis in hepatocytes (Lif) (Ashburner et al., 2000; Binns et 
al., 2009; Dimmer et al., 2012). The low number of genes and the limited correlation among 
themselves related to endocrine function exacerbates the interpretation of their occurrence as part of 
a suppressed biological process responding to PCB 118-treatment. 
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4.1.1.2.4. PCB 126 – impact on gene transcription in mouse livers 
 
Female C57BL/6 mice were treated with single doses of PCB 126 (250 µg/kg bw), or TCDD       
(25 µg/kg bw) for three days each. Using mRNA isolated from livers, whole genome microarray 
experiments were performed. The numbers of genes affected by PCB 126 and/or TCDD treatments 
are summarized in figure 18. Raw data from experiments with TCDD was received by courtesy of 
Christiane Lohr (Lohr, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Mouse whole genome microarray analysis. Numbers of regulated genes in mouse livers by PCB 126 
(250 µg/kg bw, three days) compared to numbers of genes regulated by TCDD (25 µg/kg bw, three days), and 
numbers of genes regulated both by PCB 126 and TCDD (TCDD-raw data by courtesy of C. Lohr; Lohr, 2013). 
A ≥ 27, p-value < 0.05. 
 
Treatment with PCB 126 (250 µg/kg bw) exerted a highly inductive effect on gene expression in 
mouse livers (figure 18). In numbers, transcription of 2587 genes was up-, and transcription of 1767 
genes was down-regulated by PCB 126 according to set cutoff-levels (A ≥ 27,│lfc│ ≥ 1 (≥ 2fold), 
p-value < 0.05). Raise of cutoff-values reduced numbers of affected genes from 976/853 (up/down-
regulated genes) for ≥ 3fold induction, over 373/424 (≥ 4fold), and 149/271 (≥ 5fold) to 63/196 (≥ 
6fold). By contrast, TCDD led to an increased transcription of genes accounting for 125 up-, and 95 
down. About half of the genes induced by TCDD were as well up-regulated by PCB 126, whereas 
overlap with respect to down-regulated genes turned out to be even smaller. From 95 genes 
repressed by TCDD, 26 were also down-regulated by PCB 126.  
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In table 30, the Top 20-list of genes, which were up-regulated by PCB 126 in mouse livers, is 
displayed.  
 
Table 30: Mouse whole genome microarray analysis. Top 20 up-regulated genes in mouse livers by PCB 126 (250 
µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
PCB 126 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
6.292 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
3.873 A_55_P2097048 Unknown   A_55_P2097048 
3.417 XM_001477211 similar to Major urinary protein 1 (LOC100048884)   CU104690.1 
3.250 NM_198171 cDNA sequence BC015286 BC015286 
3.195 NM_008618 malate dehydrogenase 1 NAD (soluble)  Mdh1 
3.184 NM_172054 thioredoxin domain containing 9  Txndc9 
3.172 NM_027872 solute carrier family 46 member 3  Slc46a3 
3.163 XM_985615 
similar to NADH dehydrogenase (ubiquinone) 1 subcomplex 
unknown 2 LOC675851 
3.159 NM_025535 SAR1 gene homolog B (S. cerevisiae) Sar1b 
3.134/2.086 NM_011034 peroxiredoxin 1  Prdx1 
3.129 NM_007451 
solute carrier family 25 (mitochondrial carrier adenine 
nucleotide translocator) member 5  Slc25a5 
3.123 NM_145925 pituitary tumor-transforming 1 interacting protein  Pttg1ip 
1.845-3.097 NM_172588 serine incorporator 5  Serinc5 
3.095 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
3.085 NM_031170 keratin 8  Krt8 
3.049/2.144 NM_001122660 predicted gene 10639  Gm10639 
3.016/1.175 NM_009725 ATP synthase  H+ transporting  mitochondrial F0 complex Atp5f1 
2.989 NM_001101534 predicted gene 5584  Gm5584 
2.972 NM_029814 chromatin modifying protein 5   Chmp5 
2.971 NM_025615 RIKEN cDNA 2810004N23 gene  2810004N23Rik 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
The Top 20-list of genes up-regulated by PCB 126 (table 30) was headed by Cyp1a1 (NM_009992; 
lfc = 6.292). Although not among the Top 20 of induced genes, Cyp1a2 and Cyp1b1 were up-
regulated by PCB 126 in mouse livers. With regards to extent of induction, Cyp1b1 (NM_009994; 
lfc = 2.557) was very closely followed by Cyp1a2 (NM_009993; lfc = 2.555).  
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Further affected genes and predicted genes associated with xenobiotic metabolism were Gsta1 
(NM_008181; lfc = 3.095), predicted gene 10639 (Gm110639, NM_0011226600;                     
lfc (max) = 3.049), and predicted gene 5584 (Gm5584, NM_001101534; lfc = 2.989). 
Corresponding encoded predicted proteins were proposed to bear GST (Protein GM10639), and 
SULT (predicted gene 5584, MCG8002; Sult2a4) activity, respectively (Binns et al., 2009; Dimmer 
et al., 2012). 
 
Indications of altered lipid metabolism and biosynthesis in livers of PCB 126-treated mice gave 
reduced transcription of cDNA sequence BC015286 (BC015286; NM_198171; lfc = 3.250), and 
serine incorporator 5 (Serinc5, NM_172588; lfc = 3.097). The protein product of BC015286 
(MCG142671, isoform CRA_B; Ces2b) clusters with an acylcarnitine hydrolase. Acylcarnitine 
hydrolases release fatty acids coupled to L-carnitine after entering the cell (Binns et al., 2009; 
Dimmer et al., 2012; Furihata et al., 2003). 
 
Another gene, of which transcription was induced by PCB 126, was malate dehydrogenase 1 
(Mdh1, NM_008618; lfc = 3.195). The protein MDH1 is involved in the tricarboxylic acid cycle, 
and was further discussed in the context of hepatotoxicity and liver necrosis (Clifford and Rees, 
1967; Zieve et al., 1985). In this regard, MDH1 was proposed to serve as biomarker for 
hepatocellular carcinomas and the severity of acute hepatitis (Amacher et al., 2005; Kawai and 
Hosaki, 1990).  
 
As its encoded protein plays major role within electron transport complexes of the respiratory chain, 
the induction of ATP synthase H+ transporting mitochondrial F0 complex (Atp5f1, NM_009725;  
lfc = 3.016) gave indication of a high energy turnover in hepatocytes from PCB 126-treated mice 
(Dimmer et al., 2012). Further hints towards trancriptionally and metabolically active conditions in 
mouse livers were given by inhibited transcription of Slc46a3 (NM_027872; lfc = 3.172; 
transmembrane transport mechanisms including transport of nucleotides, peptides, steroids, 
carbohydrates, and hydrogen peroxide), SAR1 gene homolog B (Sar1b, NM_025535; lfc = 3.159; 
intracellular transport), and chromatin modifying protein 5 (Chmp5, NM_029814; lfc = 2.972; 
protein transport/endosome to lysosome transport) (Binns et al., 2009; Dimmer et al., 2012). 
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Thioredoxin domain containing 9 (Txndc9; NM_172954; lfc = 3.184), and peroxiredoxin 1 (Prdx1; 
NM_011034; lfc (max) = 3.134) are genes related to oxidative stress and are involved in redox 
regulation of cells. A number of further members belonging to the thioredoxin/thioredoxin 
reductase redox system were induced by PCB 126: Txndc17 (NM_026559; lfc = 1.985), 
Thioredoxin reductase 3 (Txnrd3, NM_153162; lfc = 1.821), Txnrd1 (NM_001042523; lfc = 1.747), 
Txn1 (NM_011660; lfc = 1.55), Thioredoxin-interacting protein (Txnip, NM_001009935;              
lfc = 1.521), Txndc15 (NM_175150; lfc = 1.459), and Txndc12 (NM_025334; lfc = 1.156). Gene 
transcription of members belonging to the thioredoxin/thioredoxin reductase redox system was 
shown to be enhanced in a number of human cancers (Lincoln et al., 2003; Yanagawa et al., 1999). 
TXN and PRDX 1 were also found to be implicated in processes inhibiting apoptosis (Baker et al., 
1997; Egler et al., 2005; Kim et al., 2000).  
Beyond, PCB 126 induced further genes correlated with apoptosis: Slc25a5 (NM_007451;            
lfc = 3.129), and keratin 8 (Krt8, NM_031170; lfc = 3.085) were members of the Top 20-list. The 
protein Keratin-8 (K8) potentially moderates TNF-α-induced, c-Jun N-terminal kinase (JNK; 
member of the MAPK family) intracellular signaling as well as NF-ĸB activation and hence the 
apoptotic effects of TNF-α. These effects were discussed in association with K8’s feasible functions 
regarding liver regeneration, hepatotoxin sensitivity, and its diagnostic, persistent expression in 
several carcinomas (Caulin et al., 2000).  
Within current mouse whole genome microarray experiment, neither TNF-α, nor NF-ĸB gene 
products were regulated by any of the tested DL-congeners, whereas transcription of genes 
encoding the proteins MAPK 1 and MAPK 11 was significantly affected by PCB 126: Mapk1 
(NM_011949; lfc (max) = 2.027) was up-regulated, while Mapk11 (NM_011161; lfc = -1.833) was 
down-regulated in response to treatment with PCB 126 in mouse livers. 
 
Pituitary tumor-transforming 1 interacting protein (Pttg1ip, NM_145925; lfc = 3.123) was up-
regulated by PCB 126. Encoded protein specifically interacts with the oncogene pituitary tumor-
transforming gene 1 (PTTG1) in vitro and in vivo, and facilitates PTTG1 nuclear translocation, 
subsequently enhancing its force as transcription factor (Chien and Pei, 2000; Li et al., 2013; Pei 
and Melmed, 1997). Pttg1 was not affected by any tested congener throughout the entire mouse 
microarray experiment.  
 
TopGO analysis provided the list of 20 most significant GO terms displayed in table 31, which were 
over-representated within the group of differentially expressed genes. This classical enrichment 
analysis was performed using Fisher’s exact test. The TopGO subgraph is shown in figure 19. 
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Table 31: Mouse whole genome microarray analysis – TopGO analysis (PCB 126): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; 
descending order. Mouse liver, PCB 126 (250 µg/kg bw, three days). Top five GO terms indicated in bold. 
PCB 126 
 
GO ID 
 
 
GO term 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
oxidation-reduction process GO:0055114 262/1237 7.6E-21 
translation GO:0006412 165/658 8.1E-21 
cellular catabolic process GO:0044248 341/1853 1.2E-16 
translational elongation GO:0006414 74/225 1.3E-16 
cellular ketone metabolic process GO:0042180 201/948 2.7E-16 
carboxylic acid metabolic process GO:0019752 193/918 2.6E-15 
oxoacid metabolic process GO:0043436 193/918 2.6E-15 
organic acid metabolic process GO:0006082 195/937 5.3E-15 
cofactor metabolic process GO:0051186 85/311 1.4E-13 
catabolic process GO:0009056 367/2156 8.6E-13 
coenzyme metabolic process GO:0006732 71/250 1.9E-12 
small molecule metabolic process GO:0044281 459/2829 2.1E-12 
cellular metabolic process GO:0044237 1469/10684 1.2E-11 
metabolic process GO:0008152 1686/12490 5.0E-11 
glutathione metabolic process GO:0006749 24/48 1.3E-10 
peptide metabolic process GO:0006518 33/84 1.7E-10 
intracellular transport GO:0046907 201/1088 2.0E-10 
sulfur compound metabolic process GO:0006790 55/189 2.0E-10 
establishment of protein localization GO:0045184 247/1406 2.9E-10 
protein transport GO:0015031 240/1358 2.9E-10 
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Figure 19: Mouse whole genome microarray analysis – TopGO analysis (PCB 126, 250 µg/kg bw, three days; mouse liver): The GO subgraph plot induced by the top 
five GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant GO terms. 
Box color represents relative significance ranging from dark red (most significant) to light yellow (least significant). 
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Pathway analyis respecting up-regulated genes in mouse livers in response to in vivo treatment with 
PCB 126 predominantly was related with metabolic, in particular catabolic (GO:0044248), 
processes most significantly including ‘oxidation-reduction processes’ (GO:0055114), and 
translation (‘translational elongation’, GO:0006414) corresponding to the inductive effect of the 
congener (table 31, figure 19). Out of 20 GO-terms, 13 were associated with metabolism and 
included GO terms correlated with lipid metabolism like ‘carboxylic acid metabolic process’ 
(GO:0019752), or ‘peptide metabolic process’ (GO:0006518). Besides, highly processive 
hepatocytes were as well indicated by up-regulated genes annotated to ‘intracellular transport’ 
(GO:0046907), ‘establishment of protein localization’ (GO:0045184), and ‘protein transport’ 
(GO:0015031).  
 
Half of the probes (24 out of 48) annotated to ‘glutathione metabolic process’ (GO:0006749) were 
up-regulated by PCB 126 in mouse livers. Among them, ten encoded GSTs plus several genes 
involved in GSH-regeneration or protection of cells from oxidative damage, such as superoxide 
dismutase 2 (Sod2, NM_013671), glutathione peroxidases (Gpx1, NM_008160; Gpx3, 
NM_008161; Gpx4, NM_001037741), and glutathione reductase (Gsr, NM_010344). 
Altogether, the subgraph induced by the top five GO terms regarding up-regulated genes responding 
to PCB 126-treatment showed fairly clustering genes uncovering the congener’s impact on gene 
transcription and metabolism.  
 
PCB 126 inhibited transcription of 1767 genes (≥ 2fold) in mouse livers subsequent to three days of 
single dose exposure (250 µg/kg bw). The Top 20 of down-regulated genes is displayed in table 32. 
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Table 32: Mouse whole genome microarray analysis. Top 20 down-regulated genes in mouse livers by PCB 126 
(250 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 126 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
-4.502/ 
-4.480 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-4.207 NR_004413 U1b6 small nuclear RNA  Rnu1b6 
-4.029 NM_011302 retinoschisis (X-linked juvenile) 1 (human)   Rs1 
-3.951 NM_013877 calcium binding protein 5  Cabp5 
-3.949 NM_199022 SHC (Src homology 2 domain containing) family member 4  Shc4 
-3.941 NM_197945 ProSAPiP1 protein  RP23-100C5.8 
-3.940 NM_011371 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 1 St6galnac1 
-3.936 XM_001478202 hypothetical protein LOC100047464  LOC100047464 
-3.925 NM_181319 T-box 22 (Tbx22) transcript variant 2   Tbx22 
-3.900 NM_001169153 CD300 antigen like family member F  Cd300lf 
-3.892 NM_016659 killer cell lectin-like receptor subfamily A member 1  Klra1 
-3.892 XM_981891 predicted gene EG665802 transcript variant 6   Gm7792 
-3.889 NM_001033960 RAB GTPase activating protein 1  Rabgap1 
-3.889 AK036325 
16 days neonate cerebellum cDNA RIKEN full-length 
enriched library clone:9630056N24  Syn3 
-3.880 NM_153522 sodium channel voltage-gated type III beta Scn3b 
-3.826 NM_194336 macrophage activation 2 like  Mpa2l 
-3.823 NM_011562 teratocarcinoma-derived growth factor 1  Tdgf1 
-3.822 NM_010418 
hect (homologous to the E6-AP (UBE3A) carboxyl terminus) 
domain and RCC1 (CHC1)-like domain (RLD) 2  Herc2 
-3.807- 
-2.754 NM_008103 glial cells missing homolog 1 (Drosophila) Gcm1 
   
 
Value range of more than two (n) oligos: values a-n. 
 
Most effectively down-regulated Serpina4-ps1 (BC031891/NR_002861; lfc (max) = -4.502) by 
PCB 126 represented one of six genes within the Top 20-list (table 32) implicated in immune 
function (Binns et al., 2009; Dimmer et al., 2012): Tbx22 (NM_181319; lfc = -3.925; encodes a 
probable transcriptional regulator involved in developmental processes; major determinant crucial 
to palatogenesis), Cd300lf (NM_001169153; lfc = -3.900; encoded protein participates in osteoclast 
differentiation), Klra1 (NM_016659; lfc = -3.892; encodes T-cell surface glycoprotein YE1/48, a 
MHC class I receptor), and Tdgf1 (NM_011562; lfc = -3.823). Serpina4-ps1 and Tdgf1 are also 
involved in apoptotic processes (Binns et al., 2009; Bustos et al., 2009; Dimmer et al., 2012). 
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Notably and not only regarding these immune-related genes, PCB 126’s list of down-regulated 
genes resembled the Top 20-list for inhibitory effects on transcription for 4-PeCDF-treatment with 
respect to several genes. Two more examples represented St6galnac1 (NM_011371; lfc = -3.940; 
encodes a glycosyltransferase, which plays a role in glycosylation of proteins), and Rabgap1, 
NM_001033960; lfc = -3.889; encodes a protein possessing Rab GTPase activator activity; 
proposed involvement in cell cycle regulation) (Binns et al., 2009; Dimmer et al., 2012). 
 
Further down-regulated genes within PCB 126’s Top 20-list were involved in forming cell junctions 
(ProSAPiP1 protein, RP23-100C5.8, NM_197945; lfc = -3.941), or DNA repair (hect (homologous 
to the E6-AP (UBE3A) carboxyl terminus) domain and RCC1 (CHC1)-like domain (RLD) 2, 
Herc2, NM_010418; lfc = -3.822) (Binns et al., 2009; Dimmer et al., 2012). 
 
Table 33 presents results regarding TopGO analysis with respect to down-regulated genes in mouse 
livers subsequent to PCB 126-treatment. 
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Table 33: Mouse whole genome microarray analysis – TopGO analysis (PCB 126): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding down-regulated 
genes; descending order. Mouse liver, PCB 126 (250 µg/kg bw, three days). Top five GO terms indicated in bold. 
PCB 126 
 
GO term 
 
 
GO ID 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
positive regulation of synaptic plasticity GO:0031915 6/10 3.1E-05 
cell fate commitment GO:0045165 40/272 4.5E-05 
diencephalon development GO:0021536 15/76 1.6E-04 
endocrine system development GO:0035270 21/132 3.9E-04 
cytotoxic T cell differentiation GO:0045065 2/3 4.4E-04 
ethanolamine metabolic process GO:0006580 5/10 4.6E-04 
phosphatidylethanolamine biosynthetic process GO:0006646 5/10 4.6E-04 
ethanolamine biosynthetic process GO:0046335 5/10 4.6E-04 
positive regulation of epithelial cell proliferation GO:0050679 23/144 5.5E-04 
ameboidal cell migration GO:0001667 20/119 6.3E-04 
pituitary gland development GO:0021983 11/48 7.8E-04 
regulation of cartilage development GO:0061035 11/48 7.8E-04 
phosphatidylethanolamine metabolic process GO:0046337 5/11 7.9E-04 
positive regulation of histone methylation GO:0031062 5/12 1.3E-03 
skeletal muscle tissue development GO:0007519 29/210 1.3E-03 
histone H3-K4 methylation GO:0051568 8/30 1.4E-03 
positive regulation of cAMP-mediated signaling GO:0043950 3/4 1.7E-03 
CDP-choline pathway GO:0006657 4/8 1.8E-03 
S-adenosylmethioninamine metabolic process GO:0046499 4/8 1.8E-03 
spinal cord development GO:0021510 14/77 1.8E-03 
    
 
According to the top five GO terms identified by the classic algorithm for scoring GO terms for 
enrichment regarding down-regulated genes, low correlation between these processes was observed 
(table 33). Overall, significances regarding over-representation of GO terms for down-regulated 
genes and accordant clusters among the Top 20 GO terms by means of PCB 126-treatment were 
low (raw p-values ≥ 3.1E-05). 
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Statistically slightly dominating paths within the top five and correlated GO terms among the Top 
20-list issued into ‘positice regulation of synaptic plasticity’ (GO:0031915), ‘cytotoxic T cell 
differentiation’ (GO:0045065), and ‘diencephalon development’ (GO:0021536). The path issuing 
into the latter also involved another top five GO term: ‘endocrine system development’ 
(GO:0035270). Within, 21 out of 132 annotated probes were negatively affected by PCB 126. 
Respective genes are listed in table 34. 
 
Table 34: Mouse whole genome microarray analysis. Down-regulated genes by PCB 126 (250 µg/kg bw, three 
days) annotated to the GO term ‘endocrine system development’ (GO:0035270); mouse liver.                        
Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05.  
PCB 126 
 
Gene name 
 
 
Gene systematic name 
 
 
Gene description 
   
Nog NM_008711 noggin  
Fgf2 NM_008006 fibroblast growth factor 2  
Apoa1 NM_009692 apolipoprotein A-I  
LOC100044968 XM_001473421 Mus musculus similar to modulator recognition factor 2  
Drd2 NM_010077 dopamine receptor 2 
Nkx6-1 NM_144955 NK6 homeobox 1  
Onecut1 NM_008262 one cut domain family member 1 
Nkx2-2 NM_010919 NK2 transcription factor related 
Pou1f1 NM_008849 POU domain 
Tcf7l2 NM_001142920 transcription factor 7-like 2 
Lhx3 NM_001039653 LIM homeobox protein 3  
Il6ra NM_010559 interleukin 6 receptor 
Nf1 NM_010897 neurofibromatosis 1 
ENSMUST00000089855 ENSMUST00000089855 oxidase 2 
Foxe3 NM_015758 forkhead box E3  
Smo NM_176996 smoothened homolog  
Tcf7l2 NM_001142923 transcription factor 7-like 2 
Bmp4 NM_007554 bone morphogenetic protein 4 
Pbx1 NM_183355 pre B-cell leukemia transcription factor 1 
Onecut2 NM_194268 one cut domain family member 2 
LOC100048479 XM_001480325 similar to hepatocyte nuclear factor 6 beta  
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The genes and respective encoded proteins listed in table 34 are involved in several diverging 
processes within ‘endocrine system development’ (GO:0035270). These included lipid metabolism, 
glucose homeostasis, steroidogenesis, immune response, acute-phase reactions and hematopoiesis. 
For instance, the protein encoded by apolipoprotein A-I (Apoa1, NM_009692) participates in the 
transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from 
tissues and by acting as a cofactor for lecithin cholesterol acyltransferase (Lcat). Lcat (NM_008490) 
was not regulated by any of the tested congeners. Ten probes out of significantly down-regulated 
probes annotated to ‘endocrine system development’ (GO:0035270; sign./annot.: 21/132 in total) 
matched those annotated to ‘diencephalon development’ (GO:0021536) sign./annot.: 15/76 in total). 
Both of these subsets of genes did not clearly appear obviously straight-lined regarding their 
specific roles in respective process (Ashburner et al., 2000; Binns et al., 2009; Dimmer et al., 
2012). 
 
Processes involved in lipid biosynthesis with correlating significant annotated genes were 
‘phosphatidylethanolamine biosynthetic process’ (GO:0006646), ‘phosphatidylethanolamine 
metabolic process’ (GO:0046337), and ‘CDP-choline pathway’ (GO:0006657). To these processes, 
solute carrier family 27, member 1 (Slc27a1, NM_011977; fatty acid transporter), cholin kinase 
alpha (Chka, NM_013490), and Chkb (NM_007692) represented significantly down-regulated 
genes by PCB 126-treatment. These genes and respective GO terms are of relevance with respect to 
biosynthesis of glycerophospholipids, especially of phosphatidylcholin (Ashburner et al., 2000; 
Binns et al., 2009; Dimmer et al., 2012). 
 
Within GO term ‘cytotoxic T cell differentiation’ (GO:0045065), two out of three probes annotated 
were affected significantly by PCB 126, representing both annotated genes (one of the genes was 
tested with two different probes): CD8 antigen (Cd8a, NM_009857), and aquamous cell carcinoma 
antigen recognized by T-cells 1 (Sart1, NM_016882). These genes are required for both 
development and activity of cytotoxic T cells (Fung-Leung et al., 1991; Kikuchi et al., 1999). 
 
A few epigenetic processes were included in the Top 20-list for down-regulating effects on gene 
expression by PCB 126: ‘S-adenosylmethioninamine metabolic process’ (GO:0046499), ‘positive 
regulation of histone methylation’ (GO:0031062), and ‘histone H3-K4 methylation’ (GO:0051568). 
To these processes, DNA methyltransferases (Dnmt1, NM_010066; Dnmt3b, NM_001003961), 
histone-lysine N-methyltransferases (Kmt2d (MII2), NM_001033276, encoded protein methylates 
‘Lys-4’ of histone 3; Kmt2e (MII5), NM_026984, encoded methyltransferase specifically mono- 
and dimethylates ‘Lys-4’ of histone H3), O-linked N-acetylglucosamine transferase (Ogt, 
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NM_139144; encoded protein glycosylates diverse proteins including histone H2B, AKT1, or        
6-phosphofructokinase), and dpy-30 homolog (Dpy30, NM_001146224; encoded protein is part of 
the MLL1/MLL complex, involved in the methylation of histone H3 at ‘Lys-4’, particularly 
trimethylation) were annotated and significantly down-regulated by the congener.  
Histone H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation and 
is associated with active genes. Besides their denoted general impact on epigenetics, information on 
more specific roles is available for some of the described genes. MII2 and Ogt are concerned with 
insulin sensitivity and glucose tolerance, whereas KMT2E represents a key regulator of 
hematopoiesis involved in terminal myeloid differentiation and in the regulation of hematopoietic 
stem cell self-renewal by a DNA methylation-dependent mechanism (Ashburner et al., 2000; Binns 
et al., 2009; Dimmer et al., 2012; Goldsworthy et al., 2013; Heuser et al., 2009; Jiang et al., 2011; 
Santos-Rosa et al., 2002). 
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# of down-regulated genes
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4.1.1.2.5. PCB 156 – impact on gene transcription in mouse livers 
 
Treatment with single doses of PCB 156 (150000 µg/kg bw) for three days exerted highly inductive 
effects on gene expression in mouse livers. Observations regarding ≥ 2fold up to ≥ 6fold 
inductive/repressive effects by PCB 156 on gene transcription in comparison to ≥ 2fold effects by 
TCDD is illustrated in figure 20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Mouse whole genome microarray analysis. Numbers of regulated genes in mouse livers by PCB 156 
(150000 µg/kg bw, three days) compared to numbers of genes regulated by TCDD (25 µg/kg bw, three days), and 
numbers of genes regulated both by PCB 156 and TCDD (TCDD-raw data by courtesy of C. Lohr; Lohr, 2013). 
A ≥ 27, p-value < 0.05. 2071; 
 
In mouse livers, in vivo treatment with PCB 156 led to both induction and respression of more than 
2000 genes each (figure 20) within set cutoff-values (A ≥ 27, │lfc│ ≥ 1 (≥ 2fold); p-value < 0.05). 
By change of cutoff-levels to effects, numbers of affected genes constantly reduced from 810 (up), 
and 1144 (down) (≥ 3fold) to 82 (up), and 209 (down) (≥ 6fold). Overlap of PCB 156-, and TCDD-
affected genes (125 up-, and 95 down-regulated genes) accounted for 93 up-, and 57 down-
regulated genes accordantly regulated with respect to ≥ 2fold effects.  
In table 35 (following page), the Top 20-list of genes, which were up-regulated in response to 
treatment with PCB 156 (150000 µg/kg bw, three days) in mouse livers is depicted.  
 
TCDD 
≥ 2fold 
93↑ 
57↓ 
1978↑ 
2036↓ 32↑ 
38↓ 
PCB 156 
≥ 2fold 
≥ 2fold      ≥ 2fold       ≥ 3fold       ≥ 4fold      ≥ 5fold      ≥ 6fold 
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Table 35: Mouse whole genome microarray analysis. Top 20 up-regulated genes in mouse livers by PCB 156 
(150000 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
PCB 156 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
7.467 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1  Cyp1a1 
4.006 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
3.939/2.268 NM_001122660 predicted gene 10639  Gm10639 
3.861 NM_010210 fragile histidine triad gene   Fhit 
3.816 NM_009028 RAS-like family 2 locus 9   Rasl2-9 
3.796 NM_010002 cytochrome P450 family 2 subfamily c polypeptide 38  Cyp2c38 
3.718 NAP029947-1 Unknown  NAP029947-1 
3.671/1.734 NM_011034 peroxiredoxin 1 Prdx1 
3.652 NM_009994 cytochrome P450  family 1 subfamily b polypeptide 1  Cyp1b1 
3.584 NM_198171 cDNA sequence BC015286   BC015286 
3.549/2.267 NM_172881 UDP glucuronosyltransferase 2 family polypeptide B35  Ugt2b35 
3.493 NM_008030 flavin containing monooxygenase 3 Fmo3 
3.463 NM_017475 Ras-related GTP binding C  Rragc 
3.429/3.387 NM_145603 carboxylesterase 2  Ces2 
3.402 NM_009993 cytochrome P450 family1 subfamily a polypeptide 2  Cyp1a2 
3.368 NM_025535 SAR1 gene homolog B (S. cerevisiae)   Sar1b 
3.270 XM_902301 predicted gene EG546797 transcript variant 1 Gm5978 
3.246 A_55_P2168781 Unknown  A_55_P2168781 
3.234 NR_003625 RIKEN cDNA 1700073E17 gene  1700073E17Rik 
3.209 NM_001081325 predicted gene 6957  Gm6957 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
The highest up-regulated gene in mouse livers in response to treatment with PCB 156 was Cyp1a1 
(NM_009992; lfc = 7.467). Cyp1b1 (NM_009994; lfc = 3.652), and Cyp1a2 (NM_009993;           
lfc = 3.402) were also within the Top 20-list of up-regulated genes (table 35). Transcription of 
further genes implicated in (drug) metabolism was disctinctly enhanced by PCB 156: Gsta1 
(NM_008181; lfc = 4.006), Gm10639 (NM_001122660; lfc (max) = 3.939; encoded protein 
exhibits GST activity), Ugt2b35 (NM_172881; lfc (max) = 3.549), flavin containing 
monooxygenase 3 (Fmo3, NM_008030; lfc = 3.493), and predicted gene 6957 (Gm6957, 
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NM_001081325; lfc = 3.209; encoded protein exhibits SULT-activity) were affected and listed 
among the Top 20-list (Binns et al., 2009; Dimmer et al., 2012). 
 
Indications regarding altered lipid and fatty acid metabolism were given by up-regulation of 
Cyp2c38 (NM_010002; lfc = 3.796; encodes an arachidonic acid metabolism), cDNA sequence 
BC015286 (BC015286, NM_198171; lfc = 3.584; encodes an acylcarnitine hydrolase), and Ces2 
(NM_145603; lfc (max) = 3.429; encodes an acylcarnitine hydrolase) (Binns et al., 2009; Dimmer 
et al., 2012).  
 
Treatment with PCB 156 appeared to impact transcriptional and metabolical activity in mouse 
livers, which was further hinted by up-regulation of Sar1b (NM_025535; lfc = 3.368; encoded 
protein involved in intracellular transport), and Rasl2-9 (NM_009028; lfc = 3.816; encoded GTP-
binding protein involved in nucleocytoplasmatic transport of proteins and RNA) (Binns et al., 2009; 
Dimmer et al., 2012; Kadowaki et al., 1993; Melchior et al., 1993). 
 
A member of the Top 20-list of up-regulated genes implicated in the redox status represented Prdx1 
(NM_011034; lfc (max) = 3.671). By use of reducing equivalents provided through the thioredoxin 
system, PRDX 1 enables the reduction of peroxides (Chae et al., 1994a; Chae et al., 1994b; Iwahara 
et al., 1995). Besides, PRDX 1 was discussed related to inhibition of apoptosis (Berggren et al., 
2001; Egler et al., 2005; Kim et al., 2000; Kim et al., 2008).  
Several further members of the thioredoxin/thioredoxin reductase redox system were up-regulated 
by PCB 156 in the course of current study: Txnip (NM_001009935; lfc = 1.742), Txndc12 
(NM_025334; lfc = 1.719), thioredoxin-like 4A (Txnl4a, NM_025299; lfc = 1.539), Txndc15 
(NM_175150; lfc = 1.137), Txndc17 (NM_026559; lfc = 1.107), and Txn1 (NM_011660;              
lfc = 1.053). Another up-regulated gene implicated in apoptotic processes was Fhit (NM_010210; 
lfc = 3.861). Fhit represents a pro-apoptotic tumor suppressor gene playing a role in p53/TP53-
mediated apoptosis (Binns et al., 2009; Dimmer et al., 2012).  
 
Transcription of Ras-related GTP binding C (Rragc, NM_017475; lfc = 3.463) was as well up-
regulated by PCB 156 in mouse livers. Rags are GTPases, which function as heterodimers 
consisting of RagA or B bound to RagC or D. These heterodimeric complexes are required for 
amino acid-induced relocalization of mechanistic target of rapamycin complex 1 (mTORC1) to 
lysosomes and its subsequent activation by the GTPase Ras homolog enriched in brain (RHEB). 
Consisting of TORC1 and TORC2, TOR is a key regulatory kinase regulating cellular growth and 
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metabolism. RagC/D was shown to be a key regulator in the activation of the TOR signaling 
cascade by amino acids (Russell et al., 2011; Tsun et al., 2013). Further, hepatic mTORC1 was 
reported to be involved in the control of locomotor activity and lipid metabolism (Cornu et al., 
2014).  
Besides Rragc, genes which are concerned with TOR signaling and were up-regulated by PCB 156 
in mouse livers were Rraga (NM_178376; lfc = 2.338), and Rheb (NM_053075; lfc = 1.573). Mtor 
(NM_020009) appeared slightly below cutoff regarding signal intensity (A ≥ 27), though 
tendentiously adverting to an up-regulation (A ≥ 25.91, lfc = 2.106) by PCB 156.  
 
By classical enrichment analysis performed using Fisher’s exact test, over-representation of GO 
terms within the group of differentially expressed genes was assessed. The 20 most significant GO 
terms in terms of up-regulation by PCB 156 is presented in table 36.  
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Table 36: Mouse whole genome microarray analysis – TopGO analysis (PCB 156): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; 
descending order. Mouse liver, PCB 156 (150000 µg/kg bw, three days). Top five GO terms are indicated in bold. 
PCB 156 
 
GO ID 
 
 
GO term 
 
sign./annot. 
genes 
 
 
Raw p-value 
  
  
oxidation-reduction process GO:0055114 262/1237 1.2E-24 
cellular ketone metabolic process GO:0042180 197/948 7.5E-18 
translation GO:0006412 148/658 9.8E-17 
carboxylic acid metabolic process GO:0019752 185/918 1.8E-15 
oxoacid metabolic process GO:0043436 185/918 1.8E-15 
organic acid metabolic process GO:0006082 186/937 6.8E-15 
cofactor metabolic process GO:0051186 81/311 3.1E-13 
coenzyme metabolic process GO:0006732 68/250 2.8E-12 
small molecule metabolic process GO:0044281 431/2829 1.4E-11 
intracellular transport GO:0046907 196/1088 1.6E-11 
metabolic process GO:0008152 1585/12490 2.1E-10 
cellular catabolic process GO:0044248 291/1853 1.9E-09 
glutathione metabolic process GO:0006749 22/48 1.9E-09 
protein transport GO:0015031 224/1358 2.5E-09 
translational elongation GO:0006414 57/225 2.9E-09 
establishment of protein localization GO:0045184 228/1406 7.9E-09 
cellular amino acid metabolic process GO:0006520 81/382 1.4E-08 
cellular metabolic process GO:0044237 1355/10684 1.8E-08 
response to xenobiotic stimulus GO:0009410 19/41 1.9E-08 
catabolic process GO:0009056 324/2156 2.5E-08 
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Figure 21: Mouse whole genome microarray analysis – TopGO analysis (PCB 156, 150000 µg/kg bw, three days; mouse liver): The GO subgraph plot induced by the 
top five GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant GO 
terms. Box color represents relative significance ranging from dark red (most significant) to light yellow (least significant). 
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The Top 20 GO terms assigned to TopGO pathway analysis investigating up-regulated genes by 
PCB 156 in mouse livers most prominently and statistically very significantly were related to 
metabolic processes including ‘oxidation-reduction process’ (GO:0055114), ‘carboxylic acid 
metabolic process’ (GO:0019752), and ‘translation’ (GO:0006412) (see table 36, figure 21).  
Paths included xenobiotic metabolism (Cyp1a1; Ahr, NM_013464; Ahrr, NM_009644; Ugt2b1, 
NM_152811, e.g.; annotated to ‘response to xenobiotic stimulus’, GO:0009410), and accordant 
‘glutathione metabolic process’ (GO:0006749; annotated genes: Sod2, NM_013671; Gpx3, 
NM_08161; Gsr, NM_010344; Gsta1, NM_008181; Gstm1, NM_010358; Gstp2, NM_181796; 
Gstt3, NM_133994, e.g.), as well as lipid metabolism (Aldh1a1, NM_013467; Aldh1a7, 
NM_011921; hydroxyacid oxidase 2, Hao2, NM_019545; fatty acid binding protein 2, Fabp2, 
NM_007980; Slc27a5, NM_009512; phospholipase A2, Pla2g15, NM_133792; annotated to 
‘carboxylic acid metabolic process’, GO:0019752, and ‘lipid metabolic process’, GO:0006629, 191 
significant probes out of 1245 annotated).  
 
Indications of transcriptionally and metabolically active cells in general were given by 
aforementioned top five GO term ‘translation’ (GO:0006412), as well as by ‘translational 
elongation’ (GO:0006414), ‘protein transport’ (GO:0015031), and ‘establishment of protein 
localization’ (GO:0045184).  
 
In table 37, the Top 20 genes of 2093 down-regulated genes affected in mouse livers subsequent to 
PCB 156-treatment are listed. 
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Table 37: Mouse whole genome microarray analysis. Top 20 down-regulated genes in mouse livers by PCB 156 
(150000 µg/kg bw, three days). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 156 
 
lfc 
 
Gene  
systematic name 
 
 
Gene description 
 
 
Gene name 
 
 
  
-4.481/ 
-4.279 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-4.098- 
-2.451 NM_008103 glial cells missing homolog 1 (Drosophila) Gcm1 
-4.094 XM_001472203 similar to Ubtf protein (LOC100039072)  Gm2033 
-3.964 NR_004413 U1b6 small nuclear RNA  Rnu1b6 
-3.839- 
-2.362 NM_009946 complexin 2  Cplx2 
-3.788 XM_001472970 similar to R10D12.10 (LOC100039488)   Gm2264 
-3.754 NM_008341 insulin-like growth factor binding protein 1  Igfbp1 
-3.714 
ENSMUST0000
0106778 
Probable ATP-dependent RNA helicase DDX5 (DEAD box 
protein 5)  
ENSMUST00000
106778 
-3.645 XM_889044 predicted gene EG624491  Gm6508 
-3.629 XM_001474429 similar to cyclic nucleotide gated channel beta 1 Gm2690 
-3.556 XM_001480348 similar to gag (LOC100043516)  Gm4492 
-3.547 NM_153522 sodium channel voltage-gated type III beta  Scn3b 
-3.537 A_55_P1986743 Unknown     A_55_P1986743 
-3.509 AK017236 
adult male pituitary gland cDNA RIKEN full-length enriched 
library  clone:5330406M23 5330406M23Rik 
-3.495 NM_001169153 CD300 antigen like family member F   Cd300lf 
-3.470 NM_001033960 RAB GTPase activating protein 1   Rabgap1 
-3.459 XM_001478202 hypothetical protein LOC100047464  LOC100047464 
-3.451 NM_011562 teratocarcinoma-derived growth factor Tdgf1 
-3.419 NM_197945 ProSAPiP1 protein    RP23-100C5.8 
-3.410 NM_013932 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25   Ddx25 
-3.407 NM_181319 T-box 22 (Tbx22) transcript variant 2 mRNA  Tbx22 
   
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
Among down-regulated genes by PCB 156 (table 37), several representatives implying a potential 
role of the congener on immune function and/or response included Serpina4-ps1 
(BC031891/NR_002861; lfc (max) = -4.481), Cplx2 (NM_009946; lfc (max) = -3.839; proposed 
involvement in mast cell degranulation), Cd300lf (NM_001169153; lfc = -3.495; encoded protein 
participates in osteoclast differentiation), Tdgf1 (NM_011562; lfc = -3.451), and Tbx22 
(NM_181319; lfc = -3.407; encodes a probable transcriptional regulator involved in developmental 
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processes; major determinant crucial to palatogenesis) (Binns et al., 2009; Dimmer et al., 2012). 
Besides, Serpina4-ps1 and Tdgf1 are also involved in apoptotic processes (Binns et al., 2009; 
Bustos et al., 2009; Dimmer et al., 2012). 
 
A further down-regulated gene transcript by PCB 156 was Igfbp1 (NM_008341; lfc = -3.754). The 
encoded protein is implicated in insulin receptor signaling pathways and is further proposed to be 
involved in regulation of cell growth and tissue regeneration (Binns et al., 2009; Dimmer et al., 
2012). With respective proteins supposedly playing roles in cell cycle regulation or in formation of 
cell junctions, Rabgap1 (NM_001033960; lfc = -3.470), and RP23-100C5.8 (NM_197945;           
lfc = -3.419; encoding ProSAPiP1 protein) were among the Top 20 of down-regulated genes by 
PCB 156 (Binns et al., 2009; Dimmer et al., 2012). 
 
Down-regulated DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 (Ddx25, NM_013932;                  
lfc = -3.410), and ‘probable’ ATP-dependent RNA helicase DEAD box protein 5 (Ddx5; 
ENSMUST00000106778; lfc = -3.714) (‘probably’) encode RNA helicases from the DEAD-box 
family, which use energy from ATP hydrolysis and are associated with many processes ranging 
from RNA synthesis to RNA degradation. Connection of DEAD-box proteins to these processes 
includes p53-dependent apoptosis (DDX5, e.g.), innate immune response (esp. DDX1, DDX3, 
DDX5, DDX9, DDX17, and DDX41), and regulation of ER-α dependent transcription (DDX17, 
e.g) (Bates et al., 2005; Fuller-Pace, 2013; Rocak and Linder, 2004; Soulat et al., 2008; Worthham 
et al., 2009).  
 
Including mentioned members of the Top 20-list, several DEAD-box protein gene transcripts were 
affected by PCB 156-treatment: six were up-regulated (Ddx51, NM_027156; lfc = 1.821; Ddx54, 
NM_028041; lfc = 1.435; Ddx20, NM_017397; lfc = 1.4; Ddx41, NM_134059; lfc =1.274; Ddx27, 
NM_153065; lfc = 1.106; Ddx21, NM_019553; lfc = 1.078), and four were down-regulated 
(ENSMUST00000106778 (Ddx5), lfc = -3.714; Ddx25, NM_013932; lfc = -3.410; Ddx5, 
NM_007840; lfc = -2.058; Ddx1, NM_134040; lfc = -1.21) within set cutoff-values.  
 
Table 38 shows TopGO results with respect to down-regulated genes by PCB 156. 
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Table 38: Mouse whole genome microarray analysis – TopGO analysis (PCB 156): Fisher’s exact test. Top 20 
GO terms identified by the classic algorithm for scoring GO terms for enrichment regarding down-regulated 
genes. Mouse liver, PCB 156 (150000 µg/kg bw, three days). Top five GO terms are indicated in bold. 
PCB 156 
 
GO term 
 
 
GO ID 
 
sign./annot.  
genes 
 
 
Raw p-value 
  
  
regulation of RNA metabolic process GO:0051252 382 / 3478 1.8E-08 
regulation of nitrogen compound metabolic process GO:0051171 434 / 4055 4.0E-08 
transcription, DNA-dependent GO:0006351 382 / 3503 4.1E-08 
regulation of gene expression GO:0010468 424 / 3952 4.5E-08 
RNA biosynthetic process GO:0032774 382 / 3507 4.7E-08 
regulation of nucleobase-containing compound metabolic pr. GO:0019219 429 / 4018 6.4E-08 
regulation of biosynthetic process GO:0009889 430 / 4036 8.0E-08 
regulation of transcription, DNA-templated GO:0006355 370 / 3402 9.2E-08 
regulation of RNA biosynthetic process GO:2001141 370 / 3403 9.5E-08 
regulation of cellular biosynthetic process GO:0031326 425 / 3993 1.1E-07 
regulation of cellular macromolecule biosynthetic process GO:2000112 393 / 3707 5.4E-07 
cellular developmental process GO:0048869 352 / 3271 5.6E-07 
regulation of macromolecule biosynthetic process GO:0010556 399 / 3789 8.7E-07 
cell differentiation GO:0030154 335 / 3106 8.9E-07 
negative regulation of nitrogen compound metabolic pr.  GO:0051172 150 / 1208 9.7E-07 
negative regulation of nucleobase-containing metabolic pr. GO:0045934 148 / 1196 1.4E-06 
negative regulation of cellular biosynthetic process GO:0031327 155 / 1267 1.5E-06 
negative regulation of biosynthetic process GO:0009890 157 / 1287 1.6E-06 
triglyceride biosynthetic process GO:0019432 17 / 55 1.6E-06 
RNA metabolic process GO:0016070 443 / 4300 2.1E-06 
    
 
Most of the Top 20 GO terms, and especially respective top five GO terms, obtained by view on 
down-regulated genes by PCB 156 were related to ‘regulation of gene expression’ (GO:0010468), 
‘transcription’ (DNA-dependent, GO:0006351), and ‘regulation of RNA metabolic processes’ 
(GO:0051252) (see table 38). In addition, these processes appeared to be closely connected to each 
other, indicating a quite defined mode of action regarding inhibited processes in mouse livers.  
These observations might be a result of PCB 156’s high inducing effect in mouse livers, since 
excessively and probably redundantly synthezised gene transcripts might be catabolized. Further, 
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these results might represent a feedback-regulation after three days of the single dose treatment with 
the DL-congener.  
 
Besides, ‘triglyceride biosynthetic process’ (GO:0019432) as a more specified biological process 
occured in the Top 20-list of GO terms obtained via investigation of down-regulated genes by PCB 
156. Exemplarily, among significantly affected probes annotated to this GO term (17 out of 55), 
fatty acid synthase (Fasn, NM_007988), 1-acylglycerol-3-phosphate O-acyltransferase 6 (Agpat6, 
NM_018743), elongation of very long chain fatty acids 2, and 4 (Elovl2, NM_019423; Elovl4, 
NM_148941), and acyl-CoA synthetase long-chain family member 5 (Acsl5, NM_027976) were 
located.  
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4.1.1.3. Mouse microarrays – Investigations among congeners 
 
Of particular interest with respect to understanding mechanisms of action of different DL-congeners 
and potential degree of involvement of the AhR, might be an examination of mouse whole genome 
microarray results among congeners. To primarily approach to this topic, correlations of gene lists 
between congeners and ‘together’ regulated genes were investigated, as already indicated in 
respective congener-specific chapters. 
 
Table 39 (following page) gives an overview of numbers of genes regulated by individual 
congeners, as well as ‘together’ regulated genes considering several combinations. Implied cutoff 
values were A ≥ 27 regarding signal intensity, │lfc│ ≥ 1 with respect to (log2) fold change (≥ 2fold 
induction/repression), and p-value < 0.05, as applied throughout mouse whole genome microarray 
analysis. 
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Table 39: Mouse whole genome microarray analysis. Numbers of ‘together’ regulated genes in mouse livers by 
treatment with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, or PCB 156 (three days); several correlations 
among congeners. TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013). A ≥ 27,│lfc│ ≥ 1, p-value < 0.05. 
congener or 
correlation 
# of significantly  
affected genes 
congener or 
correlation 
# of significantly  
affected genes 
congener or 
correlation 
# of significantly  
affected genes 
 
 
 
   
  
  
TCDD* 125↑   95↓ 
   
TCDD &    
1-PeCDD 319↑  374↓ TCDD & 
  
4-PeCDF 3051↑  2843↓ 
 
1-PeCDD 
4-PeCDF 74↑ 
 
32↓ 
 
PCB 118 353↑  363↓ TCDD &     
PCB 126 2587↑  1767↓   
PCB 156 2071↑  2093↓ 
 
1-PeCDD 
 
4-PeCDF 
 
PCB 118 
 
PCB 126 
 
PCB 156 
92↑ 
 
94↑ 
 
29↑ 
 
64↑ 
 
93↑ 
61↓ 
 
47↓ 
 
12↓ 
 
26↓ 
 
57↓ 
PCB 118 
PCB 126 
PCB 156 25↑ 7↓ 
         
      
      
      
TCDD &  
1-PeCDD 
4-PeCDF 
PCB 118 
PCB 126 
PCB 156 22↑ 5↓ 
TCDD &  
 
1-PeCDD 
4-PeCDF 
PCB 126 
PCB 156 48↑ 19↓ 
TCDD & 
 
PCB 126 
PCB 156 58↑ 26↓ 
         
         
1-PeCDD &   1-PeCDD & 
  
  
  
1-PeCDD & 
4-PeCDF 
PCB 118 
PCB 126 
PCB 156 
220↑ 
44↑  
141↑  
215↑  
304↓ 
37↓ 
223↓ 
305↓  
PCB 118 
PCB 126  
PCB 156 37↑ 32↓ 
PCB 126  
PCB 156 132↑ 218↓ 
         
4-PeCDF &   4-PeCDF &   4-PeCDF & 
  
PCB 118 
PCB 126 
PCB 156 
321↑ 
2229↑   
1884↑   
346↓ 
1660↓ 
1952↓ 
PCB 118 
PCB 126  
PCB 156 276↑ 328↓ 
PCB 126  
PCB 156 1500↑ 1487↓ 
         
         
PCBs         
         
PCB 118 
PCB 126  314↑ 345↓ 
PCB 118 
PCB 156 305↑ 344↓ 
PCB 126 
PCB 156 1548↑ 1513↓ 
         
PCB 118 
PCB 126 
PCB 156 283↑ 332↓       
         
*raw data regarding TCDD-treatment was obtained by courtesy of Christiane Lohr (Lohr, 2013). 
 
 
Results – whole genome mouse microarray analysis 
 
  129 
Oral treatment of mice with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, or PCB 156 led to 
highly diverging numbers of regulated genes in livers among congeners. Ranging around 100 to 400 
up-, and down-regulated genes, TCDD, 1-PeCDD, or PCB 118 regulated comparable amounts of 
genes in mouse livers. By contrast, treatments with 4-PeCDF, PCB 126, or PCB 156 affected very 
high numbers of around 2000, up to more than 3000 genes.  
 
Overlap between TCDD-derived effects (125↑ 95↓) and those obtained by 1-PeCDD, or 4-PeCDF, 
was by tendency most prominent among congeners, but was still limited to around half/up to three 
quarters of genes regulated by TCDD (TCDD & 1-PeCDD: 92↑ 61↓; TCDD & 4-PeCDF: 94↑ 47↓). 
The amount of accorantly regulated genes was limited regarding DL-PCBs and TCDD. By view on 
all DL-PCBs compared with TCDD, 25 accordantly up-, and 7 down-regulated genes remained, 
which slightly increased by exception of PCB 118 (58↑ 26↓). Hence, overlap was minor for the 
correlation TCDD & PCB 118 (29↑ 12↓); less than 10% of PCB 118-regulated genes were as well 
affected by TCDD-treatment.  
Generally, overlap between PCB 118-derived effects and impact of the remaining DL-compounds 
was limited excepting the correlation 4-PeCDF & PCB 118 (321↑ 346↓). Overall, 4-PeCDF-derived 
effects quite well correlated with those obtained with DL-PCBs. Around 90% of genes affected by 
each PCB were accordantly regulated by 4-PeCDF in mouse livers. Among DL-PCBs, modes of 
action appeared to be fairly comparable in view of numbers and percentage of ‘together’ regulated 
genes. 
Correlating 1-PeCDD-impacted genes (319↑ 374↓) with other DL-congeners, strongest overlap was 
revealed together with 4-PeCDF (220↑ 304↓). For the remaining compounds, the consent tended to 
be slightly higher than with TCDD with around twice as much ‘together’ regulated genes each.  
In the attachments, the Top 20-gene lists containing accordantly up-, and down-regulated genes for 
1-PeCDD & TCDD, 4-PeCDF & TCDD, PCB 126 & TCDD, and PCB 156 & TCDD are shown. 
Further, the gene-list containing accordantly regulated genes (48↑ 19↓) of DL-congeners excepting 
PCB 118 is found in the attachments. 
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4.1.1.3.1. Mouse microarrays – ‘all’ DL-congeners 
 
The number of genes, which were regulated by every investigated DL-congener (TCDD, 1-PeCDD, 
4-PeCDF, PCB 118, PCB 126, or PCB 156; ‘all’ DL-congeners), was limited to 22 up-regulated 
and five down-regulated genes (compare table 39). Respective list of genes is presented in table 40. 
Raw-data on TCDD-derived effects was obtained by courtesy of Christiane Lohr (Lohr, 2013).  
 
The list of up-regulated genes impacted by ‘all’ DL-congeners was headed by Cyp1a1, and Cyp1a2. 
Cyp1b1 was missing in this table, since lfc for PCB 118 was slightly below cutoff                         
(lfc (PCB 118, Cyp1b1) = 0.935). The majority of regulated genes by DL-compounds was related to 
(xenobiotic) metabolism (Gsta1, Gsta2, Gstp1, Gstp2, Fmo3, Gm10639, and Ugt2b35), followed by 
genes involved in lipid metabolism (Tmem86b, Cyb5, Ces2, BC015286, Apoa1, and Etnk2), 
carbohydrate metabolic processes (Pgk1, Ugdh, LOC676974, and G6pc) or other cellular processes 
implicating highly processive cells and metabolically active conditions (Slc46a3 and Car2).  
Fhit and Htatip2 both represent tumor suppressor genes, and were correlated with apoptotic 
processes (Binns et al., 2009; Dimmer et al., 2012; Zhao et al., 2008a). 
 
‘Dioxin’-mediated effects were further investigated by TopGO pathway analysis. By classical 
enrichment analysis performed using Fisher’s exact test, over-representation of GO terms within the 
group of up-regulated genes was assessed. The 20 most significant GO terms in terms of up-
regulation by ‘all’ DL-congeners are presented in table 41. The GO subgraph induced by the top 
five GO terms is depicted in figure 22 (for table 41 and figure 22, see following pages). 
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Table 40: Mouse whole genome microarray analysis. 22 accordantly up-regulated and five down-regulated genes 
in mouse livers by treatment with DL-congeners TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, or PCB 156. 
Listed in descending order according to TCDD-derived effects. TCDD-raw data by courtesy of Christiane Lohr 
(Lohr, 2013). Cutoff values: A ≥ 27, │lfc│ ≥ 1, p-value < 0.05. 
 
 
lfc (TCDD) 
 
Gene  
systematic name 
DL-congeners 
 
Gene description 
 
 
Gene name 
  
 
 
  
up 
 
9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2 Cyp1a2 
3.582 NM_010210 fragile histidine triad gene  Fhit 
3.379 NM_017379 tubulin alpha 8 Tuba8 
3.103 NM_027872 solute carrier family 46 member 3 Slc46a3 
2.819 NM_008181 glutathione S-transferase alpha 1 (Ya) Gsta1 
2.678 NM_016865 HIV-1 tat interactive protein 2 homolog (human) Htatip2 
2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
2.153 NM_023440 transmembrane protein 86B Tmem86b 
1.857/1.362 NM_013541 glutathione S-transferase pi 1 Gstp1 
1.853 NM_001122660 predicted gene 10639  Gm10639 
1.696/1.65 NM_145603 carboxylesterase 2  Ces2 
1.63 NM_198171 cDNA sequence BC015286  BC015286 
1.559 NM_181796 glutathione S-transferase pi 2 Gstp2 
1.481 NM_008030 flavin containing monooxygenase 3  Fmo3 
1.441 NM_009150 selenium binding protein 1  Selenbp1 
1.394 NM_172881 UDP glucuronosyltransferase 2 family polypeptide B35 Ugt2b35 
1.391 NM_009466 UDP-glucose dehydrogenase  Ugdh 
1.297 NM_008182 glutathione S-transferase alpha 2 (Yc2) Gsta2 
1.156 NM_008828 phosphoglycerate kinase 1  Pgk1 
1.105 NM_025797 cytochrome b-5 Cyb5 
1.093 NM_009801 carbonic anhydrase 2  Car2 
  
down 
 
-1.821 XM_001003154 similar to Glucose phosphate isomerase 1 transcript variant 2 LOC676974 
-1.425 NM_008061 glucose-6-phosphatase catalytic G6pc 
-1.387-  
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
-1.113 XM_001471861 hypothetical protein LOC100044148 Etnk2 
-1.103 XM_001481023 hypothetical protein LOC100043770  Gm4635 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Figure 22: Mouse whole genome microarray analysis – TopGO analysis for ‘all’ DL-congeners (1-PeCDD,          
4-PeCDF, PCB 118, PCB 126, PCB 156) & TCDD: The GO subgraph plot induced by the top five GO terms 
identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes. Boxes 
indicate the five most significant GO terms. Box color represents relative significance ranging from dark red 
(most significant) to light yellow (least significant). Mouse liver; three days of treatment. TCDD-raw data 
obtained by courtesy of Christiane Lohr (Lohr, 2013). 
 
 
 
 
 
 
 
 
 
 
(1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 156) & TCDD 
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Table 41: Mouse whole genome microarray analysis – TopGO analysis for ‘all’ DL-congeners (1-PeCDD,           
4-PeCDF, PCB 118, PCB 126, PCB 156) & TCDD: Fisher’s exact test. Top 20 (+8) GO terms identified by the 
classic algorithm for scoring GO terms for enrichment regarding up-regulated genes; descending order. Mouse 
liver, three days of treatment. Top five GO terms are indicated in bold. TCDD-raw data obtained by courtesy of 
Christiane Lohr (Lohr, 2013). 
(1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 156) & TCDD 
 
GO term  
 
 
GO ID 
 
 
Rank 
  
 
xenobiotic metabolic process GO:0006805 I 
cellular response to xenobiotic stimulus GO:0071466 II 
response to xenobiotic stimulus GO:0009410 III 
small molecule metabolic process GO:0044281 IV 
carboxylic acid metabolic process GO:0019752 V 
oxoacid metabolic process GO:0043436 VI 
organic acid metabolic process GO:0006082 VII 
cellular ketone metabolic process GO:0042180 VIII 
glutathione metabolic process GO:0006749 IX 
xenobiotic catabolic process GO:0042178 X 
peptide metabolic process GO:0006518 XI 
common myeloid progenitor cell proliferation GO:0035726 XII 
neutrophil aggregation GO:0070488 XIII 
negative regulation of monocyte chemotactic protein-1 production GO:0071638 XIV 
regulation of neutrophil aggregation GO:2000428 XV 
negative regulation of neutrophil aggregation GO:2000429 XVI 
regulation of peroxidase activity GO:2000468 XVII 
negative regulation of peroxidase activity GO:2000469 XVIII 
drug metabolic process GO:0017144 XIX 
reactive oxygen species metabolic process GO:0072593 XX 
response to chemical stimulus GO:0042221 > XXa 
cellular metabolic process GO:0044237 > XXb 
metabolic process GO:0008152 > XXc 
cellular response to chemical stimulus GO:0070887 > XXd 
cellular process GO:0009987 > XXe 
biological process GO:0008150 > XXf 
response to stimulus GO:0050896 > XXg 
cellular response to stimulus GO:0051716 > XXh 
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Viewing results on pathway analysis revealed by assessment of over-represented GO terms within 
the group of up-regulated genes, two biological processes issuing in two related pathways 
predominated ‘dioxin-like’ effects: ‘xenobiotic metabolic process’ (GO:0006805), and ‘carboxylic 
acid metabolic process’ (GO:0019752) (figure 22).  
Annotated and significantly impacted genes with respect to ‘xenobiotic metabolic process’ were 
Cyp1a1, Gstp1, Gstp2, Gsta1, and Gsta2 (analyzed by six probes in total). Similar genes were as 
well represented by significantly occurring annotated probes within ‘carboxylic acid metabolic 
process’: Cyp1a1, Cyp1a2, Gstp1, Gstp2, Gsta1, Ugdh, Cyb5, and Htatip2. Accordingly, the 
majority of GO terms obtained by pathway analysis were involved in xenobiotic or carboxylic acid 
metabolism (table 41). Further correlated biological processes involved ‘reactive oxygen species 
metabolic process’ (GO:0072593). Annotated, and significantly affected by ‘all’ DL-congeners 
were Cyp1a1, Cyp1a2, and Gstp1.  
 
Four GO terms within the Top 20-list were implicated in ‘neutrophil aggregation’ (GO:0070488), or 
‘negative regulation of monocyte chemotactic protein-1 production’ (GO:0071638). Closer 
investigation of annotated genes exhibited that significance with respect to these four GO terms was 
solely due to up-regulation of Gstp1 (analyzed by two probes in total). GSTP1 was reported to 
attenuate acute inflammation in mice. In this regard, GSTP1 was shown to prevent LPS-induced 
TNF-α, IL-1β, monocyte chemotactic protein 1 (MCP-1), and nitric oxide (NO) production (Luo et 
al., 2009). Relevance of an up-regulation of Gstp1 with respect to this, reflecting its role among a 
high amount of further genes involved in metabolism, needs to be considered, though. 
 
Interestingly, the TopGO-graph regarding up-regulating effects of ‘all’ DL-congeners together 
almost matched the GO subgraph plot for effects by PCB 126 & TCDD together. The comparison is 
shortly shown in figure 23. 
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Figure 23: Mouse whole genome microarray analysis – Comparison of TopGO analysis for all DL-congeners    
(1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 156) & TCDD (left), and PCB 126 (right): GO subgraph plots 
induced by the top five GO terms each identified by the classic algorithm for scoring GO terms for enrichment 
regarding up-regulated genes. Boxes indicate the five most significant GO terms including ranks (I-XX). Box 
color represents relative significance ranging from dark red (most significant) to light yellow (least significant). 
Mouse liver, three days of treatment. GO term ranks I-XX; XXa-XXh according to table 41. TCDD-raw data by 
courtesy of Christiane Lohr (Lohr, 2013). 
 
Even with similar ranking, the TopGO subgraph for TCDD & PCB 126-‘together’ derived effects 
closely resembled the TopGO subgraph induced by ‘all’ DL-congeners ‘together’. For comparison 
and identification of GO terms, as well as in figure 23 coded rankings, see table 41, and figure 22. 
For the study in hand, PCB 126 seems to represent a ‘prototype’ for DL-response regarding 
enhancement of pathways. 
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4.1.1.3.2. Mouse microarrays – TCDD & PCB 118 
 
As indicated above, with the exception of the correlation 4-PeCDF & PCB 118, smallest overlaps 
between investigated DL-congeners were obtained, as soon as PCB 118 was involved. Hence, the 
overlap with TCDD-derived effects might potentially represent one of significance understanding 
AhR-dependent response with relevance for low-affinity ligands. 
 
Comparison of up-regulating effects towards mouse livers regarding PCB 118-treatment with 
effects induced by TCDD yielded 29 accordantly up-regulated genes in total. Respective gene-list, 
which was sorted by TCDD-mediated effects, is figured in table 42. Raw data for TCDD’s impact 
was obtained by courtesy of Christiane Lohr (Lohr, 2013).  
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Table 42: Mouse whole genome microarray analysis. 29 genes accordantly up-regulated in mouse livers by    
PCB 118 (150000 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05.  
PCB 118    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
     
7.799 9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
3.311 3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2  Cyp1a2 
1.622 3.582 NM_010210 fragile histidine triad gene  Fhit 
1.654 3.379 NM_017379 tubulin alpha 8  Tuba8 
2.018 3.103 NM_027872 solute carrier family 46 member 3  Slc46a3 
3.998 2.819 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
1.503 2.678 NM_016865 HIV-1 tat interactive protein 2 homolog (human) Htatip2 
1.398 2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
2.227 2.153 NM_023440 transmembrane protein 86B  Tmem86b 
1.775/ 
2.310 
1.857/ 
1.362 NM_013541 glutathione S-transferase pi 1  Gstp1 
3.631/ 
2.279 
1.853/ 
1.036 NM_001122660 predicted gene 10639  Gm10639 
1.609 1.702 NM_007689 chondroadherin  Chad 
2.560/ 
2.621 
1.696/ 
1.650 NM_145603 carboxylesterase 2  Ces2 
2.603 1.630 NM_198171 cDNA sequence BC015286 BC015286 
2.027/ 
1.751 
1.559/ 
1.187 NM_181796 glutathione S-transferase pi 2 Gstp2 
1.194 1.481 NM_008030 flavin containing monooxygenase 3  Fmo3 
1.500 1.452 NM_008183 glutathione S-transferase mu 2  Gstm2 
1.014 1.441 NM_009150 selenium binding protein 1  Selenbp1 
1.533 1.394 NM_172881 UDP glucuronosyltransferase 2 family polypeptide B35  Ugt2b35 
1.897 1.391 NM_009466 UDP-glucose dehydrogenase  Ugdh 
1.398 1.366 NM_206537 cytochrome P450 family 2 subfamily c polypeptide 54  Cyp2c54 
2.697 1.297 NM_008182 glutathione S-transferase pi 1 Gsta2 
1.096 1.156 NM_008828 glutathione S-transferase alpha 2 (Yc2)  Pgk1 
1.050 1.146 NM_172928 doublecortin-like kinase 3  Dclk3 
2.095 1.105 NM_025797 cytochrome b-5 Cyb5 
1.133 1.093 NM_009801 carbonic anhydrase 2  Car2 
1.296 1.088 NM_009286 RIKEN cDNA C730007P19 gene    C730007P19Rik 
1.149 1.059 NM_133738 anthrax toxin receptor 2 Antxr2 
1.234 1.048 NM_016956 hemoglobin beta adult minor chain Hbb-b2 
  
 
 
 
Values b/a from oligo b/oligo a. 
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Though the overlap between PCB 118-, and TCDD-derived effects was limited regarding ‘together’ 
regulated genes (29↑ 12↓; see table 42), various genes highly affected by TCDD were induced by 
PCB 118 as well. In numbers, eleven genes out of the Top 20 genes, which were up-regulated by 
TCDD-treatment, were as well induced by PCB 118-treatment: Cyp1a1, Cyp1a2, Fhit, Tuba8, 
Slc46a3, Gsta1, Htatip2, Pcp4l1, Tmem86b, Gstp1, and Gm10639. For further information 
regarding TCDD’s impact on mouse livers, see Lohr (2013). The twelve accordantly down-
regulated genes by treatment with TCDD or PCB 118 are presented in the attachments. 
 
To gain a further insight into correlative impact by TCDD together with PCB 118, pathway analysis 
was applied. By classical enrichment analysis performed using Fisher’s exact test, over-
representation of GO terms within the group of up-regulated genes was assessed regarding PCB 118 
alone, TCDD alone, and PCB 118 together with TCDD (PCB 118 & TCDD). The obtained 
subgraphs induced by the top five GO terms each, are presented in figure 24. Corresponding top 
five GO terms are listed in subsequent table 43 (for table 43 and figure 24, see following pages). 
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Figure 24: Mouse whole genome microarray analysis – Comparison of TopGO analysis for PCB 118, TCDD, or PCB 118 & TCDD. GO subgraph plots induced by the 
top five GO terms each identified by the classic algorithm for scoring GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant 
GO terms including ranks (I-V). Box color represents relative significance ranging from dark red (most significant) to light yellow (least significant). Mouse liver, three 
days of treatment. GO term ranks I-V according to table 43 (following page). TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013). 
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Table 43: Mouse whole genome microarray analysis – TopGO analysis for PCB 118, TCDD, or PCB 118 & 
TCDD: Fisher’s exact test. Top five GO terms identified by the classic algorithm for scoring GO terms for 
enrichment regarding up-regulated genes; descending order. Mouse liver, three days of treatment. TCDD-raw 
data by courtesy of Christiane Lohr (Lohr, 2013). 
 
 
GO term 
 
 
GO ID 
TCDD 
 
Rank  
PCB 118 
 
Rank 
PCB118 
& TCDD 
Rank 
  
   
xenobiotic metabolic process GO:0006805 I II I 
cellular response to xenobiotic stimulus GO:0071466 II III II 
response to xenobiotic stimulus GO:0009410 III V III 
glutathione metabolic process GO:0006749 IV I IV 
organic ether metabolic process GO:0018904 V n.a. n.a. 
     
n.a.: not analyzed. 
 
As visuable in figure 24 and with regard to GO terms listed in table 43, most efficiently affected 
pathways were accordantly regulated by PCB 118 & TCDD with respect to induction of expression 
of genes involved in xenobiotic metabolism in mouse livers. In contrast to a quite low overlap for 
PCB 118 & TCDD regarding numbers of ‘together’ regulated genes – a proportion of about 25% of 
TCDD-induced genes (125 up-regulated genes by TCDD) was up-regulated by PCB 118-treatment 
(29 ‘together’ up-regulated genes by PCB 118 & TCDD) – PCB 118 appeared to share relevant 
properties with TCDD; at least regarding major TCDD-derived effects.  
 
4.1.1.3.3. Mouse microarrays – ‘all’ DL-congeners excepting PCB 118 
 
As described above, PCB 118 generally exhibited diverging impact on gene transcription in mouse 
livers compared to the remaining DL-congeners studied in the course of present mouse whole 
genome microarray experiment. Hence, and besides investigations implementing ‘all’ DL-
congeners, PCB 118 was disregarded from one further examination.  
Pathway analysis was performed in order to gather information on predominating accordant modes 
of action for 1-PeCDD, 4-PeCDF, PCB 126, and PCB 156 together with TCDD. The gene-lists 
containing accordantly regulated genes (48↑ 19↓) of DL-congeners except for PCB 118 are shown 
in the attachments.  
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Figure 25 represents GO subgraphs with respect to investigations on (1-PeCDD, 4-PeCDF, PCB 
126, PCB 156) & TCDD, 1-PeCDD & TCDD, 4-PeCDF & TCDD, and PCB 156 & TCDD. 
Corresponding GO terms are declared in table 44 (following page).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Mouse whole genome microarray analysis – Comparison of TopGO analysis for DL-congeners         
(1-PeCDD, 4-PeCDF, PCB 126, PCB 156) & TCDD, 1-PeCDD & TCDD, 4-PeCDF & TCDD, and PCB 156 & 
TCDD: GO subgraph plots induced by the top five GO terms each identified by the classic algorithm for scoring 
GO terms for enrichment regarding up-regulated genes. Boxes indicate the five most significant GO terms 
including ranks. Box color represents relative significance ranging from dark red (most significant) to light 
yellow (least significant). Mouse liver, three days of treatment. GO terms and ranks I-XX; XXa-XXd according to 
table 44. TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013). 
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Table 44: Mouse whole genome microarray analysis – TopGO analysis for (1-PeCDD, 4-PeCDF, PCB 126,     
PCB 156) & TCDD: Fisher’s exact test. Top 20 GO terms identified by the classic algorithm for scoring GO 
terms for enrichment regarding up-regulated genes; descending order. Mouse liver, three days of treatment. 
TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013). 
(1-PeCDD, 4-PeCDF, PCB 126, PCB 156) & TCDD 
 
GO term (significant/annotated genes; raw p-value) 
 
 
GO ID 
 
 
Rank 
  
 
carboxylic acid metabolic process GO:0019752 I 
oxoacid metabolic process GO:0043436 II 
organic acid metabolic process GO:0006082 III 
cellular ketone metabolic process GO:0042180 IV 
small molecule metabolic process GO:0044281 V 
xenobiotic metabolic process GO:0006805 VI 
cellular response to xenobiotic stimulus GO:0071466 VII 
response to xenobiotic stimulus GO:0009410 VIII 
dibenzo-p-dioxin metabolic process GO:0018894 IX 
glutathione metabolic process GO:0006749 X 
monocarboxylic acid metabolic process GO:0032787 XI 
endocannabinoid signaling pathway GO:0071926 XII 
regulation of endocannabinoid signaling pathway GO:2000124 XIII 
ether metabolic process GO:0018904 XIV 
oxidation-reduction process GO:0055114 XV 
response to chemical GO:0042221 XVI 
peptide metabolic process GO:0006518 XVII 
toxin metabolic process GO:0009404 XVIII 
response to reactive oxygen species GO:0000302 XIX 
regulation of superoxide metabolic process GO:0090322 XX 
cellular process GO:0009987 > XXa 
cellular metabolic process GO:0044237 > XXb 
metabolic process GO:0008152 > XXc 
biological process GO:0008150 > XXd 
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GO subgraphs demonstrated in figure 25 show greatly correlating effects regarding most 
prominently affected pathways concerning ‘together’ up-regulated genes with respect to (1-PeCDD, 
4-PeCDF, PCB 126, PCB 156) & TCDD, 1-PeCDD & TCDD, 4-PeCDF & TCDD, and PCB 156 & 
TCDD. For all four investigations, the same GO terms represented the top five GO terms occurring 
in only lightly divergent order, if at all. The most significantly occurring GO term ‘carboxylic acid 
metabolic process’ (GO:0019752) for all four examinations, in which the remaining of the top five 
GO terms issued into, included up-regulated genes Cyp1a1, Gstp1, Cd36, Hpgd (NM_008278), 
Htatip2, Cyp1a2, Cth (NM_145953), Gstp2, Gsta1, Pkm2 (NM_011099), MgII, and Cyb5, with 
respect to the investigation (1-PeCDD, 4-PeCDF, PCB 126, PCB 156) & TCDD.  
 
Besides further processes related to (xenobiotic) metabolism (table 44), two rather unexpected GO 
terms were found, which are involved in endocannabinoid signaling. To both occurring GO terms 
(GO:0071926, and GO:2000124), two genes were annotated and significantly up-regulated by the 
DL-congeners 1-PeCDD, 4-PeCDF, PCB 126, and PCB 156: monoglyceride lipase (MgII, 
NM_001166250), and abhydrolase domain containing 6 (Abhd6, NM_025341). Both of them 
encode potentially degradative enzymes for the endocannabinoid 2-arachidonoyl glycerol (2-AG). 
ABHD6 was reported to control accumulation and efficacy of 2-AG at cannabinoid receptors, and 
to be involved in macrophage activation subsequent to a decrease of 2-AG in the cell (Alhouayek et 
al., 2013; Marrs et al., 2010; Schlosburg et al., 2010). Though obviously regulated by all DL-
congeners except for PCB 118, these observations need to be estimated carefully, thinking about the 
dominating metabolism-related mechanisms. 
 
Referring to the gene-lists containing accordantly regulated genes (48↑ 19↓) of DL-congeners 
excepting PCB 118 (see attachments; tables 64, and 65) compared to the (22↑ 5↓)-list for ‘all’ DL-
congeners (including PCB 118; table 40) investigated, more proposed AhR-target genes were listed: 
Cyp1b1, and Tiparp in addition to Cyp1a1, and Cyp1a2, which were also impacted by PCB 118. 
Further genes within the (48↑ 19↓)-list were generally involved in the same processes as were those 
of the (22↑ 5↓)-list. Decisively different in this regard was the number of genes involved in these 
processes. In addition to those tabled in the (22↑ 5↓)-list, Cd36, Hsd17b2, Hpgd, Tiparp, MgII (up-
regulated), Pnpla3, Acly, and Acaca (down-regulated) were implicated in altered lipid metabolic 
processes. Additionally assigned genes led to higher significance with respect to TopGO 
investigations and to more conserved, and more specific GO-subgraphs (compare figures 22 and 
25), which was most prominently reflecting impact of DL-congeners on xenobiotic and lipid 
metabolism.  
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One further member of the AhR-gene batterie should be mentioned, namely Ahrr (NM_009644). 
This gene was not regulated by any DL-congener investigated within the study in hand. Ahrr-
expression was analyzed by means of two probes on the microarray slides.  
Regarding one of these probes (‘A_55_P2128388’), measured values were not significant with 
respect to all set cutoffs (A ≥ 27,│lfc│ ≥ 1, p-value < 0.05).  
With respect to the second probe (‘A_51_P254425’), results were below cutoff-level for signal-
intensity (A = 25.65). Hints towards up-regulating effects for Ahrr by congener-treatment was given 
for all DL-compounds except for PCB 118 (lfc = 0.158, p-value = 0.656); lfc (TCDD) = 3.906,     
lfc (1-PeCDD) = 2.996, lfc (4-PeCDF) = 2.89, lfc (PCB 126) = 1.54, and lfc (PCB 156 = 1.912). 
Regarding the FDR, the potentially up-regulating effects were not excluded for TCDD, 1-PeCDD, 
4-PeCDF, PCB 126, or PCB 156. Raw-data for TCDD-treatment was obtained by courtesy of 
Christiane Lohr (Lohr, 2013).  
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4.1.2. Quantitative real-time PCR – in vivo rat studies 
 
Within the framework of SYSTEQ, rat studies, which were constructed equivalently to mouse 
studies, were performed at IRAS (Van Ede et al., 2013; Van Ede et al., 2011). Dependent on 
current TEF-values, animals were exposed to varying single doses (L, M, N, O, or P) of the core 
congeners TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156, and sacrificed 
either after three, or 14 days. With regard to 14 days-studies, RNA of livers of second-highest dose 
groups (O-groups) and corresponding control groups (K-groups) were examined via qRT-PCR 
analysis. Concerning three days-studies, the following groups were analyzed: TCDD, 1-PeCDD, 
and PCB 126 – K, L, M, N; 4-PeCDF – K, L, N; PCB 118, PCB 153, and PCB 156 – K, O. To 
unravel AhR-, CAR-, and PXR-dependent effects of congeners, focused genes investigated at TU 
Kaiserslautern were Cyp1a1, Cyp2b1, and Cyp3a1, whereby Actb (encoding β-actin) was used as 
housekeeping gene. 
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4.1.2.1. QRT-PCR in vivo, rat studies – Cyp1a1  
 
Figure 26 illustrates results for qRT-PCR-analysis concerning Cyp1a1-mRNA for liver samples 
derived from three days-rat studies and treatment with core congeners. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: QRT-PCR (Cyp1a1) rat study in vivo (three days). Rats treated with single doses of TCDD, 1-PeCDD, 
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for three days. Abscissa: Treatment; ordinate: Fold 
induction (referred to β-actin mRNA-levels). One-way ANOVA with Dunnett’s post test (control vs. treatment 
groups); Two-tailed unpaired t-test (control vs. one treatment group). Six animals per group.*: p-value < 0.05, 
**: p-value < 0.01, ***: p-value < 0.001.  
 
Concentration-dependently, Cyp1a1-mRNA-levels in livers increased due to exposure of rats with 
TCDD, 1-PeCDD, or 4-PeCDF for three days (figure 26). With this regard, statistically significant 
(p-value < 0.05) deviation from respective control group was obtained for 5 µg/kg bw 4-PeCDF 
(8.8±1.5-fold induction, L-group), whereas statistically very significant (p-value < 0.01) Cyp1a1-
inductions were gained from 0.5 µg/kg bw TCDD (10.5±3.8-fold, L-group), 2.5 µg/kg bw              
1-PeCDD (18.4±3-fold, M-group), yielding up to 33.0(±8.4)-fold induction with 25 µg/kg bw        
4-PeCDF (N-group). In livers of rats exposed to 100 µg/kg bw PCB 126 (N-group), statistically 
very significant (p-value < 0.01) Cyp1a1-induction of 5.0(±3.5)-fold was revealed. Treatment of 
rats with PCB 118, or PCB 156 (150000 µg/kg bw, O-groups) led to statistically extremely           
(p-value < 0.001) significant Cyp1a1-inductions in livers accounting for 6.0(±1.8)-fold (PCB 118), 
and 6.1(±1.0)-fold (PCB 156), respectively. No effect on Cyp1a1-mRNA-levels in livers of       
PCB 153-treated rats was obtained using 150000 µg/kg bw of the congener. 
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In figure 27, Cyp1a1-qRT-PCR results obtained by analysis of livers from rats treated with core 
congeners for 14 days are compiled.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: QRT-PCR (Cyp1a1) rat study in vivo (14 days). Rats treated with single doses of TCDD, 1-PeCDD,    
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for 14 days. Abscissa: Treatment; ordinate: Fold induction 
(referred to β-actin mRNA-levels). Two-tailed unpaired t-test (control vs. treatment group). Six animals per 
group.*: p-value < 0.05, ***: p-value < 0.001.  
 
Subsequent to 14 days of exposure of rats with TCDD (25 µg/kg bw), Cyp1a1-mRNA levels in 
livers statistically significantly (p-value < 0.05) raised to 11.8(±8.0)-fold (figure 27). Comparable 
high standard deviation was manifested due to two of six animals, barely responding (0.57-, to 0.75-
fold induction). Regarding residual four animals, Cyp1a1-induction on mRNA-level consistently 
ranged from 14.8-, to 19.5-fold in livers. With the exception of PCB 153, treatment with the 
remaining core congeners led to statistically extremely significant (p-value < 0.001) Cyp1a1-
inductions in following ascending ranking order: 150000 µg/kg bw PCB 118 (17.1±2.3-fold), 
150000 µg/kg bw PCB 156 (19.1±6.3-fold), 25 µg/kg bw 1-PeCDD (24.8±8.1-fold), 250 µg/kg bw 
PCB 126 (41.8±4.7-fold), 250 µg/kg bw 4-PeCDF (42.4±11.7-fold). From statistical point of view, 
exposure to PCB 153 (150000 µg/kg bw) caused significant (p-value < 0.05) decrease of Cyp1a1-
mRNA-levels to 0.4(±0.1)-fold in rat livers.  
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4.1.2.2. QRT-PCR (in vivo, rat) – Cyp2b1  
 
Figure 28 overviews qRT-PCR-results concerning Cyp2b1, gained from examination of livers from 
rats, which were exposed to single doses of core congeners and sacrificed after three days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: QRT-PCR (Cyp2b1) rat study in vivo (three days). Rats treated with single doses of TCDD, 1-PeCDD, 
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for three days. Abscissa: Treatment; ordinate: Fold 
induction (referred to β-actin mRNA-levels). One-way ANOVA with Dunnett’s post test (control vs. treatment 
groups); Two-tailed unpaired t-test (control vs. one treatment group). Six animals per group.*: p-value < 0.05, 
***: p-value < 0.001.  
 
Slight increase of Cyp2b1-mRNA-levels in rat livers (figure 28) was obtained after three days of 
treatment with TCDD (2.5 µg/kg bw; 3.1±2.8-fold). TCDD’s impact was not considered 
statistically significant (P > 0.05). No distinct deviation from control groups was received due to 
exposure to 1-PeCDD (0.5-10 µg/kg bw), or 4-PeCDF (5-25 µg/kg bw) in tested ranges of doses. 
Along individuals with values in general ranging around those of respective control group, PCB 126 
in total led to light reduction of Cyp2b1-mRNA, whereas from statistical point of view, 25 µg/kg 
bw PCB 126 caused significant (p-value < 0.05) decrease (0.4±0.2-fold) of respective gene 
transcription. Regarding these effects, no concentration-dependency was indicated.  
PCB 118, PCB 153, or PCB 156 induced Cyp2b1-mRNA in livers of treated rats (150000 µg/kg bw 
each). Concerning PCB 156, statistically significant (p-value < 0.05) value of 626.1(±381.8)-fold 
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was gained, while PCB 153 statistically extremely significantly (p-value < 0.001) increased 
Cyp2b1-mRNA to 1065.5(±272.0)-fold. In consequence of a high standard deviation, PCB 118’s 
effect (680.3±639.4-fold) statistically was not emphasized. The high standard deviation came about 
considerable differential responses, in the course of two of six animals intensely reacting from 
1290.2-, to 1824.6-fold induction. Effect of PCB 118 towards remaining four animals ranged from 
198.5-, to 262.0-fold Cyp2b1-induction in livers. 
 
In figure 29, qRT-PCR results concerning effects of core congeners on Cyp2b1 in livers of treated 
rats (14 days) are displayed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: QRT-PCR (Cyp2b1) rat study in vivo (14 days). Rats treated with single doses of TCDD, 1-PeCDD,    
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for 14 days. Abscissa: Treatment; ordinate: Fold induction 
(referred to β-actin mRNA-levels). Two-tailed unpaired t-test (control vs. treatment group). Six animals per 
group.*: p-value < 0.05, **: p-value < 0.01, ***: p-value < 0.001. 
 
Subsequent to 14 days of TCDD-exposure (25 µg/kg bw), slight, statistically not significant 
Cyp2b1-induction in rat-livers averaging 4.0(±7.0)-fold was examined (figure 29). This induction 
cohered with a discordant value belonging to one animal, which accounted for 19.5-fold induction, 
whereas levels of the remainder ranged from 0.3-, to 1.6-fold induction. In mouse livers, Cyp2b1-
mRNA-levels due to 1-PeCDD-exposure (25 µg/kg bw, 0.5±0.1-fold) did not differ distinctly from 
respective control group.  
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Regarding 4-PeCDF, or PCB 126 (250 µg/kg bw each), light deduction (0.2±0.1-fold) of Cyp2b1–
mRNA was received. Two-tailed p-value of applied unpaired t-tests was 0.0731 for both congeners, 
which statistically was considered not quite significant. Doses of 150000 µg/kg bw of PCB 118, 
PCB 153, or PCB 156 induced Cyp2b1-levels in rat livers. Statistically significant (p-value < 0.05) 
value of 127.3(±93.5)-fold was obtained regarding PCB 156, whereby PCB 153 led to statistically 
very significant (p-value < 0.01) Cyp2b1-induction of 462.1(±213.5)-fold, and PCB 118 yielded 
statistically extremely significant (p-value < 0.001) increase of Cyp2b1-mRNA-levels of 
65.8(±17.4)-fold in rat livers.  
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4.1.2.3. QRT-PCR (in vivo, rat) – Cyp3a1  
 
Figure 30 overviews qRT-PCR-results concerning Cyp3a1-mRNA in livers of rats, which were 
exposed to single doses of TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 
for three days. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: QRT-PCR (Cyp3a1) rat study in vivo (three days). Rats treated with single doses of TCDD, 1-PeCDD, 
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for three days. Abscissa: Treatment; ordinate: Fold 
induction (referred to β-actin mRNA-levels). One-way ANOVA with Dunnett’s post test (control vs. treatment 
groups); Two-tailed unpaired t-test (control vs. one treatment group). Six animals per group.*: p-value < 0.05, 
**: p-value < 0.01, ***: p-value < 0.001. 
 
Cyp3a1-mRNA was marginally induced in rat livers subsequent to TCDD-exposure (figure 30). 
Statistically very significant (p-value < 0.01), or significant (p-value < 0.05) values were obtained 
using 2.5 µg/kg bw TCDD (2.6±1.1-fold), or 10 µg/kg bw TCDD (2.2±1.0-fold), respectively. 
Highest analyzed dose groups (N-groups) of 1-PeCDD, and 4-PeCDF led to slight, statistically very 
significant (p-value < 0.01) Cyp3a1-inductions of 2.0(±0.4)-fold (10 µg/kg bw 1-PeCDD), and 
2.4(±0.8)-fold (25 µg/kg bw 4-PeCDF). Also, samples of the N-group for PCB 126-treatment    
(100 µg/kg bw) showed slight, statistically significant (p-value < 0.05) Cyp3a1-induction in rat 
livers, accounting for 5.3(±5.1)-fold. Respectable standard deviation was originated from a 
discordant value belonging to one animal (16.2-fold induction), whereby five animals exhibited 
Cyp3a1-values ranging from 1.1-, to 6.6-fold in livers.  
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Treatment of rats with PCBs 118, 153, or 156 (150000 µg/kg bw each) led to increase of Cyp3a1-
mRNA-levels in livers. With respect to PCB 118, statistically significant (p-value < 0.05) value of 
9.1(±4.9)-fold was obtained. PCB 156 statistically very significantly (p-value < 0.01) induced 
Cyp3a1 9.8(±4.9)-fold, whereas PCB 153 statistically extremely significantly (p-value < 0.01) 
enhanced Cyp3a1-mRNA-levels (9.7±2.6-fold) compared to respective control group. 
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In figure 31, results of qRT-PCR analysis regarding Cyp3a1 and 14 days-studies with rats exposed 
to single doses of core congeners are depicted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: QRT-PCR (Cyp3a1) rat study in vivo (14 days). Rats treated with single doses of TCDD, 1-PeCDD,    
4-PeCDF, PCB 118, PCB 126, PCB 153, or PCB 156 for 14 days. Abscissa: Treatment; ordinate: Fold induction 
(referred to β-actin mRNA-levels). Two-tailed unpaired t-test (control vs. one treatment group). Six animals per 
group.*: p-value < 0.05, **: p-value < 0.01, ***: p-value < 0.001.  
 
Throughout core congeners, light inducing effects on Cyp3a1-mRNA-levels in rat livers were 
obtained subsequent to 14 days of single dose-exposures (figure 31). Smallest effects, which were 
statistically significant (p-value < 0.05), were achieved due to TCDD-, 1-PeCDD-, 4-PeCDF-, or 
PCB 126-treatment, and accounted for 2.5(±1.1)-fold (25 µg/kg bw TCDD), 3.1(±1.5)-fold          
(25 µg/kg bw 1-PeCDD), 3.2(±1.7)-fold (250 µg/kg bw 4-PeCDF), or 2.6(±0.8)-fold (250 µg/kg bw 
PCB 126), respectively.  
Slightly higher Cyp3a1-inducing effects were gained by use of 150000 µg/kg bw of PCB 118,   
PCB 153, or PCB 156. PCB 153 led to statistically significantly (p-value < 0.05) enhanced Cyp3a1-
mRNA-levels of 3.9(±1.7)-fold in rat livers, whereas treatment with PCB 156 statistically very 
significantly (p-value < 0.01) induced Cyp3a1 to 3.9(±1.7)-fold. From statistical point of view, 
extremely significantly (p-value < 0.001) increased number of Cyp3a1-gene transcripts in rat livers 
(3.3±0.7-fold) were gained with PCB 118.  
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4.2. In vitro – Liver Cell Systems 
 
4.2.1. Alamar Blue® assay 
 
Before testing compounds regarding their AhR-interacting potential, substances were profiled with 
respect to cytotoxity. For this purpose, the Alamar Blue® assay was performed after primary rat 
hepatocytes as wells as H4IIE cells were incubated with compounds for 24 h. Statistically, saponin 
(0.1%), which was used as positive control for cytotoxic effects (reviewed in Podolak et al., 2010), 
extremely significantly (p-value < 0.0001) reduced cell viability to 2.0±2.3% (n = 47) in H4IIE 
cells, and to 0.50±0.46% (n = 48) in Sprague Dawley primary rat hepatocytes, respectively. 
Viabilities are displayed in per cent related to appendant solvent controls (DMSO 0.1%). Figure 32 
overviews Alamar Blue® assay results regarding H4IIE cells treated with PCDDs for 24 h.  
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Figure 32: Alamar Blue® assay H4IIE. Cells treated with PCDDs for 24 h. Abscissa: Concentration (M); 
ordinate: Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from 
at least three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments). 
**: p-value < 0.01. 
 
Incubation with TCDD or 1-PeCDD for 24 h led to no cytotoxic effects in H4IIE cells (figure 32) in 
applied concentrations (100 pM-10 nM). For both 1,6-HxCDD and 1,4,6-HpCDD, minor but 
statistically very significant (p-value < 0.01) cytotoxic effects were determined in used range of 
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concentrations. 1,6-HxCDD maximally reduced viability of H4IIE cells to 87,2(±2.8)%                  
(1 nM 1,6-HxCDD) after 24 h. 1,4,6-HpCDD-treated H4IIE cells were viable from 84.1(±2.4)% to 
87.3(±2.7)% (5-456 nM 1,4,6-HpCDD). Concerning 1,6-HxCDD, as well as 1,4,6-HpCDD, 
determined cytotoxicities in H4IIE cells showed no concentration dependence. 
 
In figure 33, Alamar Blue® assay results for H4IIE cells treated with PCDFs (24 h) are summarized. 
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Figure 33:Alamar Blue® assay H4IIE. Cells treated with PCDFs for 24 h. Abscissa: Concentration (M); ordinate: 
Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from at least 
three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments).            
*: p-value < 0.05; **: p-value < 0.01. 
 
TCDF-incubated H4IIE cells possessed statistically significant (p-value < 0.05) and very significant 
(p-value < 0.01) reductions of viability (figure 33). The significant effect (500 nM TCDF) 
amounted to 87.8(±3.6)%, whereas very significant cytotoxicities accounted for 84.3(±4.1)% to 
85.8(±3.4)% viable cells (1-100 nM TCDF). Mentioned cytotoxicities showed no concentration 
dependence. The highest used TCDF concentration (984 nM) was not cytotoxic in this cell system, 
as well. With regard to 1,4,6-HpCDF, incubation with 5 nM for 24 h resulted in a statistically 
significant (p-value < 0.05) reduction of cell viability to 87.0(±4.1)%. However, higher 
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concentrations of this compound showed no cytotoxicity. No cytotoxic effects in H4IIE cells were 
revealed subsequent to cell-treatment with 4-PeCDF, or 1,4-HxCDF, respectively. 
 
Figure 34 compares Alamar Blue® assay results with respect to H4IIE cells, which were treated 
with PCBs for 24 h. 
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Figure 34: Alamar Blue® assay H4IIE. Cells treated with PCBs for 24 h. Abscissa: Concentration (M); ordinate: 
Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from at least 
three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments).            
*: p-value < 0.05. 
 
Figure 34 reveals no statistically significant concentration-dependent effects on viability in H4IIE 
cells resulting from PCBs in used range of concentrations after 24 h of treatment. For PCB 126, a 
statistically significant (p-value < 0.05) cytotoxic effect (90.5(±3.9)% viable cells) was found for 
the lowest determined concentration (5 nM). Incubation with PCB 77 in concentrations between     
5 nM and 1 µM statistically significantly (p-value < 0.05) reduced cell viability to a minimum of 
84.0(±11.0)%. PCBs 105, 118, 153, or 156 did not show any cytotoxic effect on H4IIE cells in the 
Alamar Blue® assay. 
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Figure 35 illustrates Alamar Blue® assay results regarding Sprague Dawley primary rat hepatocytes 
treated with PCDDs for 24 h. 
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Figure 35: Alamar Blue® assay PRH. Cells treated with PCDDs for 24 h. Abscissa: Concentration (M); ordinate: 
Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from at least 
three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments). 
 
Incubation with TCDD, 1-PeCDD, 1,6-HxCDD, or 1,4,6-HpCDD did not lead to any statistically 
significant cytotoxic effect in primary rat hepatocytes attained from male Sprague Dawley rats 
(figure 35).  
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Alamar Blue® assay results concerning Sprague Dawley primary rat hepatocytes incubated with 
PCDFs for 24 h are portrayed in figure 36. 
 
0
20
40
60
80
100
120
**
***
control
1E-09      5E-09      1E-08      5E-08     1E-07     1.58E-07     3E-07    5E-07     9.84E-07
V
ia
bi
lit
y 
(%
)
Concentration (M)
 TCDF
 4-PeCDF
 1,4-HxCDF
 1,4,6-HpCDF
 
Figure 36: Alamar Blue® assay PRH. Cells treated with PCDFs for 24 h. Abscissa: Concentration (M); ordinate: 
Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from at least 
three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments).            
*: p-value < 0.05; **: p-value < 0.01 
 
Figure 36 bears no statistically significant concentration-dependent effect on viability of primary rat 
hepatocytes subsequent to incubation with polychlorinated dibenzofurans for 24 h. However, 
several TCDF-concentrations led to statistically significant incidences. The maximum effect         
(p-value < 0.01) added up to 85.3(±4.7)% viable cells for 500 nM TCDF. In turn, the highest 
TCDF-concentration 984 nM did not impact any statistical relevance regarding cytotoxicity in 
Alamar Blue® assay. The same applied to 4-PeCDF, 1,4-HxCDF, as well as 1,4,6-HpCDF for all 
examined concentrations. 
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Figure 37 illustrates Alamar Blue® assay data received from PCB-incubated Sprague Dawley 
primary rat hepatocytes.  
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Figure 37: Alamar Blue® assay PRH. Cells treated with PCBs for 24 h. Abscissa: Concentration (M); ordinate: 
Viability (%). Viabilities displayed relative to respective solvent controls (DMSO 0.1%). Results from at least 
three independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments). 
 
No statistically significant cytotoxic effect is depicted in figure 37. Incubation of primary rat 
hepatocytes with PCBs 77, 105, 118, 126, 153, or 156 did not affect cell viability in the present test 
system. 
 
4.2.2. Ethoxyresorufin Deethylase (EROD) assay and Western Blot 
 
Defining congeners’ AhR-interacting properties towards H4IIE cells and Sprague Dawley primary 
rat hepatocytes after 24 h of exposure, CYP1A-induction was examined. To approach to this 
objective, CYP1A1- and CYP1A2-induction was studied using EROD assay. Besides, CYP1A1 
protein levels were analyzed semi-quantitatively via Western Blotting. Up to 13 diverse 
concentrations of congeners were analyzed to yield concentration-response-relations, which 
supposed to enable comparisons both among compounds and with TCDD-derived effects.  
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4.2.2.1. EROD assay and Western Blot – H4IIE cells 
 
For measurement of CYP1A1 and CYP1A2-induction on protein level by use of Western Blotting 
as well as EROD-induction, TCDD (1 nM) served as positive control for AhR-dependent enzyme-
induction in H4IIE cells. With respect to Western Blots, VDAC was measured as loading control in 
microsomes derived from treated H4IIE cells. From EROD-activities induced by congeners, 
background levels (DMSO 0.1%) were subtracted. 
 
In figure 38, the concentration-response slope illustrating EROD induction in H4IIE cells 
subsequent to 24 h of incubation with TCDD is compared to a correspondent representative 
CYP1A1-Western Blot.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: EROD assay and Western Blot H4IIE (I). Cells treated with TCDD for 24 h. Concentration (M) 
logarithmically plotted against EROD-activity (pmol resorufin/min*mg protein). EC20-level (86.0 pmol 
resorufin/min*mg protein) represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and 
VDAC-Western Blot from microsomes. Results from at least three independent experiments each. 
 
To generate a concentration-response slope concerning TCDD-derived EROD-inducing effects in 
H4IIE cells, concentrations from 5*10-13 to 10-9 M were incubated for 24 h (figure 38).  
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With 5*10-13 M TCDD, EROD-activity in H4IIE cells basically remained at background level 
(0.6±0.9 pmol resorufin/min*mg protein). From 10-12 M TCDD, a slight (7.7±4.3 pmol 
resorufin/min*mg protein), followed by an exponential increase of EROD-induction was given. 
Hence, 5*10-12 M TCDD led to an EROD-activity of 76.7(±39.0) pmol resorufin/min*mg protein in 
H4IIE cells subsequent to 24 h of incubation. Statistically (One-way ANOVA with Dunnett’s post 
test; control vs. treatments), a significant increase (p-value < 0.05) of EROD-activity      
(232.6±79.3 pmol resorufin/min*mg protein) compared to control (DMSO 0.1%, not shown) was 
observed for 10-11 M TCDD. This significance, which was accompanied by transition from an 
exponential to a logarithmical ascent of curve, passed into a statistically very significant value      
(p-value < 0.05) for 2.5*10-11 M TCDD with 354.3(±122.4) pmol resorufin/min*mg protein. 
Concentration-dependently, the increase of EROD-activity pursued, until a plateau was reached at 
429.8(±21.4) pmol resorufin/min*mg protein, given by the maintained concentration-response 
slope. The TCDD-derived EC50 amounted to 9.49(±1.71)*10-12 M TCDD under present conditions. 
20% of maximum effect was calculated for 3.80*10-12 M TCDD. The respective EROD-activity of 
86.0 pmol resorufin/min*mg protein was defined as EC20-level and used for further EROD-
investigations with H4IIE cells. Per definition, REP values (REP (EC20); REP (EC50)) for TCDD 
with respect to EROD-induction were 1. 
 
The Western Blot membrane pictured in figure 38 constitutes a representative example of four 
independent experiments. H4IIE cells were treated with eight different concentrations of TCDD, 
varying from 5*10-12 M to 10-8 M. The loading control VDAC (32 kDA) consistently was measured 
regularly for each incubation. Isolated microsomes contained no detectable CYP1A1-protein from 
solvent control (DMSO 0.1%) to 5*10-11 M TCDD.  
By use of 10-10 M TCDD, the protein CYP1A1 (56 kDa) marginally appeared on the membrane. 
With greater concentrations of TCDD, the CYP1A1-bands emerged more pronounced, which 
balanced at a maximal level for the highest tested concentrations, 5*10-9 M and 10-8 M TCDD.  
 
Comparing both methods for verification of CYP1A on protein level in H4IIE cells, different limits 
for detection were indicated by use of TCDD. Even though a statistically relevant EROD-induction 
was seen from 10-11 M TCDD, an obvious increase of EROD-activity was given even with 
concentrations from around 5*10-12 M TCDD, whereas for Western Blotting, CYP1A1 was not 
detectable below 10-10 M TCDD in the present test system. 
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Figure 39 compares EROD-induction in H4IIE cells due to treatment with 1-PeCDD, 1,6-HxCDD, 
or 1,4,6-HpCDD for 24 h with TCDD-derived effects. Besides, representative examples of Western 
Blot membranes, which semi-quantitatively show CYP1A1-induction in microsomes obtained from 
H4IIE cells incubated with 1-PeCDD, 1,6-HxCDD, or 1,4,6-HpCDD, are presented in figure 39. 
 
 
 
 
 
        
 
        
 
 
 
 
 
 
  
 
 
 
 
   
 
   
 
 
Figure 39: EROD assay and Western Blot H4IIE (II). Cells treated with TCDD, 1-PeCDD, 1,6-HxCDD, or   
1,4,6-HpCDD, 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol resorufin/min*mg 
protein). EC20-level represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and VDAC-
Western Blots from microsomes. Results from at least three independent experiments each.  
 
Tested 1-PeCDD concentrations for EROD assay were 10-12 to 5*10-10 M. Subsequent to incubation 
of 10-12 M 1-PeCDD for 24 h, EROD-activity (3.8±3.4 pmol resorufin/min*mg protein) mostly 
remained at background level (figure 39). From 2.5*10-12 M 1-PeCDD, an initial slow increase of 
active CYP1A advanced exponentially with higher concentrations. On account of this, statistically 
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very significant (p-value < 0.01; One-way ANOVA with Dunnett’s post test; control vs. treatments) 
distinctions compared to solvent control (DMSO 0.1%, not shown) appeared from 2.5*10-11 to 
5*10-10 M 1-PeCDD (426.1±103.7 pmol resorufin/min*mg protein). According to the obtained 
concentration-response slope, EC50 for 1-PeCDD-derived EROD-induction in H4IIE cells was 
1.62*10-11(±1.52*10-12) M 1-PeCDD, which led to a REP (EC50) of 0.58. The calculated EC20 
value was 5.98*10-12 M, which brought forth a REP (EC20) of 0.64 for 1-PeCDD. The maximum 
extent of EROD-activity induced by 1-PeCDD (437.2±13.3 pmol resorufin/min*mg protein) highly 
correlated with the TCDD-derived upper level (429.8±21.4 pmol resorufin/min*mg protein). 
 
Compared to TCDD- and 1-PeCDD-derived curves reflecting EROD-induction in H4IIE cells, 
curves obtained by 1,6-HxCDD, or by 1,4,6-HpCDD were sparsely shifted to higher concentrations. 
Lowest concentrations leading to statistically very significant (p-value < 0.01) increases of EROD-
induction were 10-10 M 1,6-HxCDD (248.2±75.6 pmol resorufin/min*mg protein), or 2.5*10-10 M 
1,4,6-HpCDD (242.3±62.6 pmol resorufin/min*mg protein), respectively.  
 
In a concentration-range from 5*10-10 M to 5*10-9 M, upper limits of EROD-induction were 
accomplished for both the six-and the seven-fold chlorine-substituted dioxin. Upper asymptotes of 
sigmoid curves counted to 391.7(±28.1) pmol resorufin/min*mg protein for 1,6-HxCDD, and to 
333.8(±13.1) pmol resorufin/min*mg protein for 1,4,6-HpCDD. In correspondence to similar 
concentration-response slopes, EC50-values of these congeners lay close together and amounted to 
8.25*10-11(±1.69*10-11) M 1,6-HxCDD, or 1.43*10-10(±1.64*10-11) M 1,4,6-HpCDD. Respective 
REPs (EC50) were 0.12 (1,6-HxCDD), and 0.066 (1,4,6-HpCDD). Related instances were given for 
EC20-values, which added up to 3.88*10-11 M 1,6-HxCDD, or 7.98*10-11 M 1,4,6-HpCDD, and 
correlated with REPs for EC20 of 0.10 (1,6-HxCDD), and 0.048 (1,4,6-HpCDD), respectively. 
 
Although transported slightly to higher concentrations, the run of the EROD-induction 
concentration-response curve belonging to 1-PeCDD rather reflected the TCDD-derived curve 
regarding ascent and value of the upper asymptote. Mentioned shift to higher concentrations 
appeared more prominent for six-and seven-fold chlorine-substituted dioxins. Regarding analyzed 
congeners, a higher number of chlorine-substituents correlated with a higher extent of shift to 
higher concentrations, deriving the most prominent effect for six chlorine-substituents instead of 
five. Furthermore, upper limits of EROD-induction in H4IIE cells lay in an order of magnitude for 
all tested dioxins, whereas along with lowering efficacy of compounds, the potency decreased with 
increasing number of chlorine-substituents.  
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Exemplary Western Blot membranes obtained after analysis of microsomes gained by dioxin-
incubated H4IIE cells showed consistent appearance of VDAC-loading controls (32 kDa) for all 
plotted samples. Distinct CYP1A1-inductions (56 kDa) were seen for positive controls          
(TCDD 10-9 M). From solvent control (DMSO 0.1%) to a 1-PeCDD concentration of 5*10-12 M, no 
CYP1A1 protein was detectable, whereas a minimal induction initiated with 10-11 M 1-PeCDD. 
From 5*10-11 M to 5*10-10 M of the congener, an almost indistinguishable degree of CYP1A1-
induction was manifested. In contrast, for both 1,6-HxCDD and 1,4,6-HpCDD, compound 
concentrations of 5*10-11 M led to a minor CYP1A1-induction detectable via Western Blotting, 
which initially increased using 10-10 M of respective congener, and reached maximum levels within 
a concentration range of 5*10-10 M to 5*10-9 M.  
 
The progressivity of concentration-dependent CYP1A1-induction was more pronounced by use of 
1,6-HxCDD compared to 1,4,6-HpCDD. Maximum effects due to PCDD-exposure to H4IIE cells 
induced CYP1A1-protein levels possessing similar extents compared to TCDD-controls. Regarding 
required concentrations of 1-PeCDD, 1,6-HxCDD, or 1,4,6-HpCDD, a light correlation between 
passing the EC20-level of EROD-induction and detectable CYP1A1-protein in Western Blot was 
observed.  
 
Both used methods gave comparable ranges of PCDD-concentrations for relevant, and according to 
EROD-measurement, even statistically relevant, levels of CYP1A(1)-protein in H4IIE cells:  
10-11-2.5*10-11 M 1-PeCDD; 5*10-11-10-10 M 1,6-HxCDD; and 5*10-11-2.5*10-10 M 1,4,6-HpCDD.  
 
Results - In vitro liver cell systems 
 
  166 
1E-12 1E-11 1E-10 1E-9 1E-8 1E-7 1E-6 1E-5
0
100
200
300
400
500
600
 TCDD
 TCDF
 4-PeCDF
 1,4-HxCDF
 1,4,6-HpCDF
EC20-level
ER
O
D
 
ac
tiv
ity
 
(pm
o
l r
es
o
ru
fin
/m
in
*
m
g 
pr
o
te
in
)
Concentration (M)
Following figure summarizes results for EROD-induction and appendant CYP1A1-Western Blots 
obtained after analyzing effects of PCDFs on H4IIE cells.  
 
 
 
 
     
      
 
 
 
 
 
 
 
 
 
  
 
 
 
 
   
   
                       
    
 
Figure 40: EROD assay and Western Blot H4IIE (III). Cells treated with TCDD, TCDF, 4-PeCDF, 1,4-HxCDF, 
or 1,4,6-HpCDF for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol 
resorufin/min*mg protein). EC20-level represents 20% of TCDD-induced maximum response. Exemplary 
CYP1A1-and VDAC-Western Blots from microsomes. Results from at least three independent experiments each. 
 
Studying PCDFs regarding their EROD-inducing properties after 24 h, EROD-activity in H4IIE 
cells increased in concentration-dependent manners, as it has been shown for TCDD. Referring to 
run and their position on the abscissa, the concentration-response slope received for 4-PeCDF 
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represented the most accordant of the curves for PCDFs compared to the TCDD-derived curve 
(figure 40). Subsequent to a slight increase of EROD-activity along with lowest used concentrations 
(10-13-10-12 M 4-PeCDF), the increase amplified to 64.6(±34.8) pmol resorufin/min*mg protein for 
5*10-12 M 4-PeCDF, and was followed by statistically very significant (p-value < 0.01, One-way 
ANOVA with Dunnett’s post test; control vs. treatments) EROD-inducing values starting from    
10-11 M 4-PeCDF with 150(±65.9) pmol resorufin/min*mg protein. The growth of EROD-induction 
asymptotically reached maximum levels of 368.7(±10.4) pmol resorufin/min*mg protein at around 
10-10-10-9 M 4-PeCDF.  
EC50 was 1.43*10-11(±1.73*10-11) M 4-PeCDF, whereas the EC20 value at 86 pmol 
resorufin/min*mg protein was calculated as 5.92*10-12 M 4-PeCDF. Corresponding REPs were 
0.67 (REP (EC50)), and 0.64 (REP (EC20)). 
 
Considering the constraint of a shift to higher concentrations, a similar run of the concentration-
response slope was obtained by use of 1,4-HxCDF. Statistically very significant (p-value < 0.01) 
values were gained from 5*10-11 M of the compound, and the upper asymptote level reached 
341.8(±22.7) pmol resorufin/min*mg protein.  
EC values, which both varied to an extent of a factor of ten to higher concentrations compared to 
the pentafuran’s EC values, were 9.48*10-11(±1.52*10-11) M 1,4-HxCDF for EC50, and       
4.16*10-11 M 1,4-HxCDF for EC20. Respective REPs were 0.10 for EC50, and 0.091 referring to 
EC20.  
 
The concentration-response slope gained by use of 1,4,6-HpCDF was shifted approximately another 
factor of ten to higher concentrations compared to the hexafuran’s. With this regard, REPs 
expressing EROD-inducing properties of the heptafuran were 0.015 (REP (EC50); EC50:    
6.25*10-10(±9.24*10-11) M 1,4,6-HpCDF), and 0.010 (REP (EC20); EC20: 3.72*10-19 M          
1,4,6-HpCDF).  
Statistically very significant EROD-inductions (p-value < 0.01) were obtained with                   
5*10-10 M 1,4,6-HpCDF (115.9±18.8 pmol resorufin/min*mg protein). Furthermore, the maximally 
achieved EROD-activity received by treating H4IIE cells with 1,4,6-HpCDF for 24 h was 
289.4(±11.9) pmol resorufin/min*mg protein.  
 
In contrast, the concentration-response curve deduced from incubation of H4IIE cells with TCDF 
differed concerning growth und run from the TCDD-derived curve, as well as from the curves of 
the other tested furans. The flatter ascent of slope combined with an upper asymptotic level of 
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400.5(±12.3) pmol resorufin/min*mg protein led to an EC50 value of 4.12*10-10(±8.81*10-11) M 
TCDF, and an EC20 of 8.34*10-11 M TCDF. Yielded REPs were 0.023 (EC50), and 0.046 (EC20), 
respectively. Statistically very significant increases of EROD-activities (p-value < 0.01) from 
solvent control (DMSO 0.1%, not shown) were indicated from 5*10-10 M TCDF and 232.2(±73.7) 
pmol resorufin/min*mg protein.  
 
Regarding exemplary CYP1A1 Western Blots pictured in figure 40, the protein VDAC (32 kDa) 
served as loading control and was detected rather uniformly for all analyzed microsomes. Positive 
controls (TCDD 1 nM) showed intense bands of CYP1A1-protein (56 kDa) in each case.  
Light CYP1A1-bands were detected for 10-10 M TCDF, 5*10-12-10-11 M 4-PeCDF,                        
10-10 M 1,4-HxCDF, or 5*10-10-10-9 M 1,4,6-HpCDF. These findings as well as subsequent 
exponential increases of CYP1A1-band-intensities with higher concentrations for 4-PeCDF,       
1,4-HxCDF, or 1,4,6-HpCDF mirrored conditions foreseen in EROD-measurements. Furthermore, 
listed concentrations of PCDFs generating light CYP1A1-bands approximated respective EC20-
values. Highest tested concentrations of congeners depicted CYP1A1-band-intensities in 
comparable extents to those of positive controls.  
Maximum and barely indistinguishable CYP1A1-inductions were gained using following 
concentrations of compounds: 10-8-10-7 M TCDF, 5*10-11-10-9 M 4-PeCDF, 5*10-10-10-9 M         
1,4-HxCDF, or 5*10-9-5*10-8 M 1,4,6-HpCDF.  
 
On the whole, among tested PCDFs, microsomes obtained by incubation of H4IIE cells with       
1,4-HxCDF established minor CYP1A1-band-intensities correlating with an overall lower protein 
content of samples indicated by slight VDAC-bands. Reflecting results of EROD-measurements, 
analysis of microsomes from TCDF-treated H4IIE cells exhibited less rapid exponential increases 
of CYP1A1-band-intensities compared to results obtained by TCDD or previously discussed furans, 
visible in an exemplary Western Blot membrane in figure 40. Mentioned increases proceeded over a 
concentration-range of 10-10-10-8 M TCDF, whereas such increases were completed within a half-
logarithmical modification of concentrations regarding the other PCDFs.  
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In figure 41, results for EROD measurement and CYP1A1-Western Blotting using non-ortho-
substituted PCBs (PCB 77, or PCB 126), or the mono-ortho-substituted PCB 156 compared to 
TCDD-derived effects towards H4IIE cells are compiled. 
 
 
 
 
      
 
      
 
 
 
 
 
 
 
 
 
 
 
    
   
 
 
   
 
 
Figure 41: EROD assay and Western Blot H4IIE (IV). Cells treated with TCDD, PCB 77, PCB 126, or PCB 156 
for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol resorufin/min*mg protein). 
EC20-level represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and VDAC-Western 
Blots from microsomes. Results from at least three independent experiments each. 
 
Studying PCB-mediated EROD-activities in H4IIE cells, PCB 126 most notably exhibited 
conformable characteristics compared to effects induced by TCDD (figure 41). Application of this 
3,3’,4,4’,5-pentaCB led to concentration-dependent EROD-induction in sigmoid manner subsequent 
to 24 h of incubation. Passing statistically significant (p-value < 0.05; 10-10 M PCB 126, 
230.6±104.9 pmol resorufin/min*mg protein; One-way ANOVA with Dunnett’s post test; control 
vs. treatments), and successive statistically very significant (p-value < 0.01) values from           
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5*10-10 M PCB 126 with 350.1(±103.9) pmol resorufin/min*mg protein, EROD-induction 
culminated in an asymptotic level of 369.1(±11.5) pmol resorufin/min*mg protein. Deduced from 
the concentration-response slope, EC50 was 8.18*10-11(±7.12*10-12) M PCB 126, whereas EC20 
value was 4.12*10-11 M PCB 126 with corresponding REPs of 0.12 (REP (EC50)), and 0.092 (REP 
(EC20)), respectively.  
 
Transported to higher concentrations combined with a shift to lower maximum EROD-activities of 
179.7(±5.0) pmol resorufin/min*mg protein, treatment with PCB 77 engendered an EC50 of 
7.30*10-8(±5.21*10-9) M PCB 77, and an EC20 of 6.69*10-8 M PCB 77. Respective REPs were 
0.00013 (REP (EC50)), and 0.000057 (REP (EC20)). Use of 3,3’,4,4’-tetraCB scored statistically 
very significant (p-value < 0.01) EROD inductions from 5*10-8 M PCB 77 (60.6±9.5 pmol 
resorufin/min*mg protein) to 10-6 M PCB 77 (177.9±13.8 pmol resorufin/min*mg protein).  
 
Yielding similar potency but higher efficacy, incubation with PCB 156 afforded an EC50 of 
1.87*10-7(±2.08*10-8) M PCB 156, and an EC20 of 8.13*10-8 M PCB 156 in H4IIE cells. 
Associated REPs were 0.000051 for EC50, and 0.000047 for EC20.  
Statistically very significant (p-value < 0.01) deviations from solvent control (DMSO 0.1%, not 
shown) were available from 5*10-7 to 10-6 M PCB 156, preceding a statistical significant               
(p-value < 0.05) value of 197.0(±112.0) pmol resorufin/min*mg protein for 2.5*10-7 M PCB 156. 
Focusing on the concentration-response slope gained by use of PCB 156 and EROD measurement, 
the upper asymptote was not yet reached under experimental conditions. Anyhow, according to 
progress of EROD-induction, the degree of logarithmical ascent initially lowered from around  
5*10-7 M PCB 156, mathematically indicating the approaching asymptote. Applying sigmoid fitting 
extrapolated an upper asymptotic level of 342.1(±18.4) pmol resorufin/min*mg protein.  
 
VDAC-loading controls (32 kDa) on Western Blot membranes obtained by analysis of microsomes 
from H4IIE cells incubated with PCBs for 24 h appeared consistently (figure 41). Furthermore, 
microsomes from positive control-treated (TCDD 1 nM) H4IIE cells engendered distinct CYP1A1-
protein-bands (56 kDa).  
Light CYP1A1-bands were detected due to impact of 5*10-11-10-10 M PCB 126, 5*10-8-10-7 M  
PCB 77, or 10-7 M PCB 156, which constituted ranges of concentration correlating with respective 
EC20 values for EROD-induction. With this regard, the shift amounted to three orders of magnitude 
concerning varying efficacies between PCB 77 and PCB 126, observed by means of EROD-
measurement, was reinforced by Western Blotting. Likewise, effects of PCB 77, or PCB 156 
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approximated implying a slightly higher potency of PCB 77 in terms of both methods measuring 
CYP1A-protein. Light CYP1A1-inductions concentration-dependently merged into stronger 
protein-bands from 5*10-10 M PCB 126, 5*10-7 M PCB 77, or 5*10-7 M PCB 156, comparable 
regarding extent to those affected by positive controls (TCDD 1 nM).  
 
Mono-ortho-substituted PCBs 105, or 118, as well as the NDL-PCB 153 were analyzed regarding 
their CYP1A-affecting properties towards H4IIE cells. Consequential results for EROD-
measurements and CYP1A1-Western Blots are assembled in figure 42. 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
 
Figure 42: EROD assay and Western Blot H4IIE (V). Cells treated with TCDD, PCB 105, PCB 118, or PCB 153 
for 24 h. Abscissa: Concentration (M); ordinate: EROD-activity (pmol resorufin/min*mg protein). EC20-level 
represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and VDAC-Western Blots from 
microsomes. Results from at least three independent experiments each. One-way ANOVA with Dunnett’s post 
test (control vs. treatment groups); Two-tailed unpaired t-test (control vs. TCDD 1 nM; n = 42).                         
**: p-value < 0.01; ***: p-value < 0.0001. 
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In figure 42, effects of the positive control TCDD (1 nM) on EROD-activity in H4IIE cells are 
illustrated. Average EROD-induction value was 400(±122) pmol resorufin/min*mg protein (n = 42) 
after 24 h, which statistically was considered extremely significant (p-value < 0.0001) compared to 
solvent-control (DMSO 0.1%).  
 
Mono-ortho-substituted PCB 105 had no influence on EROD-activity from 10-10 to 10-7 M of the 
compound. Using 5*10-7 M of the 2,3,3’,4,4’-pentaCB, EROD-activity slightly increased to 
2.8(±1.6) pmol resorufin/min*mg protein. Mentioned increase enforced with the highest tested 
concentration of 10-6 M PCB 105, possessing a statistically very significant (p-value < 0.01) 
EROD-induction of 11.5(±6.2) pmol resorufin/min*mg protein compared to solvent control  
(DMSO 0.1%). Although marginally exhibiting higher efficacy, related conditions were obtained 
testing mono-ortho-substituted PCB 118 on H4IIE cells, whereby statistically very significant      
(p-value < 0.01) EROD-levels were yielded from 5*10-7 to 10-6 M 2,3,4,4’,5-pentaCB amounting to 
10.1(±4.2), and 13.6(±5.0) pmol resorufin/min*mg protein, respectively. Assaying mono-ortho-
substituted PCBs 105, or 118 under present conditions, minor effects on EROD-activity remaining 
explicitly below EC20-level (86.0 pmol resorufin/min*mg protein) were gained. 
NDL-PCB 153 (2,2’,4,4’,5,5’-hexaCB) had no effect on EROD levels in any of the administered 
concentrations ranging from 10-10 to 10-6 M PCB 153.  
 
Western Blots of microsomes from PCB-treated H4IIE cells revealed a consistent appearance of 
VDAC-loading controls (32 kDa) for each plotted sample (figure 42). Analysis of microsomes from 
H4IIE cells incubated with the positive control (TCDD 1 nM) additionally resulted in pronounced 
CYP1A1-protein-bands (56 kDa). For PCB 105, 118, or 153, no CYP1A1-protein was detectable 
via Western Blotting in tested range of concentrations (10-10-10-6 M).  
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4.2.2.2. EROD assay liver cell systems – summary H4IIE cells 
 
Table 45 summarizes results obtained by analysis of H4IIE cells regarding EROD-inducing 
properties of 14 congeners. EC50- and EC20-values as well as correspondent REPs are opposed to 
current TEFs from 2005 (Van den Berg et al., 2006). 
 
Table 45: EC50-, and EC20-values and respective REPs derived from EROD-measurements with H4IIE cells 
subsequent to incubation with 14 congeners for 24 h compared to WHO-TEFs (Van den Berg et al., 2006). 
H4IIE EC50 (M) REP (EC50) EC20 (M) REP (EC20) WHO-TEF 
(2005) 
      
TCDD 9.49E-12 1 3.80E-12 1 1 
1-PeCDD 1.62E-11 0.58 5.98E-12 0.64 1 
1,6-HxCDD 8.25E-11 0.12 3.88E-11 0.10 0.1 
1,4,6-HpCDD 1.43E-10 0.066 7.98E-11 0.048 0.01 
      
TCDF 4.12E-10 0.023 8.34E-11 0.046 0.1 
4-PeCDF 1.43E-11 0.67 5.92E-12 0.64 0.3 
1,4-HxCDF 9.48E-11 0.10 4.16E-11 0.091 0.1 
1,4,6-HpCDF 6.25E-10 0.015 3.72E-10 0.010 0.01 
      
PCB 77 7.30E-08 0.00013 6.69E-08 0.000057 0.0001 
PCB 126 8.18E-11 0.12 4.12E-11 0.092 0.1 
      
PCB 105     0.00003 
PCB 118     0.00003 
PCB 156 1.87E-07 0.000051 8.13E-08 0.000047 0.00003 
      
PCB 153     - 
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4.2.2.3. EROD assay and Western Blot – primary rat hepatocytes 
 
For analysis of selected congeners’ effects on CYP1A on protein-level, primary rat hepatocytes 
(PRH) were obtained from male Sprague Dawley rats according to Seglen (1972). Subsequent to 
cultivation, cells were incubated with compounds for 24 h. TCDD (1 nM) served as positive control 
for AhR-dependent CYP1A-induction in primary rat hepatocytes with respect to both EROD-
measurements and Western Blotting. Referring to the latter, VDAC was detected as loading control 
in microsomes derived from treated hepatocytes. Solvent-control-accompanied background levels 
(DMSO 0.1%) were subtracted from EROD-activities induced by congeners.  
 
In figure 43, results for EROD-measurements obtained by incubation of PRH with TCDD, arranged 
with a correspondent representative CYP1A1-Western Blot, are assembled. 
 
 
 
                                   
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: EROD assay and Western Blot PRH (I). Cells treated with TCDD for 24 h. Concentration (M) 
logarithmically plotted against EROD-activity (pmol resorufin/min*mg protein). EC20-level (41.7 pmol 
resorufin/min*mg protein) represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and 
VDAC-Western Blot from microsomes. Results from three independent experiments each. 
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To develop a concentration-response-relationship regarding TCDD’s EROD-inducing properties 
towards Sprague Dawley primary rat hepatocytes after 24 h, TCDD-concentrations from 10-14 M to 
10-8 M were investigated (figure 43). Subsequent to a slight increase within a concentration-range 
of 10-13-10-12 M TCDD, an exponential increase of EROD-induction was present as far as a 
conversion into a logarithmical ascent followed around 5*10-12-10-10 M TCDD. Converging to an 
upper asymptote from ca. 5*10-10 M TCDD, EROD-levels of 208.5(±3.6) pmol resorufin/min*mg 
protein were approached. Summarized, the concentration-dependent increase of EROD-activity in 
PRH due to incubation with TCDD constituted a sigmoid run of curve.  
Received EC50 was 2.28*10-11(±2.39*10-12) M TCDD. Obtained EC20-level, representing 20% of 
maximum induction by TCDD, was 41.7 pmol resorufin/min*mg protein, while appendant EC20 
was calculated as 4.14*10-12 M TCDD. Per definition, REP-values were 1 in each case.  
Statistically very significant deviations (p-value < 0.01) from solvent control (DMSO 0.1%, not 
shown) were yielded from 5*10-11 M to 10-8 M TCDD scoring from 135.6(±34.6) pmol 
resorufin/min*mg protein to 196.7(±72.4) pmol resorufin/min*mg protein (One-way ANOVA with 
Dunnett’s post test; control vs. treatments). 
 
Exemplary Western Blot membrane in figure 43 comprised results from three independently 
implemented repetitions and showed consistent occurrence of VDAC-loading controls (32 kDa) for 
all samples. Starting from microsomes obtained by incubation of PRH with solvent-control  
(DMSO 0.1%) for 24 h, and followed by samples for treatment with 10-13-10-12 M TCDD, no 
further protein-band was detectable on membranes.  
Initiated from 5*10-12 M TCDD, a concentration-dependently amplifying appearance of CYP1A1-
protein (56 kDa) was measured. Progressivity of this protein’s appearance ended in almost 
indistinguishably occurring CYP1A1-band-intensities from about 10-10-5*10-10 M to 10-9 M TCDD. 
The initial band of CYP1A1-protein for treatment with 5*10-12 M TCDD highly correlated with the 
EC20 (4.14*10-12 M TCDD) obtained by EROD-measurements. Further, the range of TCDD-
concentrations regarding enhancement of CYP1A1-protein and subsequent indistinguishable band-
intensities approximated the run of EROD-induction’s associated concentration-dependent sigmoid 
curve.  
 
Usage of TCDD (1 nM, 24 h) as positive control for further investigations resulted in ascent of 
EROD-activity in statistically extremely significant (p-value < 0.0001) manner to 162(±37) pmol 
resorufin/min*mg protein (Two-tailed unpaired t-test (control vs. TCDD 1 nM; n = 43) in PRH.  
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An assembly of results from EROD-measurements and CYP1A1-Western Blots referring to 24 h of 
incubation of PRH with 1-PeCDD, 1,6-HxCDD, or 1,4,6-HpCDD, compared to TCDD-derived 
EROD-induction, is shown in figure 44. 
 
 
 
        
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
  
 
Figure 44: EROD assay and Western Blot PRH (II). Cells treated with TCDD, 1-PeCDD, 1,6-HxCDD, or      
1,4,6-HpCDD for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol 
resorufin/min*mg protein). EC20-level represents 20% of TCDD-induced maximum response. Exemplary 
CYP1A1-and VDAC-Western Blots from microsomes. Results from three independent experiments each.  
 
Incubation of PRH with PCDDs resulted in EROD-inductions in concentration-dependent manners 
(figure 44). Comparing the TCDD-derived curve to effects caused by 1-PeCDD, the combination of 
an exponential ascent of EROD-activity slightly shifted to higher concentrations                          
(10-12-10-11 M 1-PeCDD) with a lightly enhanced gradient in the logarithmical part of the slope, 
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whereas the upper asymptotic level of 203.7(±8.5) pmol resorufin/min*mg protein was reached 
around 5*10-10-10-9 M 1-PeCDD, highly correlating with the TCDD-gained asymptote. Since the 
logarithmical section of curve was slightly shifted to higher concentrations, EC50 for 1-PeCDD of 
5.73*10-11(±1.21*10-11) M led to a correspondent REP (EC50) of 0.40. The EC20-level of 41.7 
pmol resorufin/min*mg protein was accomplished with 1.32*10-11 M 1-PeCDD, bearing a REP 
(EC20) of 0.31. Statistically very significant (p-value < 0.01; One-way ANOVA with Dunnett’s 
post test; control vs. treatments) EROD-inductions were present from 5*10-11 M 1-PeCDD with 
90.5(±25.3) pmol resorufin/min*mg protein.  
 
Transported about one order of magnitude to higher concentrations, incubation with 1,4,6-HpCDD 
brought forth a sigmoid regarding EROD-induction in PRH, comprising a logarithmical ascent 
approximately reflecting conditions in the TCDD-derived slope. Yielding an upper EROD-inducing 
level of 193.6(±6.5) pmol resorufin/min*mg protein, the curve passed through an EC20 of   
1.38*10-10 M (REP (EC20): 0.030), and an EC50 of 6.13*10-10(±1.05*10-10) M                          
(REP (EC50): 0.037). From 5*10-10 M 1,4,6-HpCDD (88.7±7.6 pmol resorufin/min*mg protein), 
induced EROD-activities were considered statistically very significant (p-value < 0.01).  
Closely located to the 1,4,6-HpCDD-derived concentration-response curve, whereby connected 
with flatter ascent of slope lightly moved to lower concentrations and establishing efficacy to a 
lesser extent, usage of 1,6-HxCDD led to statistically very significant (p-value < 0.01) EROD-
inductions in PRH from 5*10-11 M of the congener (38.2±2.8 pmol resorufin/min*mg protein). 
Reaching an asymptotic value of 162.8(±9.1) pmol resorufin/min*mg protein, EC50 for              
1,6-HxCDD scored 1.98*10-10(±5.32*10-11) M, correlating to a REP (EC50) of 0.12. EC20 
amounted to 5.14*10-11 M 1,6-HxCDD, affording a REP (EC20) of 0.081.  
 
Western Blot membranes, exemplarily pictured in figure 44, revealed reasonably uniformly 
occurring protein-bands constituting loading controls (VDAC, 32 kDa). Examination of positive 
controls from microsomes of PRH incubated with TCDD (1 nM, 24 h) resulted in appearances of 
obvious bands (56 kDa) representing CYP1A1-protein. Using PCDDs, respective microsomes 
revealed slight CYP1A1-protein-bands from 10-11-5*10-11 M 1-PeCDD, 5*10-11 M 1,6-HxCDD, or 
5*10-10 M 1,4,6-HpCDD. Growing band-intensities within ranges of about two orders of magnitude 
in concentration were followed by stable CYP1A1-band-intensities for around 10-9-10-8 M 1-
PeCDD, 10-8-3*10-8M 1,6-HxCDD, or 10-8-10-7 M 1,4,6-HpCDD.  
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Any finding regarding CYP1A-inducing properties of PCDD-concentrations closely resembled 
among both examined methods, most significantly noting correlations between EROD’s EC20-
values and initial CYP1A1-protein-bands. 
 
In figure 45, results for EROD-measurements and Western Blotting derived by incubation of PRH 
with PCDFs are shown.  
 
 
 
 
              
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
                      
   
  
 
Figure 45: EROD assay and Western Blot PRH (III). Cells treated with TCDD, TCDF, 4-PeCDF, 1,4-HxCDF, or 
1,4,6-HpCDF for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol 
resorufin/min*mg protein). EC20-level represents 20% of TCDD-induced maximum response. Exemplary 
CYP1A1-and VDAC-Western Blots from microsomes. Results from three independent experiments each.  
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Measuring EROD-activity in PRH due to 4-PeCDF-incubation, subsequent to a rapid, but compared 
to effects caused by TCDD delayed, exponential increment, the logarithmical growth of EROD-
values implied the steepest ascent among results plotted in figure 45, including the TCDD-derived 
concentration-response-relationship. From 5*10-11 M 4-PeCDF and 46.1(±8.3) pmol 
resorufin/min*mg protein, statistically very significant (p-value < 0.01; One-way ANOVA with 
Dunnett’s post test; control vs. treatments) EROD-inductions were obtained.  
The sigmoid curve passed an EC20 of 4.50*10-11 M 4-PeCDF (REP (EC20): 0.092), and an EC50-
value of 1.12*10-10(±6.52*10-12) M 4-PeCDF (REP (EC50): 0.20), approaching an asymptote of 
194.1(±2.7) pmol resorufin/min*mg protein, which lay close to TCDD’s asymptote regarding both 
value of abscissa and value of ordinate.  
 
The concentration-response slope referring to 1,4-HxCDF’s properties towards PRH was proceeded 
about one order of magnitude to higher concentrations compared to the curve obtained by TCDD, 
but revealed similar degree of ascent within the logarithmical section.  
Values from 10-10 M 1,4-HxCDF and 37.6(±13.7) pmol resorufin/min*mg protein were considered 
statistically very significant (p-value < 0.01), whereas upper asymptotic level was 136.6(±3.3) pmol 
resorufin/min*mg protein. 1,4-HxCDF’s sigmoid curve intersected the EC20-level at 1.25*10-10 M, 
and EC50-value was 2.71*10-10(±2.83*10-11) M 1,4-HxCDF, correspondent to REPs of 0.033   
(REP (EC20), and 0.084 (REP (EC50), respectively.  
 
Transferred another order of magnitude to higher concentrations, 1,4,6-HpCDF led to a sigmoid 
regarding EROD-inducing properties in PRH with less intense ascent compared to the TCDD-
derived slope. Initial statistically very significant (p-value < 0.01) deviations from solvent control 
(DMSO 0.1%, not shown) were present from 5*10-10 M 1,4,6-HpCDF (41.3±2.8 pmol 
resorufin/min*mg protein), closely followed by a calculated EC20 of 5.74*10-10 M 1,4,6-HpCDF, 
which associated a REP (EC20) of 0.0072. EC50 scored 1.41*10-9(±1.05*10-10) M 1,4,6-HpCDF, 
revealing a REP (EC50) of 0.016. Maximum EROD-inductions obtained by 1,4,6-HpCDF in PRH 
were 136.7(±1.9) pmol resorufin/min*mg protein.  
 
Possessing an even flatter ascent across the entire concentration-response curve, TCDF led to 
statistically very significant (p-value < 0.01) EROD-activities from 10-11 M TCDF with 34.4(±9.9) 
pmol resorufin/min*mg protein. Running through an EC20 of 2.49*10-11 M TCDF                    
(REP (EC20): 0.17), and an EC50 of 8.89*10-11(±2.93*10-11) M TCDF (REP (EC50): 0.26), upper 
limit of EROD-induction by TCDF was 137.5(±9.4) pmol resorufin/min*mg protein.  
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According to Western Blot analysis represented in figure 45, detection of VDAC-loading-controls 
(32 kDa) was considered as constant. Microsomes obtained by PRH incubated with TCDD 1 nM 
for 24 h served as positive controls, and brought forth considerable bands indicating the protein 
CYP1A1 (56 kDa).  
Correlating with EROD-derived EC20-values, initial CYP1A1-protein-bands slightly appeared by 
use of 10-11 M TCDF, 5*10-11 M 4-PeCDF, 10-10 M 1,4-HxCDF, or 10-10-5*10-10 M 1,4,6-HpCDF. 
Further strengthening of CYP1A1-band-intensities with higher concentrations of congeners 
proceeded in course of around two orders of magnitude in concentration.  
Blotting of microsomes from hepatocytes exposed to highest concentrations of PCDFs                
(10-8 M TCDF, 10-9-10-8 M 4-PeCDF, 10-9-5*10-8 M 1,4-HxCDF, or 10-8-*10-7 M 1,4,6-HpCDF) 
revealed thick CYP1A1-protein-bands comparable concerning extent to those of positive controls.  
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The mono-ortho-substituted PCB 156, as well as non-ortho-substituted PCBs 77, or 126, were 
examined regarding their CYP1A-inducing properties in PRH and contrasted with TCDD-
originated characteristics. Results of EROD-measurements and CYP1A1-Western Blots are 
summarized in figure 46. 
 
 
 
 
      
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
   
 
 
Figure 46: EROD assay and Western Blot PRH (IV). Cells treated with TCDD, PCB 77, PCB 126, or PCB 156 
for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD-activity (pmol resorufin/min*mg protein). 
EC20-level represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and VDAC-Western 
Blots from microsomes. Results from three independent experiments each.  
 
In an almost parallel course, quite accurately shifted one order of magnitude to higher 
concentrations, the sigmoid curve describing CYP1A-inducing effects in PRH due to incubation 
with PCB 126 for 24 h reached an upper asymptotic level of 162.8(±5.8) pmol resorufin/min*mg 
protein (figure 46). Considering statistical relevance, a significant (p-value < 0.05; One-way 
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ANOVA with Dunnett’s post test; control vs. treatments) value of 56.2(±16.3) pmol 
resorufin/min*mg protein using 10-10 M PCB 126 was followed by very significant (p-value < 0.01) 
inductions from 5*10-10 M PCB 126 (115.9±25.1 pmol resorufin/min*mg protein). EC20-value 
scored 7.20*10-11 M PCB 126, and EC50 was 2.11*10-10(±5.11*10-11) M PCB 126, constituting 
respective REPs of 0.058 (REP (EC20)), and 0.11 (REP (EC50).  
 
A farther transfer of curve of about two orders of magnitude on the x-axis in combination with a 
flatter degree of ascent pictured concentration-dependent EROD-induction due to PCB 77 in PRH. 
Passed EC20- and EC50-values of 9.63*10-9 M PCB 77 (REP (EC20): 0.00043), and           
1.22*10-8(±1.56*10-9) M PCB 77 (REP (EC50): 0.0019), respectively, asymptotically margined 
94.0(±2.7) pmol resorufin/min*mg protein. PCB 77 led to statistically very significant (P<0.01) 
deviations from 5*10-9 M (29.5±6.7 pmol resorufin/min*mg protein) regarding EROD-activity in 
PRH.  
Furthermore, slightly moved to higher concentrations, but with respect to the curve derived by   
PCB 77 exhibiting a steeper ascent, treatment with PCB 156 resulted in a concentration-response 
slope yielding an asymptote, mathematically indicated due to reducing degree of ascent for around 
5*10-7-10-6 M PCB 156, of 146.1(±16.7) pmol resorufin/min*mg protein of EROD-activity in PRH. 
Attaining statistically very significant (p-value < 0.01) EROD-values from 7.5*10-8 M PCB 156 
(64.8±42.1 pmol resorufin/min*mg protein), the sigmoid ran through an EC20 of 3.85*10-8 M   
PCB 156 (REP (EC20): 0.00011), and an EC50 of 1.24*10-7(±4.16*10-8) M PCB 156                
(REP (EC50): 0.00018). 
 
Focusing on exemplary Western Blot membranes in figure 46, loading controls (VDAC, 32 kDa) 
were detected in consistent manner. Bold CYP1A1-protein-bands (56 kDa) were visible analyzing 
positive controls gained by microsomes from TCDD-treated (1 nM, 24 h) PRH.  
With 10-8-5*10-8 M PCB 77, 5*10-11 M PCB 126, or 5*10-8 M PCB 156, light CYP1A1-bands 
appeared on Western Blot membranes, linking respective concentrations to EC20-values of 
congeners in EROD-measurements. Subsequent to an ascent throughout 1-1.5 orders of magnitude 
of PCB 77-, PCB 126-, or PCB 156-concentration, CYP1A1-band-intensities succeeded proportions 
comparable to those of TCDD-positive controls (5*10-7-10-6 M PCB 77, 10-9-10-7 M PCB 126, or 
5*10-7-10-6 M PCB 156). 
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In figure 47, EROD-assay- and Western Blot-results derived by analysis of NDL-PCB 153, and 
mono-ortho-substituted PCBs 105, or 118, on PRH are contrasted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
    
 
 
Figure 47: EROD assay and Western Blot PRH (V). Cells treated with TCDD, PCB 105, PCB 118, or PCB 153 
for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: EROD activity (pmol resorufin/min*mg protein). 
EC20-level represents 20% of TCDD-induced maximum response. Exemplary CYP1A1-and VDAC-Western 
Blots from microsomes. Results from three independent experiments each. 
 
Incubation of PRH with mono-ortho-substituted PCB 105 for 24 h led to a slight increase of 
EROD-activity from about 5*10-8 M (8.0±0.6 pmol resorufin/min*mg protein), which enhanced and 
yielded statistically very significant (p-value < 0.01; One-way ANOVA with Dunnett’s post test; 
control vs. treatments) EROD-induction levels from 10-7 M PCB 105 with 18.2(±5.4) pmol 
resorufin/min*mg protein (figure 47). Using highest tested concentration of 10-6 M PCB 105, 
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maximum EROD-activity of 46.2(±11.3) pmol resorufin/min*mg protein was achieved. Due to 
polynomial fitting, an EC20 of 7.86*10-7 M PCB 105 was evolvable, corresponding to a REP 
scoring 0.0000053.  
 
Comparable findings were obtained by analysis of PCB 118-derived EROD-inducing effects, 
whereby polynomial fitting generated a concentration-response-relationship positioned slightly 
below PCB 105’s fit.  
Subsequent to slightly increasing EROD-activities from 5*10-8 M PCB 118 (8.0±0.6 pmol 
resorufin/min*mg protein), statistically very significant (p-value < 0.01) enzyme-inductions were 
gained from 5*10-7 M PCB 118 amounting to 25.8(±8.1) pmol resorufin/min*mg protein. 
Maximally reached EROD-activity examining 10-6 M PCB 118 amounted to 38.0(±16.3) pmol 
resorufin/min*mg protein. Being located minimally above this highest concentration, deduced 
EC20 was 1.25*10-6 M, correlating with a REP of 0.0000032.  
Compared to effects caused by PCB 105, EC20 and statistically relevant values due to treatment of 
PRH with PCB 118 were transferred about half an order of magnitude to higher concentrations.  
 
Focusing on Western Blot membranes obtained by analysis of microsomes from primary rat 
hepatocytes exposed to PCBs 105, or 118, both substances slightly induced CYP1A1-protein       
(56 kDa) using 5*10-7 M of respective congener, sparsely intensifying with 10-6 M. As well as for 
the exemplary Western Blot-membrane referring to PCB 153, membranes showed regularly 
occurring bands indicating the VDAC-loading-control (32 kDa). Constantly, TCDD-positive-
controls generated distinct CYP1A1-bands. Regarding NDL-PCB 153, effects on CYP1A-levels 
were observed attempting neither method.  
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4.2.2.4. EROD assay liver cell systems – summary primary rat hepatocytes 
 
In table 46, EC-values and correspondent REPs obtained by EROD-measurements in Sprague 
Dawley primary rat hepatocytes exposed to polychlorinated dibenzo-p-dioxins, polychlorinated 
dibenzofurans, or polychlorinated biphenyls, are compared to current TEF (2005)-values (Van den 
Berg et al., 2006). 
 
Table 46: EC50-and EC20-values and respective REPs derived from EROD-measurements with PRH 
subsequent to incubation with 14 congeners for 24 h compared to WHO-TEFs (Van den Berg et al., 2006). 
PRH EC50 (M) REP (EC50) EC20 (M) REP (EC20) WHO-TEF 
(2005) 
      
TCDD 2.28E-11 1 4.14E-12 1 1 
1-PeCDD 5.73E-11 0.40 1.32E-11 0.31 1 
1,6-HxCDD 1.98E-10 0.12 5.14E-11 0.081 0.1 
1,4,6-HpCDD 6.13E-10 0.037 1.38E-10 0.030 0.01 
      
TCDF 8.89E-11 0.26 2.49E-11 0.17 0.1 
4-PeCDF 1.12E-10 0.20 4.50E-11 0.092 0.3 
1,4-HxCDF 2.71E-10 0.084 1.25E-10 0.033 0.1 
1,4,6-HpCDF 1.41E-09 0.016 5.74E-10 0.0072 0.01 
      
PCB 77 1.22E-08 0.0019 9.63E-09 0.00043 0.0001 
PCB 126 2.11E-10 0.11 7.20E-11 0.058 0.1 
      
PCB 105   7.86E-07 0.0000053 0.00003 
PCB 118   1.25E-06 0.0000032 0.00003 
PCB 156 1.24E-07 0.00018 3.85E-08 0.00011 0.00003 
      
PCB 153     - 
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4.2.2.5. EROD assay liver cell systems – H4IIE cells vs. PRH 
 
Summarizing EROD assay results derived from both used liver cells systems, varying EROD-
inducing properties using primary rat hepatocytes, or the cell-line H4IIE, were remarkable. 
Exemplarily, in figure 48, sigmoid curves reflecting EROD-inducing effects of TCDD in both cell 
types are contrasted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: EROD assay H4IIE vs. PRH. Cells treated with TCDD for 24 h. Abscissa (logarithm.):   
Concentration (M); ordinate: EROD-activity (pmol resorufin/min*mg protein). Results from three independent 
experiments each. 
 
The exponential increase of EROD-activity using low TCDD-concentrations comprised an equal 
range of concentration (10-12-5*10-12 M) for both cell systems displayed in figure 48.  
Yet, differences concerning degree of exponential increase existed, with H4IIE-cells revealing a 
higher extent accompanied by a slightly sooner transition into the logarithmical section of the curve. 
This logarithmical segment furthermore exhibited a steeper ascent using H4IIE-cells instead of 
PRH. In addition, the upper asymptote of the sigmoid curve was both reached with about 0.5 orders 
of magnitude lower TCDD-concentration, and, most remarkably, at a higher absolute level. 
Precisely, the maximum EROD-level due to TCDD-treatment doubled switching from PRH to 
H4IIE cells. Taken together, mentioned deviations of sigmoid curves were associated with varying 
EC-values. Whereas EC20-values for TCDD differed less than ten percent, the shift regarding EC50 
appeared more prominent, being twice as high for PRH compared to H4IIE. 
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Throughout tested compounds, differing properties towards H4IIE-cells and PRH explained above 
emerged by trend. Exceptionally, mono-ortho-substituted PCBs 105, or 118 yielded minor EROD-
inductions in H4IIE-cells barely distinguishable from background levels, whereat EROD-activities 
due to these PCBs at least reached the respective EC20-level in primary rat hepatocytes.  
 
Table 47 overviews REPs acquired by EROD-measurements using H4IIE cells or primary rat 
hepatocytes, and opposes these to valid WHO-TEFs from 2005 (Van den Berg et al., 2006). 
 
Table 47: REPs derived from EROD-measurements with PRH and H4IIE cells subsequent to incubation with   
14 congeners for 24 h compared to WHO-TEFs (Van den Berg et al., 2006). 
EROD REP (EC50) 
PRH 
REP (EC50) 
H4IIE 
REP (EC20) 
PRH 
REP (EC20) 
H4IIE 
WHO-TEF 
(2005) 
      
TCDD 1 1 1 1 1 
1-PeCDD 0.40 0.58 0.31 0.64 1 
1,6-HxCDD 0.12 0.12 0.081 0.10 0.1 
1,4,6-HpCDD 0.037 0.066 0.030 0.048 0.01 
      
TCDF 0.26 0.023 0.17 0.046 0.1 
4-PeCDF 0.20 0.67 0.092 0.64 0.3 
1,4-HxCDF 0.084 0.10 0.033 0.091 0.1 
1,4,6-HpCDF 0.016 0.015 0.0072 0.010 0.01 
      
PCB 77 0.0019 0.00013 0.00043 0.000057 0.0001 
PCB 126 0.11 0.12 0.058 0.092 0.1 
      
PCB 105   0.0000053  0.00003 
PCB 118   0.0000032  0.00003 
PCB 156 0.00018 0.000051 0.00011 0.000047 0.00003 
      
PCB 153     - 
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4.2.3. In vitro Liver Cell Systems – qRT-PCR 
 
To approach to the objective to distinguish properties of chlorinated compounds, besides enzyme-
activity measurements and protein analysis, investigations on mRNA-level were processed. Even 
though gene transcription is necessarily required for translation, the presence of mRNA in a cell 
merely constitutes a sufficient condition for transcribing mRNA to protein. Confining strategy to 
protein analysis might implicate losses on information regarding potency and/or efficacy of 
substances. Hence, several genes were examined on mRNA-level to focus congeners’ impact on the 
fundamental process of gene transcription in liver cell systems. 
 
4.2.3.1. QRT-PCR in vitro – TCDD & eight potential target genes 
 
Based on several investigations within the SYSTEQ project, eight potential AhR-target genes were 
chosen. Genes supposed to be determined were those encoding CYP1A1, CYP1A2, CYP1B1, 
AhRR, ALDH3A1, CD36, HSD17B2, and TIPARP. For this purpose, H4IIE cells as well as 
primary rat hepatocytes were incubated with eight different TCDD-concentrations for 24 h. Yielded 
mRNA was transcribed to cDNA and analyzed by qRT-PCR using SYBR Green, whereby ACTB 
encoding β-actin served as housekeeping gene.  
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4.2.3.1.1. QRT-PCR in vitro – Cyp1a1, Cyp1a2, Cyp1b1 
 
Focused CYP-enzymes, whose gene transcripts were measured via qRT-PCR, were Cyp1a1, 
Cyp1a2, and Cyp1b1. Effects of TCDD on respective mRNA-levels in PRH, or H4IIE cells after   
24 h of incubation are overviewed in figure 49.  
 
control 0.1 pM 1 pM 5 pM 10 pM 50 pM 100 pM 500 pM 1 nM  
0
200
400
600
800
2000
4000
6000
8000
** **
**
**
**
** * ** **
**
**
** ** **
**
**
**
**
**
Fo
ld
 
in
du
ct
io
n
(re
fe
rr
ed
 
to
 
β-a
ct
in
 
m
RN
A
-
le
v
el
s)
TCDD-concentration
 Cyp1a1 H4IIE
 Cyp1a1 PRH
 Cyp1a2 H4IIE
 Cyp1a2 PRH
 Cyp1b1 H4IIE
 Cyp1b1 PRH
 DMSO 0.1%
 
Figure 49: QRT-PCR (Cyp1a1, Cyp1a2, Cyp1b1) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-
concentration (M) plotted against fold induction (referred to β-actin mRNA-levels). Results from four 
independent experiments each. One-way ANOVA with Dunnett’s post test (control vs. treatments).                      
*: p-value < 0.05; **: p-value < 0.01. 
 
Slight Cyp1a1-inductions in H4IIE cells on mRNA-level (figure 49) were detectable from            
10-12 M TCDD (18.0±11.0-fold), getting more prominent from 5*10-12 M (354.1±144.9-fold). 
Concentration-dependently increasing, fold induction reached statistically very significant upper 
values (p-value < 0.01) from 5*10-11-10-9 M TCDD with 3544.8(±543.8)-4626.8(±1594.4)-fold 
enhanced mRNA-levels.  
 
In contrast, maximum effects analyzing PRH were 145.0(±54.0)-fold Cyp1a1-inductions         
(5*10-10 M TCDD), concentration-dependently increasing from 5*10-11 M TCDD (23.6±8.8-fold). 
Statistically very significant (p-value < 0.01) Cyp1a1-inductions in PRH were obtained from        
10-10 M TCDD (82.3±22.8-fold).  
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Regarding enhancement and highest mRNA-levels, Cyp1a1-fold inductions measured in H4IIE 
cells were shifted about 0.5-1 order of magnitude to lower concentrations, and in around 30-fold 
higher extent than in PRH.  
 
In contrast, Cyp1b1-qRT-PCR-measurements resulted in a reverse order concerning yielded 
efficacies in liver cells systems. Using PRH, highest and statistically very significant inductions   
(p-value < 0.01) of 532.5(±258.3)-759.1(±229.2)-fold were gained with 5*10-10-10-9 M TCDD. 
More than five times lower upper induction-levels (statistically very significant; p-value < 0.01) 
were obtained in H4IIE cells testing a TCDD-concentration-rage of 5*10-11-10-9 M (126.3(±49.4) to 
138.9(±74.9)-fold induction). Progress of Cyp1b1-induction retained in concentration-dependent 
manner for both cell systems, distinctly increasing from 5*10-12 to 10-11 M TCDD (H4IIE), or from 
10-11 to 5*10-11 M TCDD (PRH), representing potencies about 0.5-1 order of magnitude higher in 
H4IIE cells than in PRH.  
 
Regarding Cyp1a2-mRNA-levels, smallest concentration-dependent effects among focused CYP-
enzymes were obtained, yielding statistically very significant (p-value < 0.01) inductions scoring 
16.2(±9.6)-, and 19.0(±11.4)-fold in PRH using 5*10-10 M, or 10-9 M TCDD.  
Being around twice as efficient in H4IIE cells, TCDD led to statistically very significant elevations 
(p-value < 0.01) accounted for 42.1(±25.7)- to 45.9(±26.0)-fold within a concentration-range of 
5*10-11-10-9 M TCDD. Statistically significant (p-value < 0.05) value of 41.4(±21.5)-fold was 
measured incubating H4IIE cells with 10-10 M TCDD. 
 
Constantly, TCDD-derived potencies regarding examined Cyp-mRNA-levels were greater in H4IIE 
cells than in PRH. Analogical findings were obtained comparing TCDD’s efficacies towards liver 
cell models, excepting Cyp1b1-inductions, being more excessive in PRH.  
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4.2.3.1.2. QRT-PCR in vitro – Ahrr 
 
In figure 50, qRT-PCR-data concerning TCDD-treated PRH, or H4IIE cells and corresponding 
Ahrr-mRNA-levels are summarized. 
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Figure 50: QRT-PCR (Ahrr) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-concentration (M) 
plotted against fold induction (referred to β-actin mRNA-levels). Results from three independent experiments 
each. One-way ANOVA with Dunnett’s post test (control vs. treatments). *: p-value < 0.05; **: p-value < 0.01. 
 
Incubation with TCDD for 24 h led to a concentration-dependent enhancement of AhRR-mRNA-
levels in PRH (figure 50). Beginning from 10-11 M TCDD, increase progressed passing a 
statistically significant (p-value < 0.05) value of 172.9(±134.6)-fold (5*10-10 M TCDD), and 
achieved maximal, statistically very significant (p-value < 0.01) induction of 175.8(±104.8)-fold 
(10-9 M TCDD). Sigmoid fitting (not shown) educed an EC50 of 1.79*10-10(±4.16*10-11) M TCDD, 
and respective upper asymptotic value was 183.1(±13.1)-fold. 
 
Usage of H4IIE cells, response with regard to Ahrr-induction on mRNA-level was absent by use of 
tested TCDD-concentrations (10-13-10-9 M). 
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4.2.3.1.3. QRT-PCR in vitro – Aldh3a1 
 
Results of qRT-PCR-investigations regarding Aldh3a1 in PRH, or H4IIE subsequent to treatment 
with TCDD for 24 h are compiled in figure 51. 
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Figure 51: QRT-PCR (Aldh3a1) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-concentration (M) 
plotted against fold induction (referred to β-actin mRNA-levels). Results from four independent experiments 
each. One-way ANOVA with Dunnett’s post test (control vs. treatments). *: p-value < 0.05; **: p-value < 0.01. 
 
Concentration-dependently, Aldh3a1-mRNA-levels in H4IIE cells increased after incubation with 
TCDD (figure 51). Statistically relevant (p-value < 0.05) inductions were obtained with            
5*10-10-10-9 M TCDD, scoring 33.3(±33.1)-32.0(±15.7)-fold.  
With more than 10-fold higher efficacy, revealed inductions in PRH due to TCDD-exposure   
(5*10-10-10-9 M) amounted to statistically very significant (p-value < 0.01) values of 
3134.1(±2373.0)-, and 5093.4(±2302.2)-fold.  
 
Progress of mRNA-level-enhancement proceeded resembled among both tested cell-types, implying 
conformable potencies responding to TCDD.  
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4.2.3.1.4. QRT-PCR in vitro – Cd36 
 
Presented qRT-PCR-results in figure 52 display relative Cd36-mRNA-levels obtained from H4IIE 
cells or PRH after 24 h of TCDD-exposure. 
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Figure 52: QRT-PCR (Cd36) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-concentration (M) 
plotted against fold induction (referred to β-actin mRNA-levels). Results from three independent experiments 
each. One-way ANOVA with Dunnett’s post test (control vs. treatments). 
 
Incubation of H4IIE cells, or PRH, with TCDD in a range of concentration of 10-13-10-9 M, led to 
no deviations regarding count of mRNA-transcripts of the gene encoding Cd36 compared to control 
(figure 52).  
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4.2.3.1.5. QRT-PCR in vitro – Hsd17b2 
 
Assembly of qRT-PCR-results obtained by analysis of gene-transcripts encoding Hsd17b2 in PRH, 
and H4IIE cells treated with TCDD for 24 h is shown in figure 53. 
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Figure 53: QRT-PCR (Hsd17b2) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-concentration (M) 
plotted against fold induction (referred to β-actin mRNA-levels). Results from three independent experiments 
each. One-way ANOVA with Dunnett’s post test (control vs. treatments). *: p-value < 0.05. 
 
Incubation of PRH with TCDD resulted in concentration-dependently increasing Hsd17b2-mRNA-
levels after 24 h (figure 53). Comparably light enhancement peaked with the highest tested TCDD-
concentration of 10-9 M at a statistically significant (p-value < 0.05) value of 16.0(±10.9)-fold 
induction.  
 
In contrast, TCDD-exposure to H4IIE cells led to no statistically relevant deviation of respective 
mRNA-levels from controls. Slight concentration-dependent increase in H4IIE cells maximally 
achieved Hsd17b2-induction of 9.0(±6.9)-fold using 10-9 M TCDD. 
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4.2.3.1.6. QRT-PCR in vitro - Tiparp 
 
Subsequent figure gives summary of results concerning measurement of Tiparp-mRNA-levels in 
PRH, or H4IIE-cells exposed to TCDD for 24 h (figure 54). 
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Figure 54: QRT-PCR (Tiparp) H4IIE vs. PRH. Cells treated with TCDD for 24 h. TCDD-concentration (M) 
plotted against fold induction (referred to β-actin mRNA-levels). Results from four independent experiments 
each. One-way ANOVA with Dunnett’s post test (control vs. treatments). *: p-value < 0.05; **: p-value < 0.01. 
 
Consequence of incubation with TCDD for 24 h was a concentration-dependent increase of Tiparp-
mRNA-levels in PRH (figure 54). Slightly enhancing from 5*10-11 M TCDD, fold induction gained 
statistically significant (p-value < 0.05; 10-10 M TCDD, 7.6±1.2-fold) value, and reached 
statistically very significant (p-value < 0.01) heights of 15.1(±2.4)-, and 17.9(±7.7)-fold from   
5*10-10 to 10-9 M TCDD.  
Sigmoid fitting (not shown) generated an EC50 of 1.51*10-10(±2.93*10-11) M TCDD, and an upper 
limit of 18.4(±0.9)-fold induction.  
 
Count of gene-transcripts according to Tiparp was not affected concentration-dependently in H4IIE 
cells due to TCDD-exposure. However, a slight, statistically significant (p-value < 0.05) fold 
induction of 4.6(±2.5) was attained using 5*10-11 M TCDD. 
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4.2.3.2. QRT-PCR in vitro – core congeners & four potential AhR-target genes 
 
Based on findings derived from qRT-PCR-analysis regarding impact of TCDD on eight potential 
AhR-target genes in PRH and H4IIE cells, a further selection was made due to responsiveness and 
concentration-dependence in both tested liver cell systems. Hence, Cyp1a1, Cyp1a2, Cyp1b1, and 
Aldh3a1 were chosen, and effects of core congeners (TCDD, 1-PeCDD, 4-PeCDF, PCB 118,     
PCB 126, PCB 153, and PCB 156) on both H4IIE cells and PRH were investigated via q-RT-PCR.  
 
4.2.3.2.1. QRT-PCR H4IIE cells – Cyp1a1 
 
In figure 55, impact of TCDD, 1-PeCDD, or 4-PeCDF on Cyp1a1-mRNA-levels in H4IIE cells are 
contrasted. Cells were incubated with compounds for 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: QRT-PCR (Cyp1a1) H4IIE (I). Cells treated with TCDD, 1-PeCDD, or 4-PeCDF for 24 h.        
Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to β-actin mRNA-levels).        
EC20-level represents 20% of TCDD-induced maximum response (865-fold). Results from at least three 
independent experiments each. 
 
QRT-PCR-measurements regarding effects of TCDD, 1-PeCDD, or 4-PeCDF on Cyp1a1 revealed 
quite comparable output among these congeners (figure 55). Concentration-dependently, incubation 
with each substance for 24 h led to an increase of relative Cyp1a1-mRNA-levels in H4IIE cells, 
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asymptotically yielding maximum levels, and accordingly outlining sigmoid curves. Upper 
asymptote obtained subsequent to TCDD-exposure was 4327.3(±188.0)-fold, bearing an EC20-level 
of 865-fold, and a correspondent EC20 of 6.76*10-12 M TCDD. Respective EC50 amounted to 
1.55*10-11(±2.92*10-12) M TCDD.  
Statistically very significant (p-value < 0.01; One-way ANOVA with Dunnett’s post test; control 
vs. treatments) deviations from solvent control (DMSO 0.1%, not shown) were present from    
5*10-11 M TCDD (3544.8±543.8-fold).  
 
Being almost as potent as was TCDD, 4-PeCDF gained an EC50 of 1.51*10-11(±3.46*10-12) M 
(REP (EC50): 1.0), and was furthermore about ten per cent less efficient, compared to TCDD’s 
properties (upper asymptote (4-PeCDF): 3841.6±196.8-fold). Calculated EC20 scored 7.99*10-12 M 
4-PeCDF, correlating with a REP (EC20) of 0.85.  
Statistically significant (p-value < 0.05) value was accomplished with 10-11 M 4-PeCDF 
(1308.8±630.9-fold), followed by statistically very significant (p-value < 0.01) inductions starting 
from 5*10-10 M 4-PeCDF (3204.8±436.2-fold).  
 
1-PeCDD attained further, slightly lower potency, yielding an EC50 of 2.46*10-11(±1.62*10-12) M 
1-PeCDD, corresponding with a REP (EC50) of 0.63. On the other hand, accompanied by a slightly 
steeper ascent in the logarithmical segment of the curve, maximum Cyp1a1-induction due to          
1-PeCDD-incubation in H4IIE cells amounted to 5095.2(±75.6)-fold, which was more than 15% 
higher compared to the TCDD-derived maximum. Reflecting the lightly delayed ascent, EC20 
scored 9.80*10-12 M 1-PeCDD and resulted in a REP (EC20) of 0.69.  
Statistically very significant (p-value < 0.01) Cyp1a1-inductions were obtained from 5*10-11 M     
1-PeCDD (3826.9±1285.8-fold). 
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A comparison of qRT-PCR-results analyzing effects of PCB 118, PCB 126, PCB 153, PCB 156, or 
TCDD on Cyp1a1-mRNA in H4IIE cells is imaged in figure 56.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: QRT-PCR (Cyp1a1) H4IIE (II). Cells treated with TCDD, PCB 118, PCB 126, PCB 153, or PCB 156 
for 24 h. Axes with varying scales. Abscissae (logarithm.): Concentration (M); ordinates: Fold induction 
(referred to β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (865-fold). 
Results from at least three independent experiments each.  
 
Shifted around one order of magnitude to higher concentrations compared to TCDD-derived effects, 
concentration-dependent increase of Cyp1a1-mRNA-levels in H4IIE cells due to incubation with 
PCB 126 appeared in sigmoid manner (figure 56).  
EC50 was 1.14*10-10(±1.96*10-11) M PCB 126, bringing forth a REP (EC50) of 0.14, whereas 
upper asymptote lay at 2672.5(±134.0)-fold induction, consequently exhibiting almost 40% lower 
efficacy than TCDD. Ascending in lightly less extent, EC20-level was reached with 7.86*10-11 M 
PCB 126 (REP (EC20): 0.086).  
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Statistically very significant increases of Cyp1a1-mRNA were obtained from 10-10 M PCB 126 
(1197.9±216.7-fold; p-value < 0.01; One-way ANOVA with Dunnett’s post test; control vs. 
treatments).  
 
Contrasted with PCB 126, the additionally substituted chlorine atom at position 2 in PCB 156 led to 
a further shift on the abscissa of around three orders of magnitude. Respective EC50 accounted for 
8.01*10-08(±2.59*10-9) M PCB 156, revealing a REP (EC50) of 0.00019. Running along an even 
steeper ascent compared to the TCDD-curve, the upper limit of sigmoid scored 2612.6(±100.6)-fold 
induction, scaling consistent efficacy of PCBs 126 and 156.  
An EC20 of 7.60*10-8 M PCB 156 rendered a REP (EC20) of 0.000089, whereby statistically very 
significant (p-value < 0.01) Cyp1a1-inductions were gained beginning with 10-7 M PCB 156 
(2504.0±679.2-fold).  
 
Due to minor effects towards H4IIE cells, PCB 118-induced modifications were hidden in the main 
diagram in figure 56. With the aid of varied scaling, an additional display detail elaborated Cyp1a1-
induction referable to PCB 118-exposure.  
Among tested concentrations, slight increase of mRNA-levels was obtained for 5*10-7 M PCB 118 
(14.5±3.9-fold), enhancing with the highest concentration of 10-6 M PCB 118 to 20.3(±6.8)-fold. 
Noted values statistically very significantly (p-value < 0.05) differed from solvent control (DMSO 
0.1%, not shown). Hypothetically constructing PCB 118 from PCB 156, under abstraction of the 
chlorine substituent at position 3, led to inaccessibility concerning EC50-, as well as EC20-values 
under present conditions.  
 
Cyp1a1-mRNA in H4IIE cells remained at base levels after application of PCB 153 throughout 
tested concentrations (5*10-9-10-6 M). 
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4.2.3.2.2. QRT-PCR H4IIE cells – Cyp1a2 
 
Investigations of Cyp1a2-mRNA in H4IIE cells affected by core congeners were evaluated and 
summarized in figure 57. 
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Figure 57: QRT-PCR (Cyp1a2) H4IIE. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,     
PCB 153, or PCB 156 for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to 
β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (8.77-fold). Results 
from at least three independent experiments each. 
 
As seen in figure 57, incubation of H4IIE cells with TCDD led to a concentration-dependent 
increase of Cyp1a2-mRNA in sigmoid manner. Running through an EC20 of 2.16*10-12 M TCDD, 
and an EC50 of 1.02*10-11(±8.46*10-13) M TCDD, an asymptote limited maximum induction level 
at 43.9(±0.8)-fold.  
Statistically significant (p-value < 0.05; One-way ANOVA with Dunnett’s post test; control vs. 
treatments) Cyp1a2-induction was obtained for 10-10 M TCDD (41.4±21.5-fold). Statistically very 
significant (p-value < 0.01) values were present for 5*10-11 M TCDD (42.1±25.7-fold), and from 
5*10-10 M TCDD.  
Attention should be paid to the lower limit of TCDD-derived effects on Cyp1a2-mRNA-levels, 
which with 7.8(±0.9)-fold induction lay quite high and additionally very close to the appropriate 
H4IIE – qRT-PCR Cyp1a2 
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EC20-level of 8.77-fold. Concurring with all other tested compounds’ lower limits, which lay in a 
range of 0.6-2.4-fold induction, a reduction of congeners’ EC20-REPs was affected.  
 
Treatment with 4-PeCDF caused concentration-dependently increased formation of Cyp1a2-mRNA 
in H4IIE cells, whereas the appendant sigmoid function featured shorter and lightly flatter ascent in 
the logarithmical part of the curve compared to the TCDD-derived.  
Furthermore, the slope was transferred to higher concentrations almost by a factor of two, revealing 
an EC50 of 1.79*10-11(±3.83*10-12) M (REP (EC50): 0.57) and yielding an upper limit of 
28.3(±1.3)-fold induction. Associated with a lower extent regarding exponential ascent initiating the 
sigmoid, EC20-level was crossed with 9.94*10-12 M 4-PeCDF (REP (EC20): 0.22).  
Statistically very significant (p-value < 0.01) fold induction was gained from 5*10-11 M 4-PeCDF 
(23.9±9.5-fold). Contrasted with TCDD, 4-PeCDF rendered about 35% less efficacy and around  
40-80% (depending on the focused segment of curve) less potency towards H4IIE cells after 24 h of 
incubation.  
 
Using 1-PeCDD, revealed concentration-response curve concerning Cyp1a2-induction on mRNA-
level spanned a shorter excerpt on the ordinate, yielding an upper asymptote at 21.7(±1.1)-fold 
induction. Hence being about 50% less efficient than TCDD, relative potency referring to EC-levels 
added up to REP (EC50): 0.76 (EC50: 1.35*10-11±6.88*10-12 M 1-PeCDD), or REP (EC20): 0.19 
(EC20: 1.16*10-11 M 1-PeCDD). Lying close together, depicted EC-values reflected a run of curve 
located close to the 4-PeCDF-derived, which was slightly delayed regarding initiation of ascent, 
combined with the steepest incline of slope among tested compounds.  
Statistically very significant (p-value < 0.05) deviations of Cyp1a2-mRNA-levels compared to 
control (DMSO 0.1%, not shown) were obtained from 5*10-11 M 1-PeCDD (22.0±5.9-fold 
induction).  
 
Moved to higher concentrations more than one order of magnitude, and proceeding less steep 
ascending, the concentration-response curve belonging to PCB 126’s effects on Cyp1a2-mRNA-
levels in H4IIE cells asymptotically reached 19.3(±1.2)-fold induction, thus being slightly less 
efficient than 1-PeCDD.  
EC50 was 1.08*10-10(±2.35*10-11) M PCB 126, whereas EC20 scored 8.98*10-11 M PCB 126, 
corresponding to respective REPs of 0.095 (REP (EC50)), and 0.024 (REP (EC20)). Statistically 
very significant (p-value < 0.01) Cyp1a2-inductions were present from 10-10 M PCB 126    
(9.8±1.7-fold).  
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Following a further shift about three orders of magnitude on the x-axis, the sigmoid representing 
concentration-dependent increase of Cyp1a2-mRNA-levels in H4IIE cells due to PCB 156-exposure 
delineated.  
Ascending in comparable degree to the TCDD-derived curve within the logarithmical section, upper 
asymptotic value approached 44.3(±0.5)-fold induction, depicting TCDD-equivalent efficacy. EC50 
amounted to 9.09*10-8(±1.83*10-9) M PCB 156, whereas EC20 scored 5.12*10-8 M PCB 156, 
revealing corresponding REPs of 0.00011 (REP (EC50)), and 0.000042 (REP (EC20)).  
Statistically significant (p-value < 0.05) Cyp1a2-induction was obtained for 10-7 M PCB 156 
(26.2±6.5-fold), followed by statistically very significant deviations from 5*10-7 M PCB 156 
(44.7±21.2-fold; p-value < 0.01).  
 
Subsequent to incubation of H4IIE cells with PCB 118, or PCB 153, relative quantity of Cyp1a2-
mRNA remained on levels indistinguishable from those of solvent control. 
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4.2.3.2.3. QRT-PCR H4IIE cells – Cyp1b1 
 
In figure 58, effects of core congeners on Cyp1b1-mRNA-levels in H4IIE cells measured by qRT-
PCR are compiled. 
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Figure 58: QRT-PCR (Cyp1b1) H4IIE. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,     
PCB 153, or PCB 156 for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to 
β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (27.2-fold). Results 
from at least three independent experiments each. 
 
Cyp1b1-induction in H4IIE cells due to TCDD-exposure indicated in figure 58 described a 
concentration-dependent increase asymptotically limited at 135.8(±1.3)-fold induction. Sigmoid 
curve ran through an EC20 of 9.76*10-12 M at 27.2-fold induction, and an EC50 of               
1.75*10-12(±8.41*10-13) M TCDD. Statistically very significant (p-value < 0.01; One-way ANOVA 
with Dunnett’s post test; control vs. treatments) deviations from solvent control (DMSO 0.1%, not 
shown) were achieved from 5*10-11 M TCDD (126.3±49.4-fold).  
 
The sigmoid curve figuring Cyp1b1-mRNA-enhancing impact of 1-PeCDD ran through the EC20-
level at a point very close to the TCDD-derived curve, precisely at 9.96*10-12 M, affording a      
REP (EC20) of 0.98. Since 1-PeCDD with maximal induction of 186.5(±14.2)-fold yielded higher 
efficacy (ca. 35%), and the slope ascended to slightly less extent, EC50 accounted for          
3.60*10-11(±1.04*10-11) M 1-PeCDD, generating a respective REP (EC50) of 0.49.  
H4IIE – qRT-PCR Cyp1b1 
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From 5*10-11 M 1-PeCDD (123.6±33.1-fold), statistically very significant (p-value < 0.01) Cyp1b1-
inductions were obtained.  
 
At 1.04*10-11 M, as well crossing the EC20-level close to TCDD’s sigmoid curve, treatment of 
H4IIE cells with 4-PeCDF engendered a REP (EC20) of 0.93 regarding Cyp1b1-induction on 
mRNA-level. Describing a flatter curve, sigmoid fitting unveiled an upper asymptotic value of 
184.0(±23.3)-fold induction due to 4-PeCDF-exposure, being related to 1-PeCDD’s upper induction 
level. EC50 scored 9.50*10-11(±3.82*10-11) M 4-PeCDF, corresponding to a REP (EC50) of 0.18. 
Statistically, significant (p-value < 0.05) Cyp1b1-induction was obtained by use of 10-10 M            
4-PeCDF, amounting to 95.2(±37.5)-fold, whereas very significant (p-value < 0.01) inductions were 
present from 5*10-10 M 4-PeCDF.  
 
Proceeding rather parallel to the 1-PeCDD-derived curve, the concentration-response curve 
depicting increase of Cyp1b1-mRNA-levels in H4IIE cells due to PCB 126-influence was shifted 
almost one order of magnitude to higher concentrations. Respective EC50 was                      
2.46*10-10(±5.11*10-11) M PCB 126 (REP (EC50): 0.071), whereas EC20 valued 6.49*10-11 M  
PCB 126, providing a REP (EC20) of 0.15. From statistical point of view, very significant Cyp1b1-
inductions were gained beginning with 5*10-10 M PCB 126 at 138.5(±44.7)-fold (p-value < 0.01).  
 
Contrasting with results for TCDD, 1-PeCDD, 4-PeCDF, or PCB 126, the sigmoid describing 
Cyp1b1-inducing effects of PCB 156 was both transferred to higher concentrations and yielded a 
lower asymptotic level at 87.8(±0.7)-fold induction. Being hence about 35% less efficient than 
TCDD, relative potencies of PCB 156 regarding Cyp1b1-induction in H4IIE cells based on EC-
values were 0.00012 (EC20: 8.41*10-8 M PCB 156), and 0.00019 (EC50: 9.21*10-8±5.68*10-10 M 
PCB 156). Statistically very significant (p-value < 0.01) deviations from control were given from 
5*10-7 M PCB 156 (88.5±34.6-fold induction).  
 
Incubation with PCB 118 led to minor Cyp1b1-induction in H4IIE cells after 24 h. Usage of     
5*10-7 M PCB 118 caused slight, but statistically significant increase to 2.5(±1.1)-fold Cyp1b1-
mRNA-levels (p-value < 0.05). Under present conditions, maximal and statistically very significant 
value was reached with 10-6 M PCB 118 and scored 3.0(±0.7)-fold induction (p-value < 0.01).  
 
PCB 153 did not affect Cyp1b1-mRNA-levels in H4IIE cells within the tested range of 
concentration (5*10-9-10-6 M PCB 153).  
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4.2.3.2.4. QRT-PCR H4IIE cells – Aldh3a1 
 
An assembly of qRT-PCR results regarding impact of core congeners on Aldh3a1-mRNA-levels in 
H4IIE cells is pictured in figure 59. 
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Figure 59: QRT-PCR (Aldh3a1) H4IIE. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,   
PCB 153, or PCB 156 for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to 
β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (6.58-fold). Results 
from at least three independent experiments each.  
 
Concentration-dependent effects of TCDD on Aldh3a1-mRNA-levels in H4IIE cells comprised 
elevated standard deviations (figure 59). Anyway, process of enhancement approved sigmoid fitting 
and revealed an EC50 of 8.03*10-11(±3.79*10-12) M TCDD, and an upper asymptote at    
32.9(±0.7)-fold induction. 20% of TCDD-induced maximum response was yielded with       
3.76*10-11 M TCDD, and respective EC20-level cut the ordinate at 6.58-fold induction.  
Statistically significant (p-value < 0.05; One-way ANOVA with Dunnett’s post test; control vs. 
treatments) increase of Aldh3a1-mRNA was obtained for 5*10-10 M TCDD (33.3±33.1-fold), and 
10-9 M TCDD (32.0±15.7-fold).  
 
Exhibiting a flatter ascent in the logarithmical segment, the concentration-response curve derived 
by 1-PeCDD-exposure gained an upper limit of 20.8(±1.2)-fold induction and an EC50 of    
H4IIE – qRT-PCR Aldh3a1 
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1.06*10-10 M 1-PeCDD (REP (EC50): 0.76) regarding Aldh3a1-mRNA-levels in H4IIE cells. EC20 
scored 5.74*10-11 M 1-PeCDD, accompanying a REP (EC20) of 0.66.  
Relevant data concerning statistical analysis were obtained for 10-10 M 1-PeCDD (p-value < 0.05), 
and beginning from 5*10-10 M 1-PeCDD (p-value < 0.01; 20.4±2.9-fold induction).  
 
Presumably being located within the upper section of the logarithmical part of curve testing up to 
10-9 M 4-PeCDF, sigmoid fitting under weighting of standard deviations extrapolated an upper 
value regarding Aldh3a1-induction of (32.3±12.5)-fold for this congener. Referring sigmoid implied 
an EC20 of 5.03*10-11 M 1-PeCDF, and an EC50 of 1.59*10-10(±1.07*10-10) M 1-PeCDF, leading 
to REPs of 0.75 (REP (EC20)), and 0.50 (REP (EC50)).  
Statistically very significant deviations (p-value < 0.01) from solvent-control (DMSO 0.1%, not 
shown) were gained for 5*10-10 M 4-PeCDF (24.8±12.4-fold), and 10-9 M 4-PeCDF, scoring 
31.2(±11.0)-fold.  
 
Ascending an even flatter slope, sigmoid function illustrating PCB 126-induced increase of 
Aldh3a1-mRNA-levels approached an asymptote at 16.5(±3.0)-fold induction. Being about half as 
efficient as TCDD, relative potencies based on EC-values scored 0.052 (REP (EC50)), regarding an 
EC50 of 1.55*10-9(±7.28*10-10) M PCB 126, and 0.042 (REP (EC20)), respecting the EC20 of 
8.88*10-10 M PCB 126.  
Statistically very significant (p-value < 0.01) induction of Aldh3a1-mRNA in H4IIE cells was 
present from 5*10-10 M PCB 126, amounting up to 12.7(±2.5)-fold (10-9 M PCB 126).  
 
Depicting an approximately parallel course, the sigmoid delineating concentration-response 
relations of Aldh3a1-induction in H4IIE cells due to PCB 156-exposure was shifted about two 
orders of magnitude to higher concentrations compared to the PCB 126-derived. Respective EC50 
was 1.95*10-7(±1.44*10-7) M PCB 156, and REP (EC50) scored 0.00041. EC20-level was crossed 
with 2.40*10-7 M PCB 156 (REP (EC20): 0.00016), and upper limit added up to 11.1(±3.2)-fold 
induction of Aldh3a1.  
Statistically relevant values were obtained for 5*10-7 M PCB 156 (p-value < 0.05; 7.9±4.0-fold), 
and 10-6 M PCB 156 (p-value < 0.01), yielding 10.1(±6.8)-fold induction.  
 
Regarding PCB 118, or PCB 153, no effects on Aldh3a1-mRNA-levels in H4IIE cells were 
determined after 24 h of incubation.  
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4.2.3.2.5. QRT-PCR H4IIE cells – summary 
 
Table 48 assembles qRT-PCR results regarding core congeners’ effects on transcription of genes 
encoding CYP1A1, CYP1A2, CYP1B1, or ALDH3A1 in H4IIE cells. EC-values and respective 
REPs are contrasted with current WHO-TEFs from 2005 (Van den Berg et al., 2006). 
 
Table 48: EC50-, EC20-values and respective REPs derived from qRT-PCR analysis (Cyp1a1, Cyp1a2, Cyp1b1, 
Aldh3a1) with H4IIE cells subsequent to incubation with core congeners for 24 h compared to WHO-TEFs (Van 
den Berg et al., 2006). 
H4IIE 
 
EC50 (M) REP (EC50) EC20 (M) REP (EC20) WHO-TEF 
(2005) 
Cyp1a1      
TCDD 1.55E-11 1 6.76E-12 1 1 
1-PeCDD 2.46E-11 0.63 9.80E-12 0.69 1 
4-PeCDF 1.51E-11 1.0 7.99E-12 0.85 0.3 
PCB 126 1.14E-10 0.14 7.86E-11 0.086 0.1 
PCB 118     0.00003 
PCB 156 8.01E-08 0.00019 7.60E-08 0.000089 0.00003 
PCB 153     - 
      
Cyp1a2      
TCDD 1.02E-11 1 2.16E-12 1 1 
1-PeCDD 1.35E-11 0.76 1.16E-11 0.19 1 
4-PeCDF 1.79E-11 0.57 9.94E-12 0.22 0.3 
PCB 126 1.08E-10 0.095 8.98E-11 0.024 0.1 
PCB 118     0.00003 
PCB 156 9.09E-08 0.00011 5.12E-08 0.000042 0.00003 
PCB 153     - 
      
Cyp1b1      
TCDD 1.75E-11 1 9.76E-12 1 1 
1-PeCDD 3.60E-11 0.49 9.96E-12 0.98 1 
4-PeCDF 9.50E-11 0.18 1.04E-11 0.93 0.3 
PCB 126 2.46E-10 0.071 6.49E-11 0.15 0.1 
PCB 118     0.00003 
PCB 156 9.21E-08 0.00019 8.41E-08 0.00012 0.00003 
PCB 153     - 
      
Aldh3a1      
TCDD 8.03E-11 1 3.76E-11 1 1 
1-PeCDD 1.06E-10 0.76 5.74E-11 0.66 1 
4-PeCDF 1.59E-10 0.50 5.03E-11 0.75 0.3 
PCB 126 1.55E-09 0.052 8.88E-10 0.042 0.1 
PCB 118     0.00003 
PCB 156 1.95E-07 0.00041 2.40E-07 0.00016 0.00003 
PCB 153     - 
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4.2.3.2.6. QRT-PCR primary rat hepatocytes – Cyp1a1 
 
QRT-PCR results according to incubation of PRH with TCDD, 1-PeCDD, or 4-PeCDF for 24 h and 
affected Cyp1a1-mRNA-levels are presented in figure 60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: QRT-PCR (Cyp1a1) PRH (I). Cells treated with TCDD, 1-PeCDD, or 4-PeCDF for 24 h.          
Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to β-actin mRNA-levels). EC20-
level represents 20% of TCDD-induced maximum response (26.8-fold). Results from at least three independent 
experiments each.  
 
Concentration-dependent increase of Cyp1a1-mRNA-levels in PRH (figure 60) due to TCDD-
exposure for 24 h delineated a sigmoid course. Under test conditions, maximal effects were 
confined to 134.1(±10.0)-fold induction. Consequential EC20-level amounted to 26.8-fold 
induction, implicating an EC20 of 1.78*10-11 M TCDD. EC50 was 6.94*10-11(±1.99*10-11) M 
TCDD. Statistically very significant (p-value < 0.01; One-way ANOVA with Dunnett’s post test; 
control vs. treatments) Cyp1a1-elevations were obtained beginning from 10-10 M TCDD with 
82.3(±22.8)-fold induction.  
 
Increasing with slightly lower concentrations compared to TCDD, the concentration-response curve 
representing 1-PeCDD’s effects on Cyp1a1-mRNA cut the EC20-level with 1.25*10-11 M              
1-PeCDD, generating a REP (EC20) of 1.4. Accompanied by a flattened ascent in the logarithmical 
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segment, and passing an EC50 of 3.45*10-11(±7.32*10-12) M 1-PeCDD, the sigmoid approached 
94.2(±3.3)-fold induction, evincing about 70% of TCDD’s efficacy. REP (EC50) expressed a 
potency of 2.0 in relation to TCDD.  
Statistically significant (p-value < 0.05) deviation from solvent control (DMSO 0.1%, not shown) 
was obtained with 10-11 M 1-PeCDD, (26.3±8.5-fold) whereas from 5*10-11 M 1-PeCDD, 
statistically very significant (p-value < 0.01) inductions up to 96.2(±17.1)-fold were yielded.  
 
Slightly shifted to higher concentrations, the sigmoid curve illustrating concentration-
responsiveness regarding Cyp1a1-mRNA in PRH due to 4-PeCDF-treatment reached the EC20-
level at 3.73*10-11 M 4-PeCDF (REP (EC20): 0.48) and yielded 116.8(±3.8)-fold induction. Hence, 
4-PeCDF’s efficacy was situated lower than TCDD’s, but higher than 1-PeCDD’s. EC50 amounted 
to 1.25*10-10(±1.90*10-11) M 4-PeCDF, revealing a REP (EC50) of 0.56.  
From statistical point of view, 4-PeCDF led to significant (P< 0.05) Cyp1a1-induction using    
5*10-10 M of the congener (87.9±24.5-fold), and very significant (p-value < 0.01) inductions from 
10-10 M 4-PeCDF (107.9±48.6-fold) in PRH after 24 h of incubation.  
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Figure 61 presents Cyp1a1-qRT-PCR results referable to incubation of PRH with TCDD, PCB 118, 
PCB 126, PCB 153, or PCB 156 for 24 h. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61: QRT-PCR (Cyp1a1) PRH (II). Cells treated with TCDD, PCB 118, PCB 126, PCB 153, or PCB 156 for 
24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to β-actin mRNA-levels). 
EC20-level represents 20% of TCDD-induced maximum response (26.8-fold). Results from at least three 
independent experiments each.  
 
Treatment of PRH with PCB 126 led to concentration-dependently increasing Cyp1a1-mRNA-
levels (figure 61). Compared to TCDD’s effects, sigmoid fitting generated a curve exhibiting a less 
steep slope across the entire graph, further transferred about 1.5 orders of magnitude to higher 
concentrations. This shift respecting the middle of the curve implied an EC50 of                   
1.10*10-9(±4.50*10-10) M PCB 126 (REP (EC50): 0.063). EC20-level was crossed with       
7.28*10-11 M PCB 126, bringing forth a REP (EC20) of 0.24. Maximally achieved Cyp1a1-
indcution in PRH due to PCB 126-treatment was 146.5(±8.7)-fold under present conditions. 
Statistically very significant (p-value < 0.01; One-way ANOVA with Dunnett’s post test; control 
vs. treatments) deviations from control (DMSO 0.1%, not shown) were given from 10-8 M PCB 126 
(104.3±24.4-fold).  
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Shifted about three orders of magnitude to higher concentrations and attaining almost 20% less 
efficacy scoring 109.3(±5.7)-fold induction compared to the curve derived by TCDD-exposure, the 
sigmoid reflecting PCB 156-induced effects implied an EC50 of 7.61*10-8(±9.12*10-9) M PCB 156 
(REP (EC50): 0.00091). EC20 amounted to 4.64*10-8 M PCB 156, revealing a respective           
REP (EC20) of 0.00038.  
Statistically very significant (p-value < 0.01) Cyp1a1-inductions in PRH due to PCB 156-treatment 
were gained from 10-7 M PCB 156 (73.9±7.5-fold). Comparing PCB 156 to PCB 126, the additional 
chlorine atom in position 2 led to decreased potency (2-3 orders of magnitude), as well as reduced 
efficacy (75%) regarding Cyp1a1-induction in PRH.  
 
Cyp1a1-mRNA-levels lightly increased beginning with around 10-7 M PCB 118 (3.5±2.1-fold), by 
exponential enhancement reaching statistically very significant values from 5*10-7 to 10-6 M      
PCB 118, not exceeding 29.0(±8.1)-fold induction (p-value < 0.01). By means of polynomial 
fitting, an EC20 of 7.62*10-7 M PCB 118 was established, correspondent to a REP (EC20) of 
0.000023.  
Respecting Cyp1a1-induction in PRH, hypothetical abstraction of the chlorine atom in position 3 
implicated decreased potency (~1.5 orders of magnitude regarding EC20-values) and, under given 
test conditions, a lack of knowledge regarding maximal effects and accessible EC50, comparing 
PCB 118 with PCB 156.  
Contrasting PCB 118 to PCB 126, potency lowered about 4 orders of magnitude (applying EC20-
values) along with a theoretical exchange of chlorine substituents from position 3 to 2.  
 
No effect on Cyp1a1-mRNA-levels was obtained due to PCB 153-exposure (5*10-9-10-6 M) to 
PRH.  
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4.2.3.2.7. QRT-PCR primary rat hepatocytes – Cyp1a2 
 
In figure 62, qRT-PCR results regarding Cyp1a2-mRNA and effects of core congeners after 24 h of 
incubation towards PRH are summarized. 
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Figure 62: QRT-PCR (Cyp1a2) PRH. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,       
PCB 153, or PCB 156 for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to 
β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (3.28-fold). Results 
from at least three independent experiments each. 
 
Increase of Cyp1a2-mRNA in PRH due to TCDD-treatment indicated a concentration-response-
relationship in sigmoid manner (figure 62). Correspondent fitted curve passed an EC50 of   
1.03*10-10(±3.28*10-11) M TCDD and was asymptotically limited at 16.4(±1.4)-fold induction. 20% 
of maximum induction (3.28-fold) was obtained with 2.94*10-11 M TCDD.  
Regarding statistical aspects, very significant (p-value < 0.01; One-way ANOVA with Dunnett’s 
post test; control vs. treatments) Cyp1a2-inductions were gained using ≥5*10-10 M TCDD 
(≤19.0±11.4-fold).  
 
Slightly orientated to lower concentrations, the sigmoid depicting 1-PeCDD’s effects on Cyp1a2-
mRNA in PRH exhibited a slightly flattened ascent and approached an asymptote at 14.1(±0.8)-fold 
induction. EC50 accounted for 4.91*10-11(±1.61*10-11) M 1-PeCDD, whereby EC20 scored 
PRH – qRT-PCR Cyp1a2 
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8.40*10-12 M 1-PeCDD. Respective REPs amounted to 2.1 (REP (EC 50), and 3.5 (REP (EC20)). 
Statistically significant (p-value < 0.05) Cyp1a2-induction of 7.5(±0.8)-fold was yielded with   
5*10-11 M 1-PeCDD, and very significant (p-value < 0.01) values, beginning from 10-10 M             
1-PeCDD, achieved up to 15.6(±3.1)-fold induction.  
Thus, compared to TCDD, 1-PeCDD manifested slightly lower (~15%) efficacy towards PRH, but 
higher potency according to revealed REPs.  
 
Transferred about one order of magnitude to higher concentrations (REP (EC50): 0.13), and 
furthermore showing less ascent, the sigmoid curve displaying effects of 4-PeCDF on Cyp1a2-
mRNA ran through an EC50 of 7.84*10-10(±1.89*10-10) M 4-PeCDF, and yielded an upper level at 
14.0(±0.9)-fold induction, representing an efficacy equal to 1-PeCDD’s. EC20-level was cut at 
7.55*10-11 M 4-PeCDF, generating a REP (EC20) of 0.39.  
Statistically, values regarded significant (p-value < 0.05), and very significant (p-value < 0.01), 
were obtained by use of 10-9 M 4-PeCDF (8.2±4.3-fold), and from 5*10-9-10-8 M 4-PeCDF (up to 
12.2±4.7-fold), respectively.  
 
Ascending in comparable extent, but shifted about one order of magnitude to higher concentrations 
regarding EC50 (7.19*10-9±5.55*10-9 M PCB 126), the concentration-response curve illustrating 
PCB 126’s Cyp1a2-inducing effects gained around 40% greater efficacy (19.6±2.0-fold) than did  
4-PeCDF. Calculated EC20 was 9.37*10-11 M PCB 126. REPs representing potencies relative to 
TCDD accounted for 0.31 (REP (EC20)), and 0.014 (REP (EC50), whereas PCB 126 yielded 
almost 20% higher efficacy than TCDD.  
Due to comparatively high standard deviations, statistically significant (p-value < 0.05) Cyp1a2-
induction of 19.3(±14.4)-fold was given with 10-6 M PCB 126.  
 
With respect to effects of PCB 156, incubation of PRH with this compound led to Cyp1a2-
induction on mRNA-level in a concentration-dependent manner, apart from a slightly steeper slope 
resembling the TCDD-derived sigmoid, but located approximately three orders of magnitude at 
higher concentrations. EC50 scored 7.79*10-8(±6.14*10-9) M PCB 156, revealing a REP (EC50) of 
0.0013. Upper asymptote lay at 13.8(±0.5)-fold induction, implying efficacy similar to 4-PeCDF’s, 
or PCB 126’s. The curve crossed the EC20-level with 5.15*10-8 M PCB 156, revealing a REP 
(EC20) of 0.00057.  
Respecting statistical analysis, PCB 156-concentrations beginning from 10-7 M (10.4±4.1-fold) very 
significantly (p-value < 0.01) induced Cyp1a2.  
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Due to minor potency of PCB 118 to induce Cyp1a2 in PRH within 24 h and tested range of 
concentration, only an initiating exponential course of increase was examined. Polynomial fitting 
unveiled an EC20 of 3.16*10-7 M PCB 118, respecting a REP (EC20) of 0.000093, hence 
extrapolating more than four orders of magnitude lesser potency of PCB 118 compared to TCDD’s. 
Statistically, testing 10-6 M PCB 118, the Cyp1a2-induction amounting to 6.5(±4.2)-fold was 
regarded significant (p-value < 0.05).  
 
PCB 153 showed no Cyp1a2-induction accessible via qRT-PCR measurements towards PRH under 
present test conditions.  
 
4.2.3.2.8. QRT-PCR primary rat hepatocytes – Cyp1b1 
 
Results of qRT-PCR-analysis regarding Cyp1b1 in PRH incubated with core congeners for 24 h are 
compiled in figure 63. 
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Figure 63: QRT-PCR (Cyp1b1) PRH. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,       
PCB 153, or PCB 156 for 24 h. Abscissa (logarithm.): Concentration (M); ordinate: Fold induction (referred to 
β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum response (153-fold). Results from 
at least three independent experiments each. 
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Incubation of PRH with TCDD led to a concentration-dependently increasing level of Cyp1b1-
mRNA (figure 63). The respective sigmoid comprised a steep slope, ran through an EC50 of 
2.91*10-10(±3.68*10-11) M TCDD, and yielded maximal effects of 765.8(±29.4)-fold induction. 
EC20, which crossed an induction-level of 153-fold, accounted for 1.38*10-10 M TCDD. 
Considering statistical aspects, very significant (p-value < 0.01; One-way ANOVA with Dunnett’s 
post test; control vs. treatments) Cyp1b1-inductions from 5*10-10 M TCDD (532.5±258.3-fold) 
were emphasized.  
 
Comparing these findings with 1-PeCDD-affected mRNA-levels in PRH, the sigmoid illustrating 
Cyp1b1-induction depicted a lightly less steep ascent approaching an asymptote at       
714.9(±52.0)-fold converging to the TCDD-derived upper level. EC50 amounted to              
5.98*10-10(±1.29*10-10) M 1-PeCDD, revealing a REP (EC50) of 0.49, whereas EC20 scored 
1.97*10-10 M 1-PeCDD, yielding a REP (EC20) of 0.70.  
Statistically significant (p-value < 0.05) Cyp1b1-inductions were obtained with 5*10-10 to 10-9 M   
1-PeCDD, and very significant (p-value < 0.01) effects of up to 685.4(±115.7)-fold were given with 
5*10-9-10-8 M 1-PeCDD.  
 
With regard to TCDD’s sigmoid, the curve reflecting impact of 4-PeCDF on Cyp1b1 in PRH was 
transferred about one third order of magnitude to higher concentrations, and possessed an EC50 of 
8.57*10-10(±5.73*10-11) M 4-PeCDF (REP (EC50): 0.34), reaching up to 518.4(±15.0)-fold 
induction. Hence affording about 30% lower efficacy than TCDD, treatment of PRH with 4-PeCDF 
disclosed an EC20 of 5.83*10-10 M 4-PeCDF and a correspondent REP (EC20) of 0.24.  
Statistically relevant were very significant (p-value < 0.01) deviations from control samples 
(DMSO 0.1%, not shown) starting from 10-9 M 4-PeCDF (301.3±122.6-fold) with respect to 
Cyp1b1-induction.  
 
In contrast to TCDD-derived concentration-response curve, the sigmoid displaying PCB 126’s 
impact on Cyp1b1-mRNA-levels was shifted about one order of magnitude to higher 
concentrations, slightly surpassing TCDD’s upper level with maximally 795.3(±15.5)-fold 
induction. Assigned EC50 was 3.63*10-9(±5.09*10-10) M PCB 126 (REP (EC50): 0.080), whereas 
EC20-level was cut with 1.47*10-10 M PCB 126, revealing a REP (EC20) of 0.094.  
From 10-8 M PCB 126 (665.3±197.4-fold), statistically very significant (p-value < 0.01) Cyp1b1-
inductions were obtained in PRH.  
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Minor efficacy of PCB 156 towards Cyp1b1-induction on mRNA-level led to a flat sigmoid curve 
distinctly lying below the EC20-level. Upper asymptote yielded 65.6(±1.8)-fold induction, 
indicating more than 90% less efficacy than TCDD, whereas potency referring to EC50      
(1.10*10-7±7.34*10-9 M PCB 156) accounted for 0.0026 (REP (EC50).  
Statistically significant Cyp1b1-induction in PRH was obtained for 5*10-7-10-6 M PCB 156 scoring 
62.4(±48.1)-68.8(±44.0)-fold (p-value < 0.01).  
 
In tested concentrations, PCB 118 led to marginal increase of Cyp1b1-mRNA in PRH after 24 h. 
From statistical point of view, significant (p-value < 0.05) deviation from control was obtained with 
5*10-7 M PCB 118 (2.6±1.1-fold), whereby very significant enhancement using 10-6 M PCB did not 
exceed (3.4±0.6)-fold induction (p-value < 0.01).  
 
NDL-PCB 153 did not alter Cyp1b1-mRNA-levels in PRH within 24 h and applied range of 
concentration (5*10-9-10-6 M PCB 153). 
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4.2.3.2.9. QRT-PCR primary rat hepatocytes – Aldh3a1 
 
QRT-PCR results focusing Aldh3a1 and analysis of PRH incubated with core congeners for 24 h 
are diagramed in figure 64. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: QRT-PCR (Aldh3a1) PRH. Cells treated with TCDD, 1-PeCDD, 4-PeCDF, PCB 118, PCB 126,      
PCB 153, or PCB 156 for 24 h. Axes with varying scales. Abscissae (logarithm.): Concentration (M); ordinates: 
Fold induction (referred to β-actin mRNA-levels). EC20-level represents 20% of TCDD-induced maximum 
response (859-fold). Results from at least three independent experiments each.  
 
Concentration-dependent increase of Aldh3a1 due to TCDD-treatment for 24 h was highly 
responsive in PRH, revealing a sigmoid function, which comprised a steep slope and approached 
4293.6(±446.6)-fold induction (figure 64). Passed EC50 amounted to 2.41*10-10(±9.16*10-11) M 
TCDD, and the EC20-level of 859-fold induction led to an EC20 of 1.24*10-10 M TCDD.  
From statistical point of view, very significant (p-value < 0.01; One-way ANOVA with Dunnett’s 
post test; control vs. treatments) enhancement of Aldh3a1-mRNA-levels was obtained from      
5*10-10 M TCDD (3134.1±2373.0-fold).  
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Concentration-dependent Aldh3a1-induction in PRH by 1-PeCDD described a course with slightly 
lower degree of ascent. Fitted sigmoid implicated an EC50 of 7.71*10-10(±7.05*10-11) M 1-PeCDD 
(REP (EC50): 0.31), and an upper asymptote at 4180.1(±144.7)-fold induction.  
Statistically significant value was indicated with 10-9 M 1-PeCDD (1661.0±453.9-fold;                  
p-value < 0.05), whereas from 5*10-9 M 1-PeCDD (2300.0±74.3-fold), very significant Aldh3a1-
inductions were obtained (p-value < 0.01). EC20-level was crossed with 2.72*10-10 M 1-PeCDD, 
bringing forth a REP (EC20) of 0.46.  
 
4-PeCDF led to concentration-dependent increase of Aldh3a1-mRNA-levels in PRH indicating a 
sigmoid manner, although under test conditions, upper induction limit was not reached yet. 
Assuming that 4-PeCDF’s properties would not exceed TCDD’s efficacy, sigmoid fitting revealed 
an EC50 of 2.55*10-9(±1.34*10-10) M 4-PeCDF, corresponding to a REP (EC50) of 0.094.         
REP (EC20) added up to 0.17, calculated by an EC20 of 7.35*10-10 M 4-PeCDF.  
Statistically significant (p-value < 0.05) Aldh3a1-induction of 1145.4(±477.1)-fold was gained with 
10-9 M 4-PeCDF, and very significant (p-value < 0.01) values were examined from 5*10-9 M         
4-PeCDF (2786.5±943.4-fold).  
 
Providing an around 1.5 orders of magnitude lesser potency than TCDD based on REPs            
(REP (EC50): 0.055; REP (EC20): 0.043), the sigmoid reflecting Aldh3a1-inducing effects by   
PCB 126 approximated an upper level at (2541.2±76.0)-fold induction, implying an efficacy of the 
compound about 60% of TCDD’s. Respective EC50 scored 4.37*10-9(±9.43*10-10) M PCB 126, 
and EC20 amounted to 2.90*10-9 M PCB 126.  
Starting from 10-8 M PCB 126, and 2015.4(±244.0)-fold induction, statistically very significant 
elevation of Aldh3a1-mRNA-levels was obtained (p-value < 0.01).  
 
PCB 156 affected transcription of gene encoding ALDH3A1 in concentration-dependent, sigmoid 
manner, revealing almost three orders of magnitude lower potency compared to TCDD. Yielding 
minor efficacy among tested compounds, sigmoid’s upper asymptote approached 329.3(±38.0)-fold 
induction. Hence, rendering less than 10% of TCDD’s efficacy, EC20-level of 859-fold induction 
was not achieved. EC50 scored 9.09*10-8(±2.77*10-8) M PCB 156, implying a REP (EC50) of 
0.0026.  
Statistical analysis characterized Aldh3a1-induction in PRH of 219.7(±91.7)-fold due to usage of 
10-7 M PCB 156 as significant (p-value < 0.05), and very significant from 5*10-7 M PCB 156 
(263.4±58.9-fold; p-value < 0.01).  
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Incubation of PRH with PCB 118 led to a slight concentration-dependent increase of Aldh3a1-
mRNA-levels adding up to 15.8(±13.4)-fold induction with 5*10-7 M PCB 118, yielding 
statistically significant value of 37.6(±23.4)-fold testing the highest concentration of 10-6 M       
PCB 118.  
 
Aldh3a1-mRNA-levels in PRH treated with PCB 153 for 24 h (5*10-9-10-6 M PCB 153) remained 
indistinguishable from those of solvent controls.  
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4.2.3.2.10. QRT-PCR primary rat hepatocytes – summary 
 
Table 49 summarizes QRT-PCR results concerning impact of core congeners on the genes CYP1A1, 
CYP1A2, CYP1B1, and ALDH3A1 in PRH. Obtained EC20-, and EC50-values and corresponding 
REPs are collated and compared to WHO-TEFs from 2005 (Van den Berg et al., 2006). 
 
Table 49: EC50-, EC20-values and respective REPs derived from qRT-PCR analysis (Cyp1a1, Cyp1a2, Cyp1b1, 
Aldh3a1) with PRH subsequent to incubation with core congeners for 24 h compared to WHO-TEFs (Van den 
Berg et al., 2006). 
PRH 
 
EC50 (M) REP (EC50) EC20 (M) REP (EC20) WHO-TEF 
(2005) 
Cyp1a1      
TCDD 6.94E-11 1 1.78E-11 1 1 
1-PeCDD 3.45E-11 2.0 1.25E-11 1.4 1 
4-PeCDF 1.25E-10 0.56 3.73E-11 0.48 0.3 
PCB 126 1.10E-09 0.063 7.28E-11 0.24 0.1 
PCB 118   7.62E-07 0.000023 0.00003 
PCB 156 7.61E-08 0.00091 4.64E-08 0.00038 0.00003 
PCB 153     - 
      
Cyp1a2   
  
 
TCDD 1.03E-10 1 2.94E-11 1 1 
1-PeCDD 4.91E-11 2.1 8.40E-12 3.5 1 
4-PeCDF 7.84E-10 0.13 7.55E-11 0.39 0.3 
PCB 126 7.19E-09 0.014 9.37E-11 0.31 0.1 
PCB 118   3.16E-07 0.000093 0.00003 
PCB 156 7.79E-08 0.0013 5.15E-08 0.00057 0.00003 
PCB 153     - 
      
Cyp1b1   
  
 
TCDD 2.91E-10 1 1.38E-10 1 1 
1-PeCDD 5.98E-10 0.49 1.97E-10 0.70 1 
4-PeCDF 8.57E-10 0.34 5.83E-10 0.24 0.3 
PCB 126 3.63E-09 0.080 1.47E-09 0.094 0.1 
PCB 118     0.00003 
PCB 156 1.10E-07 0.0026   0.00003 
PCB 153     - 
      
Aldh3a1   
  
 
TCDD 2.41E-10 1 1.24E-10 1 1 
1-PeCDD 7.71E-10 0.31 2.72E-10 0.46 1 
4-PeCDF 2.55E-09 0.094 7.35E-10 0.17 0.3 
PCB 126 4.37E-09 0.055 2.90E-09 0.043 0.1 
PCB 118     0.00003 
PCB 156 9.09E-08 0.0026   0.00003 
PCB 153     - 
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4.2.3.2.11. QRT-PCR H4IIE vs. QRT-PCR PRH – summary 
 
Figure 65 compares qRT-PCR results for Cyp1a1, Cyp1a2, Cyp1b1, and Aldh3a1 regarding TCDD-
treatment of H4IIE to respective results concerning PRH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65: QRT-PCR (Cyp1a1, Cyp1a2, Cyp1b1, Aldh3a1) H4IIE vs. PRH. Cells treated with TCDD for 24 h. 
Axes with varying scales. Abscissae (logarithm.): Concentration (M); ordinates: Fold induction (referred to       
β-actin mRNA-levels). Results from four independent experiments each. 
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Contrasting effects on Cyp1a1 in H4IIE cells with impact on Aldh3a1 in PRH by means of qRT-
PCR measurements (figure 65), TCDD-treatment yielded comparable efficacy but almost 1.5 orders 
of magnitude lower potency (REP [Cyp1a1 (H4IIE)/ Aldh3a1 (PRH)]: 0.064). Similar findings, but 
extenuated regarding differing potencies [REP Cyp1b1 (H4IIE)/Cyp1a1 (PRH): 0.25] were obtained 
comparing Cyp1b1 (H4IIE) with Cyp1a1 (PRH). Further correlation was indicated between 
TCDD’s efficacy towards Cyp1a2, and Aldh3a1 in H4IIE cells, where measured upper induction 
limits lay close together.  
 
Focusing TCDD’s efficacy in both liver cell systems in general, impact on Cyp1a1, or Cyp1a2 was 
higher in H4IIE cells compared to PRH, whereas concerning Cyp1b1, or Aldh3a1, TCDD-treatment 
yielded greater efficacy in PRH than in H4IIE cells. Ranking order of TCDD-yielded efficacies in 
total was 
Cyp1a1 (H4IIE) ≈ Aldh3a1 (PRH) >> Cyp1b1 (PRH) >> Cyp1b1 (H4IIE) ≈ Cyp1a1 (PRH)  
> Cyp1a2 (H4IIE) ≥ Aldh3a1 (H4IIE) > Cyp1a2 (PRH),  
regarding treatment of cells for 24 h under present test conditions.  
 
Taking account of relative potencies regarding attained EC-values, TCDD constantly revealed 
higher potency towards H4IIE cells compared to its impact on PRH. With this regard, contrasting 
EC-values for all genes among each other, REPs (H4IIE/PRH) were consistently below 1. 
Exceptions of this outcome, whereat TCDD’s efficacy was situated conversely, were received 
considering subsequent potencies in descending order:  
REP (EC20) [Aldh3a1 (H4IIE)/ Cyp1a1 (PRH)]: 2.12,  
REP (EC20) [Aldh3a1 (H4IIE)/ Cyp1a2 (PRH)]: 1.28,  
REP (EC50) [Aldh3a1 (H4IIE)/ Cyp1a1 (PRH)]: 1.16. 
 
Comparing impact on same genes in different cell systems, a ranking order regarding degree of 
distinction between cell systems and respective EC50-values of  
REP [Cyp1b1 (H4IIE/PRH): 0.060] > REP [Cyp1a2 (H4IIE/PRH): 0.10]  
> REP [Cyp1a1 (H4IIE/PRH): 0.060] > REP [Aldh3a1 (H4IIE/PRH): 0.33] was obtained.  
 
With respect to EC20-values, similar ranking order was established:  
REP [Cyp1b1 (H4IIE/PRH): 0.071] > REP [Cyp1a2 (H4IIE/PRH): 0.073]  
> REP [Aldh3a1 (H4IIE/PRH): 0.30] > REP [Cyp1a1 (H4IIE/PRH): 0.38].  
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REPs (H4IIE/PRH) concerning EC50-values scored from  
0.035 (REP [Cyp1a2 (H4IIE)/ Cyp1b1 (PRH)]) to  
0.78 (REP [Aldh3a1 (H4IIE)/ Cyp1a2 (PRH)]), whereas regarding EC20-values, REPs ranged from 
0.016 (REP [Cyp1a2 (H4IIE)/ Cyp1b1 (PRH)]) to  
0.55 (REP [Cyp1b1 (H4IIE)/ Cyp1a2 (PRH)]).  
 
Assessed based on EC50-values, responsivity of genes beginning with lowest TCDD-concentrations 
ranked from  
EC50 (Cyp1a2 H4IIE) < EC50 (Cyp1a1 H4IIE) < EC50 (Cyp1b1 H4IIE) < EC50 (Cyp1a1 PRH)  
< EC50 (Aldh3a1 H4IIE) < EC50 (Cyp1a2 PRH) < EC50 (Aldh3a1 PRH) < EC50 (Cyp1b1 PRH). 
 
Responsivity regarding EC20-values rated  
EC20 (Cyp1a2 H4IIE) < EC20 (Cyp1a1 H4IIE) < EC20 (Cyp1b1 H4IIE) < EC20 (Cyp1a1 PRH)  
< EC20 (Cyp1a2 PRH) < EC20 (Aldh3a1 H4IIE) < EC20 (Aldh3a1 PRH) < EC20 (Cyp1b1 PRH). 
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An assembly of REPs obtained by qRT-PCR analysis with H4IIE cells and PRH is compared to 
current WHO-TEFs from 1005 in table 50 (Van den Berg et al., 2006). 
 
Table 50: REPs derived from qRT-PCR measurements with PRH and H4IIE cells subsequent to incubation with 
core congeners for 24 h compared to WHO-TEFs (Van den Berg et al., 2006). 
QRT-PCR 
 
REP (EC50) 
pRH 
REP (EC50) 
H4IIE 
REP (EC20) 
pRH 
REP (EC20) 
H4IIE 
WHO-TEF 
(2005) 
Cyp1a1      
TCDD 1 1 1 1 1 
1-PeCDD 2.0 0.63 1.4 0.69 1 
4-PeCDF 0.56 1.0 0.48 0.85 0.3 
PCB 126 0.063 0.14 0.24 0.086 0.1 
PCB 118   0.000023  0.00003 
PCB 156 0.00091 0.00019 0.00038 0.000089 0.00003 
PCB 153     - 
      
Cyp1a2   
 
 
 
TCDD 1 1 1 1 1 
1-PeCDD 2.1 0.76 3.5 0.19 1 
4-PeCDF 0.13 0.57 0.39 0.22 0.3 
PCB 126 0.014 0.095 0.31 0.024 0.1 
PCB 118   0.000093  0.00003 
PCB 156 0.0013 0.00011 0.00057 0.000042 0.00003 
PCB 153     - 
      
Cyp1b1   
 
 
 
TCDD 1 1 1 1 1 
1-PeCDD 0.49 0.49 0.70 0.98 1 
4-PeCDF 0.34 0.18 0.24 0.93 0.3 
PCB 126 0.080 0.071 0.094 0.15 0.1 
PCB 118     0.00003 
PCB 156 0.0026 0.00019  0.00012 0.00003 
PCB 153     - 
      
Aldh3a1   
 
 
 
TCDD 1 1 1 1 1 
1-PeCDD 0.31 0.76 0.46 0.66 1 
4-PeCDF 0.094 0.50 0.17 0.75 0.3 
PCB 126 0.055 0.052 0.043 0.042 0.1 
PCB 118     0.00003 
PCB 156 0.0026 0.00041  0.00016 0.00003 
PCB 153     - 
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Throughout tested core congeners, differing properties in particular regarding responsiveness 
towards H4IIE-cells and PRH explained above for TCDD emerged by trend for 1-PeCDD,             
4-PeCDF, and PCB 126 (table 50). 
Comparing impact on same genes in different cell systems, comparable findings as revealed for 
TCDD were obtained concerning 1-PeCDD, 4-PeCDF, or PCB 126, revealing higher potency 
towards H4IIE cells compared to its effect on PRH. With this regard, contrasting EC-values for all 
genes among each other, REPs (H4IIE/PRH) were consistently below 1, involving exceptionally 
higher potency of 1-PeCDD regarding Cyp1a2 (REP EC20 1-PeCDD [Cyp1a2 (H4IIE/PRH): 1.4]), 
and of 4-PeCDF towards PRH regarding Cyp1a1 than in H4IIE                                                   
(REP EC20 PCB 126 [Cyp1a1 (H4IIE/PRH): 1.1]). 
 
1-PeCDD revealed potency comparable to TCDD’s, gaining the lowest among examined genes 
concerning Aldh3a1 with a REP (EC50) of 0.31. Excepting Cyp1a1, and Cyp1a2 in PRH, 1-PeCDD 
yielded higher potency than TCDD. In general, 1-PeCDD’s efficacy approached TCDD’s, but with 
respect to Cyp1a1, and Cyp1a2 in PRH, or Cyp1a2, and Aldh3a1 in H4IIE, the congener attained 
lightly lower efficacy than TCDD. In contrast, 1-PeCDD was more efficient regarding Cyp1a1, and 
Cyp1b1 in H4IIE cells compared to TCDD. 
 
Except for its impact on Cyp1a1 in H4IIE cells (REP (EC50): 1.0), 4-PeCDF attained slightly lower 
potency than TCDD, accomplishing REPs of 0.094 (REP (EC50), Aldh3a1 PRH) at the least.         
4-PeCDF’s efficacy tended to approach TCDD’s efficacy regarding Aldh3a1 (H4IIE, PRH), and 
Cyp1b1 in H4IIE cells, but revealed lightly lower efficacy concerning remained genes in both cell 
types.  
 
Deriving still less potency, PCB 126 yielded REPs scoring from 0.014 (REP (EC50) Cyp1a2, PRH) 
to 0.31 (REP (EC20) Cyp1a2 PRH). By trend achieving efficacy comparable to TCDD’s         
(PRH: Cyp1a1, Cyp1a2, Cyp1b1; H4IIE: Cyp1b1), lower efficacy of PCB 126 was received 
concerning Aldh3a1 (H4IIE, PRH), Cyp1a1 (H4IIE), and Cyp1a2 (H4IIE).  
 
Responsivity of liver cell systems due to PCB 156-incubation differed from those of TCDD or 
previously described core congeners. Assessed based on EC50-values, responsiveness of genes 
beginning with lowest PCB 156-concentrations ranked from  
EC50 (Cyp1a1 PRH) < EC50 (Cyp1a2 PRH) < EC50 (Cyp1a1 H4IIE) < EC50 (Cyp1a2 H4IIE)  
= EC50 (Aldh3a1 PRH) < EC50 (Cyp1b1 H4IIE) < EC50 (Cyp1b1 PRH) < EC50 (Aldh3a1 H4IIE).  
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Overall, deviation of PCB 156’s EC50-values, which lay close together, ranged from           
7.61*10-8 M PCB 156 (EC50 (Cyp1a1 PRH)) to 1.95*10-7 M PCB 156 (EC50 (Aldh3a1 H4IIE)). 
This contrasted with effects induced by TCDD, whose EC50-values comprised an about one order 
of magnitude wider range of concentration.  
Comparing impact on same genes in different cell systems, except for REP (EC50) Cyp1b1      
(REP EC50 PCB 156 [Cyp1b1 (H4IIE/PRH): 0.83]), potency attained by PCB 156 was higher 
towards PRH than in H4IIE cells, consistently resulting in REPs (H4IIE/PRH) ≥ 1. According to 
these findings, PCB 156 revealed higher potency towards PRH, which was even accompanied by 
efficacies comparable to TCDD’s regarding Cyp1a1, and Cyp1a2.  
Controversially, mRNA-levels of Cyp1b1, and Aldh3a1 in PRH were marginally affected by     
PCB 156 and yielded less than 10% of TCDD’s efficacy, hence retaining below corresponding 
EC20-levels. Regarding H4IIE cells, depending on respective genes, PCB 156 gained 34-65% of 
TCDD’s efficacy (Cyp1a1, Cyp1b1, Aldh3a1), whereas Cyp1a2 in H4IIE was equally efficiently 
affected by PCB 156 than by TCDD. 
 
So far, core congeners induced gene transcription in present liver cell systems in sigmoid manner, 
whereas DL-PCB 118 in tested range of concentrations of up to 10-6 M PCB 118 comparably led to 
minor effects within 24 h of incubation.  
Slightly increasing mRNA-levels in PRH beginning from 0.44% (Cyp1b1), over 0.88% of 
maximum TCDD-induced response for Aldh3a1, PCB 118-derived effects initially trespassed 
respective EC20-level at 21.6% (Cyp1a1), and culminated in maximal effects regarding Cyp1a2 
yielding 39.9% of TCDD’s maximum response. Cyp1a1 in H4IIE cells was slightly affected 
(0.47%) by PCB 118, which was closely followed by effects on Cyp1b1, accomplishing 2.2% of 
TCDD’s upper limit.  
With respect to Cyp1a2, and Aldh3a1 in H4IIE cells, response due to PCB 118-treatment was 
absent under given test conditions.  
 
Incubation with NDL-PCB 153 did not modify mRNA-levels of tested genes in both used liver cell 
systems.  
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4.3. In vitro investigations using human PBMCs 
 
In order to gain information on potential impact of TCDD on cells of the immune system, freshly 
isolated primary human PBMCs were exposed to the compound. After characterization of applied 
cells by flow cytometry and subsequent incubation for 24 h in presence or in absence of a defined 
stimulus, mRNA of cells was isolated and investigated by use of whole genome microarray 
experiments as well as qRT-PCR. Aim of these examinations was to presumably disclose TCDD’s 
mechanism(s) and mode(s) of action towards these immune cells and to identify possible overlap(s) 
with genes identified by mouse whole genome microarray analysis. Such observations could help 
understanding TCDD’s immunotoxic effects and the role of the AhR in this regard, and might be 
feasible in view of a future establishment of potential novel biomarker(s). 
 
4.3.1. Characterization of PBMCs by Flow Cytometry 
 
Freshly isolated human PBMCs from four individuals were analyzed by means of flow cytometry 
(BD FACSCanto II, BD Biosciences, Heidelberg, Germany) in order to gain an insight into the 
composition of obtained cell suspensions.  
Using monoclonal antibodies specifically binding CD3, CD19, or CD14 on the surface of cells, 
definite subsets of cells were identified as T lymphocytes (CD3+), B lymphocytes (CD19+), or 
monocytes/macrophages (CD14+).  
Cell populations were identified per forward scatter (FSC)/sideward scatter (SSC) dot blots 
according to their properties regarding cell size (FSC) and granularity (SSC). In figure 66, an 
exemplary dot plot for a flow cytometric analysis of freshly isolated human PBMCs is presented.  
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Figure 66: FACS analysis. Dot plot obtained by measurement of human PBMCs; FSC plotted against SSC. Two 
populations of cells were identified: PBMC subset I (80.9%), and PBMC subset II (10.1%). Sample from 
individual 2 (male). 10,000 events. Threshold count: 20,000. 
 
As exemplarily shown in figure 66, two obvious populations of cells were identified by view on dot 
plots during FACS measurement of PBMCs.  
A first subset of cells (‘PBMC subset I’) represented around 80% of sample particles analyzed by 
the flow cytometer. According to measured intensities for FSC and SSC, cells’ properties added up 
to comparably low size and granularity, as compared to the second population of cells (‘PBMC 
subset II’). This population accounted for about 10% of 10,000 events measured in total. Cell debris 
and other particles of smaller size and of low granularity constituted the majority of the remaining 
10%. A few single events detected at higher levels for FSC and SSC might indicate scattered 
neutrophiles and/or granulocytes.  
Proportions ranged from around 72 to 90% for PBMC subset I and from 5 to 16% for PBMC subset 
II of totally measured events. There was no gender-specific significant difference between samples 
from male and female individuals.  
 
By means of specifically binding monoclonal antibodies and flow cytometry, CD3+-, CD19+-, or 
CD14+-cells were identified within the two populations PBMC subset I and II. Figure 67 
exemplarily shows verifications of CD3+-, and CD19+-cells.  
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Figure 67: FACS analysis. Histograms (I) obtained by measurement of human PBMCs treated with antibodies. 
Relative fluorescence units (RFU; APC) logarithmically plotted against number of cells exhibiting respective 
fluorescence intensity. CD3+-cells (left, light blue), and CD19+-cells (right, light blue), plus respective isotyp 
control (IgG1, κ; red). Relative frequencies within parent cell subsets and median APC-values shown in legends. 
Samples from individual 4 (female). 10’000 events each. Threshold count: 20,000. 
 
For exclusion and hence implication of yet emergent non-specific binding of antibodies, cells were 
exposed to respective isotyp control antibodies; IgG1, κ in case of CD3-, and CD19-antibodies. 
Relative fluorescence units (RFUs) were plotted as histograms versus those obtained by 
measurement of CD3-, or CD19-stained cells (figure 67). Occurring with diverging frequence, 
RFUs of both CD3-, and CD19-antibody-stained cells were shifted to great extent to higher 
fluorescence intensities (more than 10,000 each, light blue) compared to cells stained with isotyp 
control antibody (median APC-A: 50, red). Among samples from individuals, ∆RFUs ranged from 
8,300 to 28,000 for CD3+-stained cells, and from 4,100 to 21,000 for CD19+-stained cells.  
 
CD3+-cells represented around three quarters of PBMC subset I (‘frequ. of parent’), which itself 
represented around three quarters of the total amount of particles measured by the flow cytometer 
each sample. CD19+-cells were present to a lower extent, accounting for around 5% of PBMC 
subset I.  
With respect to the whole flow cytometry experiment, proportions of CD3+-cells within PBMC 
subset I ranged from 70 to 87%, whereas proportions of CD19+-cells within PBMC subset I ranged 
from 4 to 7%.  
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In figure 68, an example for the characterization of CD14+-cells within freshly isolated human 
PBMCs is illustrated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: FACS analysis. Histogram (II) obtained by measurement of human PBMCs treated with antibodies. 
Relative fluorescence units (RFU; APC) logarithmically plotted against number of cells exhibiting respective 
fluorescence intensity. CD14+-cells (light blue), plus respective isotyp control (IgG2a, κ; red). Relative frequencies 
within parent cell subsets and median APC-values shown in legend. Samples from individual 4 (female).     
10,000 events each. Threshold count: 20,000. 
 
Figure 68 represents a typical histogram obtained by measurement of CD14+-cells within isolated 
PBMC-suspension. CD14+-cells were located within PBMC subset II to around 70%, and the shift 
to greater RFU-values compared to required isotyp control (IgG2a, κ) measurement amounted to 
about 4,000. Dependent on the individual, ∆RFUs ranged from around 4,000 to 11,000 for 
characterization of CD14+-cells without gender-specific differences.  
Frequency of CD14+-cells within PBMC subset II accounted for 81-98% throughout the complete 
FACS analysis.  
 
Taken together, yielding 1.2 (±0.5)*106 cells/mL blood, obtained PBMC-suspensions, which were 
used for further gene expression measurements, constituted of 70 (±12)% CD3+-cells                     
(T lymphocytes), 6.0 (±1.0)% CD19+-cells (B lymphocytes), and 10 (±3)% CD14+-cells 
(monocytes/macrophages).  
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4.3.2. Human whole genome microarray analysis 
 
Freshly isolated and characterized human PBMCs composed of 70 (±12)% CD3+-cells, 6.0 (±1.0)% 
CD19+-cells, and 10 (±3)% CD14+-cells, were exposed to either TCDD alone (10 nM TCDD), 
TCDD and LPS (10 nM TCDD + 1 µg/mL LPS), or TCDD combined with PHA (10 nM TCDD + 
1.5% PHA) for 24 h, corresponding to control treatments (DMSO 0.1%; 1 µg/mL LPS; 1.5% PHA). 
Subsequently, mRNA was isolated and checked on integrity (2100 Bioanalyzer, Agilent 
Technologies GmbH, Waldbronn, Germany), and two-color microarray-based gene expression 
analysis was perfomed applying Human GE 4x44K v2 Microarray Kits (Agilent Technologies 
GmbH, Waghaeusel-Wiesental, Germany) by implementation of dye-swop procedures to reduce 
potential artifactual effects due to diverging dye properties. Data normalization and statistical 
analyses were performed using Bioconductor R package Limma (Smyth, 2004). Results were 
filtered by cutoff values for signal intensity A ≥ 27, logarithmic (log2) fold change │lfc│ ≥ 1, and 
p-value < 0.05.  
 
4.3.2.1. Principal component analysis 
 
An initial step examining microarray data was represented by view on principal component analysis 
(PCA). By clustering of information to reduce data dimensionality, a first insight into identification 
of general properties of individual samples was enabled by this method. 
 
In figure 69 (following page), PCA-results concerning human whole genome microarray analysis 
and effects of TCDD alone, TCDD + LPS, or TCDD + PHA on gene expression in vitro in human 
PBMCs are presented. 
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Figure 69: PCA human whole genome microarray analysis (human primary PBMCs, in vitro, 24 h, n = 4). 
Examination of RNA from human PBMCs treated with TCDD (light green), TCDD + LPS (red), or TCDD + 
PHA (yellow), focusing on treatment groups (left), and individuals (right; green: individual 1 (female, f); pink: 
individual 2 (male, m); orange: individual 3 (m), blue: individual 4 (f)). 3D scatter plot view of data with respect 
to their correlation to the first three principal components (PC1-3). 
 
Presented PCA-results focused on different treatment groups (left, figure 69) and individuals (right, 
figure 69). Among treatment groups (light green, red, and yellow colored), the clustering of 
principal components appeared limited. Treatment with TCDD + PHA (yellow) or with TCDD 
alone (light green) to lightly lesser extent, slightly contrasted with the treatment TCDD + LPS (red). 
Inter-individual differences obviously emerged in reference to the image on the right hand side in 
figure 69.  
By view on these PCA results, individual 4 (f) diverged most significantly from the other 
individuals, indicating to represent an explicit outlier. Closer examinations of raw data led to the 
conclusion to discard individual 4 from most of further investigations of the microarray analysis, as 
corresponding results differed greatly from individuals 1, 2, and 3, even if taking account of 
considerable present inter-individual differences overall. Though a reduction of sample size was 
implied by this decision, it was an important one to enforce from both statistical and biological 
point of view, in order to improve relevance of data regarding the complete human whole genome 
microarray experiment. 
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4.3.2.2. Human whole genome microarray analysis – regulated genes 
 
Three treatment groups (in vitro for 24 h) were investigated by whole genome microarray analysis 
of human PBMCs: TCDD (10 nM), TCDD+LPS (10 nM TCDD + 1 µg/mL LPS), or TCDD+PHA 
(10 nM TCDD + 1.5% PHA). The analysis was prepared by direct, internal correlation of treatment 
on control samples, whereas respective mRNA was obtained from PBMCs treated with either the 
solvent (DMSO 0.1%), or respective stimulus (1 µg/mL LPS, or 1.5% PHA).  
 
As indicated in preceding chapter, considerable inter-individual differences were revealed by whole 
genome investigations. Hence, data was not analyzed globally, as it was carried out regarding 
mouse whole genome microarrays. Still, if setting identical cutoff criteria as for the mouse whole 
genome microarray experiment (logarithmic (log2) fold change │lfc│ ≥ 1, p-value < 0.05; 
corrected by false discovery rate (FDR) using the Benjamini-Hochberg method (Benjamini and 
Hochberg, 1995), A-mean value ≥ 27), no single gene was affected by two out of three treatments, 
namely TCDD, as well as TCDD+LPS, for neither up-, nor down-regulation regarding both 
treatments. With respect to treatment of human PBMCs with TCDD+PHA, 16 genes were up-, and 
three genes were down-regulated within these cutoff-levels.  
 
In order to gain an insight with respect to potential tendencies of TCDD or TCDD+LPS-treatment-
derived effects on gene expression in human PBMCs, one of the cutoffs was eased. The false 
discovery rate (FDR), representing a method for identification of false positive hypotheses, was 
disregarded to approach to this objective (Benjamini and Hochberg, 1995). The remaining cutoffs 
(│lfc│ ≥ 1, p-value < 0.05, A-mean value ≥ 27) were maintained.  
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4.3.2.3. Human whole genome microarray analysis – TCDD 
 
If FDR was disregarded, in vitro treatment of human PBMCs with TCDD (10 nM, 24 h) 
tendencially led to up-regulation of seven genes, and to down-regulation of twelve genes, 
respectively. These genes are listed in table 51. 
 
Table 51: Human whole genome microarray analysis. Up-, and down-regulated genes in human PBMCs treated 
with TCDD (10 nM), in vitro, 24 h, n = 4. Descending order each. Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
FDR disregarded.  
TCDD 
 
lfc 
 
Gene  
systematic name 
PBMCs 
 
Gene description 
 
 
Gene name 
 
 
  
up 
   
1.798 NM_000499 cytochrome P450, family 1, subfamily a, polypeptide 1 CYP1A1 
1.585 NM_002981 chemokine (C-C motif) ligand 1  CCL1 
1.102 NM_138451 IQ motif containing D  IQCD 
1.055 NM_025139 armadillo repeat containing 9  ARMC9 
1.042 NM_020731 aryl-hydrocarbon receptor repressor  AHRR 
1.023 NM_004694 solute carrier family 16 member 6 SLC16A6 
1.003 NM_000160 glucagon receptor  GCGR 
    
down 
   
-2.056 NM_001565 chemokine (C-X-C motif) ligand 10  CXCL10 
-1.463 NM_001710 complement factor B  CFB 
-1.361 ENST00000449753 immunoresponsive 1 homolog (mouse)   ENST00000449753 
-1.347 NM_004244 CD163 molecule  CD163 
-1.344 NM_002988 
chemokine (C-C motif) ligand 18  
(pulmonary and activation-regulated)  CCL18 
-1.241 NR_026875 Neuralized homolog 3 (Drosophila) pseudogene  NEURL3 
-1.229 NM_058173 mucin-like 1  MUCL1 
-1.095/ -1.035 NM_000619 interferon gamma IFNG 
-1.087/ -1.029 NM_006274 chemokine (C-C motif) ligand 19  CCL19 
-1.082 NM_001017986 Fc fragment of IgG high affinity Ib receptor (CD64) FCGR1B 
-1.054 NM_006658 chromosome 7 open reading frame 16  C7orf16 
-1.053 NM_005064 chemokine (C-C motif) ligand 23 CCL23 
    
Values b/a from oligo b/oligo a. 
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Up-regulated genes by TCDD in PBMCs 
 
Disregarding FDR-cutoff, the most effectively up-regulated gene in PBMCs responding to TCDD-
treatment for 24 h was CYP1A1 (NM_000499; lfc = 1.798). One further AhR-related representative 
tended to be up-regulated in this regard: AHRR (NM_020731; lfc = 1.042) (see table 51).  
 
Chemokine (C-C motif) ligand 1 (CCL1, NM_002981; lfc = 1.585) encodes a cytokine representing 
a small glycoprotein, which is secreted by activated T-lymphocytes and possesses chemotactic 
properties towards monocytes. CCL1 further binds to C-C chemokine receptor 8 (CCR8) (Dimmer 
et al., 2012; Miller and Krangel, 1992). CCR8 (NM_005201) was not affected within this study by 
any treatment.  
 
Armadillo repeat containing 9 (ARMC9, NM_025139; lfc = 1.055) is annotated to the cellular 
component ‘extracellular vesicular exosome’ (GO:0070062). This component is defined as ‘A 
membrane-bounded vesicle that is released into the extracellular region by fusion of the limiting 
endosomal membrane of a multivesicular body with the plasma membrane’ (Binns et al., 2009). 
Exosomes represent small membrane vesicle (50-90 nm in diameter), which are secreted by most 
hematopoietic cells (Caby et al., 2005). 
 
Another gene, which tended to be up-regulated by TCDD in PBMCs in vitro, was solute carrier 
family 16 member 6 (SLC16A6; NM_0046994; lfc = 1.023). The encoded protein, monocarboxylate 
transporter 7, catalyzes the rapid transport across the plasma membrane of many monocarboxylates 
such as lactate, pyruvate, branched-chain oxo-acids derived from leucine, valine and isoleucine, and 
ketone bodies such as acetoacetate, beta-hydroxybutyrate and acetate (Binns et al., 2009; Dimmer et 
al., 2012).  
 
Besides, glucagon receptor (GCGR, NM_000160; lfc = 1.003) was directed towards up-regulation 
in TCDD-exposed PBMCs. In general, encoded G-protein coupled receptor for glucagon plays a 
central role in the regulation of blood glucose levels and glucose homeostasis. It further plays a role 
in signaling via a phosphatidylinositol-calcium second messenger system. Though known to be 
expressed on mononuclear blood cells, definite role(s) of the glucagon receptor with respect to these 
cells was barely examined (Binns et al., 2009; Goldstein et al., 1975). 
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Down-regulated genes by TCDD in PBMCs 
 
Among down-regulated genes by TCDD-treatment in human PBMCs (see table 51), four genes 
encoded chemokines: chemokine (C-X-C motif) ligand 10 (CXCL10, NM_001565; lfc = -2.056), 
chemokine (C-C motif) ligand 18 (CCL18, NM_002988; lfc = -1.344), chemokine (C-C motif) 
ligand 19 (CCL19, NM_006274, lfc (max) = -1.087), and chemokine (C-C motif) ligand 23 
(CCL23, NM_005064; lfc = -1.053). They are chemotactic for T-lymphocytes (CCL10, CCL18, 
CCL19, and CCL23), monocytes (CCL10, CCL23), B-lymphocytes (CCL19), and neutrophils 
(CCL23) (Binns et al., 2009; Dimmer et al., 2012). 
 
Down-regulated complement factor B (CFB, NM_001710; lfc = -1.463) is part of the alternate 
pathway of the complement system, and has been implicated in proliferation and differentiation of 
preactivated B-lymphocytes due to inhibitory effects on the proliferation of preactivated                 
B lymphocytes (Binns et al., 2009; Dimmer et al., 2012). 
 
Suppressed CD163 (NM_004244; lfc = -1.347) encodes CD163, which represents a hemoglobin 
scavenger receptor expressed in the monocyte-macrophage system. CD163 is an acute phase-
regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes as 
well as in scavenging of components of damaged cells, and thus is implicated in protection of 
tissues from free hemoglobin-mediated oxidative damage, for instance. The receptor was discussed 
to play an anti-inflammatory role correlated with macrophage activation and response of monocytes 
(Binns et al., 2009; Buechler et al., 2000; Moestrup and Møller, 2004). 
 
IFNG (NM_000619; lfc (max) = -1.095) also tended to be down-regulated by TCDD-treatment in 
PBMCs. IFN-γ is produced by activated lymphocytes promoting Th1-specific immune responses 
including response of CTLs, potentially activates macrophages, and further was discussed to bear 
antiproliferative effects on transformed cells (Dimmer et al., 2012; Garbe et al., 1990; Jetten, 2009).  
 
The putatively down-regulated Fc fragment of IgG high affinity Ib receptor (FCGR1B, 
NM_001017986; lfc = -1.082) encodes the protein high affinity immunoglobulin gamma Fc 
receptor IB (IgG Fc receptor IB). Binding with lower affinity to the Fc region of immunoglobulins 
gamma, FCGR1B might play an important role in mechanisms by which Fc gamma receptors 
participate in the humoral immune response (Binns et al., 2009; Porges et al., 1992). 
 
Results – PBMCs 
 
  239 
Another potentially down-regulated gene listed in table 51, chromosome 7 open reading frame 16 
(C7orf16, NM_006658; lfc = -1.054), encodes a protein with serine/threonine protein phosphatase 
inhibitor activity (GO:0004865) (Binns et al., 2009; Dimmer et al., 2012).  
 
Down-regulated mucin-like 1 (MUCL1, NM_058173; lfc = 1.229) is annotated to the biological 
process ‘O-glycan processing’ (GO:0016266), and is related to ‘O-linked glycosylation of mucins’ 
(REACT_115606) (Binns et al., 2009; Dimmer et al., 2012). 
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4.3.2.4. Human whole genome microarray analysis – TCDD+LPS 
 
Disregarding FDR, in vitro treatment of human PBMCs with TCDD (10 nM) combined with LPS 
(1 µg/mL) resulted in three genes tendentially up-regulated and 15 genes tending to be inhibited 
after 24 h. In table 52, respective genes are presented. 
 
Table 52: Human whole genome microarray analysis. Up-, and down-regulated genes in human PBMCs treated 
with TCDD (10 nM) + LPS (1 µg/mL), in vitro, 24 h, n = 3. Descending order each. Cutoff values: A ≥ 27, lfc ≥ 1, 
p-value < 0.05. FDR disregarded. 
TCDD  
+ LPS 
lfc 
 
Gene  
systematic name 
PBMCs 
 
Gene description 
 
 
Gene name 
 
 
  
up 
   
1.671 NM_000499 cytochrome P450, family 1, subfamily a, polypeptide 1 CYP1A1 
1.07 NM_015508 TCDD-inducible poly(ADP-ribose) polymerase TIPARP 
1.059 NM_003246 thrombospondin 1 THBS1 
    
down 
   
-1.576 NM_007286 synaptopodin  SYNPO 
-1.498 
ENST00000 
449753 immunoresponsive 1 homolog (mouse) ENST00000449753 
-1.434 NM_001565 chemokine (C-X-C motif) ligand 10  CXCL10 
-1.397 NM_005623 chemokine (C-C motif) ligand 8  CCL8 
-1.378 NM_138456 basic leucine zipper transcription factor ATF-like 2 BATF2 
-1.362 NM_002988 
chemokine (C-C motif) ligand 18  
(pulmonary and activation-regulated) CCL18 
-1.314 NM_001710 complement factor B  CFB 
-1.279/ -1.105 NM_006274 chemokine (C-C motif) ligand 19  CCL19 
-1.173 NM_058173 mucin-like 1 MUCL1 
-1.167 NR_026875 neuralized homolog 3 (Drosophila) pseudogene  NEURL3 
-1.152 NM_014398 lysosomal-associated membrane protein 3  LAMP3 
-1.14 NM_005064 chemokine (C-C motif) ligand 23  CCL23 
-1.131- (-1.002) NM_001040058 secreted phosphoprotein 1 SPP1 
-1.075 NM_001017986 Fc fragment of IgG high affinity Ib receptor (CD64) FCGR1B 
-1.06 NM_004244 CD163 molecule  CD163 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Up-regulated genes by TCDD+LPS in PBMCs 
 
Two of three up-regulated genes in human PBMCs treated with TCDD (10 nM) + LPS (1 µg/mL) 
represented AhR-responsive targets: CYP1A1, and TIPARP (table 52).  
 
The third gene, which was tended to be up-regulated along with this experiment, was 
thrombospondin 1 (THBS1, NM_003246; lfc = 1.059). The protein TSP-1 represents an inhibitor of 
angiogenesis, which is able to limit vessel density in normal tissues and to reduce tumor growth. 
This process, as well as related TSP-1-induced apoptosis in endothelial cells, was suggested to be 
dependent on CD36 (Dawson et al., 1997; Jiménez et al., 2000). TSP-1 can further be involved in 
the activation of latent TGF-β, and is induced at sites of tissue damage, where it co-occurs with 
endoplasmatic reticulum (ER) stress response. There, TSP-1 was reported to augment and protect 
ER function, by which protein production and resolution of misfolded proteins is regulated in case 
of ER stress response (Lynch et al., 2012; Murphy-Ullrich and Poczatek, 2000). 
 
Synaptopodin (SYNPO, NM_007286; lfc = -1.576) tended to be most effectively down-regulated by 
TCDD+LPS-treatment in human PBMCs. Encoded, actin-associated protein may play a role in 
modulating actin-based shape and motility of dendritic spines and is involved in synaptic plasticity 
(Binns et al., 2009; Dimmer et al., 2012). Further, SYNPO recently was shown to be expressed in 
endothelial cells in response to laminar shear stress and to participate in the mediation of 
accompanied wound healing process (Mun et al., 2014).  
 
Down-regulated genes by TCDD+LPS in PBMCs 
 
Regarding potentially down-regulated genes by TCDD+LPS-treatment (see table 52), several genes 
encoding chemokines appeared. Besides those mentioned with respect to down-regulation by 
TCDD-treatment already (CXCL10, CCL18, CCL19, and CCL23), CCL8 (NM_005623; lfc = -
1.397) occurred additionally in this regard. Encoded monocyte chemotactic protein 2 (MCP-2) 
attracts monocytes, lymphocytes, basophils and eosinophils (Binns et al., 2009; Dimmer et al., 
2012).  
 
The protein encoding down-regulated basic leucine zipper transcription factor ATF-like 2 (BATF2, 
NM_138456; lfc = -1.378) represents an activating protein-1 (AP-1) family transcription factor, 
which participates in the control of differentiation of immune cells, and is an important regulator of 
gene expression in leukocytes (Foletta et al., 1998). BATF2 is inducible by type I interferon, 
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whereas down-regulated expression was found to be associated with a poor prognosis in 
hepatocellular carcinoma (Dimmer et al., 2012; Ma et al., 2011). 
 
Further implicated with type I immunity was the protein osteopontin, which is encoded by the 
down-regulated secreted phosphoprotein 1 (SPP1, NM_001040058; lfc (max) = -1.131). 
Osteopontin, which appears to be essential in the pathway leading to type I immunity, acts as a 
cytokine and participates in the enhanced production of IFN-γ and IL-12, as well as in the reduction 
of IL-10 production (Binns et al., 2009; Dimmer et al., 2012).  
 
Lysosomal-associated membrane protein 3 (LAMP3, NM_014398; lfc = -1.152), which was down-
regulated in the course of the study in hand by TCDD+LPS-treatment in vitro in PBMCs, was found 
to progressively be induced during DC-differentiation on protein level, as well as upon activation 
with LPS, or TNF-α. It was suggested that LAMP3 might impact lysosome function after transfer of 
peptide-MHC class II molecules to the surface of DCs (De Saint-Vis et al., 1998). LAMP3 was 
further reported to be expressed in B lymphocytes on protein level (Duchez et al., 2011). 
 
The remaining genes (CFN, MUCL1, FCGR1B, and CD163) were also implemented with respect to 
potential down-regulating effects on gene expression by TCDD-treatment of PBMCs (see table 51 
and corresponding text below). 
 
4.3.2.5. Human whole genome microarray analysis – TCDD+PHA 
 
With respect to treatment of human PBMCs with TCDD+PHA, 16 genes were up-, and three genes 
were down-regulated in due consideration of FDR. Since regarding the incubations with TCDD 
alone as well as the combined incubation with TCDD+LPS, cutoffs were chosen less stringent with 
respect to disregarding FDR, this examination was also applied regarding TCDD+PHA-treatment.  
 
Hence, 32 up-regulated and twelve down-regulated genes were obtained. Respective gene-list with 
potentially up-regulated genes is shown in table 53. Values, which accomplished the more stringent 
FDR-cutoff, were marked within the table. 
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Table 53: Human whole genome microarray analysis. 32 up-regulated genes in human PBMCs treated with 
TCDD (10 nM) + PHA (1.5%) in vitro, 24 h, n = 3. Descending order. Cutoff values: A ≥ 27, lfc ≥ 1,                      
p-value < 0.05. *: In due consideration of FDR. 
TCDD 
+ PHA 
lfc 
 
Gene  
systematic name 
PBMCs 
 
Gene description 
 
 
Gene name 
    
up    
2.599 NM_000499 cytochrome P450, family 1, subfamily a, polypeptide 1 CYP1A1* 
2.342-1.259 NM_003246 thrombospondin 1 THBS1 
2.225 NM_002522 neuronal pentraxin I  NPTX1* 
2.084 NM_020731 aryl-hydrocarbon receptor repressor  AHRR* 
1.936 NM_000361 thrombomodulin  THBD 
1.846 NM_000784 cytochrome P450, family 27, subfamily a, polypeptide 1 CYP27A1* 
1.734 NM_016150 ankyrin repeat and SOCS box containing 2  ASB2* 
1.64 NM_015508 TCDD-inducible poly(ADP-ribose) polymerase  TIPARP* 
1.608-1.036 NM_000222 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog  KIT* 
1.574-1.561 NM_000104 cytochrome P450, family 1, subfamily b, polypeptide 1 CYP1B1* 
1.55 NM_002775 HtrA serine peptidase 1  HTRA1 
1.537 NM_001432 epiregulin  EREG 
1.477 NM_003485 G protein-coupled receptor 68  GPR68* 
1.454 NM_138375 Cdk5 and Abl enzyme substrate 1  CABLES1* 
1.431-1.384 NM_004994 matrix metallopeptidase 9 (gelatinase B) MMP9 
1.358-1.307 NM_002982 chemokine (C-C motif) ligand 2 CCL2 
1.318 NM_176798 pyrimidinergic receptor P2Y P2RY6* 
1.298 NM_138356 Src homology 2 domain containing F  SHF* 
1.273 NM_016205 platelet derived growth factor C  PDGFC 
1.233 NM_002575 serpin peptidase inhibitor SERPINB2* 
1.188-1.172 NM_001185156 interleukin 24  IL24 
1.16 NM_130848 chromosome 5 open reading frame 20  C5orf20 
1.159 NM_005767 lysophosphatidic acid receptor 6  LPAR6 
1.154 NM_138788 transmembrane protein 45B  TMEM45B 
1.139 NM_013451 myoferlin  MYOF* 
1.129 NM_001268 
regulator of chromosome condensation (RCC1) and BTB (POZ) 
domain containing protein 2  RCBTB2* 
1.118 NM_023037 furry homolog  FRY 
1.082 NM_012282 KCNE1-like  KCNE1L 
1.06 NM_033120 naked cuticle homolog 2 NKD2* 
1.04 NM_014331 solute carrier family 7 member 11 SLC7A11 
1.027 NM_002993 chemokine (C-X-C motif) ligand 6  CXCL6 
1.022 NM_080747 keratin 72  KRT72 
    
Values a-n: value range of more than two (n) oligos. 
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Up-regulated genes by TCDD+PHA in PBMCs 
 
Four members of a proposed AhR-gene batterie, including CYP1A1 (NM_000499; lfc = 2.599), 
AHRR (NM_020731; lfc = 2.084), TIPARP (NM_015508; lfc = 1.64), and CYP1B1 (NM_000104; 
lfc (max) = 1.574), were up-regulated genes by treatment of PBMCs with TCDD+PHA (24 h), and 
even were within the FDR-cutoff (table 53).  
A further up-regulated gene related to response to xenobiotics was CYP27A1 (NM_000784;          
lfc = 1.846), as the encoded protein was annotated to the biological process ‘xenobiotic metabolic 
process’ (GO:0006805). CYP27A1 catalyzes the first step in the oxidation of the side chain in sterol 
intermediates, and possesses cholestanetriol 26-monooxygenase-, cholesterol 26-, and calcidiol 25-
hydroxylase activity (Binns et al., 2009; Dimmer et al., 2012). 
 
In addition to CYP1A1, AHRR, TIPARP, and to one gene, which as well was probably up-regulated 
by TCDD+LPS (THBS1, NM_003246; lfc (max) = 2.342), the genes occurring in table 53 were not 
affected in response to the other investigated PBMC-treatments.  
Among these genes, two chemokines were present: CCL2 (NM_002982; lfc (max) = 1.358), and 
CXL6 (NM_002993; lfc = 1.027). Encoded chemokines attract monocytes and basophiles (CCL2), 
or neutrophil granulocytes (CXL6). Besides, the latter possesses antibacterial activity against gram-
positive and negative bacteria.  
 
The up-regulated genes are implicated in several and diverging processes. Ubiquitination and 
subsequent proteasomal degradation of target proteins represents a mechanism correlated with 
ankyrin repeat and SOCS box containing 2 (ASB2, NM_016150; lfc = 1.734), and naked cuticle 
homolog 2 (NKD2, NM_033120; lfc = 1.06). The latter was reported to be an inducible Wnt/β-
catenin signaling pathway antagonist. Wnt/β-catenin signals are crucial in development and 
neoplasia, and aberrant activation of the pathway is often correlated with overexpression of the      
c-myc oncogene. Respective processes include Wnt/β-catenin promoted proliferation of cells as 
well as c-Myc induced apoptosis (Binns et al., 2009; Dimmer et al., 2012; You et al., 2002; Zeng et 
al., 2000; Zhang et al., 2012). 
Further genes up-regulated by TCDD+PHA-treatment related to apoptotic processes were Cdk5 and 
Abl enzyme substrate 1 (CABLES1, NM_138375; lfc = 1.454), Neuronal pentraxin I (NPTX1, 
NM_002522; lfc = 2.225), and serpin peptidase inhibitor (SERPINB2, NM_002575; lfc = 1.233). 
Serpin 2 represents a major product of macrophages in response to endotoxin and inflammatory 
cytokines, which is able to inhibit TNF-α induced apoptosis (Binns et al., 2009; Dickinson et al., 
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1995; Dimmer et al., 2012). NPTX1 further is annotated to the biological processs ‘cellular response 
to glucose stimulus’ (GO:0071333).  
Glucose metabolism constitutes a regulated process in lymphocytes affecting immune cell function 
and survival, and is required to maintain immune homeostasis. Beyond, pyrimidinergic receptor 
P2Y (P2RY6, NM_176798; lfc = 1.318) which was up-regulated in PBMCs subsequent to 
TCDD+PHA-treatment, is a gene encoding a receptor for extracellular UDP, UTP, and ATP. Its 
activity is mediated by G-proteins which activate a phosphatidyinositol (PI)-calcium second 
messenger system.  
A biological process, to which P2RY6 hence is annotated is ‘phospholipase C-activating G-protein 
coupled receptor signaling pathway’ (GO:0007200). Potentially, if a growth factor or cytokine 
binds to its receptor on a T cell’s surface, phosphatidyinositol-3 kinase (PI-3K) is activated. Thus, 
PI is converted to PI 3,4,5-triphosphate (PIP3), subsequently recruiting Akt to the cell’s surface. 
There it becomes activated and in turn up-regulates GLUT-1 expression, glucose uptake, and 
glycolysis (Binns et al., 2009; Communi et al., 1996; Dimmer et al., 2012; MacIver et al., 2008). 
 
Among further potentially up-regulated genes by TCDD+PHA in PBMCs, several were of 
diverging function. Serine protease HTRA1, which is encoded by potentially up-regulated HtrA 
serine peptidase 1 (HTRA1, NM_002775; lfc = 1.55), is involved in the regulation of insulin-like 
growth factors (IGFs) by cleaving IGF-binding proteins.  
Implicated in the stimulation of localized cell proliferation and angiogenesis is epiregulin (EREG, 
NM_001432, lfc = 1.537), as the encoded protein represents a ligand of the EGF receptor 
(Komurasaki et al., 1997).  
MMP-9, which is encoded by matrix metallopeptidase 9 (MMP9, NM_004994; lfc (max) = 1.431), 
was proposed to play a role in leukocyte migration and in local proteolysis of the extracellular 
matrix (Tschesche et al., 1992).  
Platelet derived growth factor C (PDGFC, NM_016205; lfc = 1.273), which encodes PDGF-C is 
involved in wound healing in terms of inflammation, proliferation, and remodeling, as well as in 
fibrotic diseases. PDGF-C was further reported to participate in induction of liver fibrosis, steatosis, 
and hepatocellular carcinoma (Campbell et al., 2005).  
A cysteine/glutamate receptor is encoded by solute carrier family 7 member 11 (SLC7A11, 
NM_014331; lfc = 1.04). Interestingly, the gene was annotated to the biological process ‘response 
to toxic substance’ (GO:0009636). The annotation was due to findings by Flach et al. (2007). The 
authors found up-regulated LC7A11 mRNA-levels in acute cholera patients (Flach et al., 2007).  
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Thrombomodulin is a specific endothelial cell receptor, which is involved in coagulation 
mechanisms by reducing the amount of thrombin generated (THBD, NM_000361; lfc = 1.936) 
(Binns et al., 2009; Dimmer et al., 2012). 
 
The twelve putatively down-regulated genes in PBMCs after treatment with TCDD+PHA, setting 
less stringent cutoffs (FDR disregarded), is presented in table 54. Values, which accomplished the 
more stringent FDR-cutoff, were marked within the table. 
 
Table 54: Human whole genome microarray analysis. Twelve down-regulated genes in human PBMCs treated 
with TCDD (10 nM) + PHA (1.5%) in vitro, 24 h. Descending order. Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
*: In due consideration of FDR. 
TCDD 
+ PHA 
lfc 
Gene  
systematic 
name 
PBMCs 
 
Gene description 
 
 
Gene name 
 
 
  
down    
-1.61- (-1.544) NM_000619 interferon gamma IFNG 
-1.285- (-1.088) NM_001955 endothelin 1  EDN1 
-1.258 NM_005064 chemokine (C-C motif) ligand 23  CCL23 
-1.21 NM_001955 endothelin 1  EDN1 
-1.198 NM_024021 membrane-spanning 4-domains subfamily A member 4 MS4A4A* 
-1.155 NM_006658 chromosome 7 open reading frame 16  C7orf16 
-1.152 NM_001775 CD38 molecule  CD38 
-1.148 NM_001710 complement factor B  CFB* 
-1.042 NM_017414 ubiquitin specific peptidase 18  USP18 
-1.023 NM_058173 mucin-like 1  MUCL1* 
-1.012 NM_002988 
chemokine (C-C motif) ligand 18  
(pulmonary and activation-regulated)  CCL18 
-1.004 NM_006274 chemokine (C-C motif) ligand 19  CCL19 
    
Values a-n: value range of more than two (n) oligos. 
 
Down-regulated genes by TCDD+PHA in PBMCs 
 
Within the table of down-regulated genes by TCDD+PHA-treatment in PBMCs (table 54), several 
were also down-regulated by TCDD alone (see table 51): IFNG, CCL18, CCL19, CFB, and 
MUCL1, and by TCDD+LPS-treatment (see table 52) with respect to the chemokines.  
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A further down-regulated gene by TCDD+PHA-treatment was Endothelin-1 (EDN-1, NM_001955; 
lfc (max) = -1.285), which was annotated to biological processes ‘protein kinase C deactivation’ 
(GO:0042313), and ‘nitric oxide transport’ (GO:0030185). In this regard, elevated endothelin-1 
levels were correlated with impaired nitric oxide homeostasis through a PKC-dependent pathway 
(Ramzy et al., 2006).  
 
The protein encoding chromosome 7 open reading frame 16 (C7orf16, NM_006658; lfc = -1.155) 
potentially inhibits phosphatase activities of protein phosphatase 1 (PP1) and protein phosphatase 
2A (PP2A) complexes.  
 
CD38 (CD38, NM_001775; lfc = -1.152) is implicated in the synthesis of second messengers 
(cyclic ADP-ribose and nicotinate-adenine dinucleotide phosphate) involved in glucose-induced 
insulin secretion. Further, CD38 was annotated to the biological process ‘positive regulation of B 
cell proliferation’ (GO:0030890) since its diverging expression in B cell chronic lymphocytic 
leukemia was discussed in terms of involvement in cell proliferation (Joshi et al., 2007).  
 
Ubiquitin specific peptidase 18 (USP18; NM_017414; lfc = -1.042) is implicated in maintaining 
balance of specialized proteins. The encoded Ubl carboxyl-terminal hydrolase 18 is involved in the 
hydrolysis of ester-, thioester-, amide-, and peptide bonds formed by the C-terminal Gly of 
ubiquitin (Binns et al., 2009; Dimmer et al., 2012).  
 
The protein encoded by MS4A4A (CD20 antigen-like 1; MS4A4A, NM_024021; lfc = -1.198) is an 
integral membrane-component, which might be involved in signal transduction as a component of a 
multimeric receptor complex. MS4A4A belongs to the MS4A gene family, of which MS4A1 
(NM_152866) encodes the B lymphocyte antigen CD20, which is indicated to be involved in the 
regulation of B cell activation and proliferation (Binns et al., 2009; Dimmer et al., 2012). MS4A1 
itself was not regulated by any investigated treatment of human PBMCs in this study, whereas other 
members of this gene family (27 probes present on array slides in total) were enormously below 
cutoff-level for signal-intensity: MS4A6A (NM_152852; lfc = -1.069, A = 23.49), MS4A8B 
(NM_031457; lfc = -1.018, A = 22.41), and MS4A10 (NM_206893; lfc = -1.069, 23.66), regarding 
TCDD+PHA-treatment, and MS4A2 (NM_000139; lfc = -1.386, A = 24.21), MS4A3 (NM_006138; 
lfc = -1.447, A = 24.59), MS4A6A (NM_152852; lfc = 1.885, A = 23.49),  MS4A13 (NM_001012417; 
lfc = -1.395, A = 23.07), with respect to TCDD+LPS-treatment.  
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4.3.2.6. Human whole genome microarray analysis – ‘target’ & several genes 
 
In a further step, human whole genome microarray data was analyzed in terms of probale TCDD-
mediated impact on transcription of eight ‘potential’ AhR-target genes (CYP1A1, CYP1A2, 
CYP1B1, AHRR, TIPARP, ALDH3A1, CD36, and HSD17B2), and of several cytokines (IL2, IL4, 
IL5, IL6, IL10, IL12, IL13, IL17A, IL17F, IL18, IL21, IL22, IL23, IFNG), and of the transcription 
factor FoxP3 (FOXP3) with specific roles in T cell lineage specification (reviewed in Jetten, 2009). 
Further examined was the expression of TDO2. IDO1, IDO2, and TDO degrade L-tryptophan to    
L-kynurenine and were proposed to be correlated with Treg differentiation and with AhR-dependent 
antitumor immune responses (Nguyen et al., 2010; Mezrich et al., 2010; Opitz et al., 2011).  
 
To approach to this objective, three different considerations of human whole genome microarray 
data were focused:  
Firstly, presented data for n = 3 (individuals 1, 2, and 3) was further investigated with view of these 
genes. This data gives information on differentially regulated genes in response to the tree 
implemented treatments: TCDD, TCDD+LPS, and TCDD+PHA.  
Secondly, each individual (individuals 1-4) was regarded separately.  
The third examination combined gender-specific results to gain a female vs. male consideration.  
 
Due to the limited volume of data, both the individual-specific and the female vs. male-
consideration were only realizable by consolidation of the three treatment groups. With respect to 
these three considerations, the cutoff was eased. The false discovery rate (FDR), representing a 
method for identification of false positive hypotheses, was disregarded (Benjamini and Hochberg, 
1995). Principally, the remaining cutoffs were set: │lfc│ ≥ 1, p-value < 0.05, A-mean value ≥ 27.  
 
The data is presented in table 55. In case a value accomplished more stringent cutoff(s), or if a value 
was below the lfc-cutoff or the A-mean-value cutoff, the value was marked accordingly.  
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Table 55: Human whole genome microarray analysis. Impact of TCDD on eight ‘potential’ target genes, and on 
genes implicated in T cell lineage specification. Treatment groups: TCDD (10 nM); TCDD+LPS (1 µg/mL), and 
TCDD+PHA (1.5%). Considerations: Individuals (i1-i4; treatment groups consolidated), female (f) vs. male (m) 
(treatment groups consolidated), and n = 3 (i1-3). PBMCs in vitro, 24 h; up-(↑), and down-regulation (↓) of genes. 
Cutoff values: A ≥ 27, │lfc│ ≥ 1, p-value < 0.05. FDR disregarded; *: in due consideration of FDR. Values in 
brackets: below A-mean value cutoff, and/or lfc-cutoff (new cutoff│lfc│ ≥ 0.585; 1.5-fold). 
 Individuals  Female vs. male n = 3 
Gene i1 (f) i2 (m) i3 (m) i4 (f) f m TCDD 
TCDD 
+LPS 
TCDD 
+PHA 
          
‚Target’ Genes          
CYP1A1 ↑ ↑ ↑ ↑ ↑ ↑* ↑ ↑ ↑* 
CYP1A2   (↑)      (↑) 
CYP1B1 ↑ ↑ (↑) (↑) (↑) ↑* (↑) (↑) ↑* 
AHRR ↑ ↑ ↑ (↑) ↑ ↑ ↑ (↑) ↑* 
TIPARP ↑ ↑ ↑ (↑) ↑* ↑* (↑) ↑ ↑* 
ALDH3A1   (↓) (↑) (↑)     
CD36   (↑) (↓) (↓)      
HSD17B2 (↑) (↓) (↑) (↑) (↓) (↑) (↑) (↑) (↓) (↑) (↓) (↓) (↑) (↓) 
          
Genes implicated in T cell lineage specification       
IL2 (↓) (↓) (↓) (↑) (↓) (↓) (↓) (↓) (↑) (↓) (↓) 
IL4   (↓)   (↓)   (↓) 
IL5 (↑)      (↑)   
IL6  (↓)       (↓) 
IL12    (↑) (↓) (↓)   (↑) (↓) 
IL17A    (↓)      
IL18 (↓) (↓) (↓) (↓) (↓) (↓) (↓) (↓) (↓) 
IL21    (↓)  (↓)   (↓) 
IL23 (↓)   (↓) (↓)     
IFNG (↓) (↓) (↓) (↓) ↓ ↓ ↓ (↓) ↓ 
FOXP3    (↓)      
TDO2 (↑) (↓) (↑) (↑) (↑)  (↑)  (↑) 
          
 
As shown in table 55, one TCDD-responsive gene in human PBMCs was discovered obviously, 
constantly, and for each individual, namely CYP1A1. Inter-individual variations were as follows:  
lfc (i1) = 2.105, lfc (i2) = 2.107, lfc (i3) = 1.857, and lfc (i4) = 1.027. Apart from that, CYP1B1, 
AHRR, and TIPARP were as well clearly induced by TCDD with diverging specifity and statistical 
significance, dependent on the individual or treatment. Response with respect to CYP1A2 was 
Results – PBMCs 
 
  250 
minor and of low statistical relevance. TCDD-mediated effects on ALDH3A1, CD36, and HSD17B2 
were low and undirected.  
 
Regarding the female vs. male consideration, the male-group on the most part was more responsive 
compared to the female-group with respect to all investigated genes except for ALDH3A1, IL12, and 
IL23. This was very likely most prominently due to effects in PBMCs from individual 4 (f). As 
indicated before, this individual differed from the others to the greatest extent regarding TCDD-
dependent effects on gene expression in PBMCs. Response with respect to ‘potential’ AhR-target 
genes generally was weaker compared to the other individuals, whereas regarding genes implicated 
in T cell lineage specification, cells from individual 4 slightly tended to be affected to greater 
extent.  
 
Impact of TCDD on transcription of genes involved in T cell lineage specification overall was 
limited and was accompanied by moderate inter-individual differences. Most prominently, and 
throughout the whole investigation presented in table 55, IFNG was down-regulated by treatment of 
human PBMCs with TCDD. Further, IL18, which encodes the formerly termed ‘IFN-γ inducing 
factor’, was also down-regulated by tendency.  
 
TCDD’s impact on IL12-transcription appeared not clearly directional and was supposedly 
dependent on the treatment: The interleukin tendentially was up-regulated after TCDD+LPS-
treatment, and down-regulated subsequent to TCDD+PHA-incubation.  
Regarding TCDD’s proposed impact on further interleukins, IL2 was lightly but not distinctly 
directed to down-regulation. Slight indications for down-regulation by TCDD were given with 
respect to IL4, IL6, IL17A, IL21, and IL23. IL5 tended to be up-regulated by TCDD. Gene 
expression of FOXP3 encoding the transcription factor FoxP3 tended to be down-regulated only in 
TCDD-treated PBMCs from individual 4. 
Little evidence of a TCDD-mediated dysregulating effect on expression on TDO2, which was 
directing towards up-, or down-regulation dependent on the individual and on treatment, was given. 
 
Probable effects on transcription of further genes implicated in T cell lineage specification (IL1A, 
IL1B, IL10, IL13, IL17F, IL22, TGFB1, TNF, STAT3, STAT4, STAT5, STAT6, TBX21, GATA3, 
RORA, and RORC) were as well investigated. These genes were not differentially regulated by any 
treatment, in PBMCs of any individual, or in view of the female vs. male consideration, 
respectively. 
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4.3.2.7. Human whole genome microarray analysis – summary 
 
According to characterization by flow cytometry, human PBMC-suspensions contained 70 (±12)% 
CD3+-cells (T lymphocytes), 6.0 (±1.0)% CD19+-cells (B lymphocytes), and 10 (±3)% CD14+-cells 
(monocytes/macrophages). These cells were treated with TCDD (10 nM), TCDD and LPS (10 nM 
TCDD + 1 µg/mL LPS), or TCDD combined with PHA (10 nM TCDD + 1.5% PHA) for 24 h. 
Corresponding control-treatments were DMSO (0.1%), LPS (1 µg/mL LPS), or PHA (1.5%), to 
which respective TCDD-treatment was correlated. 
 
Inter-individual differences 
Viewing whole genome microarray data obtained by treatment of freshly isolated PBMCs with 
either TCDD alone, together with LPS, or together with PHA, the results in total were very limited. 
Results varied markedly among the four investigated individuals (2 f, 2 m), leading to low clusters 
of accordant effects between the individuals. In this regard, impact induced by individual 4 (f) 
differed to the greatest extent from the three other individuals, which was further evident in view of 
the individual-specific, as well as the female vs. male consideration used for closer examination of 
TCDD’s impact on several specific genes.  
Efficacies regarding differential regulation of ‘potential’ AhR-target genes were constantly lowered 
compared to those in other individuals, whereas more genes involved in T cell lineage specification 
tended to be down-regulated in PBMCs from individual 4. Thus, corresponding data was excluded 
from most of further investigations to lightly increase correlance between the individuals and to 
yield statistically more reliable data.  
 
Samples from male vs. samples from female individuals 
The male-group on the most part was more responsive compared to the female-group with respect 
to all investigated genes except for ALDH3A1, IL12, and IL23. This was very likely most 
prominently due to effects in PBMCs from individual 4 (f). As indicated before, this individual 
differed from the others to the greatest extent regarding TCDD-dependent effects on gene 
expression in PBMCs. Response with respect to ‘potential’ AhR-target genes generally was weaker 
compared to the other individuals, whereas regarding genes implicated in T cell lineage 
specification, cells from individual 4 slightly tended to be more affected 
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Numbers of genes affected by TCDD and AhR-dependent genes 
Setting cutoff-values as they were applied in mouse whole genome microarray analysis (A ≥ 27, 
logarithmic (log2) fold change │lfc│ ≥ 1, and p-value < 0.05; in due consideration of FDR), only 
regarding one of three treatments, namely the TCDD+PHA-treatment, a small amount of genes was 
obtained to be significantly differentially regulated (16↑ 3↓). Hence, one of the cutoffs was 
loosened in order to gain an insight with respect to potential tendencies of TCDD or TCDD+LPS-
treatment-derived effects on gene expression in human PBMCs. The false discovery rate (FDR), 
which represents a method for identification of false positive hypotheses, was disregarded to 
approach to this objective (Benjamini and Hochberg, 1995).  
 
By ease of this cutoff, a few genes were found to potentially be differentially regulated in response 
to the treatments with TCDD alone (7↑ 12↓), as well as regarding combined treatment with 
TCDD+LPS (3↑ 15↓). The number of genes affected by TCDD+PHA-treatment increased          
(32↑ 12↓) due to this consideration. For the treatments with TCDD alone, down-regulating effects 
prevailed, whereas a reversed situation was observed for the treatment TCDD+PHA. 
Among affected genes, CYP1A1 was up-regulated for all three treatments. As further members of 
the AhR gene battery, TIPARP occurred in the list of up-regulated genes regarding TCDD+LPS-
treatment, whereas AHRR was up-regulated by TCDD alone in human PBMCs. Regarding 
incubation with TCDD+PHA, both AHRR and TIPARP were induced. Further, CYP1B1 was up-
regulated with respect to TCDD+PHA-treatment.  
 
TCDD’s potential impact on genes involved in immune response 
Search of potentially relevant genes with respect to a better understanding of TCDD’s mode(s) of 
action on cells of the immune system proved to be difficult due to small amounts of relatively 
diverging genes affected.  
 
 TCDD 
Taking view on unstimulated PBMCs treated with TCDD, mRNA of one chemokine was up-
regulated (CCL1), and four (CXCL10, CCL18, CCL19, and CCL23) were down-regulated. By 
tendency, chemotaxis might be affected directed to inhibition with respect to T lymphocytes 
(CXCL10, CCL18, CCL19, and CCL23), B lymphocytes (CCL19), and neutrophils (CCL23). With 
respect to chemotactic properties towards monocytes, hints both enhancing (CCL1) as well as 
inhibiting effects were given (XCL10, CCL23). Further paths of potentially inhibited immune 
responses by TCDD included Th1-specific immune responses and response of CTLs (IFNG), 
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humoral immune response (FCGR1B), and macrophage activation as well as response of monocytes 
(CD163). One up-regulated gene might indicate a role of TCDD on signaling via a 
phosphatidylinositol-calcium second messenger system (GCGR).  
 
 TCDD+LPS 
Regarding stimulation of PBMCs with LPS and concurrent incubation with TCDD, the majority of 
differentially regulated genes was down-regulated. Out of 15 down-regulated genes, five encoded 
chemokines. Besides the four chemokines as well inhibited by TCDD alone (CXCL10, CCL18, 
CCL19, and CCL23), CCL8 was down-regulated. Altogether, down-regulation of these chemokines 
might indicate inhibited chemotactic properties towards T lymphocytes (CCL8, CXCL10, CCL18, 
CCL19, and CCL23), B lymphocytes (CCL19), monocytes (CCL8, CCL23), neutrophils (CCL23), 
as well as basophils and eosinophils (CCL8). Besides, possibly inhibited immune reactions due to 
TCDD-treatment might be type I immunity (SPP1), humoral immune response (FCGR1B), and 
macrophage activation as well as response of monocytes (CD163). 
 
 TCDD+PHA 
Regarding PHA-stimulated PBMCs, several differentially regulated genes indicated an impact of 
TCDD on apoptosis (CABLES1, NPTX1, SERPINB2, and NKD2). NKD2 represents an inducible 
Wnt/β-catenin signaling pathway antagonist, which might suggest a role of TCDD with respect to  
c-myc expression. C-myc itself was not regulated along with the PBMC microarray experiment.  
Of chemokines regulated by TCDD+PHA-treatment in human PBMCs, two were up-regulated, 
which might indicate an augmented chemotaxis towards monocytes and basophiles (CCL2), and 
neutrophil granulocytes (CXL6).  
The down-regulated chemokines on the other hand hinted directing inhibited chemotactic properties 
towards T lymphocytes (CCL18, CCL19, and CCL23), B lymphocytes (CCL19), as well as 
monocytes and neutrophils (CCL23). Further impact indicated TCDD-mediated inhibitory effects 
on Th1-specific immune responses and response of CTLs (IFNG), and on the regulation of B cell 
activation and proliferation (MS4A4A, CD38). Implicated in altered glucose-dependent immune 
homeostasis were NPTX1, HTRA1, and CD38, whereas up-regulated P2RY6 might reflect an 
involvement in a phosphatidyinositol-calcium second messenger system. 
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TCDD’s effect on ‘potential’ AhR-target genes in PBMCs 
Reflecting the eight ‘potential’ AhR-target genes investigated along with the whole genome 
micorarray experiment using human PBMCs, CYP1A1 proved to be constantly, although varying 
with respect to efficacy of induction, up-regulated by TCDD for all treatments (TCDD; 
TCDD+LPS; TCDD+PHA) and every individual. As well clearly induced by TCDD were CYP1B1, 
AHRR, and TIPARP. From statistic point of view, highest relevance was attributed to the 
TCDD+PHA-treatment, followed by TCDD alone for AHRR, and the TCDD+LPS-treatment 
regarding TIPARP. Whereas TCDD-mediated impact on CYP1A2-expression was minor, its effects 
on ALDH3A1, CD36, and HSD17B2 were low and undirected. 
 
TCDD’s potential impact on genes involved in T cell lineage specification 
Accompanied by inter-individual differences, transcription of genes involved in T cell lineage 
specification was limitedly impacted by TCDD in human PBMCs. A bunch of involved genes 
(IL1A, IL1B, IL10, IL13, IL17F, IL22, TGFB1, TNF, STAT3, STAT4, STAT5, STAT6, TBX21, 
GATA3, RORA, and RORC) was not regulated by any TCDD-treatment or in any individual.  
 
Distinct down-regulation of IFNG in response to every TCDD-treatment, as well as tendencies to 
lightly suppressed transcription of IL18 was observed. With respect to IL2, and IL12, inter-
individual and/or ‘inter-treatment’ differences were obtained concerning direction of differential 
regulation. In general, IL2 tended to be down-regulated by TCDD, whereas with respect to the 
TCDD+LPS-treatment, as well es regarding individual 4 (f), different probes on the microarray 
slides provided evidence for both up-, and down-regulation of IL2. Similarly, IL12 tendentially was 
down-regulated by treatment of PBMCs with TCDD+PHA, and within the female-group, but was 
up-regulated by TCDD+LPS-treatment and showed both up-and down-regulating effects in cells 
from individual 4. With generally low impact and statistical significance, IL4, IL6, IL17A, IL21, 
IL23, and FOXP3 tended to be down-regulated by TCDD. Transcription of IL5, and TDO2 was 
slightly directed towards up-regulation, though not for every individual with respect to the latter. In 
total, TCDD’s impact on transcription of genes in human PBMCs involved in T cell lineage 
specification was minor and of statistical low significance. 
 
Overall, the human whole genome microarray experiment investigating effects of TCDD with and 
without stimuli gave an insight into probable impact of the congener towards immune cells. Still, 
due to the intricate situation regarding statistics and generally few effects and as well as with 
respect to inter-individual differences, referred results needed to be considered critically.  
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4.3.3. Quantitative real-time PCR – human PBMCs 
 
Eight ‘potential’ AhR-target genes were chosen in the course of SYSTEQ project: CYP1A1, 
CYP1A2, CYP1B1, AHRR, TIPARP, ALDH3A1, CD36, and HSD17B2. In addition to the global 
investigations of TCDD on gene expression in freshly isolated human PBMCs by means of whole 
genome microarray analysis, these target genes were examined by qRT-PCR.  
As used for microarray analysis, treatments (24 h) of interest were TCDD (10 nM), TCDD (10 nM) 
+ LPS (1 µg/mL), or TCDD (10 nM) + PHA (1.5%) as well as accordant controls; DMSO (0.1%), 
LPS (1 µg/mL), or PHA (1.5%). Samples of all four individuals, two of them female and two of 
them male, were implemented and respective results were presented individually to study potential 
inter-individual differences. In accordance with observations obtained by microarray analysis, 
individual 4 (f) was excluded from statistical investigations.  
 
4.3.3.1. QRT-PCR human PBMCs – CYP1A1 
 
As well-investigated AhR-target gene, CYP1A1 was analyzed in cDNA-samples of PBMCs, which 
were treated with either TCDD alone, with TCDD+LPS, or with TCDD+PHA. Measurement of 
ACTB as housekeeping gene was implemented. QRT-PCR-results obtained by measurement of 
respective cDNA-samples regarding CYP1A1 are presented in figure 70. 
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Figure 70: QRT-PCR (CYP1A1) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. *: p-value < 0.05, ***: p-value < 0.001. 
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Principally, CYP1A1 was inducible in response to treatment with TCDD in human PBMCs on 
mRNA-level (figure 70).  
Highest CYP1A1-induction was obtained by treatment of cells with TCDD+PHA, adding up to    
13-fold induction for individual 3 (m), and to 10(±2)-fold for n = 3, being statistically significant 
(p-value < 0.05). Incubation of PBMCs with TCDD alone led to a maximal CYP1A1-induction of 
8.0-fold (individual 1, f), with a mean value for individuals 1 to 3 of 4.4(±1.3)-fold, which 
statistically was not considered significant. Among the three different treatments using TCDD, 
transcription of CYP1A1-mRNA was least efficiently induced by TCDD+LPS-treatment, amounting 
to 2.6(±1.3)-fold induction for n = 3, and maximally achieving a 3.7-fold induction for individual 1 
(f).  
 
Interestingly, expression of CYP1A1 lightly appeared to be inhibited by treatment with PHA (1.5%) 
alone. The maximum effect (0.09-fold) was obtained by investigation cDNA-samples from 
individual 2 (m), averaging 0.1(±0.2)-fold for n = 3, which statistically was extremely significant 
(p-value < 0.001).  
 
Among individuals 1, 2, and 3, light inter-individual differences were obtained regarding induction 
of CYP1A1-mRNA in PBMCs in respond to TCDD. Still, fold-inductions were fairly comparable 
and lay within an order of magnitude.  
By contrast, the response in PBMCs obtained from individual 4 (f) mostly distinguished from the 
other individuals. Admittedly, treatment with TCDD alone led to a conformable CYP1A1-mRNA 
induction (3.2-fold), and highest CYP1A1-induction for individual 4 was measured in the sample 
from TCDD+PHA-treated PBMCs. Though, the latter was notably lowered (5.3-fold) compared to 
the remaining individuals.  
The greatest difference regarding response of PBMCs from individual 4 contrasted with individuals 
1 to 3 was revealed by treatments implying LPS: CYP1A1-mRNA was induced by LPS (1 µg/mL) 
alone (4.3-fold), but was slightly inhibited (0.7-fold ‘induction’) by combined incubation with 
TCDD (TCDD+LPS-treatment).  
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4.3.3.2. QRT-PCR human PBMCs – CYP1A2 
 
Relative mRNA-expression levels of CYP1A2 were analyzed in cDNA-samples obtained from 
PBMCs, which were treated with TCDD alone or in combination with the stimuli LPS, or PHA. 
ACTB served as housekeeping gene. Results of this investigation are presented in figure 71. 
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Figure 71: QRT-PCR (CYP1A2) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. *: p-value < 0.05, **: p-value < 0.01. 
 
Overall, responsiveness of CYP1A2 was limited in PBMCs with respect to given conditions    
(figure 71). Highest inductive impact was obtained by treatment of PBMCs with TCDD+LPS, 
accounting for 2.6(±0.6)-fold induction for n = 3. This effect statistically was considered significant 
(p-value < 0.05).  
Most responsive individuals were individual 2 regarding incubation of PBMCs with TCDD+LPS 
(3.2-fold induction), and individual 1 with respect to treatment with TCDD alone (2.8-fold 
induction).  
Treatment with PHA alone inhibited expression of CYP1A2-mRNA in PBMC-samples from all four 
individuals. Values ranged from 0.4-, to 0.06-fold ‘induction’, and averaged 0.2(±0.1)-fold for        
n = 3, which statistically was considered very significant (p-value < 0.01). 
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4.3.3.3. QRT-PCR human PBMCs – CYP1B1 
 
Effects of chosen treatments on human PBMCs involving TCDD as well as LPS or PHA with 
respect to CYP1B1-induction on mRNA-level were examined. Findings obtained in association with 
measurement of ACTB as housekeeping gene are summarized in figure 72. 
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Figure 72: QRT-PCR (CYP1B1) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. *: p-value < 0.05, ***: p-value < 0.001. 
 
CYP1B1-mRNA was lightly inducible in human PBMCs in this study (figure 72). CYP1B1-mRNA 
most effectively was induced by treatment of cells with TCDD+PHA. This 3.7(±0.8)-fold induction 
was statistically considered significant (p-value < 0.05; n = 3). Though statistically not significant 
and to a quite low extent, transcription of CYP1B1 was also induced by treatment with TCDD alone 
(1.8±0.5-fold), followed by combined treatment of TCDD+LPS (1.4±1.1-fold). CYP1B1 was 
inhibited (0.06±0.2-fold) by treatment of PBMCs with PHA alone, implicating a statistically 
extreme significance (p-value < 0.001).  
Inter-individually, the strongest distinction among andividuals was obtained regarding individual 4 
(f). With respect to TCDD+PHA-treatment, the lowest inductive effect on CYP1B1 was yielded 
among individuals (1.5-fold). Beyond, treatment of PBMCs from individual 4 had a lightly 
inhibitory effect (0.6-fold) on CYP1B1 gene expression in PBMCs contrasting the up-regulating 
effects in PBMCs from individuals 1 to 3. 
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4.3.3.4. QRT-PCR human PBMCs – AHRR 
 
As putative AhR-responsive representative, the AhR repressor encoded by AHRR was implemented 
in the in vitro studies studying TCDD-mediated response in human PBMCs. Gene expression was 
examined and referred to measurements of ACTB, which served as housekeeping gene. Obtained 
results are shown in figure 73. 
DMSO LPS 1 µg/mL PHA 1.5% TCDD 10 nM TCDD + LPS TCDD + PHA
0
2
4
6
8
10
12
14
*
Fo
ld
 
in
du
ct
io
n
 AHRR indiv. 1 (f)
 AHRR indiv. 2 (m)
 AHRR indiv. 3 (m)
 AHRR indiv. 4 (f)
 AHRR n = 3
 DMSO 0.1%
 
Figure 73: QRT-PCR (AHRR) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. *: p-value < 0.05. 
 
Except for inhibition of AHRR-transcription by PHA-treatment, no obvious or consensual effect on 
AHRR gene expression was revealed by investigation of chosen PBMC-treatments (figure 73). Sole 
statistically significant (p-value < 0.05) effect was due to aforementioned PHA-treatment (0.3±0.1-
fold; n = 3).  
Results hinted towards lightly up-regulating effects by TCDD-treatment alone (2.5±0.7-fold; n = 3), 
as well by LPS alone (2.9±1.2-fold; n = 3).  
Overall, apparently undirected inter-individual differences dominated effects for all treatments 
regarding expression of AHRR.  
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4.3.3.5. QRT-PCR human PBMCs – TIPARP 
 
Impact of treatment with TCDD, TCDD+LPS, or TCDD+PHA on transcription of TIPARP in 
human PBMCs was investigated by qRT-PCR. Accordant results including respective control-
measurements are shown in figure 74. 
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Figure 74: QRT-PCR (TIPARP) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. *: p-value < 0.05, **: p-value < 0.01. 
 
Statistically significant (p-value < 0.05) induction of TIPARP in human PBMCs responding to 
treatment with TCDD+PHA was found (figure 74). In this regard, a light induction value of 
4.6(±0.8)-fold for n = 3 was revealed.  
Slight, but not considered statistically significant TIPARP-inductions were as well obtained with 
respect to TCDD-treatment (2.3±0.6-fold; n = 3), and TCDD+LPS-treatment (2.7±1.4-fold; n = 3).  
 
Inter-individual variations were not as prominent as regarding the other investigated genes with the 
exception of individual 4 (f). Incubation of PBMCs led to a statistically very significant down-
regulation of TIPARP (0.14±0.07-fold; n = 3; p-value < 0.05). 
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4.3.3.6. QRT-PCR human PBMCs – ALDH3A1 
 
As a further potential AhR-target gene, ALDH3A1-gene expression in PBMCs was investigated. 
Implicating measurements of ACTB serving as housekeeping gene, the respective results are 
presented in figure 75.  
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Figure 75: QRT-PCR (ALDH3A1) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), 
or TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-
levels). Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment 
group). Female, f; male, m. **: p-value < 0.01. 
 
ALDH3A1-gene expression was statistically very significantly (p-value < 0.01) down-regulated 
(0.2±0.1-fold; n = 3) by treatment with PHA in PBMCs (figure 75). Apart from that, no distinct 
impact due to any treatment was obtained. Results might indicate a slight up-regulating effect by 
treatment with TCDD (2.1±0.7-fold; n = 3).  
Overall, inter-individual variations were predominating within this examination.  
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4.3.3.7. QRT-PCR human PBMCs – CD36 
 
Results of qRT-PCR measurements of CD36 with respect to samples from human PBMCs treated 
for 24 h with TCDD (10 nM), TCDD (10 nM) + LPS (1 µg/mL), or TCDD (10 nM) + PHA (1.5%), 
and appropriate controls, are depicted in figure 76. 
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Figure 76: QRT-PCR (CD36) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), or 
TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-levels). 
Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment group). 
Female, f; male, m. ***: p-value < 0.001. 
 
As obtained with respect to aforementioned and measured potential AhR-target genes, treatment of 
PBMCs with PHA led to down-regulation (0.1±0.03-fold; n = 3) of CD36-gene transcription  
(figure 76). The effect statistically was considered extremely significant (p-value < 0.001).  
 
Remarkable were great variations of individual results. Cells from individuals tended to bear similar 
effects, at least compared among individuals, almost independent from treatment. PBMCs from 
individual 1 (f) were quite responsive to LPS-(4.3-fold), or TCDD (3.5-fold)-treatment, which was 
similar regarding individual 2 (m) with respect to TCDD-treatment (2.1-fold) but occured with 
lower extent.  
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4.3.3.8. QRT-PCR human PBMCs – HSD17B2 
 
PBMCs incubated with TCDD, LPS, PHA, or an appropriate combination, were examined 
regarding impact of treatments on HSD17B2-expression. Results implicating measurements of 
ACTB as housekeeping gene are illustrated in figure 77. 
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Figure 77: QRT-PCR (HSD17B2) human PBMCs. Cells treated with TCDD (10 nM), TCDD + LPS (1 µg/mL), 
or TCDD + PHA (1.5%) for 24 h. Abscissa: Treatment; ordinate: Fold induction (referred to ACTB mRNA-
levels). Results from four individuals (indiv.; see legend). Two-tailed unpaired t-test (control vs. treatment 
group). Female, f; male, m. 
 
Overall, any treatment had an effect on HSD17B2-gene expression in human PBMCs subsequent to 
24 h of incubation (figure 77). With one exception, no obvious trend was distinguishable in this 
regard. A value of 2.2(±0.4)-fold induction by TCDD-incubation might lightly direct towards an up-
regulating effect due to this treatment.  
Even inter-individual differences were less prominent regarding impact on HSD17B2-gene 
transcription.  
 
 
 
 
Results – PBMCs 
 
  264 
4.3.3.9. QRT-PCR human PBMCs – summary 
 
In human PBMCs, in vitro gene expression of a set of ‘potential’ AhR-target genes was analyzed by 
qRT-PCR. Hence, expression of CYP1A1, CYP1A2, CYP1B1, AHRR, TIPARP, ALDH3A1, CD36, 
and HSD17B2 using incubations with TCDD (TCDD, 10 nM; TCDD, 10 nM + LPS, 1 µg/mL; or 
TCDD, 10 nM + PHA, 1.5%), and respective controls (DMSO, 0.1%; LPS 1 µg/mL; or PHA, 1.5%) 
was assessed.  
Overall, effects of TCDD and combined incubations with the stimuli LPS or PHA on gene 
expression in human PBMCs was impacted greatly by inter-individual differences.  
 
Highest, but also highly varying inductions of gene transcription were obtained regarding CYP1A1-
expression by TCDD-treatments, whereas only the treatment TCDD+PHA led to a statistically 
significant result. Comparable findings but with lower efficacy were revealed regarding CYP1B1. 
The least responsive gene among CYPs was represented by CYP1A2. In this regard, impact 
enforced by TCDD+LPS-treatment solely was considered statistically significant among examined 
TCDD-treaments.  
 
Investigations concerning TIPARP yielded similar results to those obtained for CYP1B1. In fact, 
treatments with TCDD, or with TCDD+LPS, led to an even higher, although statistically not 
significant gene expression with respect to TIPARP-induction contrastet with results obtained for 
CYP1B1. 
Concerning further investigated genes AHRR, ALDH3A1, CD36, and HSD17B2, no significant 
response was reported by treatment with TCDD or combined incubations with LPS or PHA.  
 
Interestingly, PHA (1.5%) constantly possessed statistically significant repressive effects on 
transcription of all investigated ‘potential’ target genes except for HSD17B2. 
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5 
Discussion 
 
5.1. Discussion – Mouse Whole Genome Microarray Analysis  
 
Impact of DL-congeners on gene expression in mouse livers was primarily and with strongest 
significance correlated with enhanced xenobiotic metabolic processes. Followed by alterations 
towards lipid-, and carbohydrate metabolism, further implicated mechanisms were oxidative 
processes, apoptosis, and immune response. Dependent on the congener, these processes were 
involved to diverging degree.  
 
PCB 118 
Effects due to treatment with PCB 118 were mostly limited to drug metabolism in mouse livers. 
Slight indications with respect to the compound’s impact on insulin receptor signaling, 
carbohydrate-induced expression of liver enzymes essential for de novo lipogenesis as well as 
glycolysis, and correlated glucose homeostasis were given.  
Considering down-regulated genes by PCB 118, the congener might tend to be involved in immune 
response, as regarding type 2 immune response and B cell differentiation, or IFN-γ production and 
Th1-differentiation, for instance. Most notably concerning down-regulated genes, statistical 
significances with respect to appearance of clustered GO terms was limited, which complicated the 
interpretation of these microarray results even more.  
Further, the number of clustered genes within significant (‘Top 20’) GO terms in total was low, 
even regarding the most obviously affected path of xenobiotic metabolism. Hence, properties of 
more than 300 up-, and down-regulated genes were difficult to predict, as less than 100 were clearly 
assigned.  
 
1-PeCDD 
Treatment of mice with 1-PeCDD led to most comparable effects regarding gene expression in 
livers compared to those obtained in TCDD-treated mice. The highest overlap regarding numbers of 
‘together’ regulated genes with TCDD was received in this respect. Besides ‘oxidation-reduction 
processes’, which was the most significantly affected GO term by 1-PeCDD and implied xenobiotic 
metabolic processes, a dominating effect on lipid metabolism represented the congener’s impact.   
1-PeCDD further tended to be involved in altered carbohydrate- and glucose-metabolism. 
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4-PeCDF, PCB 126, and PCB 156 
Effects by 4-PeCDF, PCB 126, and PCB 156 were highly concentrated on (xenobiotic) metabolism 
and reflected a huge amount of transcribed as well as processed genes. Overlap between regulated 
genes by 4-PeCDF and PCBs, including PCB 118 as well, was respectable.  
 
Overlap among DL-congeners 
Among all DL-congeners, overlap turned out to be limited to 22 up-, and five down-regulated genes 
– a conserved list mainly composed of genes related to xenobiotic metabolism, followed by genes 
involved in lipid metabolic processes. Excluding PCB 118 from respective examination of DL-
congeners, genes of resulting gene-list (48↑ 19↓) principally participated in the same processes as it 
was observed for all DL-congeners together in the (22↑ 5↓) gene list.  
The higher number of differentially regulated genes within these processes, which represented the 
decisive difference between these analyses, yielded in a higher significance with respect to 
involvement in xenobiotic metabolic processes and, even more pronounced, regarding lipid 
metabolism.  
 
Even though the ‘DL-overlap’ tended to be limited, DL-congeners shared impact on gene 
expression in mouse livers with respect to (xenobiotic) metabolic processes as well as lipid 
metabolism, whereas correlance appeared with greater significance by exclusion of PCB 118 with 
respect to this investigation.  
 
‘Relative effect potencies’ of congeners 
Regarding investigations for estimation of REPs, for instance by measurement of genes involved in 
xenobiotic metabolism such as Cyp1a1, these facts quasi ‘reflected’ basis principles of a TEF-
concept, by which these congeners were and are classified according to their potencies. By persuing 
this thought, potential difficulties associated with this system might become obvious.  
 
Considering the DL-congeners implemented in the study in hand, three potentially possible options 
were represented considering results obtained within present study. As obtained, all of (examined) 
congeners consensually shared impact with respect to xenobiotic metabolism, as well as particularly 
regarding Cyp1a1, which potentially is measured for estimation of REPs. One might measure 
Cyp1a1-inductions with divergent REPs for congeners with diverging properties in this regard. This 
would thus reflect diverging impact on consensually affected xenobiotic metabolism and might 
reflect AhR-mediated effects, which hence would match with the basic idea of the TEF concept. 
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Potential difficulties in this regard might occur during assessment of both those congeners 
possessing small overlap with TCDD, like PCB 118 (overlap around 25% with respect to TCDD’s 
effects), and those compounds bearing quite considerable overlap with TCDD, like 4-PeCDF 
(overlap around 50-75% with respect to TCDD’s effects). Regarding the latter, a huge amount of 
genes was induced and repressed besides these TCDD-overlapping effects.  
In percentage, a similar situation might be obtained regarding PCB 118 – Although sharing around 
25% ‘properties’ referring to inductive effects on gene expression with TCDD, this overlap 
represents as few as 10% of PCB 118’s substance-specific impact.  
 
Hence, estimation of REPs in the course of TEF-investigations might well reflect congeners’ AhR-
dependent effects, but dependent on the congener, a considerable amount of information gets lost. 
Even if the relevance of such ‘additional’ congener-specific impact remains unclear for now, it 
might be relevant for the assessment of a congener’s toxic potential. 
 

Discussion 
 
 269 
5.2. Discussion – Liver Cell Systems 
 
Rat liver cell systems are widely used and well established regarding their use in verification and 
differentiation of dioxin-like effects. With respect to the study in hand, a set of 13 DL-congeners 
(TCDD, 1-PeCDD, 1,6-HxCDD, 1,4,6-HpCDD, TCDF, 4-PeCDF, 1,4-HxCDF, 1,4,6-HpCDF,  
PCB 77, PCB 105, PCB 118, PCB 126, and PCB 156) and the NDL-PCB 153 were investigated 
with respect to their potential EROD-inducing effects, and on CYP1A1-induction on protein level 
via Western Blotting in H4IIE cells and primary rat hepatocytes (PRH) from Sprague Dawley rats. 
Subsequent to a screening experiment examining TCDD’s impact on gene transcription of eight 
‘potential’ target genes (Cyp1a1, Cyp1a2, Cyp1b1, Aldh3a1, AhRR, Tiparp, Cd36, and Hsd17b2)  
in H4IIE cells and PRH, a further selection was made due to responsiveness and concentration-
dependence in both tested liver cell systems. Hence, the seven ‘core’ congeners, TCDD, 1-PeCDD, 
4-PeCDF, PCB 118, PCB 126, PCB 156, and the NDL-PCB 153 were examined with respect to 
their impact on transcription of Cyp1a1, Cyp1a2, Cyp1b1, and Aldh3a1 in both H4IIE cells and 
primary rat hepatocytes. An incubation time of 24 h was applied for all examinations. 
 
H4IIE vs. primary rat hepatocytes 
As obtained in several studies, H4IIE cells were constantly more sensitive towards dioxin-
dependent effects (Schmitz et al., 1995; Zeiger et al., 2001). One exception was obtained in this 
regard – the ‘potential’ AhR-target gene Aldh3a1 was induced in PRH more potently as well as with 
higher efficacy compared to effects in H4IIE cells.  
 
Contrasting effects on Cyp1a1 in H4IIE cells with impact on Aldh3a1 in PRH by means of qRT-
PCR measurements, TCDD-treatment yielded comparable efficacy and around 1.5 orders of 
magnitude lower potency in PHR compared with values in H4IIE cells, which was around three 
orders of magnitude lower potency, but around 30 times higher efficacy contrasted with Cyp1a1-
induction in PRH.  
By contrast, Aldh3a1 was least responding in H4IIE cells, the actual more sensitive liver cell 
system. Thus, Aldh3a1 was considered a gene, which was responsive to DL-compounds, whereas 
Aldh3a1-induction by these chemicals was suggested not be exclusively dependent on the AhR. 
Interestingly, Aldh3a1 was also reported to be induced in livers by in vivo-treatment of mice with 
phenobarbital, which actually represents a chemical functioning via the receptors CAR and/or PXR 
(Gährs et al., 2013; Pappas et al., 2003; Xie et al., 2000). An involvement of the AhR regarding 
Aldh3a1-induction was indicated, since potencies of all investigated congeners were comparable to 
those regarding Cyp1a1-induction, for instance.  
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Responsiveness of ‘AhR-target genes’ 
For both liver cell systems (after ‘removing’ of Aldh3a1 as an inconclusive AhR-dependent gene), 
Cyp1a1 was the most responsive target gene, followed by Cyp1b1, and Cyp1a2, as obtained in 
literature as well (Lai et al., 2006; Xu et al., 2000).  
 
Comparison of REPs between the two applied rat liver cell systems provided information 
concerning their sensitivity towards a specific compound. Regarding Cyp1a1-induction, REPs for 
1-PeCDD were higher in PRH than those in H4IIE cells, indicating a higher sensitivity in PRH 
compared to H4IIE cells, whereas this effect was reversed for 4-PeCDF. Comparable findings were 
observed with respect to 1-PeCDD and its impact on Cyp1a2-induction, as well as for 4-PeCDF 
referring to REP (EC50). Further, 1-PeCDD appeared to be about twice as potent as was TCDD 
regarding Cyp1a1-and Cyp1a2-induction.  
 
REPs vs. TEFs 
With respect to REP-values gained by liver cell system investigations on EROD-induction, as well 
as on qRT-PCR-investigations (Cyp1a1, Cyp1a2, Cyp1b1, and Aldh3a1), the current TEFs were 
widely confirmed (Van den Berg et al., 2006).  
A REP (EC50) for 4-PeCDF of 0.14 regarding Cyp1a2-induction in primary hepatocytes from 
Spreague Dawley rats quite well matched the one obtained along with own investigations         
(REP (EC50, PRH) = 0.13). The REP (EC50) obtained for Cyp1a1-induction was distinctly lowered 
(0.03) compared to the one revealed in current study (0.56). Differences might be due to an 
extended incubation-time of 48 h, compared to 24 h-duration implemented in this study (Budinsky 
et al., 2010).  
 
Regarding EROD-investigations using PRH as well as H4IIE-cells, further slight deviations from 
current TEFs occurred. Regarding REP (EC20) for 1-PeCDD, and regarding REP (EC50) for   
1,4,6-HpCDD, REPs were twice as high in H4IIE cells compared to those in PRH.  
Besides, both REPs for effects in H4IIE cells mediated by TCDF were both lower than those 
observed for PRH and below the current TEF. This effect might be due to the flattened 
concentration-response curve corresponding to TCDF’s impact. 
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AhR-dependent effects and chemical structures of congeners 
Ranking orders regarding PCDDs, PCDFs, and PCBs, in correlation with chlorination pattern and 
probability to reach a planar conformation were comparable with observations obtained in literature 
(Budinsky et al., 2010; De Voogt et al., 1990; Zeiger et al., 2001).  
 
Higher chlorinated PCDD-congeners tended to yield lower REPs, which is suggested to be due to 
reduced binding affinities towards the AhR (Kafafi et al., 1993; Mhin et al., 2002). Further, non-
ortho-substituted PCB-congeners (PCB 126, PCB 77) tended to gain higher effects with respect to 
EROD-induction and CYP1-induction in rat liver cells, though with lowered extent regarding    
PCB 77.  
For the PCB-congeners, the chlorination pattern is of specific relevance, as it maintains the 
probability to reach a planar conformation, which further yields in higher binding affinities towards 
the AhR, since with respect to non-ortho-substituted PCBs, the two phenyl rings are able to rotate 
more easily about the shared bond (De Voogt et al., 1990). This situation tends to be sterically 
hindered in mono-ortho-PCBs like PCB 118, or PCB 156, leading to a lower potency with respect 
to AhR-dependent examinations. 
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5.3. Discussion – Human Whole Genome Microarray Analysis and QRT-PCR 
 
One aim of this study was to reveal probable TCDD-induced effects on human immune cells. To 
approach to this objective, freshly isolated human PBMCs were characterized by flow cytometry 
(70±12% CD3+-cells, T lymphocytes; 6.0±1.0% CD19+-cells, B lymphocytes; and 10±3% CD14+-
cells, monocytes/macrophages) and exposed to one of three TCDD-treatments for 24 h:  
 
TCDD (10 nM) 
TCDD and LPS (10 nM TCDD + 1 µg/mL LPS), or  
TCDD combined with PHA (10 nM TCDD + 1.5% PHA).  
 
Corresponding control-treatments were DMSO (0.1%), LPS (1 µg/mL LPS), or PHA (1.5%), to 
which respective TCDD-treatments were correlated. Integrity of isolated mRNA was checked (2100 
Bioanalyzer, Agilent Technologies GmbH, Waldbronn, Germany), before the two-color microarray-
based gene expression analysis was perfomed applying Human GE 4x44K v2 Microarray Kits 
(Agilent Technologies GmbH, Waghaeusel-Wiesental, Germany) by implementation of dye-swop 
procedures to reduce potential artifactual effects due to diverging dye properties.  
The set of ‘potential’ AhR-target genes (CYP1A1, CYP1A2, CYP1B1, AHRR, TIPARP, ALDH3A1, 
CD36, and HSD17B2) was further investigated by qRT-PCR.  
 
Human whole genome microarrays and inter-individual differences 
A first view on normalized and statistically analyzed data (Bioconductor R package Limma; Smyth, 
2004), as well as on principal component analyses (PCAs) and on individual-specific human whole 
genome microarray data, distinct inter-individual variations were obvious.  
One individual, individual 4 (f), differed greatly from the others regarding TCDD-dependent effects 
on gene expression in PBMCs. As indicated examplarily in the human microarray results-chapter, 
response with respect to ‘potential’ AhR-target genes (CYP1A1, CYP1B1, AHRR, and TIPARP, in 
particular) generally was weaker compared to the other individuals, whereas regarding genes 
implicated in T cell lineage specification, cells from individual 4 slightly tended to be more affected 
towards down-regulation. Due to close examinations on raw data, individual 4 (f) was discarded 
from most of further investigations of the microarray analysis. Hence, clustering of data among 
individuals 1, 2, and 3 improved, as well as did statistical significance and thus reliablility of data 
regarding the complete human whole genome microarray experiment. 
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Human whole genome microarrays and numbers of TCDD-regulated genes 
Initially, cutoff-values were set as they were applied in mouse whole genome microarray analysis 
(A ≥ 27, logarithmic (log2) fold change │lfc│ ≥ 1, and p-value < 0.05; in due consideration of the 
false discovery rate, FDR).  
Using these statistical limitations, only one out of three treatments investigated showed a response 
at all: In response to TCDD+PHA-treatment, a small amount of genes significantly was 
differentially regulated (16↑ 3↓). Subsequently, the FDR-cutoff was loosened in order to gain an 
insight into potential tendencies of TCDD-derived effects respecting the other two treatments 
(TCDD; TCDD+LPS). The FDR, which represents a method for identification of false positive 
hypotheses, was disregarded to approach to this objective (Benjamini and Hochberg, 1995).  
 
The genes lists still were short. In total, highest number of genes was affected after TCDD+PHA-
treatment (32↑ 12↓), followed by TCDD (7↑ 12↓), and TCDD+LPS (3↑ 15↓).  
Hochstenbach et al. (2010) found higher numbers of differentially regulated genes in human 
PBMCs subsequent to 20 h of in vitro treatment with TCDD (1 µM; 10 µM) applying a metabolic 
activation system using an Agilent whole-genome 4 x 44K microarray system (106↑ 169↓, 1 µM 
TCDD; and 117↑ 195↓, 10 µM TCDD). For metabolic activation, the authors made use of a human 
liver S9-mix (10% of a 30% S9-fraction). Statistical cutoffs as well differed from those of the study 
in hand. Hochstenbach et al. implemented a cutoff of │lfc│ ≥ 1.5fold, using three of five donors 
(Hochstenbach et al., 2010). In a more recent study by Hochstenbach et al. (2012), in a similarly 
constructed test-system, 878 (1 µM TCDD), or 1233 (10 µM TCDD) genes were differentially 
regulated in PBMCs, respectively (cutoff: │lfc│ ≥ 1.5fold, five donors; p-value < 0.05, t-test) 
(Hochstenbach et al., 2012).  
The different cutoffs as well as the use of a S9 metabolic activation system represent two major 
deviations, which might explain the varying numbers of differentially regulated genes the authors 
declared compared to those of the study in hand.  
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Differentially regulated genes – CYP1A1 
Differentially regulated genes by all three TCDD-treatments (TCDD; TCDD+LPS; TCDD+PHA) 
were headed by CYP1A1. Though with diverging statistical relevance and efficacy, this AhR-
responsive gene was up-regulated in PBMCs from every individual and throughout all TCDD-
treatments in present microarray experiment.  
Inter-individual variations were as follows: lfc (i1) = 2.105, lfc (i2) = 2.107, lfc (i3) = 1.857, and  
lfc (i4) = 1.027 (effects of all three TCDD-treatments consolidated), whereas CYP1A1-induction 
with respect to treatments accounted for lfc (TCDD) = 1.798, lfc (TCDD+LPS) = 1.671, and         
lfc (TCDD+PHA) = 2.599 (n = 3).  
Highest, but also highly varying inductions of gene transcription were obtained regarding CYP1A1-
expression by TCDD-treatments with respect to qRT-PCR results in this study, whereas again, only 
the treatment TCDD+PHA led to a statistically significant result for n = 3.  
 
According to the literature, CYP1A1 was shown to be constitutively expressed in human PMBCs 
(Krovat et al. 2000, Siest et al., 2008). Further, and in correlance with the study in hand, CYP1A1-
induction was obtained to be inducible in human PBMCs both on gene transcription and on protein 
level, exhibiting great inter-, and intra-individual variety and overall comparably low absolute 
induction values in most of the experiments (Kouri et al., 1974; Nohara et al., 2006; Vanden Heuvel 
et al., 1993; Van Ede et al., 2014b). Respective results deviated from ~3fold (100 nM TCDD, 6 h) 
over ~20fold (10 nM TCDD, 72 h), and ~60fold (10 nM TCDD, 48 h) to ~160fold (10 nM TCDD, 
48 h) CYP1A1-induction on mRNA-level in primary human PBMCs (Nohara et al., 2006; Vanden 
Heuvel et al., 1993; Van Ede et al., 2014b). 
 
Differentially regulated genes – CYP1B1 
To a lowered extent compared to CYP1A1-induction in PBMCs, CYP1B1 was up-regulated with 
respect to TCDD+PHA-treatment (lfc = 1.574). Further, PBMCs received from male individuals 
showed CYP1B1-induction of statistical significance. By ease of cutoffs (FDR disregarded,     
│lfc│ ≥ 1.5fold), indications for up-regulation of this gene were also revealed with respect to 
TCDD (lfc = 0.823)-, and TCDD+LPS (lfc = 0.805)-treatment, as well as regarding every 
individual with diverging efficacy: lfc (i1) = 1.016, lfc (i2) = 1.161, lfc (i3) = 0.995, lfc (i4) = 0.747 
(effects of all three TCDD-treatments consolidated).  
 
Similar findings were revealed by qRT-PCR-investigations of CYP1B1. Variability among 
individuals combined with a low inducibility led to minor and to statistically least significant 
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TCDD-mediated effects in human PBMCs, indicating a less reliable marker for TCDD-derived 
effects compared to CYP1A1. Findings were comparable to those in literature. Whereas CYP1B1 
was reported to be constitutively expressed in human PMBCs, elevated mRNA-levels achieved 
after TCDD-treatment varied from ~2-3fold (5 nM, 6h; 5 nM, 72 h; or 10 nM, 48 h (with PHA 
1.5%)), to around 5-8fold (1 nM, 48 h (with PHA 1.5%)) induction in PBMCs (De Waard et al., 
2008; Finnström et al., 2002; Van Duursen et al., 2005; Van Ede et al., 2014b).  
 
Further, CYP1B1-induction appeared to depend on the type of treatment in the present study. This 
effect might, at least in parts, be attributable to inductive effects by LPS itself since CYP1B1 has 
been shown to be inducible by this stimulus in human peripheral blood monocytes and 
macrophages (1 µg/mL LPS, 24 h) (Baron et al., 1998). This observation was not reproduced along 
with the study in hand. Since applied PBMCs contained 10 (±3)% monocytes/macrophages, this 
effects might have been minor with respect to the complete suspension of cells, which probably 
made an insufficient difference for detection. As LPS ‘alone’ might be able to lightly induce 
CYP1B1, the span between treatment and control might have become smaller, hence leading to a 
lower TCDD-mediated inductive effect. 
 
Differentially regulated genes – CYP1B1 and TIPARP 
Similar findings as for CYP1B1 were obtained with respect to TIPARP-induction in human PBMCs 
in response to TCDD for both the microarray experiment and qRT-PCR examinations. Emphasized 
from statistical point of view was the treatment with TCDD+PHA (lfc = 1.64, n = 3; qRT-PCR: 
3.7(±0.8)-fold induction, n = 3), as well as both gender-specific investigations.  
Yet, TIPARP was correlated with TCDD-exposure in a microarray experiment (22K Human 1A 
(V2) Oligo Microarray, Agilent) human PBMCs, where similar results for CYP1B1-and TIPARP-
induction were observed in response to incubation of cells with TCDD (500 pM, 48 h; n = 5), 
accounting for 1.40-fold (CYP1B1), and 1.73-fold (TIPARP) induction, respectively (De Waard et 
al., 2008).  
With respect to both microarray data and qRT-PCR results, no obvious gender-specific differences 
were obtained regarding CYP1B1-induction in PBMCs among the four investigated individuals 
studied along with present study. This could have been implicated since basal expression was 
proposed to be significantly higher in women than in men (Finnström et al., 2002). Probable 
differences in basal levels might also have been overlayed by quite distinct inducing effects, or 
might have been masked within the microarray experiment, since for the gender-, and individual-
specific consideration, treatment-specific results were consolidated.  
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Differentially regulated genes – AHRR 
One more AhR-dependent gene was affected by TCDD in human PBMCs with respect to the whole 
genome microarray experiment, namely AHRR. A clear, from statistical point of view most reliable 
correlation was observed for treatment of cells with TCDD+PHA (lfc = 2.084; n = 3). Concerning 
TCDD-treatment (lfc = 1.042; n = 3) as well as TCDD+LPS-treatment (lfc = 0.947; n = 3) and 
gender-, as well as individual-specific analyses, indications regarding TCDD-mediated up-
regulating effects towards AHRR-expression in human PBMCs were given by choose of less 
stringent cutoffs. Inter-individual differences were as follows: lfc (i1) = 1.474, lfc (i2) = 1.462,     
lfc (i3) = 1.137, and lfc (i4) = 0.691 (effects of all three TCDD-treatments consolidated). 
 
Regarding qRT-PCR investigations, no obvious or consensual effect on AHRR gene expression was 
revealed by investigation of chosen PBMC-treatments. Apparently undirected inter-individual 
differences dominated effects for all treatments regarding expression of AHRR. Results hinted 
towards lightly up-regulating effects by TCDD (10 nM)-treatment alone (2.5±0.7-fold; n = 3), as 
well as by LPS (1 µg/mL) alone (2.9±1.2-fold; n = 3).  
In literature, AHRR was also reported to be inducible in human PBMCs by DL-congeners. In this 
regard, around 10 to 14-fold maximal AHRR-induction by TCDD (10 nM, 48 h) was yielded on 
average in these cells (Van Ede et al., 2014b). 
 
Differentially regulated genes – CYP1A2, ALDH3A1, CD36, and HSD17B2 
Response with respect to CYP1A2 was minor and of low statistical relevance (TCDD+PHA-
treatment, n = 3; individual 3 (m)). QRT-PCR-results varied greatly inter-individually, but exhibited 
a slight, but statistically significant CYP1A2-induction for treatment of PBMCs with TCDD+LPS 
(2.6±0.6-fold induction, p-value < 0.05; n = 3). CYP1A2-expression appeared to be detectable only 
sporadically and not in every individual-specific PBMC-sample.  
On the basis of current information, CYP1A2 is also not inducible by AhR ligands in vitro in 
human blood cells (Baron et al., 1998; Finnström et al., 2002; Krovat et al. 2000, Siest et al., 2008). 
In a study using NDL-PCBs, PCB 138 was shown to down-regulate transcription of CYP1A2 in 
human PBMCs in vitro (Gosh et al., 2001).  
 
Besides, impact on ‘potential’ AhR-target genes, ALDH3A1, CD36, and HSD17B2 was low and 
undirected with respect to both the human whole genome microarray experiment and qRT-PCR 
examinations. 
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TCDD’s potential impact on PBMCs with respect to immune response 
In order to gain a better understanding in terms of TCDD’s potential mode(s) of action towards cells 
of the immune system, differentially regulated genes revealed by human whole genome microarray 
analysis were examined with respect to identification of probable relevant genes in this regard. The 
search of these potentially relevant genes proved to be difficult due to the limited amount of genes 
differentially regulated genes, which in addition clustered marginally among each other.  
 
TCDD-treatment – Chemokines 
Viewing results obtained by TCDD-treatment of human PBMCs without any stimulus, several 
genes encoding chemokines were differentially regulated. One was up-regulated (CCL1), whereas 
four members (CXCL10, CCL18, CCL19, and CCL23) were down-regulated. Hence, chemotaxis 
might be affected directing to inhibition with respect to T lymphocytes (CXCL10, CCL18, CCL19, 
and CCL23), B lymphocytes (CCL19), and neutrophils (CCL23). Regarding TCDD’s properties 
towards monocytes, evidence was provided respecting both enhancing (CCL1) as well as inhibitory 
effects (XCL10, CCL23) (Binns et al., 2009; Dimmer et al., 2012).  
CCL1 was reported to be up-regulated by PCB 126 (1 µM, 18 h) in human PBMCs in the course of 
microarray experiments, whereas CXCL10 was observed to be down-regulated (Wens et al., 2011; 
Wens et al., 2013).  
 
TCDD-treatment – T cell lineage specification  
Further indications respecting TCDD’s inhibitory impact on immune response might include Th1-
specific immune responses and response of CTLs (IFNG↓), humoral immune response (FCGR1B↓), 
and macrophage activation as well as response of monocytes (CD163↓). One up-regulated gene 
might indicate a role of TCDD on signaling via a phosphatidylinositol-calcium second messenger 
system (GCGR↑) (Binns et al., 2009; Dimmer et al., 2012). 
 
Regarding minor effects on several cytokines and other relevant proteins implicated in T cell 
lineage specification, IL2, and IL18 slightly tended to be down-regulated, whereas IL5-mRNA was 
slightly elevated by TCDD. Similarly to IFN-γ, IL18 as ‘IFN-γ inducing factor’ plays an important 
role in Th1 response, primarily due to its IFN-γ inducing ability (Dinarello, 1999). Increased IL5 on 
the other side might potentially reflect a facilitated Th2-response, whereas down-regulated IL2 
might indicate a slight repression of Treg differentiation (Jetten, 2009).  
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By tendency, TDO2 was slightly up-regulated by TCDD in human PBMCs. TDO catabolizes         
L-tryptophan (Trp) to L-kynurenine (Kyn), which itself was shown to represent an AhR-ligand and 
has been correlated with AhR-dependent antitumor immune responses. Elevated Kyn-
concentrations might further give an indication directing to a slightly facilitated Treg differentiation 
by TCDD (Nguyen et al., 2010; Mezrich et al., 2010, Opitz et al., 2011).  
 
In literature, several diverging findings are found in correlation to TCDD’s potential effects towards 
T cell lineage specification. On the one hand side, Th1-differentiation was proposed to be facilitated 
by TCDD (Fujimaki et al., 2002; Negishi et al., 2005), whereas on the other hand side, data on 
TCDD-impacted IFN-γ secretion is controversial. IFN-γ secretion was found to be up-regulated in 
several studies (Fujimaki et al., 2002; Jeong et al., 2012; Negishi et al., 2005; Vorderstrasse and 
Kerkvliet, 2001), as well as down-regulated (Prell et al., 2000; Quintana et al., 2008; Quintana et 
al., 2010), whereby the latter might correlate with the further observed hyporesponsiveness of CTLs 
(De Krey and Kerkvliet, 1995; Prell et al., 2000). 
 
TCDD-treatment – ‘Immunosuppressive effects’?! 
A further potentially repressed immune reaction responding to TCDD-treatment could implicate 
macrophage activation and response of monocytes (CD163↓).  
CD163 is an acute phase-regulated receptor involved in clearance and endocytosis of 
hemoglobin/haptoglobin complexes as well as in scavenging of components of damaged cells. 
Thus, CD163 is implicated in protection of tissues from free hemoglobin-mediated oxidative 
damage, for instance. The receptor was discussed to play an anti-inflammatory role correlated with 
macrophage activation and response of monocytes (Binns et al., 2009; Buechler et al., 2000; 
Moestrup and Møller, 2004). In an Agilent whole genome microarray experiment, CD163 was as 
well reported to be down-regulated by TCDD (10 µM, 20 h; human liver S9-mix) in human PBMCs 
(Hochstenbach et al., 2010).  
 
Taken together, proposed immune responses mediated by TCDD ‘alone’ in human PBMCs might 
involve repressed Th1-responses, slightly facilitated Th2-response, controversial findings with 
respect to Th17/Treg-differentiation, and inhibited response of monocytes/macrophages. 
Chemotaxis is suggested to be affected directing towards inhibition with respect to T lymphocytes 
(CXCL10, CCL18, CCL19, and CCL23), B lymphocytes (CCL19), and neutrophils (CCL23). 
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TCDD+LPS-treatment – Chemokines 
Regarding treatment of PBMCs with TCDD together with LPS, the majority of differentially 
regulated genes tended to be down-regulated. Besides four chemokines, which were as well 
inhibited by TCDD alone (CXCL10, CCL18, CCL19, and CCL23), CCL8 was down-regulated in 
addition. Altogether, down-regulation of these chemokines might indicate inhibited chemotactic 
properties towards T lymphocytes (CCL8, CXCL10, CCL18, CCL19, and CCL23), B lymphocytes 
(CCL19), monocytes (CCL8, CCL23), neutrophils (CCL23), as well as basophils and eosinophils 
(CCL8) (Binns et al., 2009; Dimmer et al., 2012). 
 
TCDD+LPS-treatment – T cell lineage specification / ‘Immunosuppressive effects’?! 
Potentially repressed immune reactions responding to TCDD+LPS-treatment could implicate type 1 
immunity (SPP1↓), humoral immune response (FCGR1B↓), macrophage activation and response of 
monocytes (CD163↓) (Binns et al., 2009; Buechler et al., 2000; Dimmer et al., 2012; Moestrup and 
Møller, 2004).  
SPP1 encodes the protein osteopontin, which acts as a cytokine and participates in the enhanced 
production of IFN-γ and IL-12, as well as in the reduction of IL-10 production, appears to be 
essential in the pathway leading to type 1 immunity (Binns et al., 2009; Dimmer et al., 2012).  
SPP1 as well as CD163 (aforementioned with respect to impact by TCDD ‘alone’), were as well 
down-regulated in another whole genome microarray experiment using human PBMCs incubated 
with TCDD (10 µM, 20 h, human liver S9-mix) (Hochstenbach et al., 2010).  
One further accordingly regulated gene within this study was thrombospondin 1 (THBS1). This 
gene was up-regulated and encodes an inhibitor of angiogenesis (TSP-1), which is able to limit 
vessel density in normal tissues and to reduce tumor growth. TSP-1 is induced at sites of tissue 
damage, where it co-occurs with endoplasmatic reticulum (ER) stress response. TSP-1 was shown 
to augment and protect ER function, by which protein production and resolution of misfolded 
proteins is regulated in case of ER stress response (Lynch et al., 2012; Murphy-Ullrich and 
Poczatek, 2000). 
 
Inhibited IFNG-transcription as well as associated slight indication of repressed IL18-expression 
reflected findings for the TCDD-treatment described above. The further hint of an induced 
transcription of IL12, proposed facilitated Th1-response, as it was obtained elsewhere (Fujimaki et 
al., 2002; Negishi et al., 2005). Contrary regarding Th1-response by TCDD+LPS was an indication 
given due to down-regulation of SSP1, which more hinted towards inhibited Th1-response. 
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TCDD+PHA-treatment – numbers of affected genes and apoptosis 
Compared to the TCDD-, and the TCDD+LPS-treatment, results differed from those obtained for 
TCDD+PHA starting with greater statistical significance and higher numbers of genes differentially 
regulated (32↑ 12↓).  
Among these genes, several were involved in apoptotic mechanisms (CABLES1↑, NPTX1↑, 
SERPINB2↑, and NKD2↑). NKD2 represents an inducible Wnt/β-catenin signaling pathway 
antagonist. Aberrations of Wnt/β-catenin signals are often correlated with overexpression of the     
c-myc oncogene, which might suggest a role of TCDD with respect to c-myc expression (You et al., 
2002; Zeng et al., 2000; Zhang et al., 2012). C-myc was not regulated along with the PBMC 
microarray experiment in hand.  
 
TCDD+PHA-treatment – Chemokines 
Two genes encoding chemokines were up-regulated in response to TCDD+PHA-treatment: Up-
regulated CCL2 might hint directing to facilitated chemotaxis towards monocytes and basophiles, 
and towards neutrophil granulocytes regarding CXL6. By contrast, down-regulated chemokines 
gave indications with respect to inhibited chemotactic properties towards T lymphocytes (CCL18, 
CCL19, and CCL23), B lymphocytes (CCL19), as well as monocytes and neutrophils (CCL23) 
(Binns et al., 2009; Dimmer et al., 2012).  
 
TCDD+PHA-treatment – T cell lineage specification / ‘Immunosuppressive effects’?! 
Further impact indicated TCDD-mediated inhibitory effects on Th1-specific immune responses and 
correlated response of CTLs (IFNG↓), and B cell activation and proliferation (MS4A4A↓, CD38↓). 
Implicated in altered glucose-dependent immune homeostasis were NPTX1(↑), HTRA1(↑), and 
CD38(↓), whereas up-regulated P2RY6 might reflect an involvement in a phosphatidyinositol-
calcium second messenger system (Binns et al., 2009; Dimmer et al., 2012).  
 
With respect to cytokines involved in T cell lineage specification, besides aforementioned IFNG, 
IL2, IL4, IL6, IL18, and IL21 tended to be down-regulated by TCDD+PHA. One of these findings 
theoretically might reflect and inhibitory effect of TCDD on Th2-response regarding reduced IL4, 
as it was shown in literature before in murine spleen cells (Fujimaki et al., 2002).  
Besides, Th1-, and CTL-response tended to be inhibited (IFNG, IL18), as seen in immune cells with 
TCDD before regarding IFNG (Dinarello, 1999; Prell et al., 2000; Quintana et al., 2008; Quintana 
et al., 2010), and hyporesponsiveness of CTLs (De Krey and Kerkvliet, 1995; Prell et al., 2000).  
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Controversial findings were obtained regarding Th17/Treg differentiation – down-regulated IL2 
would imply repressed Treg-differentiation, whereas IL6, and IL21 might reflect repressed Th17-
differentiation (Jetten, 2009). In mice, Treg-differentiation was proposed to be augmented by 
TCDD, whereas Th17-differentation was shown to be inhibited by the congener (Nguyen et al., 
2010; Quintana et al., 2008). 
 
By tendency, TDO2 was up-regulated by TCDD+PHA-treatment as discussed by means of the 
TCDD-treatment in the beginning of this chapter. Up-regulated TDO2 could indicate lightly 
facilitated Treg-differentiation, as revealed before (Nguyen et al., 2010; Mezrich et al., 2010), 
wherease TDO-generated Kyn was correlated with AhR-dependent antitumor immune responses 
(Opitz et al., 2011). 
 
Considering discussed data on treatment of human PBMCs with TCDD ‘alone’, with TCDD+LPS, 
or with TCDD+PHA, one needs to keep in mind that the statistical relevance of data was overall 
limited and inter-individual differences were great along with the experiment. Discussed indications 
represent suggested potential directions regarding TCDD-mediated impact on immune cells. 
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6 
Conclusions 
 
‚Dioxin-like’ compounds represent a group of chemicals which are known to exert most, if not all, 
of their biological and toxic effects by activation of the AhR. With respect to the TEF-concept, 
properties of these congeners are defined by their interaction with the AhR. Thus, potentially 
relevant substance-specific attributes might be disregarded. 
 
With respect to the mouse whole genome microarray experiment, impact of DL-congeners on gene 
expression in mouse livers was primarily and with strongest significance correlated with enhanced 
xenobiotic metabolic processes. Followed by alterations towards lipid-, and carbohydrate 
metabolism, further implicated mechanisms were oxidative processes, apoptosis, and immune 
response to a lowered extent.  
Whereas 1-PeCDD’s impact on gene expression in mouse livers correlated most prominently with 
TCDD-mediated effects, overlap between TCDD and the remaining DL-congeners was limited. 
Regarding all DL-compounds together, a small, conserved list of differentially regulated genes was 
observed. This list primarily was constituted of genes involved in xenobiotic metabolism.  
 
Some of the congeners involved in mouse microarray investigations, namely PCB 126, PCB 156, 
and 4-PeCDF, revealed great impact on gene expression in mouse livers by differentially regulating 
an enormous number of up to 3000 (↑↓) affected genes, which might be due to a high-dose effect. 
Still, since overlap among DL-congeners remained limited, unresolved issue represents the role of 
AhR-independent genes. As, for instance, the overlap between TCDD and PCB 118 was low, three 
quarters of the amount of PCB 118-impacted genes did not correlate with TCDD’s, thus appeared to 
be AhR-independent but likewise of not specified ‘source’. 
 
Reflecting investigations using human PBMCs including results of the human whole genome 
microarray experiment and qRT-PCR investigations, identification of TCDD-mediated impact was 
intricate. Excepting impact on known AhR-targets - CYP1A1, CYP1B1, TIPARP, and AHRR - 
minor effects accompanied by distinct inter-individual differences were observed. Slight, but not 
clearly directed immunomodulatory impact of TCDD was indicated. 
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With respect to establishment of potential biomarkers, the search of genes, which would be 
differentially regulated in both animal experiments as well as in in vitro investigations using human 
primary cells, would be of peculiar interest.  
Thus, regulated genes from the human PBMC-experiment were looked up in mouse whole genome 
microarray data and checked on their regulation in response to treatment with DL-congeners. The 
overlap was restricted to members of the AhR-gene batterie, namely CYP1A1, CYP1B1, and 
TIPARP.  
Taking these three representatives to compare them with results obtained by gene expression 
analysis with rat liver cells, only CYP1A1, and CYP1B1 remained to be reliably significant. 
Accordingly, liver cell systems analyzed in terms of CYP1A-induction, as it was applied in the 
course of this study, still give relevant indications of ‘dioxin-like’ impact of a chemical, even 
though investigations using human primary hepatocytes tend to gain in importance.  
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I. Supplemental tables 
 
Table 56: Mouse whole genome microarray analysis. Top 20 genes accordantly down-regulated in mouse livers 
by 1-PeCDD (25 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
1-PeCDD    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
-1.320 -2.846 NM_013692 Kruppel-like factor 10 Klf10 
-2.535/ 
-2.537 
-2.573/ 
-2.488 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-2.244- 
-2.138 
-2.276- 
-2.141 NM_207655 epidermal growth factor receptor  Egfr 
-2.797- 
-2.009 
-2.125- 
-1.545 NM_007706 suppressor of cytokine signaling 2  Socs2 
-1.323 -2.025 NM_144942 cysteine sulfinic acid decarboxylase   Csad 
-1.312 -1.886 NM_009744 B-cell leukemia/lymphoma 6 Bcl6 
-1.889 -1.821 XM_001003154 
similar to Glucose phosphate isomerase 1 transcript 
variant 2  LOC676974 
-1.865 -1.806 NM_130450 
ELOVL family member 6  elongation of long chain fatty 
acids (yeast)  Elovl6 
-1.429 -1.734 NM_010390 histocompatibility 2 Q region locus 1  H2-Q1 
-1.242 -1.694 NM_001081212 insulin receptor substrate 2  Irs2 
-1.650- 
-1.372 
-1.689- 
-1.594 NM_029720 cysteine-rich with EGF-like domains 2  Creld2 
-1.281 -1.675 NM_144796 sushi domain containing 4  Susd4 
-1.616 -1.669 NM_183257 hepcidin antimicrobial peptide 2  Hamp2 
-1.556 -1.649 XM_886827 predicted gene  EG622384  Fabp5l2 
-1.894 -1.557 NM_009723 ATPase  Ca++ transporting  plasma membrane 2  Atp2b2 
-1.843 -1.538 NM_175475 cytochrome P450  family 26 subfamily b polypeptide 1  Cyp26b1 
-1.566 -1.531 NAP114472-1 Unknown    NAP114472-1 
-1.495 -1.525 NM_010634 fatty acid binding protein 5 epidermal  Fabp5 
-2.087 -1.502 NM_001111110 
cytidine monophospho-N-acetylneuraminic acid 
hydroxylase transcript variant 2  Cmah 
-1.560 -1.481 NM_028769 synovial apoptosis inhibitor 1 synoviolin  Syvn1 
  
 
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Table 57: Mouse whole genome microarray analysis. Top 20 genes accordantly up-regulated in mouse livers by 
4-PeCDF (250 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
4-PeCDF    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
5.994 9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
2.926 5.169 NM_009994 cytochrome P450 family 1 subfamily b polypeptide 1  Cyp1b1 
2.414 3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2  Cyp1a2 
3.052 3.582 NM_010210 fragile histidine triad gene Fhit 
1.880 3.379 NM_017379 tubulin alpha 8  Tuba8 
3.413 3.103 NM_027872 solute carrier family 46 member 3 Slc46a3 
3.240 2.903 NM_178892 TCDD-inducible poly(ADP-ribose) polymerase Tiparp 
2.705 2.819 NM_008181 glutathione S-transferase alpha 1 (Ya)  Gsta1 
1.580 2.722 XM_001477458 predicted gene ENSMUSG00000054044 Gm9933 
1.796 2.678 NM_016865 HIV-1 tat interactive protein 2 homolog (human)  Htatip2 
1.054 2.518 NM_025557 Purkinje cell protein 4-like 1 Pcp4l1 
1.724 2.153 NM_023440 transmembrane protein 86B  Tmem86b 
1.510 2.123 NM_026791 F-box and WD-40 domain protein 9  Fbxw9 
1.397 1.978 NM_028747 RIKEN cDNA 0610012H03 gene  0610012H03Rik 
1.629/ 
1.941 
1.857/ 
1.362 NM_013541 glutathione S-transferase  pi 1  Gstp1 
2.925/ 
2.197 
1.853/ 
1.036 NM_001122660 predicted gene 10639  Gm10639 
1.455 1.762 NM_001163577 prominin 1  Prom1 
4.227 1.758 NM_007643 CD36 antigen transcript variant 2  Cd36 
1.232 1.702 NM_007689 chondroadherin  Chad 
3.055/ 
3.085 
1.696/ 
1.650 NM_145603 carboxylesterase 2  Ces2 
  
 
 
 
Values b/a from oligo b/oligo a. 
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Table 58: Mouse whole genome microarray analysis. Top 20 genes accordantly down-regulated in mouse livers 
by 4-PeCDF (250 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD- raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
4-PeCDF    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
-6.185/ 
-6.176 
-2.573/ 
-2.488 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-2.026- 
-1.742 
-2.125- 
-2.003 NM_007706 suppressor of cytokine signaling 2 Socs2 
-2.089 -1.890 XM_001475897 similar to myosin XV  LOC100046261 
-3.233 -1.821 XM_001003154 
similar to Glucose phosphate isomerase 1  transcript 
variant 2 LOC676974 
-1.551 -1.694 NM_001081212 insulin receptor substrate 2  Irs2 
-1.063 -1.675 NM_144796 sushi domain containing 4  Susd4 
-2.335 -1.645 
ENSMUST0000
0111752 Homeobox protein cut-like 2  Cux2 
-1.551 -1.560 
ENSMUST0000
0006786 
Sodium-dependent phosphate transport protein 3 
(Sodium/phosphate cotransporter 3)(Na(+)/PI 
cotransporter 3) (Solute carrier family 17 member 2)  Slc17a2 
-1.477 -1.557 NM_009723 ATPase  Ca++ transporting plasma membrane 2 Atp2b2 
-3.971 -1.502 NM_001111110 
cytidine monophospho-N-acetylneuraminic acid 
hydroxylase  Cmah 
-3.753 -1.439 NM_001081141 gamma-aminobutyric acid (GABA) B receptor 2  Gabbr2 
-3.042 -1.432 NM_007606 carbonic anhydrase 3  Car3 
-1.048 -1.425 NM_008061 glucose-6-phosphatase catalytic  G6pc 
-3.525 -1.423 NM_134037 ATP citrate lyase  Acly 
-3.371 -1.387 AK017236 adult male pituitary gland 5330406M23Rik 
-4.422- 
-4.290 
-1.387- 
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
-2.090 -1.378 AK017143 11 days pregnant adult female ovary and uterus cDNA   5031425E22Rik 
-1.610/ 
-1.701 
-1.374/ 
-1.328 NM_027147 energy homeostasis associated Enho 
-2.076 -1.335 NM_019423 
elongation of very long chain fatty acids (FEN1/Elo2  
SUR4/Elo3 yeast)-like 2 Elovl2 
-1.853 -1.309 AK050412 adult male liver tumor cDNA  1810008I18Rik 
   
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Table 59: Mouse whole genome microarray analysis. Twelve genes accordantly down-regulated in mouse livers 
by PCB 118 (150000 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 118    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
-1.383 -2.846 NM_013692 Kruppel-like factor 10  Klf10 
-1.023 -1.890 XM_001475897 similar to myosin XV (LOC100046261) LOC100046261 
-2.119 -1.886 NM_009744 B-cell leukemia/lymphoma 6  Bcl6 
-1.636 -1.821 XM_001003154 
similar to Glucose phosphate isomerase 1 transcript 
variant 2 (LOC676974)   LOC676974 
-2.255 -1.694 NM_001081212 insulin receptor substrate 2  Irs2 
-1.044 -1.675 NM_144796 sushi domain containing 4  Susd4 
-1.879 -1.425 NM_008061 glucose-6-phosphatase catalytic  G6pc 
-2.033 -1.387 AK017236 
adult male pituitary gland cDNA RIKEN full-length 
enriched library  5330406M23Rik 
-1.265 
-1.235 
-1.387- 
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
-1.209 -1.113 XM_001471861 hypothetical protein LOC100044148  Etnk2 
-1.003 -1.103 XM_001481023 hypothetical protein LOC100043770 Gm4635 
-1.035 -1.055 NM_001081065 zinc finger protein 707  Zfp707 
   
 
 
Value range of more than two (n) oligos: values a-n. 
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Table 60: Mouse whole genome microarray analysis. Top 20 genes accordantly up-regulated in mouse livers by 
PCB 126 (250 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
PCB 126    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
Gene 
name 
     
6.292 9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1  Cyp1a1 
2.557 5.169 NM_009994 cytochrome P450 family 1 subfamily b polypeptide 1  Cyp1b1 
2.555 3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2  Cyp1a2 
2.056 3.582 NM_010210 fragile histidine triad gene  Fhit 
1.767 3.379 NM_017379 tubulin alpha 8  Tuba8 
3.172 3.103 NM_027872 solute carrier family 46 member 3  Slc46a3 
1.431 2.903 NM_178892 TCDD-inducible poly(ADP-ribose) polymerase  Tiparp 
3.095 2.819 NM_008181 glutathione S-transferase alpha1 (Ya)  Gsta1 
1.134 2.678 NM_016865 HIV-1 tat interactive protein 2 homolog (human)  Htatip2 
1.451 2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
2.542 2.153 NM_023440 transmembrane protein 86B    Tmem86b 
1.423 2.123 NM_026791 F-box and WD-40 domain protein 9  Fbxw9 
1.159/ 
2.161 
1.857/ 
1.362 NM_013541 glutathione S-transferase pi 1  Gstp1 
3.049/ 
2.144 
1.853/ 
1.036 NM_001122660 predicted gene 10639  Gm10639 
1.464 1.762 NM_001163577 prominin 1  Prom1 
2.282 1.758 NM_007643 CD36 antigen Cd36 
2.860/ 
2.770 
1.696/ 
1.650 NM_145603 carboxylesterase 2  Ces2 
1.035 1.653 NM_001166250 monoglyceride lipase  Mgll 
3.250 1.630 NM_198171 cDNA sequence BC015286 BC015286 
1.381/ 
2.045 
1.621/ 
1.211 NM_025341 abhydrolase domain containing 6 Abhd6 
  
 
 
 
Values b/a from oligo b/oligo a. 
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Table 61: Mouse whole genome microarray analysis. Top 20 genes accordantly down-regulated in mouse livers 
by PCB 126 (250 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 126    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
  
 
  
-4.502/ 
-4.480 
-2.573/-
2.488 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A 
member 4  pseudogene 1 Serpina4-ps1 
-1.345 -1.890 XM_001475897 similar to myosin XV  LOC100046261 
-1.479 -1.821 XM_001003154 similar to Glucose phosphate isomerase 1  LOC676974 
-2.174 -1.502 NM_001111110 
cytidine monophospho-N-acetylneuraminic acid 
hydroxylase  Cmah 
-1.879 -1.439 NM_001081141 gamma-aminobutyric acid (GABA) B receptor  2  Gabbr2 
-1.230 -1.432 NM_007606 carbonic anhydrase 3  Car3 
-2.087 -1.425 NM_008061 glucose-6-phosphatase  catalytic  G6pc 
-1.873 -1.423 NM_134037 ATP citrate lyase    Acly 
-1.809 -1.387 AK017236 adult male pituitary gland cDNA  5330406M23Rik 
-3.308- 
-3.260 
-1.387- 
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
-1.068/ 
-1.067 
-1.295/ 
-1.229 NM_009569 zinc finger protein  multitype 1  Zfpm1 
-1.259 -1.276 NM_145368 acyl-coenzyme A amino acid N-acyltransferase 2   Acnat2 
-1.091 -1.214 NM_144836 
solute carrier family 17 (sodium phosphate) 
member 2 Slc17a2 
-2.283 -1.154 NM_198414 progestin and adipoQ receptor family member IX  Paqr9 
-1.214 -1.150 NM_198649 actin binding LIM protein family  member 3  Ablim3 
-1.964 -1.135 ENSMUST00000099683 Unknown  
ENSMUST0000
0099683 
-1.051 -1.113 XM_001471861 hypothetical protein LOC100044148   Etnk2 
-2.885 -1.103 XM_001481023 hypothetical protein LOC100043770  Gm4635 
-1.894/ 
-1.951 
-1.092/ 
-1.001 ENSMUST00000099050 Unknown    
ENSMUST0000
0099050 
-1.743 -1.073 ENSMUST00000099046 Unknown    
ENSMUST0000
0099046 
   
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Table 62: Mouse whole genome microarray analysis. Top 20 genes accordantly up-regulated in mouse livers by 
PCB 156 (150000 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≥ 1, p-value < 0.05. 
PCB 156    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
     
7.467 9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
3.652 5.169 NM_009994 cytochrome P450 family 1 subfamily b polypeptide 1 Cyp1b1 
3.402 3.985 NM_009993 cytochrome P45  family 1 subfamily a polypeptide 2  Cyp1a2 
3.861 3.582 NM_010210 fragile histidine triad gene  Fhit 
2.352 3.379 NM_017379 tubulin alpha 8  Tuba8 
2.845 3.103 NM_027872 solute carrier family 46 member 3  Slc46a3 
1.331 2.903 NM_178892 TCDD-inducible poly(ADP-ribose) polymerase  Tiparp 
4.006 2.819 NM_008181 glutathione S-transferase  alpha 1 (Ya)  Gsta1 
1.033 2.722 XM_001477458 predicted gene ENSMUSG00000054044  Gm9933 
2.494 2.678 NM_016865 HIV-1 tat interactive protein 2  homolog (human)  Htatip2 
1.359 2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
1.016 2.386 NM_013872 phosphomannomutase 1  Pmm1 
2.236 2.153 NM_023440 transmembrane protein 86B   Tmem86b 
2.067 2.123 NM_026791 F-box and WD-40 domain protein 9   Fbxw9 
1.720 1.978 NM_028747 RIKEN cDNA 0610012H03 gene   0610012H03Rik 
1.900/ 
1.174 
1.931/ 
1.039 NM_007618 serine (or cysteine) peptidase inhibitor clade A member 6  Serpina6 
2.309/ 
2.269 
1.857/ 
1.362 NM_013541 glutathione S-transferase  pi 1  Gstp1 
3.939/ 
2.268 
1.853/ 
1.036 NM_001122660 predicted gene 10639  Gm10639 
2.622 1.758 NM_007643 CD36 antigen  Cd36 
1.556 1.702 NM_007689 chondroadherin   Chad 
  
 
 
 
Values b/a from oligo b/oligo a. 
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Table 63: Mouse whole genome microarray analysis. Top 20 genes accordantly down-regulated in mouse livers 
by PCB 156 (150000 µg/kg bw, three days), and TCDD (25 µg/kg bw, three days). TCDD-raw data by courtesy of 
Christiane Lohr (Lohr, 2013). Cutoff values: A ≥ 27, lfc ≤ -1, p-value < 0.05. 
PCB 156    
&   TCDD 
           lfc            lcf 
Gene  
systematic  
name 
 
 
Gene description 
 
 
Gene name 
     
-1.423 -2.846 NM_013692 Kruppel-like factor 10 Klf10 
-4.279/ 
-4.481 
-2.573/ 
-2.488 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-2.005- 
-2.089 
-2.276- 
-2.141 NM_207655 epidermal growth factor receptor  Egfr 
-1.549 -1.890 XM_001475897 similar to myosin XV  LOC100046261 
-2.090 -1.886 NM_009744 B-cell leukemia/lymphoma 6   Bcl6 
-2.953 -1.821 XM_001003154 similar to Glucose phosphate isomerase 1  LOC676974 
-1.002 -1.734 NM_010390 histocompatibility 2  Q region locus 1 H2-Q1 
-2.591 -1.694 NM_001081212 insulin receptor substrate 2  Irs2 
-1.619 -1.675 NM_144796 sushi domain containing 4  Susd4 
-1.374 -1.669 NM_183257 hepcidin antimicrobial peptide 2   Hamp2 
-1.451 -1.560 
ENSMUST0000
0006786 
ens|Sodium-dependent phosphate transport protein 3 
(Sodium/phosphate cotransporter 3)(Na(+)/PI 
cotransporter 3)(Solute carrier family 17 member 2)   Slc17a2 
-1.311 -1.557 NM_009723 ATPase  Ca++ transporting  plasma membrane 2  Atp2b2 
-2.491 -1.502 NM_001111110 
cytidine monophospho-N-acetylneuraminic acid 
hydroxylase (Cmah)  transcript variant 2  Cmah 
-2.730 -1.439 NM_001081141 gamma-aminobutyric acid (GABA) B receptor  2   Gabbr2 
-2.945 -1.432 NM_007606 carbonic anhydrase 3   Car3 
-3.060 -1.425 NM_008061 glucose-6-phosphatase catalytic  G6pc 
-3.297/ 
-1.584 
-1.423/ 
-1.313 NM_134037 ATP citrate lyase (Acly)  mRNA [NM_134037]   Acly 
-3.509 -1.387 AK017236 
adult male pituitary gland cDNA RIKEN full-length 
enriched library clone:5330406M23 
product:unclassifiable  full insert sequence 5330406M23Rik 
-2.821- 
-2.710 
-1.387- 
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
  
 
 
 
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
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Table 64: Mouse whole genome microarray analysis. 48 accordantly up-regulated genes in mouse livers by 
treatment with DL-congeners TCDD, 1-PeCDD, 4-PeCDF, PCB 126, or PCB 156. Listed in descending order 
according to TCDD-derived effects. TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013).                
Cutoff values: A ≥ 27, │lfc│ ≥ 1, p-value < 0.05. 
 
lfc (TCDD) 
Gene  
systematic name 
DL-congeners excepting PCB 118 
Gene description 
 
Gene name 
    9.478 NM_009992 cytochrome P450 family 1 subfamily a polypeptide 1 Cyp1a1 
5.169 NM_009994 cytochrome P450 family 1 subfamily b polypeptide 1 Cyp1b1 
3.985 NM_009993 cytochrome P450 family 1 subfamily a polypeptide 2 Cyp1a2 
3.582 NM_010210 fragile histidine triad gene  Fhit 
3.379 NM_017379 tubulin alpha 8 Tuba8 
3.103 NM_027872 solute carrier family 46 member 3 Slc46a3 
2.903 NM_178892 TCDD-inducible poly(ADP-ribose) polymerase  Tiparp 
2.819 NM_008181 glutathione S-transferase alpha 1 (Ya) Gsta1 
2.678 NM_016865 HIV-1 tat interactive protein 2 homolog (human) Htatip2 
2.518 NM_025557 Purkinje cell protein 4-like 1  Pcp4l1 
2.153 NM_023440 transmembrane protein 86B Tmem86b 
1.857/1.362 NM_013541 glutathione S-transferase pi 1 Gstp1 
1.853 NM_001122660 predicted gene 10639  Gm10639 
1.758 NM_007643 CD36 antigen  Cd36 
1.696/1.65 NM_145603 carboxylesterase 2  Ces2 
1.653 NM_001166250 monoglyceride lipase  MgII 
1.63 NM_198171 cDNA sequence BC015286  BC015286 
1.621/1.211 NM_025341 abhydrolase domain containing 6 Abhd6 
1.602 NM_010902 nuclear factor erythroid derived 2 like 2 Nfe2l2 
1.559 NM_181796 glutathione S-transferase pi 2 Gstp2 
1.499 NM_026428 dicarbonyl L-xylulose reductase  Dcxr 
1.481 NM_008030 flavin containing monooxygenase 3  Fmo3 
1.441 NM_009150 selenium binding protein 1  Selenbp1 
1.441 NM_009150 selenium binding protein 1  Selenbp1 
1.423 NM_011099 pyruvate kinase muscle Pkm2 
1.394 NM_172881 UDP glucuronosyltransferase 2 family polypeptide B35 Ugt2b35 
1.391 NM_009466 UDP-glucose dehydrogenase  Ugdh 
1.316 NM_009768 basigin  Bsg 
1.297 NM_008182 glutathione S-transferase alpha 2 (Yc2) Gsta2 
1.286 NM_001145875 RIKEN cDNA 9530008L14 gene  9530008L14Rik 
1.282 XM_129965 Mus musculus gene model 1833 Gm1833 
1.259 NM_001081372 predicted gene 5158  Gm5158 
1.247/1.209 NM_008278 hydroxyprostaglandin dehydrogenase 15 (NAD)  Hpgd 
1.244 NM_145953 cystathionase (cystathionine gamma-lyase)  Cth 
1.198 NM_019771 destrin  Dstn 
1.181 A_55_P2168781 Unknown A_55_P2168781 
1.156 NM_008828 phosphoglycerate kinase 1  Pgk1 
1.15 NM_011671 uncoupling protein 2 (mitochondrial) Ucp2 
1.136 NM_020008 C-type lectin domain family 7 Clec7a 
1.127 NAP096647-001 MUSXPGK phosphoglycerate kinase  NAP096647-001 
1.111 NM_019749 gamma-aminobutyric acid receptor associated protein  Gabarap 
1.105 NM_025797 cytochrome b-5 Cyb5 
1.094 NM_009811 caspase 6  Casp6 
1.093 NM_009801 carbonic anhydrase 2  Car2 
1.069 NM_026185 abhydrolase domain containing 15 Abhd15 
1.034 NM_001081036 predicted gene 9294  Gm9294 
1.002 NM_025911 coiled-coil domain containing 91  Ccdc91 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos.
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Table 65: Mouse whole genome microarray analysis. 19 accordantly down-regulated genes in mouse livers by 
treatment with DL-congeners TCDD, 1-PeCDD, 4-PeCDF, PCB 126, or PCB 156. Listed in descending order 
according to TCDD-derived effects. TCDD-raw data by courtesy of Christiane Lohr (Lohr, 2013). Cutoff values: 
A ≥ 27, │lfc│ ≥ 1, p-value < 0.05. 
 
lfc (TCDD) 
Gene  
systematic name 
DL-congeners excepting PCB 118 
Gene description 
 
Gene name 
  
 
 
-2.573/ 
-2.488 
BC031891/ 
NR_002861 
serine (or cysteine) peptidase inhibitor clade A member 4  
pseudogene 1 Serpina4-ps1 
-1.821 XM_001003154 similar to Glucose phosphate isomerase 1 transcript variant 2 LOC676974 
-1.502 NM_001111110 cytidine monophospho-N-acetylneuraminic acid hydroxylase  Cmah 
-1.439 NM_001081141 gamma-aminobutyric acid (GABA) B receptor Gabbr2 
-1.432 NM_007606 carbonic anhydrase 3  Car3 
-1.425 NM_008061 glucose-6-phosphatase catalytic G6pc 
-1.423 NM_134037 ATP citrate lyase  Acly 
-1.387-  
-1.328 NM_009692 apolipoprotein A-I  Apoa1 
-1.276 NM_145368 acyl-coenzyme A amino acid N-acyltransferase 2  Acnat2 
-1.15 NM_198649 actin binding LIM protein family Ablim3 
-1.135 
ENSMUST0000
0099683 Unknown 
ENSMUST00000
099683 
-1.113 XM_001471861 hypothetical protein LOC100044148 Etnk2 
-1.103 XM_001481023 hypothetical protein LOC100043770  Gm4635 
-1.092 
ENSMUST0000
0099050 Unknown 
ENSMUST00000
099050 
-1.073 
ENSMUST0000
0099046 Unknown 
ENSMUST00000
099046 
-1.064 NM_011169 prolactin receptor  Prlr 
-1.035 NM_021041 ATP-binding cassette Abcc9 
-1.031 
ENSMUST0000
0099035 Q4YHF0_PLABE (Q4YHF0) Pb-fam-2 protein (Fragment) 
ENSMUST00000
099035 
-1.028 XM_914710 similar to EF-hand Ca2+ binding protein p22 (LOC638627) LOC638627 
    
Values b/a from oligo b/oligo a; values a-n: value range of more than two (n) oligos. 
 
 
 
 
 
 
 
  321 
II. Curriculum Vitae               Sylke Neser 
 
 
Education                       ____________________________________________________________ 
University of Kaiserslautern, Food Chemistry and Toxikology (since 2004) 
• Research work (2008):  
’The impact of TCDD on DNA-methylation in primary rat hepatocytes’ 
• First state exam in food chemistry (2008) 
• Diploma thesis (2009) 
„Impact of apple juice extracts and apple juice ingredients on the formation 
of reactive oxygen species in vitro“ in the course of the Federal Ministry of 
Education and Research (Bundesministerium für Bildung und Forschung, 
BMBF)-funded Nutrition Net “Role of dietary components on the genesis of 
intestinal disorders and possibilities of their prevention by nutritional 
intervention“ 
• Degree: Qualified Food Chemist (Dipl.-LMChem.) 
  
 
PhD____________________________________________________________________________ 
05/2009-10/2012 Research assistant in the department of chemistry, division of food 
chemistry and toxicology at the University of Kaiserslautern;  
Working group: Prof. Dr. Dr. Dieter Schrenk: 
 Investigations on the impact of dioxins and dioxin-like 
polychlorinated biphenyls on gene expression in vitro und in vivo 
within the framework of the EU project SYSTEQ, which was funded 
under the Seventh Framework Programme of the European 
Commission. 
Since 10/2012   Draft of the doctoral dissertation to acquire the doctoral degree  
    in Natural Sciences; Dr. rer. nat. 
 
 
Further education________________________________________________________________ 
Since 2009 Participation in the postgraduate education program of the German 
Society for experimental and clinical Pharmacology and Toxicology 
(Deutsche Gesellschaft für experimentelle und klinische 
Pharmakologie und Toxikologie e.V., DGPT) and the Helmholtz 
Center Munich to graduate as toxicologist (DGPT) 
 
 
   322 
Publications_____________________________________________________________________ 
Article Neser and Schrenk: ‘Use of palmitoylethanolamide for pain therapy – 
a safe dietary food for special medical purposes? 
(Palmitoylethanolamid gegen Schmerzen – Ein sicheres diätetisches 
Lebensmittel für medizinische Zwecke?)’ 
Deutsche Apothekerzeitung 2012, Ausgabe 22 
Poster Neser et al.: Dioxin 2011 (31st International Symposium on 
Halogenated Persistent Organic Pollutants), Brussels 
 ’Induction of CYP1A activity in in vitro models as a basis for 
derivation of systemic TEFs’ 
Poster Schrenk et al.: Dioxin 2011, Brüssel 
 ’Applying TEFs in Risk Assessment  
(An Update on SYSTEQ, II)’ 
Poster Neser et al.: Regionalverbandstagung der Lebensmittelchemischen 
Gesellschaft (LChG) der Gesellschaft Deutscher Chemiker (GDCh) 
2012, Kaiserslautern 
’Gene regulating effects in mouse liver subsequent to treatment with 
selected dioxin-like compounds and PCB 153 using whole genome 
microarray analysis’ 
Poster Neser et al.: 78. Jahrestagung der Deutschen Gesellschaft für 
experimentelle und klinische Pharmakologie und Toxikologie e.V. 
(DGPT) 2012, Dresden 
’Gene regulating effects in mouse liver subsequent to treatment with 
selected dioxin-like compounds and PCB 153 using whole genome 
microarray analysis’  
Poster Lohr et al.: 78. Jahrestagung der DGPT 2012, Dresden 
„Whole genome microarray analysis of the effects of TCDD and PCB 
153 in human hepatic cell models“ 
 
 
Kaiserslautern, 7th of November 2014 
 
   323 
 
III. Eidesstattliche Erklärung 
 
Hiermit erkläre ich an Eides statt, dass ich die eingereichte Dissertation eigenständig verfasst, die 
für die Arbeit benutzten Hilfsmittel und Quellen genannt und die Ergebnisse beteiligter Mitarbeiter 
sowie anderer Autoren klar gekennzeichnet habe. Ich habe weder die Dissertation oder Teile der 
Disseration als Prüfungsarbeit bei einem anderen Fachbereich eingereicht noch ein 
Promotionsverfahren bei einer anderen Hochschule beantragt.  
 
 
Kaiserslautern, 7. November 2014 
